{"title": "Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda de Atenci\u00f3n Primaria", "author": null, "url": "https://www.aepap.org/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica/bibliografia-de-2019", "hostname": "aepap.org", "description": "Actualidad bibliogr\u00e1fica diciembre 2019Top tenComprehensive Detection of Respiratory Bacterial and Viral Pathogens in the Middle Ear Fluid and Nasopharynx of Pediatric Patients With Acute Otitis MediaSawada, Shoichi; Okutani, Fumino; Kobayashi, Taisuke Less . The Pediatric Infectious Disease Journal. 38(12):1199-1203, December 2019", "sitename": "aepap.org", "date": "2018-12-13", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Actualidad bibliogr\u00e1fica diciembre 2019\nTop ten\nComprehensive Detection of Respiratory Bacterial and Viral Pathogens in the Middle Ear Fluid and Nasopharynx of Pediatric Patients With Acute Otitis MediaSawada, Shoichi; Okutani, Fumino; Kobayashi, Taisuke Less . The Pediatric Infectious Disease Journal. 38(12):1199-1203, December 2019\nBackground: Acute otitis media (AOM) is a common ear infection caused by respiratory viruses and bacteria of the nasopharynx. The present study aimed to detect various respiratory viruses and bacteria in middle ear fluid (MEF) and nasopharyngeal aspirates (NPA) using polymerase chain reaction (PCR).\nMethods: We collected MEF and NPA samples from 122 pediatric patients with AOM. Real-time PCR detected 11 types of respiratory viruses (respiratory syncytial virus A/B, parainfluenza virus 1/2/3, human metapneumovirus, influenza virus A/B, adenovirus, human bocavirus and rhino virus) and 7 types of bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pyogenes, Legionella pneumophila and Moraxella catarrhalis). MEF specimens were also examined using bacterial culture.\nResults: At least 1 respiratory viral or bacterial pathogen was detected in MEF of 120 cases (98%) by viral and bacterial PCR and of 93 cases (76%) by viral PCR and bacterial culture. Respiratory viruses were detected in NPA of 84 cases (69%) and MEF of 67 cases (55%). The most common virus detected in MEF was respiratory syncytial virus (21%), followed by parainfluenza virus (15%). All the viruses present in MEF were also detected in NPA specimens. Bacteria were detected by PCR in MEF of 109 cases (89%); H. influenzae was the most frequently detected (65%).\nConclusions: In many cases, pediatric AOM was found to constitute a respiratory polymicrobial infection. Multiplex PCR was useful to detect multiple respiratory viruses and bacteria in AOM. To understand intractable AOM, further studies regarding the clinical features of each viral and bacterial coinfection are required.\n[Enfermedad invasiva por Streptococcus pyogenes: cambios en la incidencia y factorespron\u00f3sticos](https://www.analesdepediatria.org/es-enfermedad-invasiva-por-streptococcus-pyogenes-articulo-S169540331930030X). An Pediatr (Barc). 2019;91:286-95\nIntroducci\u00f3nLa enfermedad invasiva por Streptococcus del grupo A (EISGA) es una infecci\u00f3n grave en ni\u00f1os, habi\u00e9ndose comunicado un aumento de incidencia en los \u00faltimos a\u00f1os.\nObjetivo; Evaluar las caracter\u00edsticas y evoluci\u00f3n de la EISGA en ni\u00f1os y determinar cambios en la incidencia o gravedad.\nMaterial y m\u00e9todos\nEstudio retrospectivo de ni\u00f1os\u226416 a\u00f1os evaluados en un hospital terciario de Madrid y diagnosticados de EISGA (junio 2005-julio 2013). Se analiz\u00f3 la epidemiolog\u00eda, cl\u00ednica, microbiolog\u00eda y tratamiento, evalu\u00e1ndose cambios a lo largo del periodo estudiado y par\u00e1metros asociados a gravedad.\nResultados\nSe incluyeron 55 ni\u00f1os con EISGA; 33 (60%) mujeres, con una mediana de 48,5 (20,5-88,9) meses. Los s\u00edndromes cl\u00ednicos m\u00e1s frecuentes fueron celulitis/absceso subcut\u00e1neo (21,8%), absceso ORL (20%), neumon\u00eda (16,4%), infecci\u00f3n osteoarticular (16,4%) y mastoiditis (12,7%). La incidencia de EISGA (casos/105 urgencias/a\u00f1o) aument\u00f3 de 5,6 (4,2-7,2) entre junio 2005-mayo 2009 a 18,9 (15,1-26) entre junio 2009-mayo 2013; p=0,057. El 63,6% (n=35) y el 18,2% (n=10) de los pacientes precisaron cirug\u00eda e ingreso en UCIP, respectivamente. Los ni\u00f1os en UCIP fueron m\u00e1s peque\u00f1os (26,5 vs. 52,6 meses; p=0,116), presentaron prote\u00edna C reactiva m\u00e1s elevada (24,5 vs. 10,7mg/dl; p<0,001) y mayor frecuencia de neumon\u00eda (60 vs. 7%; p<0,001). En el an\u00e1lisis multivariante solo la prote\u00edna C reactiva fue factor de riesgo de ingreso en UCIP (OR: 1,14 [1,004-1,286]; p=0,04). No hubo secuelas.\nConclusiones\nSe objetiv\u00f3 un aumento de la incidencia de EISGA en ni\u00f1os en nuestro medio, siendo la menor edad, la presencia de neumon\u00eda y la prote\u00edna C reactiva elevada los par\u00e1metros asociados a gravedad en esta serie.\n[Infecciones invasivas por estreptococo del grupo A y por meningococo: incertidumbres y certezas](https://www.analesdepediatria.org/es-infecciones-invasivas-por-estreptococo-del-articulo-S1695403319302723). An Pediatr (Barc). 2019;91:283-5. [ Documento de posicionamiento de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda-Sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica (AEP-SEIP) sobre el tratamiento de las infecciones por bacterias multirresistentes ](https://www.analesdepediatria.org/es-documento-posicionamiento-asociacion-espanola-pediatria-sociedad-articulo-S169540331930270X) An Pediatr (Barc). 2019;91:351.e1-351.e13\nEn los \u00faltimos a\u00f1os se ha evidenciado un incremento en la incidencia de infecciones por bacterias multirresistentes. Las principales amenazas son los bacilos gramnegativos productores de \u03b2-lactamasas de espectro extendido, AmpC o carbapenemasas, Staphylococcus aureus resistente a meticilina y Enterococcus faecium resistente a vancomicina. Para hacer frente a este problema, es fundamental establecer programas de optimizaci\u00f3n en el uso de antimicrobianos espec\u00edficos para pediatr\u00eda, realizar una vigilancia epidemiol\u00f3gica activa y desarrollar una adecuada pol\u00edtica de control de infecciones. Su abordaje terap\u00e9utico es, a menudo, complejo y multidisciplinar, y precisa frecuentemente del uso de antibi\u00f3ticos menos empleados. En este documento de posicionamiento, elaborado por la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda y la Sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica, se revisa la epidemiolog\u00eda y el tratamiento de estas infecciones siguiendo la mejor evidencia disponible.\nA few years ago we were all confronted by an increase in cases of scarlet fever and a number of cases of more invasive and severe Streptococcal infections. It was interesting to read that due to a very well established global surveillance system, this raise in Streptococcal pyogenes (S pyogenes) infections has been described in detail by Lynsky NN et al . [Lancet Infect Dis 2019; 19: 1209\u201318\n[http://dx.doi.org/10.1016/S1473-3099(19)30446-3](http://dx.doi.org/10.1016/S1473-3099(19)30446-3)] First, this is a great paper on scarlet fever and is a very interesting historical review. Up until the beginning of the 20th century it was associated a significant mortality. Long before the use of antibiotics, the incidence and severity of scarlet fever started to fall, the reason for this remains unexplained. Scarlet fever notifications in England in the period 2014\u201318 have been the highest seen since 1960. It is possible that the streptococcal bacteria causing the disease might have undergone a pathogenetic change and this led to a reduction in the invasive and more severe sequelae of the illness.\nThe Archivist discovered that S pyogenes can be serotyped or genotyped on the basis of the M antigen, which is encoded by the emm gene. Changes in disease incidence can be characterised by expansion of specific emm genotypes. This study provided a molecular explanation for the association between increased incidence of scarlet fever and increased incidence of invasive S pyogenes infections. The team identified an emergent lineage of M1T1 S pyogenes (M1UK) that expanded rapidly to become the largest single contributor to both non-invasive and invasive infections in 2016. When you review the historical epidemics, it is interesting to speculate that this molecular explanation was the cause of the epidemic waves . Variations in strain pathogenicity as well as the general population susceptibility both have an influence. I found it valuable to realise that genomic analysis confirmed that the strains that cause scarlet fever are no different to those that cause streptococcal pharyngitis and rarer invasive infections. The data highlight that group A streptococcal lineages can differ in pathogenicity.\nThis group analysed changes in S pyogenes emm genotypes, and notifications of scarlet fever and invasive disease in 2014\u201316 using regional and national data. Genomes of 135 non-invasive and 552 invasive emm1 isolates from 2009 to 2016 were analysed and compared with 2800 global emm1 sequences. Coincident with national increases in scarlet fever and invasive disease notifications, emm1 S pyogenes upper respiratory tract isolates increased significantly. Sequences of emm1 isolates from 2009 to 2016 showed emergence of a new emm1 lineage (designated M1UK)\u2014with overlap of pharyngitis, scarlet fever, and invasive M1UK strains\u2014which could be genotypically distinguished from pandemic emm1 isolates (M1global) by 27 single-nucleotide polymorphisms. Phylogenetic analysis of published datasets identified single M1UK isolates in Denmark and the USA. The expanded reservoir of M1UK and recognised invasive potential of emm1 S pyogenes provide plausible explanation for the increased incidence of invasive disease, and rationale for global surveillance.\nMany more patients are labeled as penicillin-allergic than actually are allergic. The label should be analyzed with skin testing and test exposure. Patients with true penicillin allergy can be desensitized with a slow-escalation protocol under physician observation.\nReview question(s)\nHow effective or harmful are different HPV vaccine schedules (i.e. number and timing of doses) and different HPV vaccines in females and males?\nMain results\nThese results are based on research evidence to 27 September 2018. We analysed 20 studies involving 31,940 people.\nStudies comparing two doses of HPV vaccine to three doses, or comparing the time interval between doses, focus on immune system responses rather than infection or disease outcomes. Two doses of HPV vaccine result in similar immune system responses to three doses, and a longer interval (up to 12 months) between doses gives a stronger immune system response than a shorter interval. There is insufficient evidence to determine whether there was a difference between the vaccine schedules for serious adverse events and death.\nIn 16- to 26-year-old men, one study showed evidence of moderate certainty that a quadrivalent HPV vaccine provides better protection against external genital lesions and genital warts than a dummy treatment (control). In 16- to 26-year-old women, one study showed that the nonavalent and quadrivalent vaccines provide the same levels of protection against cervical, vaginal, and vulval precancer lesions and cancer (high-certainty evidence).\nThere was evidence that the quadrivalent vaccine resulted in more local adverse events (such as pain, swelling, and redness at the injection site) than a control treatment in males, and that the nonavalent vaccine resulted in more local adverse events than the quadrivalent vaccine in males and females. Evidence about serious adverse events and deaths from studies comparing different HPV vaccine types or dose schedules was of low or very low-certainty.\nIn people living with HIV, HPV vaccines result in reasonable levels of immune system response, but evidence about their effects on persistent HPV infection or HPV-related disease outcomes and harms is limited.\nResumen: revisi\u00f3n sistem\u00e1tica que incluye datos de 8 a\u00f1os de seguimiento y m\u00e1s de 80 millones de personas vacunadas frente al VPH. Los resultados muestran una evidencia contundente del impacto de la vacunaci\u00f3n en la infecci\u00f3n genital por VPH, en las lesiones CIN2 en mujeres y en la verruga genital en hombres y mujeres. Adem\u00e1s, los programas con m\u00e1s amplia cobertura vacunal tienen mayor efecto directo en la prevenci\u00f3n, as\u00ed como mejor inmunidad de grupo.\nReview question\nWe reviewed the evidence about the effect of treatments aimed at reducing S. aureus on the skin in people with atopic eczema. Eligible comparisons were similar treatments without anti-S. aureus actions. We included 41 studies involving 1753 participants (evidence is current to October 2018).\nStudy characteristics\nIncluded studies assessed a range of treatments, which they compared with placebos (an identical but inactive treatment), no treatment, other treatment, vehicle (inactive ingredient(s) which help deliver an active treatment), or textile without the anti-S.aureus component.\nStudies were conducted worldwide, and included males and females. Twelve studies recruited children; four, adults; 19, both; and six were unclear; where reported, the average participant age ranged from 1.1 to 34.6 years. Eczema severity varied from mild to severe. Treatment durations ranged from 10 minutes to 3 months; total study durations, from 15 weeks to 27 months.\nKey results\nOutcomes were measured from treatment start. We classed outcomes as short-term when treatment duration was less than four weeks, and long-term when treatment was given for more than four weeks.\nPeople may be more likely to experience slightly increased short-term improvement with topical steroid/antibiotic combinations than with steroid only (low-quality evidence, one study of infected eczema and two studies with unspecified infection). There is probably little or no difference between the combination group and the steroid only groups in short-term impact on quality of life (QoL) (moderate-quality evidence, one study of infected children). Antibiotic resistance was similar between groups in the long term, but we are uncertain of this result due to very low-quality evidence (one study of infected children).\nWhen compared to placebo, oral antibiotics may make no difference to short-term improvement (low-quality evidence, two studies: one in uninfected infants and children; the other in mainly infected infants and children). For short-term QoL, there is probably little or no difference between the groups (moderate-quality evidence, one study of infected infants and children). Short-term antibiotic resistance was similar in both groups, but we are uncertain if there is a true difference as the quality of evidence was very low (two studies of infants and children, infected in one study and uninfected in the other).\nBleach baths may make no difference to short-term improvement when compared to placebo (low-quality evidence, one study of uninfected participants). There is also probably little or no difference in short-term QoL in children of unspecified infective status (one study; moderate-quality evidence); based on the same study, we are uncertain if short-term antibiotic resistance was different between groups (very low-quality evidence).\nSide effects bad enough to stop treatment were rare in all studies; however, evidence was very low quality in all three comparisons, so we are uncertain whether there is a difference between groups. Assessment ranged from six days to two months, participants included children and adults with mixed infective status, and causes of withdrawal included worsening of eczema or itch and loose stools.\nParticipants in the topical steroid/antibiotic combination group experienced fewer minor side effects than those given steroids alone. Comparing oral antibiotics to placebo, participants experienced equally low numbers of minor side effects. However, we are uncertain if their are true differences between groups due to very low-quality evidence. Based on short-term assessment of mixed participants (children and adults, with mixed infective status), reported side effects included sickness, diarrhoea, stomach/joint pains, and itching. For bleach baths versus placebo, some long-term minor side effects (burning/stinging, dry skin) were reported in both groups, so there may be no difference between treatment groups (low-quality evidence, uninfected participants (2 to 30 years).\nIn this review we included randomized controlled trials in infants and young children that evaluated a monovalent rotavirus vaccine (RV1; Rotarix, GlaxoSmithKline) or a pentavalent rotavirus vaccine (RV5; RotaTeq, Merck).\nWe found 55 relevant studies with 216,480 participants. The trials took place in several locations worldwide. These studies compared a rotavirus vaccine versus placebo or versus no vaccine for infants and young children. The vaccines tested were RV1 (36 trials with 119,114 participants), RV5 (15 trials with 88,934 participants), and Rotavac (four trials with 8432 participants). Fifty-one studies were funded or co-funded by vaccine manufacturers, while four were independent of manufacturer funding.\nIn the first two years of life, RV1:\n\u25cfprevents more than 80% of severe cases of rotavirus diarrhoea in countries with low death rates (high-certainty evidence) \u25cfprevents 35% to 63% of severe rotavirus diarrhoea in countries with high death rates (high-certainty evidence) \u25cfprobably prevents 37% to 41% of severe cases of diarrhoea from all causes (such as any viral infection, bacterial infection, or parasitic infection) in countries with low death rates (moderate-certainty evidence) \u25cfprobably prevents 18% to 27% of severe cases of diarrhoea from all causes in countries with high death rates (moderate- to high-certainty evidence).\nIn the first two years of life, RV5:\n\u25cfprobably prevents 82% to 92% of severe cases of rotavirus diarrhoea in countries with low death rates (moderate-certainty evidence) \u25cfprevents 41% to 57% of severe cases of rotavirus diarrhoea in countries with high death rates (high-certainty evidence) \u25cfprobably prevents 15% of severe cases of diarrhoea from all causes in countries with high death rates (moderate- to high-certainty evidence); we did not identify any studies that reported on diarrhoea from all causes in countries with low death rates.\nIn the first two years of life, Rotavac:\n\u25cfprobably prevents more than 50% of severe cases of rotavirus diarrhoea in India, a country with high death rates (moderate-certainty evidence) \u25cfprobably prevents 18% of severe cases of diarrhoea from all causes in India (moderate-certainty evidence).\nRotavac has not been evaluated in a randomized controlled trial in a country with low death rates.\nWe found little or no difference in the number of serious adverse events (moderate- to high-certainty evidence), or intussusception cases (low- to very low-certainty evidence), between those receiving RV1, RV5, or Rotavac compared with placebo or no intervention. OK\nThe Pediatric Infectious Disease Journal. 38(12):e332-e335, December 2019.\nUrinary tract infections (UTIs) are usually caused by Gram-negative Enterobacteriaceae, the most common pathogens being Escherichia coli and Klebsiella pneumoniae.1,2 Antimicrobial resistance is increasing among uropathogens and the production of \u03b2-lactamases is a major resistance mechanism.3 Extended spectrum \u03b2 lactamases (ESBLs) producing pathogens exhibit resistance not only to newer \u03b2-lactams, including third generation cephalosporins and monobactams, but also to other classes of antibiotics.3,4 ESBL resistance genes are located on plasmids which are transferrable to other strains, thus posing considerable infection control issues.3,4 UTIs caused by ESBL-producing E. coli and K. pneumoniae are the most common ESBL infections in childhood.5 Herein, we summarize available data on these pathogens with a focus on treatment choices.\nCasos cl\u00ednicos\nRhabdomyolysis Associated With Primary Human Herpesvirus-6 InfectionMurakami, Ryunosuke; Adachi, Shunichi; Koga, Hiroshi Less . The Pediatric Infectious Disease Journal. 38(12):e341, December 2019.\n[Congenital Syphilis](https://www.nejm.org/doi/full/10.1056/NEJMicm1904420) N Engl J Med 2019; 381:2157 DOI: 10.1056/NEJMicm1904420\nA 6-month-old girl whose parents had recently received a diagnosis of syphilis was referred for evaluation after testing suggested that she also had syphilis. Physical examination revealed frontal bossing and a soft-tissue perirectal mass. A biopsy specimen was positive for spirochetes on immunostaining.\nWe were interested to read the report by So et al\n[1](https://adc.bmj.com/content/104/12/1237#ref-1) describing an infant who was unwell prior to receiving their first set of primary immunisations (including the four-component meningococcal B vaccine 4CMenB; Bexsero; GSK Biologicals) and was subsequently diagnosed with meningococcal group W meningitis shortly after vaccination. The authors highlight factors that would not have been consistent with an adverse event following immunisation (AEFI), namely the onset of fever prior to immunisation and the presentation with focal seizures, which is rare following 4CMenB vaccination, even when administered concurrently with routine immunisations. [2](https://adc.bmj.com/content/104/12/1237#ref-2) Such a severe clinical presentation should warrant additional investigations and the very high blood C reactive protein (CRP) level and very abnormal cerebrospinal fluid (CSF) findings (1000 white blood cells (WBC), protein 1750 mg/dL and glucose <0.3 mmol/L) would also have been inconsistent with an AEFI.\nWe would however, like to report our experience of three cases of aseptic meningitis following primary immunisation (including 4CMenB) in infants. All three presented with fever and irritability within 24 hours of vaccination, had a full septic screen including lumbar puncture and received empiric intravenous antibiotics (\n[table 1](https://adc.bmj.com/content/104/12/1237#T1)). Subsequent bacterial cultures were all negative as was PCR testing of CSF for meningococcus, pneumococcus and common viral causes of meningitis (enterovirus, parechovirus, herpes simplex and varicella zoster). Antibiotics were stopped after 36\u201348 hours, when bacterial cultures were reported negative.\nPara profundizar\nTo characterize the incidence of adverse events (AEs) associated with antibiotics used to treat acute otitis media in children.\nWe searched MEDLINE for studies conducted between January 1, 1966, and August 25, 2018. Two authors independently assessed potential studies and extracted the data. We included published randomized controlled trials, cross-sectional studies, and cohort studies that evaluated the incidence of diarrhea, generalized rash, diaper rash, and candidal diaper dermatitis associated with the use of amoxicillin, amoxicillin/clavulanate, azithromycin, cefdinir, and placebo in children with acute otitis media.\nRESULTS: We included 82 studies in the meta-analysis. The incidence of diarrhea, listed from lowest to highest, was azithromycin (2.2%), placebo (6.9%), low-dose amoxicillin (8.7%), cefdinir (13.0%), high-dose amoxicillin (13.8%), and high-dose amoxicillin/clavulanate (18.9%). The incidence of generalized rash, listed from lowest to highest, was azithromycin (1.4%), placebo (2.3%), low-dose amoxicillin (2.9%), high-dose amoxicillin/clavulanate (4.9%), and high-dose amoxicillin (6.5%). In studies of low-dose amoxicillin, we found a higher incidence of diarrhea in studies that used daily diaries to collect information about diarrhea and a lower incidence of generalized rash in studies that reported only rashes judged to be secondary to antibiotic use.\nCONCLUSIONS: The incidence of AEs varies widely depending on which antibiotic is used and how the information on AEs was collected or reported. The AEs rates reported here may be helpful to clinicians when choosing an antibiotic to treat acute otitis media.\nDe los 196 ni\u00f1o/as de <12 meses estudiados: en el primer mes, el 20% (5 de 25) de los beb\u00e9s ten\u00edan anticuerpos por debajo del umbral de protecci\u00f3n, que aument\u00f3 al 92% (22 de 24) en 3 meses. A los 6 meses, todos los beb\u00e9s ten\u00edan t\u00edtulos por debajo del umbral de protecci\u00f3n. En un an\u00e1lisis multivariable, la edad del lactante fue el predictor m\u00e1s fuerte de susceptibilidad (odds ratio = 2.13 por cada aumento adicional de mes; intervalo de confianza del 95%: 1.52-2.97).\nCONCLUSIONES: La mayor\u00eda de los lactantes eran susceptibles al sarampi\u00f3n a los 3 meses de edad en este entorno. Nuestros hallazgos informan sobre la importancia del debate de pol\u00edtica vacunal relacionada con el momento ideal de la primera dosis de la vacuna de sarampi\u00f3n y las recomendaciones de profilaxis posexposici\u00f3n infantil.\nLas recomendaciones actuales del Comit\u00e9 Asesor sobre Pr\u00e1cticas de Inmunizaci\u00f3n permiten la vacunaci\u00f3n contra el sarampi\u00f3n a los 6 meses para los beb\u00e9s que planean viajar internacionalmente, los beb\u00e9s con riesgo continuo de exposici\u00f3n durante los brotes de sarampi\u00f3n y como profilaxis postexposici\u00f3n.\nResumen: revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis de estudios que incluyen vacunas que contienen virus atenuado del sarampi\u00f3n y su eficacia. Obtienen 56 estudios de cuyo an\u00e1lisis concluyen que la administraci\u00f3n de vacuna de virus atenuado del sarampi\u00f3n por debajo de los 9 meses, induce una buena respuesta inmunitaria, si bien, la seroconversi\u00f3n es m\u00e1s probable a m\u00e1s meses tenga el ni\u00f1o. Adem\u00e1s la vacuna se muestra segura. Plantea que se cambie la recomendaci\u00f3n de vacunar solo por encima de esa edad y proponen que se recomiende la vacunaci\u00f3n, independientemente de la edad, en situaciones de alto riesgo.\nResumen: A partir de 13 estudios recuperados en una revisi\u00f3n sistem\u00e1tica analizan la respuesta serol\u00f3gica al sarampi\u00f3n tras la vacuna triple v\u00edrica (2 dosis) en pacientes que hab\u00edan recibido una dosis de vacuna frente antes de los 9 meses de edad. Los resultados muestran alta seropositividad, alta efectividad vacunal y alta respuesta de c\u00e9lulas T, independientemente de la edad a la que se puso la vacuna anterior a los 9 meses. No obstante, en uno de los estudios la media geom\u00e9trica de los t\u00edtulos de anticuerpos fue significativamente m\u00e1s baja en los que hab\u00edan recibido una dosis previa a los 9 meses de edad. Pero para los autores (y es un estudio financiado por la OMS) los resultados refuerzan la recomendaci\u00f3n de utilizar la vacuna frente al sarampi\u00f3n en menores de 9 meses en situaciones de riesgo.\nSe analizan las reacciones adversas del VAERS (Vaccine Adverse Event Reporting System) de 7244 reports\nCONCLUSIONES:\nNo se detectaron problemas de seguridad nuevos o inesperados o patrones de notificaci\u00f3n de 9vHPV con efectos adversos cl\u00ednicamente importantes. El perfil de seguridad de 9vHPV es consistente con los datos de los ensayos previos a la licencia y de los datos de seguridad posteriores a la comercializaci\u00f3n de su predecesor, la vacuna contra el virus del papiloma humano tetravalente.\nHuman papillomavirus (HPV) vaccination coverage (48.6% in 2017) in the United States remains far below the Healthy People 2020 goal of 80%, and a 10% difference in coverage between boys (44.3%) and girls (53.1%) has been reported.1 Knowledge of HPV among vaccine-eligible individuals and their parents is critical to vaccine uptake. Furthermore, the recommendation to receive an HPV vaccine from health care professionals can help parents in their decision-making to vaccinate children.2 Therefore, we evaluated the national-level estimates of (1) HPV knowledge and (2) receipt of HPV vaccine recommendation from a health care professional.\nResumen: La eficacia de la vacuna contra el rotavirus es menor y disminuye m\u00e1s r\u00e1pidamente en entornos de alta mortalidad que en entornos de baja mortalidad, pero la edad m\u00e1s precoz de las formas graves de la enfermedad en entornos de alta mortalidad significa que las vacunas vivas contra el rotavirus oral a\u00fan pueden proporcionar beneficios sustanciales.\nIntroducci\u00f3n\nObjetivo principal: describir las caracter\u00edsticas cl\u00ednicas y epidemiol\u00f3gicas de los pacientes con EMI. Objetivos secundarios: describir las diferencias entre ni\u00f1os y adultos, factores pron\u00f3sticos y cambios epidemiol\u00f3gicos en los \u00faltimos 14 a\u00f1os.\nM\u00e9todos: Estudio retrospectivo realizado en un hospital terciario. Se incluyeron los pacientes diagnosticados de EMI entre 2004 y 2017, recogi\u00e9ndose datos epidemiol\u00f3gicos, cl\u00ednicos y microbiol\u00f3gicos.\nResultadosFueron diagnosticados 84 pacientes con EMI, 50 (59,5%) ni\u00f1os. Edad mediana en ni\u00f1os 2 a\u00f1os (RIC: 0,7-7,5) y adultos 41,2 a\u00f1os (RIC: 26,4-69,3). Bacteriemia en 47 casos (56%), meningitis en 24 (28,6%) y ambas en 13 (15,5%). Predominio del serogrupo B (MenB), en el 40,5%, seguido del serogrupo C (MenC), en el 15,5%, con mayor proporci\u00f3n de MenC en adultos (26,5 vs. 8%; p=0,022). Disminuci\u00f3n en la incidencia de 2004-2010 a 2011-2017, pasando de 3,14 a 1,33 casos/100.000 urgencias en el centro de estudio (p<0,001). El 84% de los ni\u00f1os hab\u00eda recibido\u22651 dosis de vacuna frente a MenC, ninguno frente a MenB. Mayor proporci\u00f3n de ingreso en UCI en ni\u00f1os (78 vs. 44,1%; p=0,001). Tendencia a mayor letalidad en adultos (11,8 vs. 2%; p=0,153). La intubaci\u00f3n y la trombocitopenia fueron factores de riesgo independientes de desenlace adverso, y la leucopenia y el exantema purp\u00farico de gravedad.\nConclusiones Se objetiv\u00f3 un descenso en la incidencia de EMI, siendo MenB el mayoritario. El mayor porcentaje de MenC en adultos probablemente est\u00e9 relacionado con una menor cobertura vacunal. La trombocitopenia, la leucopenia y el exantema purp\u00farico fueron factores de riesgo relacionados con peor pron\u00f3stico.\nKingella kingae fue el pat\u00f3geno aislado con mayor frecuencia, responsable del 51% de las infecciones osteoarticulares (IOA), mientras que otros pat\u00f3genos cl\u00e1sicos fueron responsables del 39,7% de los casos en la cohorte molecular. Se observ\u00f3 un aumento estad\u00edsticamente significativo en la incidencia media de IOA, as\u00ed como una disminuci\u00f3n en la edad media en el momento del diagn\u00f3stico despu\u00e9s de 2007.\n[The Volume of Pediatric Blood Culture](https://journals.lww.com/pidj/Fulltext/2019/12000/The_Volume_of_Pediatric_Blood_Culture.31.aspx)Kusama, Yoshiki; Shime, Nobuaki; Ito, Kenta; Ito, Yusuke; Kasai, Masashi Less . The Pediatric Infectious Disease Journal. 38(12):e340-e341, December 2019.\nBackground\nBloodstream infections (BSIs) are a major cause of morbidity and mortality in paediatric patients. For fast and accurate diagnosis, blood culture (BC) is the reference standard. However, the procedure for blood sampling in paediatric patients, particularly the optimal blood volume, is the subject of controversy stemming from a lack of knowledge of the bacterial load and because of several obstacles such as low intravascular volume and the risk of causing anaemia.\nThe Pediatric Infectious Disease Journal. 38(12):1163-1167\nBACKGROUND: The objective is to compare the prevalence of serious bacterial infection (SBI) and invasive bacterial infection (IBI) in febrile infants <60 days of age and in those between 61 and 90 days.\nMETHODS: Prospective registry-based cohort study including all the infants \u226490 days with fever without a source evaluated in a pediatric emergency department between 2003 and 2017. We compared the prevalence of SBI and IBI in febrile infants <60 days of age and those between 61 and 90 days.\nRESULTS: We included 3,301 infants. Overall, 605 (18.3%) had a SBI (mainly urinary tract infection), of these 81 (2.5%) had an IBI (bacteremia 60, meningitis 12, sepsis 9). The prevalence of SBI in infants >60 days old was 18.5% (95% CI: 16.4-20.7) versus 16.6% (95% CI: 14.7-18.7; n.s.) in those between 29 and 60 days and versus 21.5% (95% CI: 18.6-24.7; n.s.) in those <28 days of age. The prevalence of IBI among infants >60 days old was 1.1% (95% CI: 0.6-2.2) versus 2.3% (95% CI: 1.6-3.3; P < 0.05) in those between 29 and 60 days and 5.1% (95% CI: 3.7-7.0; P < 0.05) in those <28 days of age. The prevalence of IBI in well appearing >60 days was 1.0% (versus 4.5% in those <28 days old, P < 0.01; and 2.0% in those between 29 and 60 days, P = 0.06). All bacterial meningitis, except one, were diagnosed in infants <28 days.\nCONCLUSIONS: The prevalence of IBI in febrile infants between 61 and 90 days of age is high enough to support the recommendation for obtaining urine and blood tests in this population.\nIMPORTANCE: The neonatal early-onset sepsis (EOS) calculator is a clinical risk stratification tool increasingly used to guide the use of empirical antibiotics for newborns. Evidence on the effectiveness and safety of the EOS calculator is essential to inform clinicians considering implementation.\nOBJECTIVE: To assess the association between management of neonatal EOS guided by the neonatal EOS calculator (compared with conventional management strategies) and reduction in antibiotic therapy for newborns.\nDATA SOURCES: Electronic searches in MEDLINE, Embase, Web of Science, and Google Scholar were conducted from 2011 (introduction of the EOS calculator model) through January 31, 2019.\nSTUDY SELECTION: All studies with original data that compared management guided by the EOS calculator with conventional management strategies for allocating antibiotic therapy to newborns suspected to have EOS were included.\nDATA EXTRACTION AND SYNTHESIS: Following PRISMA-P guidelines, relevant data were extracted from full-text articles and supplements. CHARMS (Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies) and GRADE (Grades of Recommendation, Assessment, Development and Evaluation) tools were used to assess the risk of bias and quality of evidence. Meta-analysis using a random-effects model was conducted for studies with separate cohorts for EOS calculator and conventional management strategies.\nMAIN OUTCOMES AND MEASURES: The difference in percentage of newborns treated with empirical antibiotics for suspected or proven EOS between management guided by the EOS calculator and conventional management strategies. Safety-related outcomes involved missed cases of EOS, readmissions, treatment delay, morbidity, and mortality.\nRESULTS: Thirteen relevant studies analyzing a total of 175 752 newborns were included. All studies found a substantially lower relative risk (range, 3%-60%) for empirical antibiotic therapy, favoring the EOS calculator. Meta-analysis revealed a relative risk of antibiotic use of 56% (95% CI, 53%-59%) in before-after studies including newborns regardless of exposure to chorioamnionitis. Evidence on safety was limited, but proportions of missed cases of EOS were comparable between management guided by the EOS calculator (5 of 18 [28%]) and conventional management strategies (8 of 28 [29%]) (pooled odds ratio, 0.96; 95% CI, 0.26-3.52; P = .95).\nCONCLUSIONS AND RELEVANCE: Use of the neonatal EOS calculator is associated with a substantial reduction in the use of empirical antibiotics for suspected EOS. Available evidence regarding safety of the use of the EOS calculator is limited, but shows no indication of inferiority compared with conventional management strategies.\nIt has been almost 20 years since the first conjugated pneumococcal vaccine (PCV) was introduced into childhood immunization schedules in the United States. Dramatic reductions in invasive pneumococcal disease (IPD) burden have been reported not only among children targeted for vaccination but also among unvaccinated children and adults in all settings following widespread use of the vaccine. These reductions are associated with reductions in nasopharyngeal colonization by vaccine serotypes and reduced transmission from vaccinated children.1 However, disease is not evenly distributed, and children with underlying clinical conditions are disproportionately represented among cases of IPD, especially among children older than 5 years.\nEste articulo muestra los resultados de un Ensayo cl\u00ednico en Fase III de la vacuna tetravalente contra el dengue ( TAK-003) realizado en regiones de Asia y Sudam\u00e9rica donde la enfermedad es end\u00e9mica. Concluye que la vacuna se ha mostrado eficaz en esas circunstancias.\nLas infecciones f\u00fangicas invasoras (IFI) constituyen un problema creciente en adultos y ni\u00f1os inmunodeprimidos, acompa\u00f1\u00e1ndose de una elevada morbimortalidad. El n\u00famero de ni\u00f1os inmunodeprimidos va en aumento. Los grupos de riesgo de IFI en pediatr\u00eda incluyen a los grandes prematuros, que se benefician de profilaxis con fluconazol, pacientes hemato-oncol\u00f3gicos sometidos a quimioterapia o trasplante de precursores hematopoy\u00e9ticos con neutropenias prolongadas, en quienes la profilaxis frente a hongos filamentosos suele recomendarse en situaciones de alto riesgo. En ni\u00f1os sometidos a trasplante de \u00f3rgano s\u00f3lido, la profilaxis depende del tipo de trasplante y factores de riesgo asociados. En pacientes con inmunodeficiencias primarias o adquiridas como la infecci\u00f3n VIH o tratamiento inmunosupresor prolongado, la profilaxis antif\u00fangica depender\u00e1 del tipo de inmunodeficiencia primaria y del grado de inmunosupresi\u00f3n. La enfermedad granulomatosa cr\u00f3nica tiene riesgo particularmente elevado de IFI y requiere siempre profilaxis frente a hongos filamentosos. En cambio, en ni\u00f1os con ingresos prolongados en cuidados intensivos la profilaxis frente a IFI habitualmente no est\u00e1 indicada. El tipo de profilaxis est\u00e1 limitado por la diferente aprobaci\u00f3n de antif\u00fangicos a distintas edades. Este documento pretende revisar la informaci\u00f3n actual disponible respecto a profilaxis antif\u00fangica en ni\u00f1os, con propuesta para la estrategia m\u00e1s apropiada en cada tipo de paciente.\nQuestion What is the frequency of primary immunodeficiency in children with invasive pneumococcal disease since the availability of pneumococcal vaccine?\nFindings In this systematic review of 17 studies that included 6022 unique patients with primary invasive pneumococcal disease, children older than 2 years without a known predisposing condition presenting with their first episode of Streptococcus pneumoniae meningitis or pneumonia or recurrent invasive pneumococcal disease had rates of primary immunodeficiency as high as 26%.\nMeaning This study\u2019s findings suggest that immune evaluation may need to be considered in all children older than 2 years presenting with invasive pneumococcal disease, including assessment for immunoglobulin deficiency, specific antibody deficiency, complement disorders, and asplenia.\nAbstract Importance Despite increasing access to vaccination, invasive pneumococcal disease (IPD) is responsible for approximately 826 000 deaths worldwide in children younger than 5 years each year. To allow early identification and prevention, an improved understanding of risk factors for IPD is needed.\nObjectives To review the literature on the prevalence of primary immunodeficiency (PID) in children younger than 18 years presenting with IPD without another predisposing condition and to inform guidelines for immunologic evaluation after the first episode of IPD based on published evidence.\nFindings In 6022 unique children with primary IPD, 5 of 393 (1.3%) to 17 of 162 (10.5%) of all children and 14 of 53 (26.4%) of those older than 2 years had a PID identified. Higher rates of PID, up to 10 of 15 (66.7%), were found in children with recurrent IPD. Antibody deficiency was the most common immunodeficiency, followed by complement deficiency, asplenia, and rarer defects in T-cell signaling. The site of infection was a key indicator for the risk of underlying PID, with the greatest risk of PID in children with meningitis or complicated pneumonia.\nConclusions and Relevance Results of this study suggest that invasive pneumococcal disease, and particularly recurrent IPD, is an important marker of underlying PID in children without other risk factors. The findings also suggest that children older than 2 years with pneumococcal meningitis or complicated pneumonia and all children with recurrent IPD should be referred for an immune evaluation.\nThe Pediatric Infectious Disease Journal. 38(12):1168-1172, December 2019.\nOBJECTIVES: To perform a comprehensive description of the epidemiology of Streptococcus pyogenes invasive disease in the pediatric population in 2 regions of Spain (Catalonia and Gipuzkoa) through 12 years.\nMETHODS: All S. pyogenes isolates causing invasive disease in pediatric patients between 2005 and 2016 were included. The emm-type and the presence of 13 exotoxin genes (speA, speB, speC, speF, speG, speH, speI, speJ, speK, speL, speM, smeZ, ssa and slo) were determined in all 93 available isolates and the Multi Locus Sequece Typing in 10% of isolates of each different emm-type.\nRESULTS: Overall, 103 cases of S. pyogenes invasive infections were detected: 77 in Catalonia and 26 in Gipuzkoa, being 50.5% females. The incidence rate per 100,000 children was 2.5 for Gipuzkoa and 2.6 for Catalonia, with no significant temporal trends. The median age was 30 months. The most frequent clinical presentations were: pneumonia (26.2%), bacteremia/sepsis (23.3%), septic arthritis/osteomyelitis (22.3%), cellulitis/mastoiditis (12.6%) and meningitis (6.8%). Eight children developed streptococcal toxic shock syndrome. Nine cases were preceded by varicella infection. The associated mortality rate was 3.9%. Three isolates were resistant to erythromycin, being one of them also resistant to clindamycin and 4 isolates were resistant to levofloxacine. Forteen different emm-types were detected being emm1/ST28 (40.9%) the most frequent clone in both regions followed by emm12/ST36-ST242, emm6/ST382, emm3/ST15, emm75/ST150 and emm4/ST38-39. speA gene was only detected in emm1 and emm3 isolates. Eight exotoxins were enough to assign an emm-type with a very high degree of accuracy (95%). The 30-valent vaccine would include 96.8% of isolates.\nTo describe the rate and risk factors of deep neck space involvement of Kawasaki disease. Study design We performed a retrospective analysis using the Kids' Inpatient Database from 2006, 2009, 2012, and 2016. Kawasaki disease and deep neck space involvement cases were identified using International Classification of Diseases codes among children aged <12 years. Demographic and outcome data of Kawasaki disease cases with and without deep neck space involvement were compared.\nResults Of 20 787 patients with Kawasaki disease, 0.6% (130 cases) had deep neck space involvement. On multivariable analysis, children aged \u22654 years (OR 8.41; 95% CI 3.79-18.7 in those aged 6-11 years), Asian or Pacific Islanders (OR 3.72; 95% CI 1.90-7.27), non-Hispanic black children (OR 2.39; 95% CI 1.34-4.28), and Northeast hospital region (OR 2.32; 95% CI 1.21-4.46) were associated with deep neck space involvement. Surgical drainage was performed in 21.7% of patients with deep neck space involvement. Deep neck space involvement was associated with longer hospital stay and greater costs.\nConclusions. Approximately 0.6% of patients with Kawasaki disease present with deep neck space involvement in the US. Deep neck space involvement of Kawasaki disease occurs primarily in older (\u22654 years old), non-white, non-Hispanic children. Deep neck space involvement is associated with operative procedures for presumed abscess, longer hospital stay, and greater costs. In caring for children with suspected deep neck space abscess, particularly when they are not responding to antibiotics, clinicians should evaluate them for the possibility of Kawasaki disease.\nResumen: la introducci\u00f3n en calendario de la vacuna decavalente neumoc\u00f3cica conjugada en Kenia, acompa\u00f1ada de una campa\u00f1a de recuperaci\u00f3n, dio como resultado una sustancial reducci\u00f3n de enfermedad neumoc\u00f3cica invasiva en ni\u00f1os y adultos sin que se haya detectado remplazamiento significativo de otros neumococos productores de enfermedad invasiva.\nResumen: la disminuci\u00f3n r\u00e1pida de la inmunidad durante los primeros a\u00f1os despu\u00e9s de la vacunaci\u00f3n por encima de los 9 meses de edad da soporte a una revisi\u00f3n de la recomendaci\u00f3n de dosis \u00fanica para esta poblaci\u00f3n objetivo en pa\u00edses end\u00e9micos. La corta duraci\u00f3n de la inmunidad en muchos vacunados sugiere que la vacuna de refuerzo es necesaria para alcanzar el umbral de inmunidad de la poblaci\u00f3n del 80% para la prevenci\u00f3n de brotes de fiebre amarilla.\nThe Pediatric Infectious Disease Journal. 38(12):e320-e325, December 2019.\nBACKGROUND: The impact of universal 13-valent pneumococcal conjugate vaccine immunization on pediatric empyema rates and pathogens in Australia is not known. We aimed to describe empyema epidemiology, clinical characteristics and treatment during an 8-year period.\nMETHODS: A retrospective study between 2011 and 2018 of empyema cases admitted to a large pediatric referral hospital, for management with either pleural drainage and fibrinolytics or surgical intervention.\nRESULTS: There were 195 cases in 8 years. Empyema incidence and ICU admission rates significantly increased during the study with a peak incidence of 7.1/1000 medical admissions in 2016 (\u03c7 for trend of incidence 37.8, P < 0.001 and for ICU admissions 15.3, P < 0.001). S. pneumoniae was the most common pathogen (75/195, 39%) with serotype 3 the most detected (27/75: 27%). S. pyogenes compared with S. pneumoniae had significantly fewer days of fever before admission (3.9 vs. 6.4, mean difference 2.4, 95% CI: 0.84-4.08, P = 0.003) and higher proportion requiring direct ICU admission (6/75; 8% vs. 7/15; 47%, P < 0.001). Compared with S. pneumoniae, cases with no pathogen detected by culture or PCR had fewer days of fever post intervention (4.4 vs. 7.4 days, mean difference 2.7 days, P = 0.002). S. aureus occurred more commonly in infants (10/25; 40% vs. 1/75; 1%, P < 0.001) and children of indigenous background (5/25; 20% vs. 1/75; 1%, P < 0.001) compared with S. pneumoniae.\nCONCLUSIONS: We report increasing rates of pediatric empyema with higher proportions requiring ICU treatment. The most common pathogens detected were S. pneumoniae, S. aureus and S. pyogenes. Despite high 13-valent pneumococcal conjugate vaccine coverage, serotype 3 was the most common S. pneumoniae serotype identified.\nThe Pediatric Infectious Disease Journal. 38(12):1208-1213, Abstract\nBACKGROUND: Several studies have shown an increasing trend in pediatric Clostridium difficile infection (CDI). However, the Public Health Agency in Sweden reports a decreasing incidence of CDI in the Swedish population since 2007. The main aim of this study is to analyze the epidemiology of CDI in children.\nMETHODS: Retrospective chart-review of patients 1 to <19 years old, positive for Clostridium difficile toxin B, tested at Karolinska University Hospital Units, over the time period from July 1, 2010 to June 30, 2018. Episodes were classified as recurrences (\u22652 weeks, \u22648 weeks from previous episode) or new episodes (>8 weeks from previous episode). New episodes were classified as hospital- (HA-CDI) or community-associated (CA-CDI). Annual infection rates/100,000 children in the catchment area were calculated.\nRESULTS: Three hundred twenty-eight positive tests in 206 patients were included of which 259 (79.0%) tests were new episodes and 69 (21.0%) recurrences. In 63/206 (30.6%) children, >1 episode of CDI was recorded. The mean infection rate was 8.5/100,000 children. There was an overall increasing trend in CDI-rate July 2010-June 2018, however not statistically significant (P = 0.061) nor for the incidence in HA-CDI (P = 0.720) or CA-CDI (P = 0.179). Underlying medical conditions were present in 226/259 (87.3%) new episodes of which the most common was malignancy. Of the new episodes, 188/259 (72.6%) were HA-CDI and 46/259 (17.8%) were CA-CDI.\nCONCLUSIONS: There was an increasing trend in CDI in children in Sweden from 2010 to 2018, although not statistically significant. CDI was associated with comorbid conditions and repeated episodes were common.\nActualidad bibliogr\u00e1fica octubre 2019\nTOP TEN\nStreptococcus pneumoniae is the leading cause of bacterial infections in children, including meningitis, bacteremia, bacteremic pneumonia, empyema, and mucosal infections such as otitis media and non-bacteremic pneumonia. After the implementation of pneumococcal conjugate vaccines (PCVs), worldwide, the burden of invasive pneumococcal diseases (IPDs) and non-invasive pneumococcal diseases due to vaccine serotypes (VTs) greatly decreased in children.\n[1] However, since 2015, several European countries have reported an increased incidence of IPDs due to non-vaccine serotypes (NVTs), which seemed variable across countries in terms of magnitude, serotypes involved, and clinical entities. [1], [2], [3], [4] This led to questions regarding the long-term benefit of PCVs.\nThis commentary presents an overview of serotype replacement in pneumococcal carriage and diseases in Europe, with a focus on IPDs. The aim is to raise awareness among pediatricians and healthcare professionals of the potential factors involved in the phenomenon of serotype replacement diversity after PCV implementation. In addition, we analyze the potential factors involved in this phenomenon. We selected European observational studies assessing the impact of PCV10 and PCV13 beyond 5 years after their implementation at the population level in children. We reviewed the literature in MEDLINE via PubMed, with no time or language restriction (last search June 30, 2019). The search algorithm was based on a combination of terms related to \u201c13-or 10-valent PCV,\u201d \u201cpneumococcal diseases or pneumococcal carriage,\u201d and \u201cimpact/effect/change.\u201d We completed this search by screening the reference lists of the selected articles.\nIn the 2017 annual report of the European Centre for Disease Prevention and Control,8 based on data from 29 European countries, when summarizing serotypes implicated in IPD in children <5 years old, serotype 24F ranked first (10.6% of cases), followed by serotypes 3 (8.5%), 12F (7.8%), 19A (7.2%), and 10A (6.9%).8\nThe frequency of pneumonia greatly decreased but not that of meningitis or bacteremia without source.9 Finally, the incidence of noninvasive pneumonia and otitis media seems not affected by the serotype replacement.19,20\nEstudio aleatorizado controlado de no inferioridad, en 17 centros de atenci\u00f3n primaria de salud en Suecia, entre septiembre de 2015 y febrero de 2018. Participaban pacientes de 6 o m\u00e1s a\u00f1os con faringoamigdalitis causada por SBHGA (cumpl\u00edan tres o cuatro criterios de Centor y una prueba r\u00e1pida de detecci\u00f3n de ant\u00edgeno positiva para el estreptococo del grupo A.). El objetivo era determinar si la exposici\u00f3n total a la penicilina V puede reducirse mientras se mantiene una eficacia cl\u00ednica adecuada.\nIntervenciones: Penicilina V 800 mg cuatro veces al d\u00eda durante cinco d\u00edas (total 16 g) en comparaci\u00f3n con la dosis actual recomendada de 1000 mg tres veces al d\u00eda durante 10 d\u00edas (total 30 g).\nPrincipales medidas de resultado: El resultado principal fue la curaci\u00f3n cl\u00ednica de cinco a siete d\u00edas despu\u00e9s del final del tratamiento con antibi\u00f3ticos. Los resultados secundarios fueron la erradicaci\u00f3n bacteriol\u00f3gica, el tiempo de alivio de los s\u00edntomas, la frecuencia de reca\u00eddas un mes despu\u00e9s del primer diagn\u00f3stico, la frecuencia de complicaciones y de faringoamigdalitis nuevas durante el per\u00edodo de estudio.\nConclusiones: La penicilina V cuatro veces al d\u00eda durante cinco d\u00edas no fue inferior en el resultado cl\u00ednico a la penicilina V tres veces al d\u00eda durante 10 d\u00edas en pacientes con faringoamigdalitis causada por SBHGA. El n\u00famero de reca\u00eddas y complicaciones no fue diferente entre los dos grupos de intervenci\u00f3n. El tratamiento de cinco d\u00edas con penicilina V cuatro veces al d\u00eda podr\u00eda ser una alternativa al r\u00e9gimen de 10 d\u00edas actualmente recomendado. OK, aunque el tratamiento recomendado no son 1000 mg 3 veces al d\u00eda, si no una vez al d\u00eda\u2026 Me parecen dosis alt\u00edsimas, tanto la que se estudia como con la que se compara\u2026 Me llama la atenci\u00f3n que la tasa de algunos efectos secundarios, los m\u00e1s frecuentes, sea m\u00e1s baja con la tasa de 5 d\u00edas. Aunque no pone si las diferencias son significativas.\nCASOS CL\u00cdNICOS\nNi\u00f1a de 9 a\u00f1os con fiebre leve durante cuatro d\u00edas y erupci\u00f3n cut\u00e1nea durante dos d\u00edas. Presenta disminuci\u00f3n de los recuentos de gl\u00f3bulos blancos, plaquetas y reticulocitos. En la reacci\u00f3n en cadena de la polimerasa cuantitativa en suero para el ADN del parvovirus B19 mostr\u00f3 10 6 copias / ml (rango de referencia: <100).\nLa erupci\u00f3n petequial localizada, como por ej. distribuci\u00f3n en traje de ba\u00f1o (figura) o el s\u00edndrome purp\u00farico-papular en guante y calcet\u00edn, puede ocurrir durante la fase inicial de la viremia, pero es inusual.\nEs prioritario descartar la enfermedad meningoc\u00f3cica.\nLa manifestaci\u00f3n m\u00e1s t\u00edpica del parvovirus B19 (erupci\u00f3n en forma de \"mejilla abofeteada\") generalmente aparece despu\u00e9s de la fase inicial de viremia.\nA 4-year-old previously healthy boy presented to the emergency department for evaluation of 5 days of fever and 6 days of diffuse pustular rash. Three days prior, he had been evaluated by his pediatrician and started on azithromycin for streptococcal infection, diagnosed by positive rapid streptococcal testing. Dermatology was consulted to evaluate for possible acute generalized exanthematous pustulosis (AGEP).\nOn examination, the patient was febrile (temperature 40.1\u00b0C). He had pustules diffusely distributed on his trunk and extremities, with confluence of lesions in the groin (\n[Figure 1](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/390657e4-dcc8-4fc4-8df3-121ecfdff579/gr1.jpg), A and B). His hands and feet were edematous, and palms and soles were erythematous. He had dry fissured lips, red strawberry tongue ( [Figure 2](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/a36d1d1c-f816-48a7-902b-e35f1c9872e5/fx1.jpg); available at [www.jpeds.com](http://www.jpeds.com/)), limbal-sparing nonexudative conjunctival injection, and cervical and inguinal lymphadenopathy. Laboratory results demonstrated sterile pyuria, normocytic anemia, hyponatremia, and elevated inflammatory markers. Based on the clinical and laboratory findings, Kawasaki disease was diagnosed. Echocardiogram revealed no structural abnormalities and normal coronary arteries. He was treated with intravenous immunoglobulin 2 g per kg and aspirin. Within 1 day of receiving intravenous immunoglobulin, his conjunctivitis resolved, and his rash improved with subsequent desquamation of involved areas. His fevers resolved over 48 hours, inflammatory markers trended downward, and he was discharged on hospital day 3. His rash had completely resolved at a 10-day follow-up visit. Repeat echocardiograms 10 days and 6 weeks later remained normal.\nA 3-year-old boy presented to the emergency department with a 5-day history of a progressive painful swelling to his scalp. He had recently returned to Australia following a 3-month vacation in East Africa. He was systemically well, with no previous medical history of note. Just before presentation, apparent movement had been noted at the punctum of the lesion, and a single larva had been expressed and removed by the patient's mother.\nExamination revealed a 10-mm-wide, nonfluctuant furuncular swelling overlying the occiput with a 5-mm-wide crusted punctum (\n[Figure 1](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/6d53df2d-1962-4848-b406-fe892ff8d54c/gr1.jpg)). There were no other cutaneous lesions, and the remainder of the examination was unremarkable. The larva ( [Figure 2](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/1c35c824-9247-4260-ba6d-6c0c68a45240/gr2.jpg)), brought in by the patient's mother, was 18 mm long and still motile ( [Video](https://www.jpeds.com/cms/10.1016/j.jpeds.2019.05.037/attachment/c661d16f-9215-4a14-98fe-c4d3b71fd82c/mmc1.mp4); available at [www.jpeds.com](http://www.jpeds.com/)).\nThe larva was identified as that of the Tumbu fly (Cordylobia anthropophaga. C. anthropophaga is a common cause of furuncular myiasis in sub-Saharan Africa.1 .\nThe Pediatric Infectious Disease Journal. 38(10):e277-e278\nWe read the article by Gordon et al\n[1](https://journals.lww.com/pidj/Fulltext/2019/10000/Fever_Without_a_Focus__A_Rare_Presentation_of.31.aspx#R1-31) regarding the clinical presentation of Pediatric Mycoplasma pneumoniae infections. In their article, the authors stated that fever accompanied 33.4% of patients, and duration of symptoms was between 3 and 9 days. Different than these findings herein 4 cases of M. pneumoniae with community-associated pneumonia presenting with fever without a focus are presented.\nFour cases of mycoplasma, between 4 and 17 years of age were admitted with prolonged fever and rash to our centers. The duration of fever was 8\u201328 days before onset of pneumonia. Signs of pneumonia (like dyspnea or retraction, rales on physical examination) and pneumonic infiltration on chest radiograph were not present at admission and all occurred after prolonged fever.\nNasopharyngeal viral multiplex polymerase chain reaction was negative but mycoplasma polymerase chain reaction was positive for all 4 patients and they all responded well to macrolide therapy. Fever was the first resolving symptom and dropped off in 24 hours of treatment.\nGordon et al also reported that children older than 6 years were more likely to have chest radiograph\u2013confirmed pneumonia, while younger children were more likely to have other respiratory manifestations. But it should be kept in mind that radiologic or physical findings might be absent and prolonged fever could be the only symptom at admission likewise in our patients.\nSigns and symptoms of M. pneumoniae infections are not unique,\nFrom July 2009 to July 2015, Staphylococcus aureus isolated from pediatric sterile sites were selected from inpatients at the Santa Casa S\u00e3o Paulo Hospital, in Brazil. Polymerase chain reaction was used to detect mecA and lukS-PV/lukF-PV genes. The rate of methicillin-resistant Staphylococcus aureus was 37.7%. Ten isolates had the lukS-PV/lukF-PV genes, 2 of which were methicillin-resistant Staphylococcus aureus. Skin and soft tissues infections were significantly associated with lukS-PV/lukF-PV positive isolates, P = 0.008.\nNi\u00f1a, 2 a\u00f1os, consulta por tumoraci\u00f3n preauricular derecha. Correctamente vacunada y sin antecedentes de inter\u00e9s. Los progenitores son procedentes de Ecuador; el padre tuvo tuberculosis pulmonar tratada correctamente hace 10 anos. EF :masa a nivel de par\u00f3tida de 0,5 cm, blanda, dolorosa y picos febriles al inicio del cuadro. Se orienta como parotiditis v\u00edrica. Serolog\u00edas negativas. Se prescriben antiinflamatorios durante una semana. Presenta empeoramiento tras 20 d\u00edas de su inicio. Ecograf\u00eda imagen polilobulada de 25 mm en la par\u00f3tida derecha y adenopat\u00edas laterocervicales y mastoideas sugestivas de proceso inflamatorio abscesificado. Se inicia amoxicilina clavul\u00e1nico sin respuesta a los 7 d\u00edas ampli\u00e1ndose estudio. El Mantoux fue positivo (12 mm). Se realiza Quantiferon que resulta negativo. Se practica PAAF con cultivo positivo para Mycobacterium malmoense. Se inicia isoniacida, rifampicina, etambutol y claritromicina. La lesi\u00f3n se confirma por resonancia magn\u00e9tica y . Se drena. Tras 9 meses de tratamiento la lesi\u00f3n se mantiene estable, realiz\u00e1ndose ex\u00e9resis quir\u00fargica . En ninos, la adenitis cervical es la afectaci\u00f3n m\u00e1s frecuente de la infecci\u00f3n por micobacterias no tuberculosas (MNT) y afecta a menores de 5 anos sin comorbilidad. El compromiso de la gl\u00e1ndula par\u00f3tida es infrecuente. Mycobacterium avium-intracellulare complex es el pat\u00f3geno m\u00e1s prevalente. En el norte de Europa M. malmoense es una de las MNT de mayor incidencia. El mecanismo de transmisi\u00f3n por MNT es a\u00fan incierto. Suelen ser lesiones unilaterales, indoloras, con evoluci\u00f3n subaguda, tendencia a la cronicidad, aumento progresivo de tama\u00f1o y formaci\u00f3n de f\u00edstulas, aunque pueden resolverse espont\u00e1neamente1-3,8. DX diferencial: adenitis bacteriana, tuberculosa, y en menor frecuencia con tumores parot\u00eddeos. La confirmaci\u00f3n diagn\u00f3stica se obtiene mediante aislamiento microbiol\u00f3gico a partir de muestras de PAAF o ex\u00e9resis quir\u00fargica. La ecograf\u00eda es la prueba de elecci\u00f3n; la TAC y la RMN est\u00e1n indicadas previas a la cirug\u00eda.m\nEL Mantoux es positivo en 30 -60% de ninos, siendo poco \u00fatil para establecer el diagn\u00f3stico diferencial con Mycobacterium tuberculosis. Sin embargo, las pruebas de medici\u00f3nde interfer\u00f3n gamma inducido (IGRA) son t\u00edpicamente negativas, La identificaci\u00f3n de MNT mediante t\u00e9cnicas de diagn\u00f3stico molecular permite el aislamiento r\u00e1pido del pat\u00f3geno, con una sensibilidad de hasta \u2265 90%. El tratamiento es controvertido. Se recomienda farmacoterapia combinada para evitar resistencias, incluyendo un macr\u00f3lido asociado a rifabutina, fluoroquinolonas o etambutol, durante un m\u00ednimo de 6 meses. La intervenci\u00f3n quir\u00fargica, en algunos estudios considerada de elecci\u00f3n, no est\u00e1 exenta de complicaciones: sobreinfecciones de la herida quir\u00fargica y lesiones neurovasculares, como par\u00e1lisis del nervio facial.\nNi\u00f1o de 2 meses , prematuro 26 + 5 semanas (35 semanas corregidas) y 757 g. Presentaba distr\u00e9s respiratorio y posible hemorragia intraventricular derecha junto con un ductus arterioso persistente, cerrado mediante cirug\u00eda. Ante un empeoramiento de su estado cl\u00ednico, se enviaron al servicio de microbiolog\u00eda muestras de piel de pericat\u00e9ter y 2 hemocultivos seriados. Los datos anal\u00edticos m\u00e1s importantes fueron: PCR 24,9 mg/l, Hb 8,7 g/dl, neutr\u00f3filos 9,22 \u00d7 103/l, hematocrito 29,5%, plaquetas 75 \u00d7 103/l. El primer hemocultivo extra\u00eddo a trav\u00e9s de la vena perif\u00e9rica fue positivo a las 23 h de incubaci\u00f3n y el segundo a las 17 h. El microorganismo fue identificado como Herbaspirillum huttiense mediante espectrometr\u00eda de masas. El aislado result\u00f3 resistente a colistina y amikacina, pero sensible a trimetoprim-sulfametoxazol , meropenem , ceftazidima, levofloxacina y minociclina.. Tras el informe se decidi\u00f3 cambiar el tratamiento de ceftriaxona a cefotaxima y posteriormente a meropenem. Tanto los hemocultivos de control y el cultivo de posteriores fueron est\u00e9riles.\nMycoplasma pneumoniae pneumonia is prevalent in children and can be followed by upper airway carriage for months. Treatment of M pneumoniae pneumonia with macrolides is widespread and can lead to the development of macrolide resistance. The clinical consequences of chronic M pneumoniae carriage are unknown. In this article, we describe a child with acute lymphoblastic leukemia who developed macrolide-susceptible M pneumoniae pneumonia confirmed by nasopharyngeal secretions polymerase chain reaction and culture with good response to azithromycin. Five months later, the patient developed another M pneumoniae pneumonia that was diagnosed with positive macrolide-resistant M pneumoniae polymerase chain reaction and culture from the bronchoalveolar lavage.\nCongenital syphilis (CS) is a preventable infection, yet the incidence has surged to the highest rates in 20 years. Because 50% of live-born infants with CS are asymptomatic at birth, there is an increasing likelihood that pediatric providers will encounter older infants whose diagnoses were missed at birth, emphasizing the importance of timely prenatal screening and treatment. We present one such case of an infant admitted twice at 3 and 4 months of age with long bone fractures and suspected nonaccidental trauma. On her second presentation, several additional symptoms prompted evaluation for and eventual diagnosis of CS. In this case, it is demonstrated that an isolated long bone fracture can be a first presentation of CS, with other classic findings possibly appearing later. Pediatric providers should be familiar with the varied presentations of CS in older children, including the radiographic findings that we describe. The rising rates of CS reveal deficiencies in our current strategy to prevent CS and, thus, we recommend reconsideration of universal syphilis screening in the third trimester and at delivery, with timely treatment to prevent CS during pregnancy.\nPARA AMPLIAR\nDescribir las caracter\u00edsticas epidemiol\u00f3gicas de un importante brote de tuberculosis en el \u00e1mbito universitario y los principales factores de riesgo asociados.\nM\u00e9todo\nSe realiz\u00f3 un an\u00e1lisis descriptivo de los datos recogidos de las personas enfermas y de los contactos. Para el estudio de contactos se siguieron las pautas establecidas en el Programa de Tuberculosis de la Comunidad Aut\u00f3noma del Pa\u00eds Vasco. Seis de las cepas del brote fueron enviadas al Centro Nacional de Microbiolog\u00eda para su tipado molecular.\nResultados\nEl n\u00famero total de casos del brote fue de 11. La tasa de infecci\u00f3n tuberculosa en el aula del caso \u00edndice, incluidas las personas enfermas, fue del 88,1% (59 infectados y solo 8 no infectados). La demora diagn\u00f3stica del caso \u00edndice fue de 260 d\u00edas, y en los otros 8 casos sintom\u00e1ticos oscil\u00f3 entre 10 y 70 d\u00edas. El patr\u00f3n obtenido por las 2t\u00e9cnicas de genotipado fue id\u00e9ntico en las 6 cepas estudiadas.\nConclusiones\nLa gran demora diagn\u00f3stica del caso \u00edndice aut\u00e9ntico, que se diagnostic\u00f3 en el estudio de contactos, y las malas condiciones de ventilaci\u00f3n del aula determinaron el alto n\u00famero de casos secundarios asociados a este brote.\nEl prop\u00f3sito de este estudio fue evaluar las caracter\u00edsticas demogr\u00e1ficas y cl\u00ednicas de los ni\u00f1os con neumon\u00eda adquirida en la comunidad (NAC) por Mycoplasma pneumoniae (Mp) como \u00fanica bacteria (Mp mono-detecci\u00f3n) y Mp en co-detecci\u00f3n (virus, bacterias: Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus)\nLos resultados fueron: En el 38.18% presentaban una co-detecci\u00f3n con al menos otro pat\u00f3geno. La detecci\u00f3n conjunta fue m\u00e1s com\u00fan entre los ni\u00f1os de \u22643 a\u00f1os. No se encontraron diferencias significativas en la mayor\u00eda de los s\u00edntomas cl\u00ednicos, complicaciones, afecciones subyacentes y par\u00e1metros de gravedad de la enfermedad entre los grupos etiol\u00f3gicos, con las siguientes excepciones. Primero, la duraci\u00f3n prolongada de la fiebre, la falta de apetito y el goteo nasal fueron m\u00e1s frecuentes entre los ni\u00f1os con NAC y la detecci\u00f3n conjunta de metaneumovirus. En segundo lugar, los pacientes con co-detecci\u00f3n con virus (excluyendo rinovirus) ten\u00edan m\u00e1s probabilidades de presentar fiebre prolongada. En tercer lugar, los\npacientes con co-detecci\u00f3n de MP-bacterias ten\u00edan m\u00e1s probabilidades de tener alteraci\u00f3n de los gases sangu\u00edneos. Adem\u00e1s, los ni\u00f1os con NAC y co-detecci\u00f3n Mp-rinovirus ten\u00edan significativamente m\u00e1s probabilidades de presentar secreci\u00f3n nasal severa en comparaci\u00f3n con aquellos con monodetecci\u00f3n por Mp\nConclusi\u00f3n: La detecci\u00f3n conjunta de Mp con pat\u00f3genos virales y / o bacterianos es com\u00fan en la pr\u00e1ctica cl\u00ednica. Sin embargo, no hay diferencias aparentes entre la monodetecci\u00f3n de Mp y las codetecciones de Mp en t\u00e9rminos de caracter\u00edsticas cl\u00ednicas y gravedad de la enfermedad.\n. Actualmente, en ni\u00f1os hospitalizados con neumon\u00eda adquirida en la comunidad (NAC), Staphylococcus aureus es el agente etiol\u00f3gico del 1% de los casos y del 15% de las NAC t\u00edpicas bacterianas. Adem\u00e1s, se ha evidenciado un incremento progresivo en la proporci\u00f3n de cepas de S. aureus resistentes a meticilina (SARM). Estos aislamientos se caracterizan por tener una alta virulencia, al producir con m\u00e1s frecuencia leucocidina de Panton-Valentine (LPV) siendo las neumon\u00edas por SARM m\u00e1s frecuentes en ni\u00f1os de menor edad, especialmente en lactantes. Se ha realizado una revisi\u00f3n retrospectiva de los ni\u00f1os menores de 2 a\u00f1os ingresados en nuestro hospital por NAC por SARM en los \u00faltimos 5 a\u00f1os (2013-2017). Se identificaron 3 casos, todos menores de 6 meses y nacidos en Espa\u00f1a de familias inmigrantes. Los 3 desarrollaron neumon\u00edas graves, asociadas a derrame pleural y necrosis parenquimatosa con empeoramiento cl\u00ednico con el tratamiento antibi\u00f3tico habitual. Todos los aislamientos fueron sensibles in vitro a clindamicina y trimetoprim-sulfametoxazol. Tras conocer el resultado del cultivo, se modific\u00f3 la pauta antibi\u00f3tica a linezolid en 2 casos, manteniendo vancomicina en el otro, pero que se tuvo que sustituir despu\u00e9s por linezolid por mala evoluci\u00f3n.\nLa resistencia a meticilina en S. aureus adquirido en la comunidad en ni\u00f1os suponen entre un 5 y un 10% de los aislamientos de S. aureus comunitarios en ni\u00f1os 5. La mayor\u00eda de los casos comunicados son infecciones de piel y partes blandas5. Las NAC por S. aureus destacan por presentar alta mortalidad (1-5%)6 y mayor riesgo de necrosis pulmonar y desarrollo de abscesos. Las neumon\u00edas por SARM presentan con frecuencia consolidaci\u00f3n unilateral, neumatoceles y derrame pleural, y son m\u00e1s frecuentes en lactantes peque\u00f1os. El estado de portador de SARM incrementa hasta 6 veces el riesgo de neumon\u00eda por esta cepa3, siendo la transmisi\u00f3n intrafamiliar muy alta. La colonizaci\u00f3n en Espa\u00f1a es m\u00e1s frecuente en la poblaci\u00f3n inmigrante, especialmente procedente de Sudam\u00e9rica. Existe actualmente un amplio debate sobre la necesidad de descolonizaci\u00f3n en ni\u00f1os y sus convivientes. Parece prudente llevarlo a cabo en ni\u00f1os que presenten factores de riesgo, como grandes prematuros, inmunodeprimidos o pacientes ingresados en unidades de cuidados intensivos, as\u00ed como en sus familiares. La Academia Americana de Pediatr\u00eda recomienda el uso de vancomicina o clindamicina en el caso de neumon\u00edas con sospecha de SARM. Linezolid es una excelente alternativa, aunque el uso de linezolid en pediatr\u00eda es off-label.\nEn conclusi\u00f3n, debe sospecharse SARM como agente causal de las NAC con empeoramiento cl\u00ednico y radiol\u00f3gico progresivo (necrosis y derrame pleural) a pesar del tratamiento antibi\u00f3tico emp\u00edrico convencional, especialmente en lactantes hijos de familias inmigrantes. Linezolid constituye una buena alternativa a vancomicina en estos pacientes.\nBackground: The use of bacterial multiplex polymerase chain reaction (PCR) in children with suspected pertussis sometimes yields unexpected positive results for Mycoplasma pneumoniae. We aimed to evaluate the clinical significance of positive M. pneumoniae results in this population.\nMethods: Retrospective cohort of consecutive patients with suspected pertussis tested with a bacterial multiplex PCR (including Bordetella pertussis and M. pneumoniae) between June 2015 and March 2017. Medical records were reviewed to compare demographics, clinical presentations and outcomes of patients positive for M. pneumoniae with those positive for B. pertussis and those with negative results, using multivariable logistic regression.\nResults: A total of 1244 patients were included as follows: 56 (4.5%) with M. pneumoniae, 116 (9.3%) with B. pertussis and 1029 (82.7%) with negative results. Mean age was respectively 4.8 years, 6.5 years and 2.8 years (P < 0.05). Children with M. pneumoniae were less likely to present with cardinal symptoms of pertussis such as paroxysmal cough [adjusted odds ratio (OR): 0.19, 95% confidence interval (CI): 0.08\u20130.40) but were more likely to have fever (adjusted OR: 10.53, 95% CI: 3.54\u201339.49) and other nonspecific respiratory symptoms compared with children with B. pertussis. Children with M. pneumoniae had very similar clinical presentations to those with a negative PCR, but were more likely to have radiologically confirmed pneumonia (adjusted OR: 5.48, 95% CI: 2.96\u20139.99) and were less likely to be diagnosed with a concomitant viral infection (adjusted OR: 0.32, 95% CI: 0.07\u20130.99).\nConclusions: In children with suspected pertussis, the detection of M. pneumoniae is clinically relevant. However, the impact of this finding on patients\u2019 outcome is still unclear.\nBackground: Intestinal parasitic infections (IPIs) represent one of the leading causes of morbidity in the world. Children involved in international adoptions constitute a special group of subjects with specific problems and specific healthcare needs. Nevertheless, in current literature there are insufficient data on IPI in this subset of children. This study aims to evaluate the prevalence of IPI in a cohort of internationally adopted children and to investigate epidemiologic factors and clinical features related to IPIs.\nMethods: A retrospective study involving internationally adopted children <18 years old for which results from 3 fecal parasitologic tests were available, evaluated between September 1, 2008 and April 31, 2018 at a tertiary level university hospital in Rome. Univariate and multivariate logistic regression analyses were carried out to identify demographic factors and clinical features associated with IPIs. Two comparisons were performed, the first one according to the positivity of the parasitologic examination of the feces and the second one according to the pathogenicity of the identified strains.\nResults: Of 584 children evaluated, 346 (59.3%) had a positive parasitologic examination (143 pathogenic parasites and 203 nonpathogenic parasites) and 238 (40.8%) had a negative parasitologic examination. About 28.9% of children were positive for 2 or more parasites. A statistically significant positive association was found between IPIs and age, macroarea of origin (Africa and Latin America), living in institutions before adoption and vitamin D deficiency (P < 0.05).\nConclusions: Intestinal parasites represent a widespread infection among internationally adopted children, especially in school-age children and those from Latin America and Africa. Importantly, the parasites found in adopted children were not pathogenic in most cases and did not cause significant alterations in growth, major micronutrient deficits or malnutrition.\nThe aim of this Cochrane Review was to assess the impact of improved disposal of child faeces on diarrhoea and soil-transmitted helminth (STH) infection. We collected and analysed all relevant studies and found 63 studies covering over 222,800 participants.\nEvidence suggests that the safe disposal of child faeces may be effective in preventing diarrhoea. However, the evidence is limited and of low certainty. The limited research on STH infections provides only low and very-low certainty evidence around effects, which means there is currently no reliable evidence that interventions to improve safe disposal of child faeces are effective in preventing such STH infections.\nWhile child faeces may represent a source of exposure to young children, interventions generally only address it as part of a broader sanitation initiative. There is a need for RCTs and other rigorous studies to assess the effectiveness and sustainability of different hardware and software interventions to improve the safe disposal of faeces of children of different age groups.\nPublic health programmes to regularly treat all children with deworming drugs do not appear to improve height, haemoglobin, cognition, school performance, or mortality. We do not know if there is an effect on school attendance, since the evidence is inconsistent and at risk of bias, and there is insufficient data on physical fitness. Studies conducted in two settings over 20 years ago showed large effects on weight gain, but this is not a finding in more recent, larger studies. We would caution against selecting only the evidence from these older studies as a rationale for contemporary mass treatment programmes as this ignores the recent studies that have not shown benefit.\nThe conclusions of the 2015 edition have not changed in this update.\nBACKGROUND: Although pharyngitis is common, group A Streptococcus is an uncommon etiology, and sequelae are rare in patients <3 years old. Inappropriate testing leads to increased cost of health care and unnecessary exposure to antibiotics. Rapid streptococcal tests (RSTs) for group A Streptococcus pharyngitis are not routinely indicated in this age group. At our urban, tertiary pediatric emergency department (ED), on average, 20 RSTs were performed each month for patients <3 years of age. Our objective was to reduce RSTs in the ED in patients aged <3 years by 50% in 18 months.\nMETHODS: We initiated this project in October 2016 at an urban, tertiary pediatric ED. We surveyed pertinent multidisciplinary stakeholders to identify factors leading to RSTs in children <3 years of age. We conducted multiple interventions and collected weekly data on the number of RSTs in children aged <3 years (outcome measure) and the number of family complaints and return visits for complications of pharyngitis (balancing measure). We used statistical process control for analysis.\nRESULTS: The mean number of RSTs ordered per month in patients aged <3 years declined by 52% in 10 months. The majority of tests during the study phase were ordered by nurse practitioners (62%) for patients aged 25 to 36 months (66%). There has been 1 family grievance and no patient complications attributable to the project.\nCONCLUSIONS: Our interventions led to a successful and sustained reduction of RSTs in patients aged <3 years. A local clinical practice guideline was developed, and the project was expanded to other acute care settings.\nEl incremento en las infecciones de transmisi\u00f3n sexual por Chlamydia trachomatis, incluyendo el linfogranuloma ven\u00e9reo, y Mycoplasma genitalium registrado en la \u00faltima d\u00e9cada plantea nuevos retos para mejorar su control y reforzar su prevenci\u00f3n. El diagn\u00f3stico cl\u00ednico habitual (uretritis/cervicitis) debe completarse con una b\u00fasqueda activa de la infecci\u00f3n en varones con disuria o proctitis, mujeres con enfermedad inflamatoria p\u00e9lvica y contactos asintom\u00e1ticos. El diagn\u00f3stico microbiol\u00f3gico debe basarse en t\u00e9cnicas moleculares, capaces de detectar Chlamydia trachomatis (diferenciando el genotipo L para linfogranuloma ven\u00e9reo) y Mycoplasma genitalium (incluyendo idealmente la detecci\u00f3n de cepas resistentes a macr\u00f3lidos). Un diagn\u00f3stico m\u00e1s r\u00e1pido y espec\u00edfico permitir\u00e1 un tratamiento dirigido con la pauta antibi\u00f3tica id\u00f3nea. El manejo de estas infecciones de transmisi\u00f3n sexual debe incluir un estudio de los contactos sexuales y en ocasiones un test de cura. Finalmente, deben ser valorados los cribados de infecci\u00f3n en grupos de poblaci\u00f3n con mayor prevalencia.\nA bronchiectasis exacerbation is defined by the British Thoracic Society (BTS) guidelines as an acute deterioration in the nature of the cough with increased sputum volume, purulence and viscosity. There may be breathlessness, wheeze and systemic symptoms.1 It is felt important to treat exacerbations due to concerns they may contribute to overall lung function decline which is related to overall prognosis.2 In the absence of culture results broad-spectrum antibiotics are used, with amoxicillin as first-line antibiotic for bronchiectasis exacerbations.1 The National Institute for Health and Care Excellence (NICE) guidelines also suggest amoxicillin, clarithromycin and doxycycline as first-line antibiotics for treatment of an acute exacerbation, with co-amoxiclav suggested as an alternative and ciprofloxacin only on specialist \u2026\nPediatrics, Oct 2019, 144 (4) e20190543\nBACKGROUND: Children with neurologic impairment (NI) face high risk of recurrent severe pneumonia, with prevention strategies of unknown effectiveness. We evaluated the comparative effectiveness of secondary prevention strategies for severe pneumonia in children with NI.\nMETHODS: We included children enrolled in California Children\u2019s Services between July 1, 2009, and June 30, 2014, with NI and 1 pneumonia hospitalization. We examined associations between subsequent pneumonia hospitalization and expert-recommended prevention strategies: dental care, oral secretion management, gastric acid suppression, gastrostomy tube placement, chest physiotherapy, outpatient antibiotics before index hospitalization, and clinic visit before or after index hospitalization. We used a 1:2 propensity score matched model to adjust for covariates, including sociodemographics, medical complexity, and severity of index hospitalization.\nRESULTS: Among 3632 children with NI and index pneumonia hospitalization, 1362 (37.5%) had subsequent pneumonia hospitalization. Only dental care was associated with decreased risk of subsequent pneumonia hospitalization (adjusted odds ratio [aOR]: 0.64; 95% confidence interval [CI]: 0.49\u20130.85). Exposures associated with increased risk included gastrostomy tube placement (aOR: 2.15; 95% CI: 1.63\u20132.85), chest physiotherapy (aOR: 2.03; 95% CI: 1.29\u20133.20), outpatient antibiotics before hospitalization (aOR: 1.42; 95% CI: 1.06\u20131.92), clinic visit before (aOR: 1.30; 95% CI: 1.11\u20131.52), and after index hospitalization (aOR: 1.72; 95% CI: 1.35\u20132.20).\nCONCLUSIONS: Dental care was associated with decreased recurrence of severe pneumonia. Several strategies, including gastrostomy tube placement, were associated with increased recurrence, possibly due to unresolved confounding by indication. Our results support a clinical trial of dental care to prevent severe pneumonia in children with NI.\nPediatrics, Oct 2019, 144 (4) e20190348\nOBJECTIVES: We assessed racial differences in sepsis recognition in a pediatric emergency department (ED) with an established electronic sepsis alert system.\nMETHODS: Quality-improvement data from June 1, 2016 to May 31, 2017 was used in this retrospective cohort study. All ED visits were included for non-Hispanic black (NHB) and non-Hispanic white (NHW) patients. The sepsis pathway was activated through the alert, 2 stages and a huddle, or outside of the alert using clinician judgment alone. We evaluated racial differences in the frequency of alerts and sepsis pathway activation within and outside of the alert. Multivariable regression adjusted for high-risk condition, sex, age, and insurance.\nRESULTS: There were 97 338 ED visits: 56 863 (58.4%) and 23 008 (23.6%) from NHBs and NHWs, respectively. NHWs were more likely than NHBs to have a positive second alert (adjusted odds ratio [aOR] 2.4; 95% confidence interval [CI] 2.1\u20132.8). NHWs were more likely than NHBs to have the sepsis pathway activated (aOR 1.4; 95% CI 1.02\u20132.1). Of those treated within the alert, there was no difference in pathway activation (aOR 0.93; 95% CI 0.62\u20131.4). Of those recognized by clinicians when the alert did not fire, NHWs were more likely than NHBs to be treated (aOR 3.4; 95% CI 1.8\u20136.4).\nCONCLUSIONS: NHWs were more likely than NHBs to be treated for sepsis, although this difference was specifically identified in the subset of patients treated for sepsis outside of the alert. This suggests that an electronic alert reduces racial differences compared with clinician judgment alone.\nLas enfermedades exantem\u00e1ticas suelen tener un patr\u00f3n definido t\u00edpico que facilita el diagn\u00f3stico cl\u00ednico, aunque ocasionalmente surgen dudas por similitud de patolog\u00edas y es preciso conocer el agente etiol\u00f3gico. La enfermedad boca mano pie siempre ha sido una de las patolog\u00edas sencillas de reconocer por su cl\u00e1sica afectaci\u00f3n cut\u00e1nea y mucosa; sin embargo, en los \u00faltimos a\u00f1os se ha visto un viraje en la distribuci\u00f3n, extensi\u00f3n y morfolog\u00eda de las lesiones, que le otorgan gran capacidad de simulaci\u00f3n. En los casos donde la cl\u00ednica es at\u00edpica, y un err\u00f3neo etiquetado diagn\u00f3stico puede privar a un paciente de la vacunaci\u00f3n frente a la varicela, la serolog\u00eda puede ser de utilidad. Presentamos un caso de enfermedad boca-mano-pie at\u00edpico en un paciente sin dermopat\u00eda previa con lesiones de gran extensi\u00f3n (patr\u00f3n en cielo estrellado), lo que gener\u00f3 dudas acerca del diagn\u00f3stico.\nLas infecciones por adenovirus humano se producen especialmente en ni\u00f1os menores de cinco a\u00f1os, se propagan f\u00e1cilmente y, en algunos casos, son muy contagiosas. La mayor\u00eda de las infecciones son autolimitadas, de tipo respiratorio y gastrointestinal, y muchas veces son dif\u00edciles de diferenciar de las ocasionadas por otros virus. Excepcionalmente se confunden cl\u00ednicamente con otros procesos graves, tal como ocurri\u00f3 en los dos casos que presentamos. En los \u00faltimos a\u00f1os, la PCR se ha convertido en el m\u00e9todo diagn\u00f3stico de elecci\u00f3n, debido a su rapidez y alta sensibilidad y especificidad para la detecci\u00f3n de AdvH Ser\u00eda deseable optimizar los m\u00e9todos diagn\u00f3sticos para abordar con m\u00e1s precisi\u00f3n estas infecciones y que nos permitan alejarnos de la incertidumbre.\nEl s\u00edndrome de Lemierre es una patolog\u00eda poco frecuente y potencialmente letal, que se origina como complicaci\u00f3n de una infecci\u00f3n localizada a nivel de cabeza y cuello que se extiende al espacio carot\u00eddeo. Se asocia a tromboflebitis s\u00e9ptica de la vena yugular interna y con frecuencia produce embolias s\u00e9pticas a distancia. Se presenta generalmente como un cuadro de fiebre y odinofagia de varios d\u00edas de evoluci\u00f3n tras el antecedente de una infecci\u00f3n orofar\u00edngea aparentemente resuelta. Otros focos infecciosos menos frecuentes pueden corresponder a mastoiditis, sinusitis u otitis media aguda. El diagn\u00f3stico es fundamentalmente cl\u00ednico y apoyado en las pruebas de imagen, como la ecograf\u00eda Doppler y la tomograf\u00eda computarizada cervical con contraste. El tratamiento consiste en antibioterapia prolongada con adecuada cobertura para anaerobios, especialmente Fusobacterium necrophorum, el pat\u00f3geno m\u00e1s frecuente. El papel de la anticoagulaci\u00f3n en el s\u00edndrome de Lemierre es controvertido. Se presenta un caso de s\u00edndrome de Lemierre secundario a una otitis media aguda.\nArchivist was reminded of acute flaccid myelitis (AFM) when he was involved with a few cases following an enterovirus D68 mini outbreak a few years ago. It is a rare diagnosis in UK. Part of the role of the general paediatrician is to be aware of these rarities and diagnose promptly. In a small case series, reported by Matesanz S et al . [J Pediatr 2019 Aug 8. pii: S0022-3476(19)30849-2. doi: 10.1016/j.jpeds.2019.07.015] the diagnostic features were highlighted. Acute flaccid myelitis (AFM) is defined as the acute onset of focal limb weakness with corresponding spinal cord grey matter-specific \u2026\nGlobally, it is estimated that respiratory syncytial virus (RSV) causes 33 million new episodes of acute lower respiratory tract infection (LRTI) in children <5 years of age and \u2248120,000 deaths annually. In infants, RSV represents the leading cause of hospitalization worldwide and the second commonest cause of mortality in low- and middle-income countries.\n[1](https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R1-23), [2](https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R2-23) RSV also causes significant disease in immunocompromised hosts and the elderly and has been associated with the development of asthma. [3](https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R3-23) The increasingly recognized burden of RSV disease has made the development of a vaccine(s) a global health priority. The World Health Organization recently released a roadmap to facilitate the development and implementation of vaccines and monoclonal antibodies (mAbs) and estimated that RSV vaccination will be available in the next 5\u201310 years. [4](https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R4-23) This review summarizes the strategies and challenges associated with RSV vaccine development and the vaccine candidates undergoing clinical evaluation, with a focus on those geared toward the pediatric population.\nObjective: To assess the efficacy of Lactobacillus reuteri DSM 17938 (L. reuteri) for the treatment of acute gastroenteritis in children.\nStudy design: Children younger than 5 years with acute diarrhea, defined as a change in stool consistency to a loose or liquid form and/or an increase in the frequency of evacuations (\u22653 in 24 hours), lasting for no longer than 5 days, were eligible for inclusion. Participants (n = 100) were recruited from the pediatrics department of a Polish hospital and randomly assigned to receive L. reuteri in a dose 2 \u00d7 108 colony-forming units or placebo, for 5 days, in addition to standard rehydration therapy. The primary outcome measure was duration of diarrhea.\nResults: Ninety-one of the 100 children randomized were included in the intention-to-treat analysis (L. reuteri n = 44; placebo n = 47). The duration of diarrhea after randomization in both groups was similar (P = 0.6). The groups were also similar with respect to all secondary outcome measures, with one exception. Compared with the placebo group, patients in the L. reuteri group had a shorter duration of hospitalization (P = 0.048). Adverse events were similar in both groups.\nConclusions: Among children with acute gastroenteritis who were younger than 5 years of age, L. reuteri compared with placebo, as an adjunct to rehydration therapy, did not reduce the duration of diarrhea; however, it reduced the duration of hospitalization.\nObjective: This cohort study, based on the design of a prior study in the United States, was conducted to elucidate the clinical features of primary human herpesvirus-6B (HHV-6B) infection.\nMethods: Between June 2014 and May 2016, febrile children younger than 5 years who visited the emergency room (ER) and underwent blood examination were enrolled in this study.\nResults: Fifty-nine (12%) of the 491 patients were diagnosed with primary HHV-6B infection. The rates of both simple and complex febrile seizure were significantly higher in patients with primary HHV-6B infection than in those without (P < 0.001 and P = 0.008, respectively). The median age at primary HHV-6B infection was 15 months. Forty-seven (79.7%) of the 59 patients with primary HHV-6B infection were younger than 2-year-old. Clinical features were compared between HHV-6B\u2013infected patients older and younger than 2 years. The frequency of apparent infection (exanthema subitum) was significantly higher in the younger patients (P = 0.01). The median leukocyte (P = 0.01) and lymphocyte (P < 0.001) counts in the patients older than 2 years were significantly lower than those in the younger patients.\nConclusions: Primary HHV-6B infection accounted for 12% of ER visits. Secondary febrile seizures, in particular the complex type, were considered to be a major contributor to the disease burden of primary HHV-6B infection. The timing of primary HHV-6B infection occurred at older ages than in past reports, and the frequency of inapparent infection was higher in older patients.\nBackground: Kingella kingae has emerged as a significant cause of osteoarticular infections in young children. Pharyngeal colonization is considered a prerequisite for invasive K. kingae infection. We conducted a prospective study to estimate the prevalence of pharyngeal carriage of K. kingae among healthy young children in Vancouver.\nMethods: From March 2016 to May 2017, children between 6 and 48 months of age visiting British Columbia Children\u2019s Hospital outpatient clinics for noninfectious causes were included in the study. Another set of participants was enrolled from a day-care center located at British Columbia Children\u2019s Hospital. A single-throat swab was collected after obtaining consent from parent/guardian. The samples were stored at \u221270\u00b0C and tested using an in-house developed real-time polymerase chain reaction assay. Epidemiologic characteristics and risk factors for K. kingae colonization were collected via a study questionnaire.\nResults: A total of 179 children were enrolled in the study, but only 174 samples were eligible for testing. Of the 174 samples, 5 had indeterminate results and the remaining 169 samples were negative by K. kingae polymerase chain reaction. The median age of participants was 23 months. About 36% of children were attending day care and had another sibling <5 years of age. Previous history of cold symptoms and antibiotic use was reported in 42% and 12%, respectively.\nConclusions: The results of our study showed no prevalence of asymptomatic pharyngeal carriage of K. kingae in young children in Vancouver. Additional multicenter studies may help to understand the differences in pharyngeal carriage rate among healthy children.\nBackground: The major clinical dilemma managing acute rhinosinusitis (ARS) in pediatric population is distinguishing uncomplicated rhinosinusitis from a complicated bacterial ARS and orbital complications, the latter requiring antimicrobials and surgical intervention. However, factors associated with severe orbital complications and the optimum management strategy remains controversial. The objectives of this study were to characterize the clinical outcomes of children with orbital complications of ARS and to identify risk factors associated with disease severity.\nMethods: This retrospective cohort analysis evaluated the clinical outcomes of 61 children admitted for orbital complications between January 1, 2002 and December 31, 2017. Descriptive statistics were performed to examine the demographics and clinical findings. We compared groups using Mann-Whitney U test for continuous variables and \u03c7 2 for categorical variables.\nResults: Although two-thirds of children had received prehospital antibiotics, half of the cohort presented with post-septal orbital complications. While 83% of isolates obtained from the same patients were susceptible to the prehospital antibiotics given, the majority of those who received prehospital antibiotics nevertheless required surgical intervention. We observed significant association between the age of presentation and disease severity. Children >5 years of age presented with more severe orbital complications despite prehospital antibiotics and were more likely to require surgical intervention (P < 0.001).\nConclusions: In this study, stage II/III orbital complications at presentation and older age were the most important determinants of medical treatment failure. Early referral to eye, nose and throat (ENT) should be considered for children >5 years with ARS due to worse orbital complications despite prehospital antibiotics.\nTo evaluate the relationship between detection of DNA viruses, ferritin, and outcomes in children with severe sepsis.\nStudy design We enrolled 75 pediatric patients with severe sepsis admitted to a tertiary care children's hospital. Plasma ferritin was measured within 48 hours of diagnosis and subsequently twice weekly. Herpes simplex type 1, human herpesvirus 6, Epstein\u2212Barr virus, cytomegalovirus, and adenovirus DNAemia were assessed by polymerase chain reaction.\nResults The incidence of DNAemia was increased significantly in patients with ferritin \u22651000 ng/mL (78% vs 28%; P < .05). Patients with ferritin \u22651000 ng/mL were more likely to have multiple DNA viruses detected in plasma (39% vs 4%; P < .001). The number of viruses detected in plasma directly correlated with the degree of hyperferritinemia and development of combined hepatobiliary and hematologic dysfunction after we controlled for bacterial and fungal coinfections (P < .05) as well as increased mortality after we controlled for severity of illness and cancer diagnosis (OR 2.6, 95% CI 1.1-6.3, P < .05).\nConclusions Viral DNAemia was associated with hyperferritinemia and adverse outcome in pediatric severe sepsis. Prospective studies are needed to determine whether hyperferritinemia may be used to identify patients at risk of occult DNAemia.\nObjective The Petechiae in Children (PiC) study assesses the utility of presenting features and rapid diagnostic tests in the diagnosis of serious bacterial infection in feverish children with non-blanching rashes. An embedded qualitative study explored parents\u2019 and clinicians\u2019 views on the acceptability of the PiC study, including the use of research without prior consent (RWPC) in studies of diagnostic test accuracy.\nDesign Semistructured qualitative interviews. Analysis was thematic and broadly interpretive, informed by the constant comparative approach.\nParticipants Fifteen parents were interviewed 55 (median) days since their child\u2019s hospital attendance (range 13\u201395). Five clinicians involved in recruitment, and consent were interviewed.\nResults Parents and clinicians supported RWPC for the PiC study and future emergency paediatric diagnostic test accuracy studies as long as there is no harm to the child and emergency care is not delayed. Parents and clinicians made recommendations around the timing and conduct of a consent discussion, which were in line with RWPC guidance. Parents enrolled in the PiC study preferred a design that included consent discussions with the research team over the alternative of \u2018opt-out\u2019 consent only.\nConclusions This embedded qualitative study demonstrates that RWPC is appropriate for use in paediatric emergency studies of diagnostic test accuracy and that the approach used in PiC was appropriate. Future diagnostic studies involving additional invasive procedures or an opt-out only approach to consent would benefit from exploring parent and clinician views on acceptability at the pretrial stage.\nConclusiones:\nRotarix es altamente efectivo para prevenir el rotavirus confirmado por laboratorio en Australia, especialmente en beb\u00e9s de 6 a 11 meses. La EV (eficacia vacunal) reducida en los grupos de mayor edad y con el tiempo sugiere una protecci\u00f3n menguante, posiblemente relacionada con la ausencia de estimulaci\u00f3n inmunol\u00f3gica subcl\u00ednica por virus en circulaci\u00f3n continua. Los genotipos G8 no han sido comunes en Australia, y su aparici\u00f3n, junto con el G3P similar a virus equino [8], puede estar relacionado con la presi\u00f3n selectiva inducida por la vacuna; sin embargo, se necesitan m\u00e1s estudios de EV espec\u00edficos de la cepa.\nRESULTADOS:\nLa tasa de respuesta fue del 65% (302 pediatras y 228 PF incluidos). Los pediatras que recomendaron encarecidamente la vacuna contra el VPH oscilaron entre el 99% para pacientes \u226515 a\u00f1os (mujeres) y el 83% para los de 11 a 12 a\u00f1os (hombres); Los PF oscilaron entre 90% para pacientes \u226515 a\u00f1os (mujeres) a 66% para aquellos de 11 a 12 a\u00f1os (hombres) (P <.0001 entre especialidades). El sesenta y cinco por ciento de los pediatras y el 42% de los PF siempre o casi siempre usaban un estilo presuntivo cuando discut\u00edan la vacuna contra el VPH (P <.0001). En general, el 40% usaba \u00f3rdenes permanentes y el 42% ten\u00eda alertas electr\u00f3nicas. Entre los pediatras, la proporci\u00f3n que inform\u00f3 una tasa de rechazo o aplazamiento \u226550% fue del 19% para pacientes femeninos y del 23% para pacientes masculinos de 11 a 12 a\u00f1os; Los FP informaron 27% y 36%, respectivamente. En la regresi\u00f3n multivariable (ambos sexos), el rechazo o el aplazamiento se asociaron con m\u00e9dicos que no recomendaron la vacuna contra el VPH a pacientes de 11 a 12 a\u00f1os de edad, no usaron un estilo presuntivo y percibieron menos resistencia al introducir la vacuna contra el VPH a 13 de un a\u00f1o de edad versus un paciente de 11 o 12 a\u00f1os, y anticipando una conversaci\u00f3n inc\u00f3moda al recomendar la vacuna contra el VPH a un paciente de 11 o 12 a\u00f1os. El ochenta y nueve por ciento de los pediatras y el 79% de los FP informaron que m\u00e1s adolescentes <15 a\u00f1os est\u00e1n completando la serie del VPH ahora que solo se recomiendan 2 dosis.\nCONCLUSIONES: Aunque la mayor\u00eda de los m\u00e9dicos recomiendan encarecidamente la vacuna contra el VPH a pacientes de 11 a 12 a\u00f1os, nuestros datos revelan \u00e1reas para mejorar las recomendaciones los m\u00e9todos de entrega. La mayor\u00eda de los m\u00e9dicos perciben que el programa de 2 dosis est\u00e1 resultando en un VPH m\u00e1s alto\nActualidad bibliogr\u00e1fica agosto-septiembre 2019\nTop ten\nAntimicrobial resistance is of global concern, and preserving the ability of many antimicrobials to kill disease-causing bacteria is likely to become more challenging over time. However, we are speeding up this process dramatically by using antibiotics too much or in the wrong way. Respecting simple key principles of optimal antibiotic prescribing together with commitment to further research in this area from the pediatric community is essential to extend the lifeline of antibiotics for the most vulnerable patients without limiting access to antibiotics for those children who require treatment.\nInfluenza is often misdiagnosed in children because of the low sensitivity of clinical diagnosis because of nonspecific signs and symptoms. This can be overcome by using digital immunoassays or rapid molecular diagnostic tests with adequate sensitivity and specificity. When using these tests at the patient care site, antibiotic consumption and number of healthcare consultations were reduced.\nRickettsiae are globally encountered pathogens with foci of endemicity and epidemic exacerbations under circumstances of crowding and decline of sanitation. Diagnosis is often missed due to misconceptions about epidemiology, confusing terminology and nonspecific clinical presentation. Rickettsioses should be considered in children with febrile illnesses exceeding the usual duration of a viral infection, in particular in children with rash, lymphadenopathy and nearly normal first-line laboratory tests, who reside in or return from endemic areas, recall a compatible contact history, have a constellation of symptoms starting after an arthropod bite, live under troubled social circumstances, or are part of a cluster of similar cases.\nEl rotavirus (RV) es la causa principal de diarrea infantil grave en todo el mundo e infecta pr\u00e1cticamente a todos los ni\u00f1os en los primeros 5a\u00f1os de vida, sobre todo en los primeros 2a\u00f1os. Existen dos vacunas atenuadas de administraci\u00f3n oral frente al RV disponibles en nuestro medio que han demostrado ser seguras y eficaces frente a la enfermedad.\nEl objetivo principal de estas vacunas ha sido reproducir la historia natural de la infecci\u00f3n y proteger frente a la enfermedad grave en los primeros meses de vida. Los reci\u00e9n nacidos prematuros son especialmente vulnerables a la enfermedad por RV, no solo por tener m\u00e1s riesgo de adquirir la infecci\u00f3n, sino tambi\u00e9n por sus complicaciones.\nLa vacunaci\u00f3n frente al RV en ni\u00f1os prematuros ha mostrado resultados de eficacia y seguridad similares a los comunicados en ni\u00f1os a t\u00e9rmino, y los datos existentes sugieren un riesgo bajo de diseminaci\u00f3n e infecci\u00f3n nosocomial cuando la vacunaci\u00f3n se realiza durante la hospitalizaci\u00f3n.\nDado que un porcentaje estimable de reci\u00e9n nacidos prematuros permanecen ingresados en las unidades neonatales m\u00e1s all\u00e1 de las 12semanas de vida, se considera que estos, siempre que su condici\u00f3n cl\u00ednica lo permita, deben recibir la vacunaci\u00f3n frente al RV sin retrasos, incluso durante la hospitalizaci\u00f3n si as\u00ed fuese necesario.\nThe continuous increase in our knowledge of HIV medicine and antiretroviral treatment has led us to draft specific consensus documents focused on topics other than antiretroviral therapy, such as treatment of opportunistic diseases, pre- and post-exposure prophylaxis, metabolic abnormalities, treatment of HBV or HCV coinfection, treatment of patients coinfected with tuberculosis, osteoporosis, kidney disorders, and cardiovascular risk. Accordingly, the AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology has promoted the drafting of this consensus document on the control and monitoring of adult patients infected with HIV. The document provides recommendations on the initial evaluation and subsequent monitoring of HIV-infected patients that will prove useful for all professionals involved in the management of this infection.\nRespiratory viral infections are associated with significant morbidity and mortality in children < 5 years of age worldwide. Among all respiratory viruses, respiratory syncytial virus (RSV) is the world\u2019s leading cause of bronchiolitis and pneumonia in young children. There are known populations at risk for severe disease but the majority of children who require hospitalization for RSV infection are previously healthy. Viral and host factors have been associated with the pathogenesis of RSV disease; however, the mechanisms that explain the wide variability in the clinical presentation are not completely understood. Recent studies suggest that the complex interaction between the respiratory microbiome, the host\u2019s immune response and the virus may have an impact on the pathogenesis and severity of RSV infection. In this review, we summarize the current evidence regarding the epidemiologic link, the mechanisms of viral\u2013bacterial interactions, and the associations between the upper respiratory tract microbiome and RSV disease severity.\nRapid group A Streptococcus point-of-care testing is not currently used in the United Kingdom in the management of acute tonsillitis. This prospective, observational study describes a strong association between a molecular-based point-of-care testing result and outpatient antibiotic prescribing (odds ratio = 48; P < 0.001) in 339 children seen at our center. It highlights challenges in implementing new rapid diagnostics.\nHuman stool contains a myriad of microorganisms, of which the vast majority are nonpathogenic and represent an important component of the healthy microbiome. The increasing use of molecular techniques has allowed the rapid identification of bacteria, viruses and parasites in human stool. This review focuses on the 3 main classes of parasite responsible for human disease, helminths, protozoa and ectoparasites, and highlights the importance of differentiating between pathogenic and nonpathogenic parasites.\nLos casos mundiales de sarampi\u00f3n son los m\u00e1s altos desde 2006, con casi el triple de casos reportados hasta la fecha en 2019 que en el mismo momento del a\u00f1o pasado, seg\u00fan el \u00faltimo informe preliminar de la Organizaci\u00f3n Mundial de la Salud.\nLos brotes m\u00e1s grandes se han visto en pa\u00edses con baja cobertura de vacunaci\u00f3n contra el sarampi\u00f3n, ya sea actualmente o en el pasado. Tambi\u00e9n se producen brotes en pa\u00edses con altas tasas nacionales de vacunaci\u00f3n, pero en grupos de personas no vacunadas, lo que normalmente ocurre en un \u00e1rea geogr\u00e1fica, comunidad o entre un grupo de edad.\nLas razones por las cuales las personas no se vacunan var\u00edan significativamente entre comunidades y pa\u00edses y van desde la falta de acceso a la atenci\u00f3n m\u00e9dica o las vacunas, hasta conflictos y desplazamientos, y la informaci\u00f3n err\u00f3nea sobre las vacunas.\nEl informe compar\u00f3 el per\u00edodo actual de 2019 con el mismo per\u00edodo en 2018 y descubri\u00f3 que:\n-La regi\u00f3n africana de la OMS: aumento del 900% en los casos, con 177 542 en lo que va del a\u00f1o, muy por encima de 55 394 en todo 2018.\n-La regi\u00f3n del Pac\u00edfico occidental: aumento del 230%, con 43 175 casos, m\u00e1s que el n\u00famero total de casos del a\u00f1o pasado (30 531)\n-La regi\u00f3n europea de la OMS: aumento del 120%, con cerca de 90 000 casos notificados a fecha, que supera las registradas para todo 2018 (84 462).\n-La regi\u00f3n del Mediterr\u00e1neo Oriental: aumento del 50% en los casos hasta ahora (15 917 en 2019), pero a\u00fan no ha alcanzado el n\u00famero total de casos en 2018 (57 960).\n-La regi\u00f3n del sudeste asi\u00e1tico: 35 778 casos hasta la fecha en 2019, 83 647 en todo 2018.\n-La regi\u00f3n de las Am\u00e9ricas: 2387 casos hasta la fecha en 2019, 55 394 en todo 2018 Ambas vieron una disminuci\u00f3n del 15% en los casos reportados, aunque los Estados Unidos est\u00e1n reportando su mayor recuento de casos de sarampi\u00f3n en 25 a\u00f1os.\nEl mayor n\u00famero de casos este a\u00f1o provino de la Rep\u00fablica Democr\u00e1tica del Congo, Madagascar y Ucrania, y tambi\u00e9n se produjeron brotes importantes en Angola, Camer\u00fan, Chad, Kazajst\u00e1n, Nigeria, Filipinas, Sud\u00e1n del Sur, Sud\u00e1n y Tailandia.\nSin embargo, el informe destac\u00f3 el impacto positivo de la campa\u00f1a nacional de vacuna contra el sarampi\u00f3n de emergencia en Madagascar, que ha visto disminuir los casos en los \u00faltimos meses.\nA principios de este a\u00f1o, Unicef inform\u00f3 que alrededor de 169 millones de ni\u00f1os en todo el mundo no hab\u00edan recibido su primera dosis de la vacuna contra el sarampi\u00f3n entre 2010 y 2017.\nInvestigadores de salud global han dicho que una barrera clave para la vacunaci\u00f3n es ahora \"incredulidad y hostilidad\" en los pa\u00edses ricos hacia los m\u00e9dicos y gobiernos que promueven la importancia de la vacunaci\u00f3n, exacerbada por la sospecha de expertos propagados por los partidos pol\u00edticos populistas.\nCasos cl\u00ednicos\nA 9-year-old girl presented to the emergency department with bilateral hip pain. Eight days before onset, she had fever and sore throat that recovered spontaneously. On physical examination, tenderness of both hip joints was observed but no heart murmur. Body temperature was 36.8\u00b0C. Blood tests showed elevated C-reactive protein (4.4 mg/dL) and antistreptolysin O titer (4540 IU/mL). Throat culture revealed Streptococcus pyogenes (M3 serotype [emm3.95 genotype] was isolated). A 12-lead standard electrocardiogram revealed a longer PR interval than that before onset (\n[Figure 1](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/c5c02c73-ecef-41c7-b3e9-2fcd933f2c95/gr1.jpg), A and B). No significant manifestations of carditis were observed on transthoracic echocardiogram. Acute rheumatic fever (ARF) was diagnosed according to the revised Jones criteria [1]; amoxicillin and ibuprofen were administered. On day 11 after onset, erythema marginatum was observed on her trunk and proximal lower extremities\nA 4-month-old girl presented with a 2-week history of patchy hair loss on her scalp; parents reported that her scalp hair began shedding while bathing. The patient had received intermittent treatment with topical glucocorticoids following a clinical diagnosis of neonatal occipital alopecia, but the hair loss did not improve. Physical examination revealed patchy, irregular, \u201cmoth-eaten\u201d patches of alopecia over the entire scalp (\n[Figure](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/0f3e6336-d3af-4696-864b-dd3942b201a6/gr1.jpg), A ). No erythematous macules with subtle scales were present on her truck, extremities, palms, or soles.\nWe describe the first 2 cases from the United States, of human parechovirus infection in infants manifesting a distinct rash of the hands and feet. We propose the term \u201cMittens and Booties Syndrome\u201d and provide a review of the literature of all published cases.\nA previously healthy 10-year-old girl became acutely unwell with headache, nausea and vomiting, all exacerbated by movement. She also had an episode of altered consciousness with subsequent retrograde amnesia and was incontinent of urine. She presented to her local hospital and was found to be afebrile with no focal neurological signs. She was discharged with a diagnosis of first-episode absence seizure.\nAn immunocompetent toddler came to medication attention with gastroenteritis, complicated by encephalopathy and hepatitis. Multiplexed testing using a polymerase chain reaction meningitis panel was positive for human herpesvirus 6 (HHV-6). Clinical correlation, quantitative HHV-6 polymerase chain reaction, and metagenomic next-generation sequencing supported a likely diagnosis of primary HHV-6B infection.\nA 6-year-old girl had a 3-year history of systemic juvenile idiopathic arthritis that was treated with prednisone and methotrexate. She presented with painful blisters, erosions, ulcerations with surface exudation, and crusts around mouth, oral mucosa, tongue, umbilicus, and right index finger (\n[Figure](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/6ef313fa-d3ca-4fe2-bcfc-730a9163e6c9/gr1.jpg)); these had been present for 40 days. Tzanck smear revealed mutinucleated giant cells. Skin biopsy taken from umbilicus revealed numerous multinucleate giant cells and ballooning degeneration of keratinocytes. Herpes simplex virus (HSV) subtype 1 was identified using polymerase chain reaction assay. Treatment of oral acyclovir 200 mg 5 times a day was initiated, and the lesions began to improve after 3 days. Unfortunately, the patient died 8 days later because of macrophage activation syndrome and multiple infections.\nSeasonal influenza infection is associated with secondary bacterial complications involving the upper and lower respiratory tract. However, the association of influenza infection with secondary severe or complicated head and neck infections is not appreciated. We report 6 cases of head and neck infections following influenza infection in pediatric patients.\nPresentamos un caso de gastroenteropat\u00eda pierde prote\u00ednas (GEPP) en el curso de una infecci\u00f3n por Mycoplasma cuyo inter\u00e9s radica tanto en lo inusual de dicha enfermedad en la infancia como en el hecho de no haber casos descritos en la literatura producidos por dicho agente etiol\u00f3gico.\nNi\u00f1a de 3 a\u00f1os acude a urgencias por v\u00f3mitos repetidos desde hace 5 d\u00edas, deposiciones blandas y decaimiento los \u00faltimos 3 d\u00edas. Refiere pico febril (38\u00b0C) el d\u00eda previo al ingreso y diuresis adecuada.\nAntecedentes: perinatales sin inter\u00e9s cl\u00ednico. Lactancia artificial. Beikost sin intolerancias. Inmunizaci\u00f3n correcta (no rotavirus). Padre con talasemia minor.\nExploraci\u00f3n al ingreso: peso: 14,3kg, T.\u00aa: 36,8\u00b0C. Regular estado general, algo deca\u00edda. Nutrici\u00f3n e hidrataci\u00f3n adecuada. No exantemas ni petequias. Orofaringe normal. Tonos card\u00edacos r\u00edtmicos, sin soplos. Buena ventilaci\u00f3n pulmonar con tos escasa. Abdomen blando, no doloroso, sin masas ni megalias. Consciente y orientada, no signos men\u00edngeos ni focalidad neurol\u00f3gica\u2026\nPara profundizar\nSome healthcare providers hold or delay vaccination because of false vaccine contraindications. This study suggests that in 21.4% of scenarios (877/4096) physicians would postpone or contraindicate the vaccination, and 24.2% (237/978) of scenarios would be vaccinated despite the existence of a true contraindication or reason for delay. Addressing false contraindications may result in increasing vaccination uptake in Europe.\nIntroducci\u00f3n En Espa\u00f1a, las vacunas frente a rotavirus (RV) est\u00e1n disponibles desde 2006 pero no est\u00e1n ni recomendadas ni financiadas por el Sistema Nacional de Salud. Sin embargo, a trav\u00e9s de las recomendaciones de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda se han alcanzado coberturas de vacunaci\u00f3n intermedias.\nMaterial y m\u00e9todos. Se ha realizado una revisi\u00f3n sistem\u00e1tica de la literatura sobre los estudios realizados en Espa\u00f1a en los \u00faltimos 12 a\u00f1os (2006-2018) en relaci\u00f3n con la infecci\u00f3n y las vacunas frente a RV.\nResultados. Se identifican 43 estudios que cumpl\u00edan los criterios de selecci\u00f3n. La carga de enfermedad en poblaci\u00f3n <5 a\u00f1os en atenci\u00f3n primaria oscila entre 15 y 19 casos por 1.000 ni\u00f1os y en hospitalaria entre 120 y 480 casos por 100.000, lo que supone una importante repercusi\u00f3n econ\u00f3mica y social. Las vacunas frente a RV han mostrado en Espa\u00f1a una efectividad de entre el 83 y el 96% y un impacto de hasta un 70% de reducci\u00f3n de hospitalizaciones, que es dependiente de la cobertura de vacunaci\u00f3n alcanzada. Se identifican adem\u00e1s nuevas l\u00edneas de investigaci\u00f3n relacionadas con el papel de la vacuna del RV y la protecci\u00f3n frente a convulsiones, o el papel del microbiota, entre otros.\nConclusiones. La informaci\u00f3n actualmente disponible refrenda la importante carga de enfermedad por RV en Espa\u00f1a y la elevada efectividad de las vacunas disponibles. Estas evidencias permiten una reevaluaci\u00f3n de las recomendaciones nacionales sobre vacunaci\u00f3n frente a RV.\nEpidemiolog\u00eda descriptiva de la infecci\u00f3n por Yersinia enterocolitica en un \u00e1rea de Castell\u00f3n (Espa\u00f1a) entre 2006 y 2013 a partir de las cepas de Yersinia enterocolitica aisladas en el \u00e1rea y confirmadas por el laboratorio de referencia nacional.\nTotal 144 casos. La incidencia estimada fue de 9,7 casos 105 persona-a\u00f1o. El grupo de edad m\u00e1s afectado fue el de 0-4 a\u00f1os (tasa 110,3 por 105 persona-a\u00f1o), con una m\u00e1ximo en lactantes de 6 a 11 meses de edad (190,4 por 105 persona-a\u00f1o). La duraci\u00f3n media de la enfermedad fue de 15,5 d\u00edas. El 7% de los pacientes fueron hospitalizados. Solo se detectaron 2 brotes, de car\u00e1cter familiar relacionados con el consumo de carne de cerdo. La evoluci\u00f3n temporal refleja mayor incidencia en invierno (enero). El factor de exposici\u00f3n m\u00e1s frecuente entre los casos fue el consumo de longaniza seca de cerdo (el 50% de los casos entrevistados). Las 58 cepas tipadas fueron todas del biotipo 4, serotipo O:3, excepto una O:9. Se distinguieron 21 pulsotipos agrupados en 8 clusters con similitud del 97%. A lo largo de algunos a\u00f1os se observ\u00f3 una sustituci\u00f3n de unos pulsotipos por otros.\nLa yersiniosis tiene una incidencia alta en nuestra \u00e1rea, con una estacionalidad clara de predominio invernal. Afecta sobre todo a ni\u00f1os muy peque\u00f1os. Las cepas son del mismo serotipo, pero la variedad de pulsotipos cambi\u00f3 a lo largo del tiempo. Como factor de exposici\u00f3n para ulteriores estudios anal\u00edticos se propone el consumo de algunos productos del cerdo, sin descartar otros factores.\nBiomarkers have become an integral part of the clinical decision-making process of clinicians dealing with febrile children. C-reactive protein, procalcitonin and white blood cell count are probably the most studied ones. Crucial to using biomarkers is the understanding of how a test result will alter post-test probabilities and then impact on clinical decision making. Improved analytical and computational platforms have enabled the next generation of advanced biomarker discovery studies. Promising combinations of candidate biomarkers for a diverse spectrum of febrile illnesses, such as viral and bacterial infections, have been identified using proteomics, RNA gene expression and metabolomics.\nOur objective was to retrospectively describe measles hospitalizations in 52 US children\u2019s hospitals. We identified 136 patients hospitalized for measles in 2004\u20132018; 17% (23/136) had complex chronic conditions, 2 of whom died or were in hospice. Among noncomplex patients only 39% received vitamin A, median length of stay was 3 days and median adjusted estimated costs were $5896.\nWe described nosocomially clustered cases of measles secondary to a nonvaccinated index case occurring in a teenage psychiatric unit despite optimum vaccine coverage. Surveillance of this fully vaccinated closed cohort showed a 7% attack rate. Vaccination limited the risk of complicated measles and the onset of a large outbreak.\nTimely, accurate diagnosis of group A streptococci (GAS) pharyngitis prevents acute rheumatic fever and limits antibiotic overuse. The illumigene group A Streptococcus assay (Meridian Bioscience, Cincinnati, OH) is a molecular test for GAS pharyngitis with high sensitivity and specificity. We sought to determine whether the illumigene test is more likely than throat culture to be positive in patients without pharyngeal symptoms and explore the limits of detection of the test.\nMethods: Patients 3\u201317 years of age were eligible if they had no history of pharyngitis or use of antibiotics within the previous 2 weeks; there were no upper respiratory infection symptoms, sore throat or fever and no signs of infection. Culture and illumigene were performed on duplicate throat swabs. Excess lysate from a subset of illumigene tests was evaluated by real-time polymerase chain reaction. Institutional Review Board approval was obtained.\nResults: We enrolled 385 patients from February 2016 to October 2017; mean age was 10 yr; 51% were male. Most visits were for health supervision (69%). Significantly more illumigene tests (78/385, 20.3%) than throat cultures (48/385, 12.5%) were positive (\u03c7 2 ; P =0.0035). Illumigene was \u201cindeterminate\u201d for 3 patients, leaving 382 pairs of swabs for analysis. Results were discordant for 32 of 382 pairs (8.4%); 31 of 32 (97%) were illumigene-positive/culture-negative (McNemar test; P < 0.000001). Real-time polymerase chain reaction was negative in 4 of 13 (31%) tested illumigene-positive lysates; the paired culture had been negative in all four. The limit of detection for the illumigene test was 55 colony forming units/mL.\nConclusions: The illumigene test is significantly more likely than throat culture to yield positive results in patients without GAS pharyngitis. Failure to appropriately select patients for testing may negatively impact antimicrobial stewardship efforts without benefit to patients.\nA 13-year-old girl presents with recurrent herpes labialis (HL) on her face. She gives a history of painful episodes occurring approximately monthly since the age of 9 years. Since becoming a teenager, she has missed a lot of school due to her worry about the cosmetic appearance of recurrences. Her parents ask whether long-term antiviral medication will prevent recurrences.\nOral long-term suppressive therapy with acyclovir or valacyclovir reduces the frequency, severity and duration of episodes in adults with recurrent herpes labialis (RHL) (grade A) but has not been the subject of a trial in children.\nOral valacyclovir reduces the frequency of episodes and increases quality of life in teenagers with RHL (grade C).\nThe optimal indication to start, choice of antiviral, as well as dosage and duration of long-term antiviral therapy is unknown.\nMaria is a 1.5-month-old healthy baby born at 39 weeks, mainly breastfed, although she has been fed artificial formula on a few occasions. In the last 2 weeks, she has been brought to the clinic with episodes of intense crying which last from 3 to 5 hours/day and occur 4\u20135 times a week. Her parents are finding it hard to soothe and calm her during these episodes, and find it very distressing. She undergoes a normal clinical examination and there do not seem to be any other associated conditions. As such, infantile colic seems to be the most probable cause of her current distress. Her parents have read that certain probiotics might help her, but you are very uncertain and want to know more.\nLactobacillus reuteri (DSM 17938) decreased the average crying time in predominantly breasted babies with infantile colic (grade A).\nThe magnitude of clinical benefit is uncertain as based on only small studies, and might be influenced by the dosage as well as the length of administration (grade D).\nMaternal vaccination provides a method for protecting the pregnant woman, fetus and neonate during a period when there is increased susceptibility to infectious diseases. A dynamic state of immune tolerance during pregnancy and the need to develop adaptive memory to a new foreign antigen-rich environment lead to windows of vulnerability to infection for the mother and neonate, respectively. Passive transfer of humoral immunity through the placenta and breast milk from the mother can bridge the gap in immunity for the neonate. Studies on boosting this natural process of antibody transfer have led to the recommendation for administering inactivated influenza, diphtheria, tetanus toxoid and acellular pertussis vaccines during pregnancy. Several new maternal vaccine candidates are on the horizon.\nBackground: In febrile children given empiric parenteral antibiotics, guidelines advise provisional reporting of negative blood cultures and antibiotic review after 36 hours incubation for neonates and 48 hours for older children. Following improvements in culture processing and childhood vaccination, we revisited this important clinical topic, assessing time to exclude clinically significant bacteremia in well-appearing febrile children with no comorbidities or features of sepsis.\nMethods: We analyzed the results of all 53,276 pediatric blood cultures taken during an 8-year period at a UK hospital.\nResults: 1308 (2.5%) cultures were positive, of which 333 (25.5%) grew pathogens typically associated with clinically significant bacteremia. The remaining 975 (74.5%) grew organisms associated with contaminated culture, or with opportunistic infection only in children with relevant risk factors. Time to positivity (TTP) from incubation was significantly shorter for the 333 definite pathogens than the 975 contaminating/opportunistic organisms, with 92% of definite pathogens identified by 24 hours incubation. Only 3 of all definite pathogens were identified after 24 hours in children otherwise eligible for discharge at 24 hours. There was no significant difference in TTP for definite pathogens between neonates and older children. Median time from specimen collection to incubation was 3 hours.\nConclusions: Clinically significant bacteremia can be excluded by 24 hours incubation in well-appearing febrile children with no comorbidities or features of sepsis. This is the largest dataset of its kind, and the second to compare neonates and older children. Our findings may inform future guidelines, facilitating earlier antibiotic review and discharge.\nBacteria compete with each other for local supremacy in biologic and environmental niches. In humans, who host an array of commensal bacteria, the presence of one species or strain can sometimes prevent colonization by another, a phenomenon known as \u201cbacterial interference.\u201d We describe how, in the 1960s, infants (and later adults) were actively inoculated with a relatively benign strain of Staphylococcus aureus, 502A, to prevent colonization with an epidemic S. aureus strain, 80/81. This introduced bacterial interference as a clinical approach to disease prevention, but little was known about the mechanisms of interference at that time. Since then, much has been learned about how bacteria interact with each other and the host to establish carriage, compete for niches and shift from harmless commensal to invasive pathogen. We provide an overview of these findings and summarize recent studies in which the genome and function of 502A were compared with those of the current epidemic strain, USA300, providing insight into differences in their invasiveness and immunogenicity. Although staphylococcal vaccines have been developed, none has yet been approved for clinical use. Further studies of staphylococcal strains and the molecular characteristics that lead to exclusion of specific bacteria from some niches may provide an alternative path to disease prevention.\nBackground: The British Thoracic Society (BTS) guideline for pediatric community-acquired pneumonia (CAP) outlines severity criteria to guide clinical decision-making. Our objective was to examine the predictive performance of the criteria on the need for hospitalization (NFH) and disposition.\nMethods: This was a retrospective cohort study of children 3 months\u201318 years of age diagnosed with CAP in an urban, pediatric emergency department (ED) in the United States from September 2014 to August 2015. Children with chronic medical conditions, recent ED visits, and ED transfers were excluded. The main outcomes were interventions or diagnoses that necessitate hospitalization (ie, NFH) and disposition (eg, admit vs. discharge). Test characteristics, stratified by age, were calculated for each outcome.\nResults: Of 518 eligible children, 56.6% (n = 293) were discharged from the ED with 372 children meeting at least 1 BTS criterion. Overall BTS criteria were specific but not sensitive for NFH nor for disposition. For children <1 year of age sensitive criteria included not feeding and temperature for NFH and tachycardia, cyanosis and not feeding for disposition. For children \u22651 year of age, tachycardia had a sensitivity of >0.60 for both outcomes. The areas under the receiver operator characteristic curves for predicting any BTS criteria was 0.57 for NFH and 0.84 for disposition.\nConclusions: The BTS CAP severity criteria had fair to excellent ability to predict NFH and disposition, respectively. Although specific, the low sensitivity and poor discriminatory ability for NFH of these criteria suggest a need for improved prognostic tools for children with CAP.\nThe Pediatric Infectious Disease Journal. 38(8):e178-e180, August 2019.\nProbiotics are increasingly used for diarrhea, but studies under the Food and Drug Administration and Investigational New Drug program are few. We conducted a phase-one placebo-controlled study of Lactobacillus reuteri DSM 17938 under Investigational New Drug program in 60 children 2\u20135 years of age (41 L. reuteri , 19 placebos) in a resource-constrained community in Peru. No differences in objective data on adverse events were noted, although some differences based on subjective parental reports for fever and diarrhea were seen.\nThe Pediatric Infectious Disease Journal. 38(6S):S39-S42\nIntroduction of conjugate vaccines against Haemophilus influenzae type b, Streptococcus pneumoniae , and Neisseria meningitidis has led to a substantial reduction in cases of acute bacterial meningitis in countries with high routine childhood immunization coverage. The majority of children hospitalized with meningitis in high-income countries have viral or aseptic meningitis and do not require antibiotic treatment. Cerebrospinal fluid analysis is irreplaceable in appropriately diagnosing and treating bacterial meningitis and avoiding unnecessary antibiotics and prolonged hospitalizations in children with viral meningitis. New diagnostic tests have improved detection of bacterial and viral pathogens in cerebrospinal fluid, underscoring the importance of promptly performing lumbar puncture when meningitis is suspected. This article provides an overview of acute bacterial and viral meningitis in children, focusing on the changing epidemiology, the advantages and limitations of conventional and newer diagnostic methods, and considerations for clinical practice.\nThe endemic mycoses are a group of infections caused by fungi with a distinct geographic distribution, defined by climatic and environmental conditions. The systemic endemic mycoses, namely histoplasmosis, blastomycosis, talaromycosis, coccidioidomycosis and paracoccidioidomycosis, occur after the inhalation of fungal spores. The cutaneous endemic mycoses, including sporotrichosis, mycetoma, entomophthoramycosis and chromoblastomycosis, enter the host via traumatic inoculation of the skin. Clinical presentation varies between these relatively heterogeneous infections, as does the susceptibility of immunosuppressed patients to disease. An understanding of the geographic range, typical manifestations, diagnostic methods, and treatment of the endemic mycoses is key in assessing patients presenting with atypical infections who may have traveled to endemic areas.\n(Bacterias resistentes en las manos de trabajadores sanitarios y en el \u00e1rea del paciente: un estudio ambiental en un hospital del sur de Italia). Rev Esp Quimioter 2019; 32(4): 303-310.\nIntroducci\u00f3n. La OMS reconoce la resistencia a los antimicrobianos como una creciente amenaza para la salud mundial con una amplia variabilidad en toda Europa: en Italia estas tasas son m\u00e1s altas que en otros pa\u00edses. El objetivo de nuestro estudio fue detectar la resistencia a los antimicrobianos en las manos de trabajadores sanitarios y en las superficies alrededor del paciente as\u00ed como evaluar la variabilidad entre los niveles de contaminaci\u00f3n bacteriana en estas superficies y los resultados obtenidos hace seis a\u00f1os.\nMaterial y m\u00e9todos. El estudio se realiz\u00f3 entre junio de 2017 y mayo de 2018 utilizando dispositivos de contacto para superficies y muestreo activo de aire. Se emple\u00f3 m\u00e9todos bioqu\u00edmicos automatizados para identificar microorganismos y la sensibilidad antimicrobiana fue realizada de acuerdo con las normas del EUCAST.\nResultados. Se analizaron 3.760 muestras, de las cuales el 16,17% fueron positivas y el 34% de ellas fueron resistentes a antibi\u00f3ticos. Al analizar los estafilococos, el 39% fueron multirresistentes y el 5% extremadamente resistentes. Un 30% de las cepas de Enterococcus faecalis fueron resistentes a gentamicina y vancomicina. Se aislaron cepas de Klebsiella pneumoniae resistentes a ceftrixona, cefoxitina, mecillinam e imipenem. Un 7% de las cepas de Acinetobacter baumannii y un 8% de las cepas de Pseudomonas aeruginosa fueron resistentes a gentamicina, imipenem y ceftazidima.\nConclusiones. Estos hallazgos est\u00e1n en l\u00ednea con los estudios publicados en otros pa\u00edses, lo que confirma que la resistencia a los antibi\u00f3ticos tambi\u00e9n est\u00e1 creciendo constantemente en Italia con tasas variadas para los diferentes pat\u00f3genos.\nNonpolio enterovirus (NPEV) infections are often present with herpangina (HA) and hand, foot and mouth disease (HFMD). Most countries sample NPEVs in HFMD cases, targeting enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16) that are associated with outbreaks and severe complications. HA is also monitored in Taiwan and several other countries, but its viral characteristics are underreported.\nMethods: Through Taiwan\u2019s National Virologic Surveillance, information regarding ~100,000 child respiratory samples (2002\u20132015) was linked to concurrent (0\u20136 days before the sampling date) outpatient records from the National Health Insurance databases, including ~15,000 HA-related and ~7000 HFMD-related samples. We assessed sample representation and NPEV positive rates, and estimated total numbers of EV-A71 and CV-A16.\nResults: There were more HA events (4.0 millions) than HFMD events (1.2 millions) in Taiwan. In every 1000 events with HFMD and HA, 6.0 and 4.1, respectively, respiratory samples were collected. The NPEV positive rate in HFMD-related samples was 48%, consistent across most sampling seasons, and predominantly EV-A71 or CV-A16 (74%). By comparison, the HA-related samples had a lower positive rate overall (43%), occasionally EV-A71 or CV-A16 (13%), and the positive rate depended strongly on HA incidence ( P < 10 \u201312 ). Compared with sampling HFMD alone, inclusion of HA-related information predicted an earlier onset of EV-A71 outbreak in 2011, and predicted 30% more EV-A71 cases.\nConclusions: This is the first representative report on viral characteristics of HA. Our findings confirm that HFMD monitoring is a reliable strategy, but there is a measurable additional benefit when HA is also monitored.\nCongenital cytomegalovirus infections are among the most common of the newborn in the developed world. These infections are the most common cause of sensorineural hearing loss. Studies utilizing ganciclovir and valganciclovir demonstrate improved hearing and Bailey Developmental scores. Because of the ease of administration, valganciclovir is the recommended treatment of choice for 6 months. Therapy should be reserved for those babies with symptomatic disease; no data are available regarding the impact of treatment on those babies with asymptomatic disease.\nIncidence of hearing loss in children with cCMV infection is discussed, and risk indicators for hearing loss are described.\nSaffold virus (SAFV) is a novel human cardiovirus that was identified in 2007. Recently, SAFV has been isolated from nasal and stool specimens of infants presenting with respiratory and gastrointestinal symptoms and from cerebrospinal fluid (CSF) specimens of children with central nervous system infection. However, little is known regarding clinical characteristics of SAFV in children.\nMethods: We reviewed 5412 specimens from the database of the infectious agents surveillance system in Niigata prefecture, Japan, between January 2006 and December 2013, and identified SAFV-infected patients. Subsequently, we retrospectively reviewed their medical records and evaluated their clinical characteristics.\nResults: We identified 9 SAFV-infected patients (median age: 5 years; range: 2\u201316 years). Seven patients were diagnosed with pharyngitis, one with meningitis and one with fever of unknown origin. Dominant symptoms were high fever, appetite loss and headache. The median duration of the fevers was 2 days in patients with pharyngitis; however, the patient with meningitis remained febrile for 5 days. All blood tests available in this case series revealed leukocytosis with a predominance of neutrophils. CSF profiles showed mild lymphocytic pleocytosis. All patients recovered fully without complications.\nConclusions: A few clinical characteristics of SAFV infection were clarified, including high fever of short duration in patients with pharyngitis, and neutrophil-dominant leukocytosis. The clinical course and CSF profiles of a case of meningitis were similar to those of other aseptic meningitis. SAFV needs to be included in the differential diagnosis of pharyngitis or meningitis when commonly identified viruses are not identified in such patients.\nThe Pediatric Infectious Disease Journal. 38(9):900-905\nBackground: Universal vaccination with Haemophilus influenzae type b conjugate vaccines has significantly changed the epidemiology of invasive H. influenzae disease in the United States. We reviewed the epidemiology, clinical features, and outcomes in 61 patients with invasive H. influenzae disease evaluated at Texas Children\u2019s Hospital (TCH).\nMethods Cases of invasive H. influenzae disease, defined as isolation of the organism from cerebrospinal fluid, blood, synovial fluid or pleural fluid, during 2011 to 2018 among children cared for at TCH in Houston, TX, were included.\nResults: We identified 61 cases of invasive H. influenzae disease in children \u226418 years of age. The overall hospitalization rate due to invasive H. influenzae disease increased between 2011 and 2018 (0 vs. 0.64/1000 hospitalizations; P = 0.019). The majority (80%) of infections occurred in children <5 years of age. Of the 61 H. influenzae infections, 24 (39.3%) infections were caused by nontypeable H. influenzae strains, 18 (29.5%) infections were caused by H. influenzae type a, 12 (19.7%) infections were caused by H. influenzae type f, 3 (4.9%) infections were caused by H. influenzae type e and 4 (6.6%) isolates were not typed. A total of 78.7% of the isolates were \u03b2-lactamase negative. The most common clinical presentations were bacteremia without a source, pneumonia and meningitis.\nConclusions: The hospitalization rate for H. influenzae invasive disease increased over an 8-year period at TCH. The overall trend was mainly driven by an increasing number of invasive infections caused by nontypeable H. influenzae and H. influenzae type a. Morbidity was substantial, especially in meningitis cases.\nBroad-range polymerase chain reaction (BR-PCR) detects infectious pathogens from clinical specimens using targets for bacteria (16S rRNA), fungi (28S rDNA), and mycobacteria (fluorescence resonance energy transfer and heat shock protein 65 gene) with reported diagnostic sensitivity and specificity ranging from 43% to 100% and 100%, respectively. We describe our experience when applying BR-PCR to clinical samples submitted for conventional infectious disease testing [conventional testing (CT)] from pediatric patients with concern for infection.\nMethods: Retrospective analysis of clinical samples obtained from Nationwide Children\u2019s Hospital microbiology laboratory from January 2011 to December 2014 and sent for BR-PCR. Medical record review collected data on patient characteristics, clinical manifestations, laboratory results and antimicrobials prescribed, and a determination of clinical value of BR-PCR was assigned.\nResults: There were 247 clinical samples from 163 patients identified; 71 (44%) patients were immunocompromised and 192 (78%) samples reflected pretreatment with antimicrobials. A clinically significant putative organism was identified for 59 samples (24%) between all diagnostic modalities. Conventional testing identified organisms in 41 (17%) samples, 17 of which were corroborated by BR-PCR. Broad-range polymerase chain reaction identified an organism in an additional 18 samples with negative CT results and was considered to provide additional important clinical information. Broad-range polymerase chain reaction detected a bacterial or fungal organism more frequently from tissue samples than from bronchoalveolar lavage or other fluid samples ( P = 0.0096, \u03c7 2 ).\nConclusions: In our cohort, BR-PCR was an important adjunctive diagnostic in identifying bacteria and fungi in complex clinical situations. Additional data are needed to define the optimal clinical circumstances and specimen type in which BR-PCR can provide the highest diagnostic yield.\nBackground: Pneumococcal meningitis (PM) is a serious disease that can rarely recur at a later time after the initial episode.\nMethods: A retrospective multicenter case\u2013control study was conducted with data for children 18 years of age or younger obtained from the National Observatory of Bacterial Meningitis in Children between January 2001 and September 2015. Cases were all patients with RPM. Each case was matched with 2 randomized controls with a single PM episode in the year of the first episode of PM in the case and born the same year. Case and control data were compared.\nResults: Among the 1634 PM episodes in children 18 years of age or younger, 24 (1.5%) children had RPM. RPM cases were significantly less frequent than single PM cases in winter (27% vs. 48%; P =0.03) and showed significantly less concomitant ear, nose and throat infections when considering the first episode (30% vs. 56%, P = 0.04) and all episodes (28% vs. 56%, P < 0.01). Cerebrospinal fluid leakage was frequent in RPM cases versus controls (83% vs. 10%, P < 0.01), including 25% discovered after the third PM episode. Immune deficiency was absent in cases and present in 15% of controls. Cases and controls did not differ in death rate or neurologic outcome.\nConclusions: RPM is rare in children. Cerebrospinal fluid leakage must be considered.\nManagement of suspected serious bacterial infections (SBIs) in infants less than 3 months old is challenging. Understanding the epidemiology of SBI is necessary to inform management decisions. Recent publications have challenged the previously accepted distribution of infections by specimen source and pathogen. We sought to describe the burden of SBIs in previously healthy infants less than 90 days old.\nMethods: We conducted a retrospective analysis of the Military Health System database to identify SBI cases among term infants less than 90 days of age from 2005 to 2015. We defined an SBI case as any previously healthy infant with positive cultures for a likely pathogen from blood, urine or cerebrospinal fluid.\nResults: Of 467,462 live births between January 2005 and September 2015, 3421 infants had positive cultures. After excluding 1781 episodes with isolates considered nonpathogenic or ICD-9 codes for chronic conditions, the overall incidence of SBI was 3.1 cases/1000 live births. The SBI rate dropped from 5.0 cases/1000 live births in 2005 to 2.0 cases/1000 live births in 2015 ( P < 0.001 for trend). The most common pathogen was Escherichia coli (51.3%).\nConclusions: In this retrospective review of 467,462 live births, the incidence of SBI decreased from 5.0/1000 to 2.0/1000 live births over time. We identified no cases of Listeria monocytogenes . These data can help inform decisions related to treatment and management of infants with suspected bacterial infections. OK\nAfter the initial identification of the H1N1 pandemic influenza strain in Mexico in April 2009 and its subsequent global spread, several monovalent influenza vaccines were developed as part of the pandemic response. Three of these vaccines, Pandemrix, Arepanrix and Focetria were adjuvanted. One of these, the AS03-adjuvanted Pandemrix vaccine, was primarily used in Europe. Following widespread Pandemrix vaccine administration in Scandinavia, an increased risk of narcolepsy was noted in observational studies. Subsequently, this increased risk was also reported in other European countries as well. In contrast, studies from Canada of a similar AS03-adjuvanted vaccine, Arepanrix, did not demonstrate a similar increased risk of narcolepsy. No studies have identified an increased risk of narcolepsy following the MF59-adjuvanted Focetria vaccine. For many potential pandemic influenza strains, adjuvants might be required to solicit a protective immune response. Thus, it is critical that we understand the nature of the association between adjuvanted vaccine receipt and narcolepsy. Here, we present a potential hypothesis for narcolepsy seen during the 2009 H1N1 pandemic in AS03-adjuvanted influenza vaccine recipients.\nWe included seven randomised controlled trials (studies in which participants are assigned to one of two or more treatment groups using a random method) that compared the effects of immunoglobulins with placebo in 486 young children hospitalised with RSV lung infections. All trials were conducted at sites in the USA; three trials included some children from South American countries (Chile and Panama); and one trial also included children from New Zealand and Australia. The trials were published between 1987 and 2014.\nWe found insufficient evidence of a difference between immunoglobulins and placebo for any review outcomes. We assessed the evidence for the effects of immunoglobulins when used as a treatment for RSV lower respiratory tract infection in hospitalised infants and young children as of low or very low certainty due to risk of bias and imprecision. We are uncertain of the effects of immunoglobulins on these outcomes, and the true effect may be substantially different from the effects reported in this review. All trials were conducted in high-income countries, and data from populations in which the rate of death from RSV infection is higher are lacking.\nKawasaki disease (KD) is an acute inflammation of the blood vessels that mainly affects children between six months and five years of age. Standard medical management of KD includes intravenous immunoglobulin (IVIG) with aspirin. This standard treatment is usually effective, but doesn't work for approximately 15% to 20% of children. When treatment is not effective, children may suffer from serious heart disease. Recently, researchers found that tumor necrosis factor-alpha (TNF-\u03b1) blockers may be effective for children with Kawasaki disease that has not been cured by standard treatment. However, we are still unclear about the benefits and risks of TNF-\u03b1 blockers for the treatment of KD, and the potential for improved efficacy and safety is ambiguous. This review therefore assessed the benefits and harms of TNF-\u03b1 blockers for the treatment of KD.\nWe included trials that used TNF-\u03b1 blockers as a treatment for children with KD and measured treatment resistance, cardiovascular events and side effects, such as infusion reactions and infections, or other symptoms. We found five completed studies with a total of 494 participants (most recent search for studies September 2018). Four studies used TNF-\u03b1 blockers as the additional treatment after IVIG treatment and one used TNF-\u03b1 blockers as the first treatment for children with KD.\nWe found a limited number of RCTs examining the effect of TNF-\u03b1 blockers for KD. In summary, low-certainty evidence indicates that TNF-\u03b1 blockers have beneficial effects on treatment resistance and the adverse effect 'infusion reaction' after treatment initiation for KD when compared with no treatment or additional treatment with IVIG. Further research will add to the evidence base. Due to the small number of underpowered trials contributing to the analyses, the results presented should be\ntreated with caution. Further large high quality trials with timing and type of TNF-\u03b1 blockers used are needed to determine the effects of TNF-\u03b1 blockers for KD. OK\nLa nueva gu\u00eda de NICE (NICE. Impetigo: antimicrobial prescribing. 2019. www.nice.org.uk/guidance/gid-ng10134/documents/draft-guideline. Google Scholar) afirma que se debe ofrecer un antis\u00e9ptico t\u00f3pico a las personas con imp\u00e9tigo localizado, no ampolloso, siempre y cuando no presente afectaci\u00f3n sist\u00e9mica o corran el riesgo de desarrollar complicaciones.\nEn algunas situaciones, los antibi\u00f3ticos seguir\u00e1n siendo adecuados, por ejemplo ante un paciente con imp\u00e9tigo no ampolloso generalizado.\nUn antibi\u00f3tico oral (flucloxacilina) debe ser el tratamiento de primera l\u00ednea si una persona tiene imp\u00e9tigo ampolloso o si presenta afectaci\u00f3n sist\u00e9mica o tiene riesgo de desarrollar complicaciones, y tambi\u00e9n es una opci\u00f3n para las personas con imp\u00e9tigo no ampolloso generalizado.\nNo se debe usar un tratamiento combinado con un antibi\u00f3tico t\u00f3pico y oral, ya que no es m\u00e1s efectivo que usar un solo tratamiento t\u00f3pico.\nEl virus sincitial respiratorio humano (VSR) pertenece a la familia Pneumoviridae, g\u00e9nero Orthopneumovirus. Es un virus ARN monocatenario de sentido negativo que produce epidemias de infecciones respiratorias que, t\u00edpicamente, alcanzan su punto m\u00e1ximo en el invierno en climas templados y durante la temporada de lluvias en climas tropicales. En general, uno de los dos genotipos (A y B) predomina en una sola estaci\u00f3n, alternando anualmente, aunque se producen variaciones regionales. El VSR es una causa de enfermedad y muerte en ni\u00f1os, personas mayores y pacientes inmunocomprometidos, y su efecto cl\u00ednico en adultos ingresados, se detecta con el uso ampliado de ensayos moleculares multiplex. Entre los adultos, el VSR produce una amplia gama de s\u00edntomas cl\u00ednicos que incluyen infecciones del tracto respiratorio superior, infecciones graves del tracto respiratorio inferior y exacerbaciones de la enfermedad subyacente. En este art\u00edculo se discute la evidencia m\u00e1s reciente sobre la carga de la enfermedad relacionada con el VSR en adultos, especialmente en aquellos con inmunocompromiso u otras comorbilidades. Revisamos las opciones terap\u00e9uticas y de prevenci\u00f3n actuales, as\u00ed como las que est\u00e1n en desarrollo.\nActualidad bibliogr\u00e1fica julio 2019\nTop Ten\nDesde la Sociedad Espa\u00f1ola de Reumatolog\u00eda Pedi\u00e1trica (SERPE) y la Sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica (SEIP) queremos comunicar nuestra preocupaci\u00f3n por el diagn\u00f3stico err\u00f3neo de la enfermedad de Lyme que se est\u00e1 llevando a cabo en ni\u00f1os con artritis idiop\u00e1tica juvenil. En los \u00faltimos a\u00f1os se han comercializado pruebas diagn\u00f3sticas no validadas cient\u00edficamente, que est\u00e1n condicionando que ni\u00f1os con artritis de etiolog\u00eda no infecciosa est\u00e9n recibiendo antibi\u00f3ticos durante tiempo prolongado. Esta tendencia puede condicionar la aparici\u00f3n de secuelas a nivel articular, y m\u00e1s grave si cabe, a nivel ocular por el desarrollo de uve\u00edtis cr\u00f3nica, que limitar\u00e1n la vida futura de estos ni\u00f1os.\nIntroducci\u00f3n y Objetivo: describir las caracter\u00edsticas cl\u00ednicas y epidemiol\u00f3gicas, tratamiento y evoluci\u00f3n de los pacientes con NAC por MP (NACM) en un hospital terciario de Valencia.\nMaterial y m\u00e9todos: Se revisaron retrospectivamente las historias cl\u00ednicas de los ni\u00f1os<14 a\u00f1os con NACM entre enero de 2010 y diciembre de 2015. Los pacientes con evidencia radiol\u00f3gica de neumon\u00eda y confirmaci\u00f3n microbiol\u00f3gica de MP (PCR de exudado nasofar\u00edngeo y/o anticuerpos IgM espec\u00edficos frente a MP) se consideraron NACM.\nResultados. Un total de 162 pacientes se diagnosticaron de NACM; mediana de edad de 6 a\u00f1os (rango intercuart\u00edlico: 4-9 a\u00f1os). La proporci\u00f3n de pruebas positivas para MP en pacientes con NAC, as\u00ed como el uso emp\u00edrico de macr\u00f3lidos, aument\u00f3 progresivamente con la edad. Hubo un pico de casos en 2011 y en 2015, con un m\u00e1ximo de casos en julio, agosto, noviembre y diciembre. El patr\u00f3n radiol\u00f3gico m\u00e1s frecuente fue el infiltrado segmentario (62,3%), mientras que 22 (13,6%) presentaron derrame pleural. Los ni\u00f1os con NACM desarrollaron una cl\u00ednica leve, con poca elevaci\u00f3n de par\u00e1metros inflamatorios. Se inici\u00f3 tratamiento emp\u00edrico con un macr\u00f3lido en el 68,5% de los casos. La necesidad de ingreso hospitalario fue inversamente proporcional a la edad del paciente.\nConclusiones: los ni\u00f1os con NAC de mayor edad tuvieron la mayor proporci\u00f3n de infecci\u00f3n por MP, siendo poco sintom\u00e1ticos y con escasa elevaci\u00f3n de par\u00e1metros inflamatorios, pudi\u00e9ndose beneficiar del tratamiento emp\u00edrico con macr\u00f3lidos.\nBackground: Mycoplasma pneumoniae (MP) is a major cause of community-acquired upper and lower respiratory infections in school-age children; however, there is increasing recognition that younger children are also affected. Clinical manifestations vary from asymptomatic, to severe complicated pneumonia sometimes with extrapulmonary manifestations.\nMethods: We reviewed the medical records of all MP positive pediatric patients admitted to the Hadassah-Hebrew University Medical Center. MP positive case was defined if MP polymerase chain reaction was positive from an oropharyngeal swab sent from 2007 to 2017.\nResults: During the study period, we identified 353 MP positive pediatric cases, of which 51.3% (181 of 353) were younger than 6 years old. Full clinical data were available for 332 of 353 (94%). The median age was 5.7 years (range, 3 weeks to 18 years). Disease presentation differed between younger and older children. Children older than 6 years were more likely to have chest radiograph confirmed pneumonia (66% vs. 52%; P = 0.009), while younger children were more likely to have other respiratory manifestations (37% vs. 25%; P = 0.017). The duration of hospitalization and pediatric intensive care unit admission rate, however, did not differ between age groups. The rate of extrapulmonary manifestations were also similar.\nConclusions: MP-associated infection is a significant cause of hospitalization in the pediatric population including younger children (<6 years old). However, the clinical presentation in younger age is less typical than is thought. These findings should prompt clinicians to consider MP infections also in children younger than 6 admitted with fever even without pneumonia.\nTo date, the actual incidence of drug allergy in the pediatric population is not well known. Epidemiologic studies report that drug allergy affects more than 10% of children and adolescents; although when these children are fully investigated <10% are confirmed to be truly allergic to the suspected drug. Until a few years ago, penicillin allergy was the most frequently reported drug allergy with a prevalence rate of 5%\u201310% in adults and children. Today amoxicillin allergy is more prevalent than penicillin allergy in children. Non-\u03b2-lactam allergy is rare in children and estimated to affect 1%\u20133% of this population following \u03b2-lactams and nonsteroidal anti-inflammatory drugs. As regards the most frequently reported reactions to non-\u03b2-lactam drugs, sulphonamides and macrolides are among the most commonly implicated antibiotics.\n[1](https://journals.lww.com/pidj/Fulltext/2019/07000/Management_of_Suspected_Antibiotic_Reactions_in.25.aspx#R1-25)\nThese so-called allergic reactions are rather common in children, most likely because of the frequency of rashes that occur during antibiotic treatment for a viral infection and reluctance to test to confirm allergy.\nNowadays, it is mandatory to rigorously confirm or exclude a diagnosis of antibiotic allergy to improve patient safety by using the most appropriate antibiotic depending on the infection to be treated and avoid alternative often more expensive, favoring antibiotic resistance.\nPediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection (PANDAS) as a clinical entity was advanced by investigators at the National Institute of Mental Health with 5 elements constituting diagnostic criteria: (1) presence of obsessive compulsive disorder (OCD) and/or tic disorder; (2) prepubertal onset of symptoms; (3) episodic course characterized by acute, severe onset and dramatic symptom exacerbations; (4) temporal relationship between group A beta-hemolytic streptococcal (GAS) infections and symptom onset and exacerbations and (5) association with neurologic abnormalities (eg, choreiform movements, motor hyperactivity, tics).\n[1](https://journals.lww.com/pidj/Fulltext/2019/07000/A_Pediatric_Infectious_Disease_Perspective_on.11.aspx#R1-11) In the original description of 50 patients with PANDAS approximately 40% of all presentations and exacerbations were able to be related to preceding or concurrent GAS infections and each patient had at least 1 episode in which the relationship to GAS was established. [1](https://journals.lww.com/pidj/Fulltext/2019/07000/A_Pediatric_Infectious_Disease_Perspective_on.11.aspx#R1-11) Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a diagnostic entity advanced more than a decade later to broaden the scope of these disorders and allow for other instigator events besides GAS. The criteria for PANS include abrupt, dramatic overnight onset of OCD or severely restricted food intake; concurrent abrupt onset of additional severe neuropsychiatric symptoms from at least 2 of the following 7 categories: (1) anxiety; (2) emotional lability and/or depression; (3) irritability, aggression and/or severe oppositional behaviors; (4) developmental regression; (5) deterioration in school performance; (6) sensory or motor abnormalities, including heightened sensitivity to sensory stimuli, hallucinations, dysgraphia, complex motor and/or vocal tics and (7) somatic signs and symptoms, including sleep disturbances, enuresis or urinary frequency and the requirement that symptoms are not better explained by a known neurologic or medical disorder. [2](https://journals.lww.com/pidj/Fulltext/2019/07000/A_Pediatric_Infectious_Disease_Perspective_on.11.aspx#R2-11)\nIn 2013, a PANS Consensus Conference was\u2026\nObjetivo: describir la tuberculosis infantil de 2005 a 2015 en Navarra, con datos demogr\u00e1ficos, cl\u00ednicos, radiol\u00f3gicos, microbiol\u00f3gicos, tratamiento y evoluci\u00f3n. Material y m\u00e9todos: estudio descriptivo retrospectivo a partir de datos de historia cl\u00ednica de los pacientes atendidos entre 2005 y 2015. Resultados: 52 pacientes, 57,7% varones, 42,3% mujeres, mediana de edad cuatro a\u00f1os, 38,5% inmigrantes, 61,5% hijos de inmigrantes. Distribuci\u00f3n homog\u00e9nea en los diez a\u00f1os, excepto un brote en 2011. Sintom\u00e1ticos el 69,2%. En el 63,5% de los pacientes el caso \u00edndice es conocido. La forma cl\u00ednica m\u00e1s frecuente es la pulmonar (82,7%). La radiolog\u00eda fue patol\u00f3gica en el 86,5%, se realiz\u00f3 tomograf\u00eda computarizada pulmonar en el 82,7% (95,3% patol\u00f3gicos). El 71,2% de los cultivos fueron positivos para Mycobacterium tuberculosis (sensibles 92,3%). Tratamiento con cuatro f\u00e1rmacos y posteriormente dos de 6 a 12 meses. Evoluci\u00f3n: 84,6% curaci\u00f3n, 13,5% secuelas y un exitus. Conclusiones: la tuberculosis es un problema de salud infantil cuya forma m\u00e1s frecuente es pulmonar. Evoluciona favorablemente, pero presenta morbimortalidad. Es imprescindible tenerla en cuenta para diagn\u00f3stico y tratamiento precoz.\nCasos cl\u00ednicos\nLa infecci\u00f3n por el virus de Epstein-Barr (VEB) es habitual y generalmente ocurre en la infancia o en la adultez temprana. El VEB es la etiolog\u00eda de la mononucleosis infecciosa, generalmente asociada con fiebre, dolor de garganta, inflamaci\u00f3n de los ganglios linf\u00e1ticos en el cuello y en ocasiones esplenomegalia. El s\u00edndrome de Alicia en el Pa\u00eds de las Maravillas (SAPM) o s\u00edndrome de Todd es una afecci\u00f3n rara, que principalmente afecta la integraci\u00f3n visual y somatoest\u00e9tica. El SAPM sigue siendo un s\u00edndrome poco conocido y probablemente mal diagnosticado, puede ocurrir a cualquier edad, pero sobre todo en los ni\u00f1os en los que se asocia principalmente con la migra\u00f1a y la infecci\u00f3n por VEB. Presentamos a una paciente de diez a\u00f1os que acudi\u00f3 al servicio de urgencias con distorsi\u00f3n visual de la forma corporal y comportamiento extra\u00f1o, sospechado inicialmente como una patolog\u00eda psiqui\u00e1trica pero posteriormente diagnosticado con mononucleosis infecciosa e infecci\u00f3n por VEB confirmada serol\u00f3gicamente. Este caso refleja la importancia de reconocer este s\u00edndrome por parte de los m\u00e9dicos de urgencias y evitar derivaciones inadecuadas al servicio psiqui\u00e1trico.\nLa dificultad respiratoria en el periodo neonatal tard\u00edo constituye un reto pedi\u00e1trico no solo diagn\u00f3stico, sino de tratamiento, ya que a las m\u00faltiples causas del cuadro se deben sumar los factores inherentes a la propia vulnerabilidad del ni\u00f1o. En la pr\u00e1ctica habitual, la principal causa de estos cuadros son las infecciones (fundamentalmente v\u00edricas), aunque se deben tener en cuenta otras etiolog\u00edas como cardiol\u00f3gicas, digestivas, metab\u00f3licas o anat\u00f3micas. Presentamos un caso cl\u00ednico de tos, dificultad respiratoria e hipoxemia en un neonato de 17 d\u00edas de vida en el que los datos de la anamnesis, la exploraci\u00f3n y el cuadro cl\u00ednico condujeron a la realizaci\u00f3n de pruebas complementarias espec\u00edficas que llevaron al diagn\u00f3stico de neumon\u00eda por Chlamydia. Realizaremos asimismo una revisi\u00f3n sobre el estado actual de la cuesti\u00f3n bas\u00e1ndonos en el cuadro cl\u00ednico que presentaba el reci\u00e9n nacido.\nMuchos ni\u00f1os manifiestan linfadenopat\u00edas en alg\u00fan momento de su infancia, debidas sobre todo a enfermedades infecciosas. Es precisa una buena historia cl\u00ednica, exploraci\u00f3n f\u00edsica y pruebas complementarias que permitan su diagn\u00f3stico diferencial. Se describen los casos de dos ni\u00f1os que presentaban un cuadro cl\u00ednico similar de linfadenopat\u00edas regionales, sin fiebre ni exantemas. Ambos ten\u00edan como antecedente la picadura de garrapata en el cuero cabelludo. El cuadro cl\u00ednico y la serolog\u00eda positiva a rickettsias nos llevaron al diagn\u00f3stico de linfoadenopat\u00eda transmitida por garrapatas, TIBOLA, DEBONEL o SENLAT. El diagn\u00f3stico serol\u00f3gico en nuestros casos se encuentra limitado por la existencia de reacciones cruzadas con las distintas especies de rickettsias, en concreto con R. conorii (que es la habitualmente detectada en nuestro medio) e incluso con otras bacterias. La evoluci\u00f3n de ambos casos fue favorable con tratamiento de azitromicina durante cinco d\u00edas. Pese a la dificultad que supone la interpretaci\u00f3n de los resultados serol\u00f3gicos, el diagn\u00f3stico de esta rickettsiosis se puede hacer a la luz de los datos cl\u00ednicos y epidemiol\u00f3gicos. Debe plantearse la utilizaci\u00f3n simult\u00e1nea de otras t\u00e9cnicas para aumentar la sensibilidad diagn\u00f3stica como pueden ser en la actualidad las t\u00e9cnicas de reacci\u00f3n en cadena de la polimerasa en biopsia cut\u00e1nea que nos dar\u00e1n el diagn\u00f3stico etiol\u00f3gico de la infecci\u00f3n\nA 2-year-old boy was referred to our hospital with a 4-week widespread itchy skin eruption that had started 6 days after receiving measles\u2013mumps\u2013rubella vaccine. The rash first appeared on his face, and then spread to the arms, hands and feet. Skin examination revealed monomorphic erythematous 3\u20135 mm papules, some covered with crusts, in a symmetrical acral distribution over the face, hands, buttocks, feet, upper and lower limbs \u2026\nPara profundizar\nCompared with children fully DTaP vaccinated, unvaccinated and undervaccinated children were at a greater risk of pertussis. However, most pertussis cases occurred among age-appropriately vaccinated children.\nIn this issue of Pediatrics, the vaccine research group at Kaiser Permanente Northern California (KPNC) contributed another important article outlining the challenges of pertussis control in a highly vaccinated population.1 Nearly one-half million children born between 1999 and 2016 and managed at KPNC from 2006 to 2017 were evaluated. Of those immunized children, all had received only diphtheria-tetanus-acellular pertussis (DTaP) vaccine. In total, 738 polymerase chain reaction\u2013confirmed pertussis cases were diagnosed. Pertussis risk was 13 times higher among unvaccinated and nearly 2 times higher among undervaccinated children when compared with those who were fully vaccinated. However, >80% of the total pertussis cases were seen in children who had received all their recommended DTaP vaccine doses. Pertussis risk increased with increasing time since vaccination, clearly demonstrating waning immunity, which the KPNC group and others had previously reported\nPediatrics Jul 2019, 144 (1) e20191375\nClinicians caring for young febrile infants have struggled with risk stratification algorithms for invasive bacterial infections (IBIs) (bacteremia and/or bacterial meningitis) for decades1\u20135 because of the tension between not wanting to miss infants with IBIs yet not wanting to over-test and over-treat these vulnerable infants.6,7 Risk stratification algorithms using compete blood counts (CBCs) with or without cerebrospinal fluid (CSF) data, developed in the 1980s and 1990s, have several limitations: (1) laboratory thresholds were not derived by statistical methods, resulting in suboptimal test accuracies; (2) algorithm precision was limited by the relatively few infants with IBIs; (3) the epidemiology of IBIs has changed in the past decades8\u201310 with an increase in Escherichia coli and a decrease in group B Streptococcus infections due to perinatal screening; (4) algorithm specificity has been insufficient to limit the use of lumbar punctures, empirical antibiotics, and hospitalizations; and (5) newer biomarkers, including C-reactive protein (CRP) and particularly procalcitonin (PCT), are substantially more sensitive than the CBC for detecting infants with these infections.7,11,12\nIn a well-conducted retrospective case-control analysis from 11 emergency departments (EDs) between 2011 \u2026\nIn this multicenter case-control study, we derive and internally validate a highly sensitive score that identifies non\u2013ill-appearing febrile infants at low probability of bacteremia and/or bacterial meningitis.\nUsing systematic, prospective blood culture collection in children admitted with CAP, this study identifies risk factors and characterizes outcomes associated with bacteremia. .\nCONCLUSIONS Blood culture results identified a causative pathogen in only 2.2% of children hospitalized with CAP, and culture results were more often positive in those with parapneumonic effusions on chest radiograph and those with severe disease requiring ICU care. Penicillin-susceptible S pneumoniae was the most common cause of bacteremic CAP in our study, supporting the existing recommendation for empirical use of narrow-spectrum aminopenicillins for most children hospitalized with suspected bacterial CAP. In an era with widespread pneumococcal vaccination and low prevalence of bacteremia in the United States, children admitted with CAP that have pleural effusion or require ICU admission may represent a high-yield population for identifying bacteremia.\nIntroducci\u00f3n: La sacroile\u00edtis pi\u00f3gena (SIP) es una entidad infrecuente que representa del 1 al 2% del total de las infecciones articulares en la edad pedi\u00e1trica. Su diagn\u00f3stico a menudo se complica y retrasa debido a la inespecificidad de sus s\u00edntomas, signos y exploraci\u00f3n f\u00edsica. Adem\u00e1s, la identificaci\u00f3n microbiol\u00f3gica puede resultar dif\u00edcil debido a la alta proporci\u00f3n de hemocultivos negativos y los riesgos implicados en la aspiraci\u00f3n de l\u00edquido articular en esta localizaci\u00f3n.\nPacientes y m\u00e9todos: Revisi\u00f3n retrospectiva de las historias cl\u00ednicas de todos los pacientes menores de 18 a\u00f1os ingresados en un hospital infantil terciario con SIP en el per\u00edodo 2008-2016.\nResultados: Se identificaron 6 casos de SIP en ni\u00f1os. Los hemocultivos fueron negativos, y la identificaci\u00f3n del agente etiol\u00f3gico requiri\u00f3 aspiraci\u00f3n de l\u00edquido sinovial en un paciente con infecci\u00f3n por Aggregatibacter aphrophilus y pruebas espec\u00edficas para la detecci\u00f3n de agentes menos frecuentes en los pacientes restantes: Kingella kingae (n=2), Brucella melitensis (n=1) y Bartonella henselae (n=1). Los pacientes recibieron reg\u00edmenes de antibioterapia espec\u00edfica, y todos presentaron una evoluci\u00f3n favorable y libre de secuelas.\nConclusiones: A pesar del reducido tama\u00f1o muestral, nuestro estudio puso de relieve la baja efectividad del hemocultivo en el diagn\u00f3stico de la SIP pedi\u00e1trica. Tambi\u00e9n evidenci\u00f3 la necesidad de mantener un elevado \u00edndice de sospecha de los agentes at\u00edpicos y de emplear precozmente m\u00e9todos diagn\u00f3sticos apropiados, como las pruebas de imagen y la (PCR) en muestras de sangre, as\u00ed como la prescripci\u00f3n de antibioterapia efectiva.\nBackground: Pediatric sacroiliitis (SI) is an uncommon entity of infectious or inflammatory etiology. Recent data regarding pediatric SI are scarce. The study objective was to describe and compare the clinical features of pediatric infectious and noninfectious SI.\nMethods: We reviewed files of children \u226418 years of age, admitted with SI in 2004\u20132017. Patients were grouped by etiology, infectious versus noninfectious. Clinical and laboratory indices, imaging, treatment protocols and outcome were compared.\nResults: Study population included 40 patients with infectious SI (range: 3\u2013192 months, median age: 15 months, 45% female) and 13 patients with noninfectious SI (range: 30\u2013216 months, median age: 168 months, 62% females). Duration of symptoms before admission averaged 5.9 \u00b1 7.5 days in the infectious group and 54.2 \u00b1 96 days in the noninfectious group (P = 0.003). Symptoms observed solely in the infectious group included refusal to stand (n = 27, 77%); walk or crawl (n = 24, 65%); irritability (n = 20, 50%) and recent constipation event (n = 8, 20%). No significant differences in laboratory results were found. Infectious SI patients had uneventful medical history, rapid response to antibiotics and a higher rate of complete resolution of symptoms without recurrences.\nConclusions: An acute unilateral presentation in young patients \u22642 years of age, without chronic medical conditions, suggests an infectious etiology of SI anticipated to completely resolve with antibiotic treatment, not necessitating further workup for noninfectious etiologies.\nIntroducci\u00f3n: El objetivo del estudio es revisar nuestra experiencia en el manejo diagn\u00f3stico y terap\u00e9utico de los abscesos cervicales profundos infantiles, y compararla con la literatura publicada.\nMaterial y m\u00e9todos: Estudio retrospectivo de todos los pacientes diagnosticados y tratados de abscesos cervicales profundos infantiles durante 15 a\u00f1os (2002-2016), analizando las caracter\u00edsticas demogr\u00e1ficas, cl\u00ednicas, diagn\u00f3sticas y terap\u00e9uticas.\nResultados: Setenta y dos casos fueron diagnosticados. Se aprecia un incremento de su incidencia en los \u00faltimos a\u00f1os. La localizaci\u00f3n m\u00e1s frecuente han sido los abscesos periamigdalinos (30,6%), seguido de las adenopat\u00edas abscesificadas (18,1%), los abscesos parafar\u00edngeos (16,7%) y los retrofar\u00edngeos (16,7%). Las menos frecuentes han sido los abscesos submandibulares (12,5%) y parot\u00eddeos (5,6%). La distribuci\u00f3n fue diferente seg\u00fan edad (p<0,001). El s\u00edntoma cl\u00ednico m\u00e1s frecuente ha sido la fiebre (70,8%), seguido de la odinofagia (55,56%). Las pruebas de imagen m\u00e1s utilizadas han sido la TAC (50,7%) y la ecograf\u00eda (28,2%). El tratamiento empleado fue farmacol\u00f3gico en el 11,1%, todos ellos adenopat\u00edas abscesificadas menores de 1,5cm de tama\u00f1o m\u00e1ximo. El otro 88,9% fue intervenido quir\u00fargicamente. Hubo recidiva en el 12,5% de los casos.\nConclusiones; La realizaci\u00f3n de amigdalectom\u00eda y/o cervicotom\u00eda precoz en abscesos mayores de 2cm o lesiones de localizaci\u00f3n profunda disminuye el n\u00famero de complicaciones graves y no presenta recidivas. Al utilizar cirug\u00eda m\u00e1s conservadora, se han encontrado un 12,5% de recidivas.\nObjective Kawasaki disease (KD) is an increasingly common vasculitis with risk of coronary artery aneurysms (CAAs). The last UK survey was in 1990, whereas current epidemiology, treatment patterns and complication rates are unknown. The aim of this study was to address this knowledge gap.\nMethods A British Paediatric Surveillance Unit survey in the UK and Ireland from 1 January 2013 to 28 February 2015 ascertained demographics, ethnicity, seasonal incidence, treatment and complication rates.\nResults 553 cases were notified: 389 had complete KD, 46 had atypical KD and 116 had incomplete KD; 2 were diagnosed at postmortem with an incidence of 4.55/100 000 children under 5 years, with a male to female ratio of 1.5:1 and a median age of 2.7 years (2.5 months\u201315 years). Presentation was highest in January and in rural areas. Most were white (64%), and Chinese and Japanese Asians were over-represented as were black African or African mixed-race children. 94% received intravenous immunoglobulin (IVIG). The overall CAA rate was 19%, and all-cardiac complications affected 28%. Those with CAA received IVIG later than in those without (median 10 days vs 7 days). Those under 1 year had fewer symptoms, but the highest CAA rate (39%). Overall 8 of 512 cases (1.6%) had giant CAA, and 4 of 86 cases (5%) under 1 year of age developed giant CAA. Mortality from KD was 0.36%.\nConclusions The UK and Ireland incidence of KD has increased and is more frequently seen in winter and rural areas. Delayed IVIG treatment is associated with CAA, suggesting earlier and adjunctive primary treatment might reduce complications to prevent CAA, particularly in the very young.\nObjective Epidemics of Kawasaki disease (KD) are well known; however, the seasonal variation in the clinical course of KD is uncertain. The aim of this study was to investigate the seasonality in the clinical course of KD.\nMethods This study included 744 patients who were admitted to six hospitals in Kitakyushu City for KD from 2010 to 2014. We divided the patients into two groups according to the average monthly temperature (warm and cold periods) and compared the clinical courses of KD.\nResults The clinical courses of 715 patients who were initially treated with intravenous immunoglobulin (IVIG) were investigated. The proportion of patients with resistance to the initial IVIG therapy was significantly higher during the warm period than during the cold period (p=0.016). There was no seasonality in the proportion of patients with coronary artery abnormalities.\nConclusion Seasonality was observed in the response to IVIG therapy of patients with KD.\nI read with interest the article by Vadoothker et al.\n[1](https://journals.lww.com/pidj/Fulltext/2019/07000/Management_of_Herpes_Simplex_Virus_Keratitis_in.33.aspx#R1-33) The authors present an interesting review in the pathogenesis and management of herpes simplex virus (HSV) keratitis in the pediatric population. Although the authors highlight the fact that the treatment of HSV keratitis in children is challenging, however, some comments can be added to the management section of this article. Epithelial keratitis can be treated with topical antivirals at discretion of the treating physician, with good results in most of the cases without the need of systemic medication, using either 3% acyclovir ointment when available (in Europe or Latin-American), trifluridine or more recently ganciclovir ointment.\nBackground Diagnosis of intrathoracic tuberculosis (ITB) is limited in children partly by their difficulty to produce sputum specimen.\nObjective To systematically review the detection yields of mycobacterial culture and Xpert MTB/RIF from induced sputum (IS), nasopharyngeal aspirate (NPA) and gastric aspirate (GA) in children with presumptive ITB.\nDesign Pubmed, Embase and Biosis databases and grey literature were searched. Randomised controlled trials, cohort, cross-sectional or case control studies using IS, GA and NPA for diagnosis of ITB published between January 1990 and January 2018 were included. Data were extracted on study design, case definition of presumptive ITB, sample collection methods, outcome measures and results.\nResults 30 studies were selected, including 11 554 children. Detection yields for culture ranged between 1% and 30% for IS, 1% and 45% for GA and 4% and 24% for NPA. For Xpert MTB/RIF, it was between 2% and 17% for IS, 5% and 51% for GA and 3% and 8% for NPA. There was a tendency of better yields with IS when the pretest probability of ITB was low to moderate and with GA when it was high. Sampling a second specimen contributed for 6%\u201333% of the cumulative yield and combination of different methods significantly increase the detection yields.\nConclusions Despite the important study heterogeneity, any of the specimen collection methods offers good potential to confirm childhood ITB. However, their operational challenges were poorly evaluated. In the absence of a sensitive non-sputum based test, only a minority of children with ITB can be confirmed.\nLa enfermedad meningoc\u00f3cica invasiva (EMI), causada por la bacteria Neisseria meningitidis, supone una mortalidad y morbilidad significativas. La incidencia de la enfermedad alcanza el m\u00e1ximo entre lactantes <1 a\u00f1o y ni\u00f1os peque\u00f1os en todo el mundo. En Europa, el serogrupo B de N. meningitidis es responsable de m\u00e1s del 50 % de todos los casos de EMI, mientras que en Latinoam\u00e9rica la mayor\u00eda de los casos de EMI se deben a los serogrupos B o C. El desarrollo de una vacuna efectiva frente al serogrupo B ha supuesto un reto para los investigadores a lo largo de m\u00e1s de medio siglo. Los polisac\u00e1ridos capsulares del serogrupo B no eran ant\u00edgenos vacunales apropiados, y el \u00e9xito de las vacunas de ves\u00edculas de la membrana externa (OMV) se limitaba a las cepas bacterianas hom\u00f3logas. La vacunolog\u00eda inversa permiti\u00f3 desarrollar una vacuna meningoc\u00f3cica de 4 componentes que inclu\u00eda tres ant\u00edgenos novedosos y las OMVs (4CMenB). Cada componente de la vacuna posee una diana distinta. La vacuna 4CMenB ha sido autorizada bas\u00e1ndose en datos de inmunogenicidad y seguridad, debido a que la baja incidencia de la enfermedad impide la realizaci\u00f3n de estudios de eficacia cl\u00ednica. El an\u00e1lisis de anticuerpos bactericidas en suero con complemento humano (hSBA) mide los anticuerpos funcionales del suero de los sujetos vacunados (es decir, la inmunogenicidad vacunal) y constituye un correlato de protecci\u00f3n aceptado. La cobertura de cepas vacunales se ha evaluado tanto mediante el an\u00e1lisis de la hSBA, como mediante otro m\u00e9todo m\u00e1s conservador denominado Sistema de Tipificaci\u00f3n de Ant\u00edgenos Meningoc\u00f3cicos (MATS). Desde 2013, se han recogido datos de efectividad en vida real de 4CMenB. La vacuna result\u00f3 efectiva en el control de brotes de Norteam\u00e9rica y los datos recientes de introducci\u00f3n de la vacuna en el programa nacional de vacunaci\u00f3n de lactantes del Reino Unido, han revelado una efectividad vacunal del 82,9 % tras las dos primeras dosis, junto a un perfil de seguridad aceptable.\nLa s\u00edfilis est\u00e1 causada por la espiroqueta Treponema pallidum subsp. Pallidum, que se transmite por v\u00eda sexual o vertical durante la gestaci\u00f3n. Su incidencia se ha incrementado en los \u00faltimos a\u00f1os, especialmente entre los hombres que tienen sexo con hombres. Sin tratamiento, la infecci\u00f3n progresa en distintas fases que terminan en complicaciones irreversibles neurol\u00f3gicas y cardiovasculares. Para su clasificaci\u00f3n diferenciamos entre s\u00edfilis precoz (primaria, secundaria y latente de menos de un a\u00f1o), que es infecciosa, de la s\u00edfilis tard\u00eda (latente de m\u00e1s de un a\u00f1o y terciaria), en la que el paciente no es contagioso. El diagn\u00f3stico y el tratamiento no es sencillo debido a la gran variedad de manifestaciones cl\u00ednicas y a la dificultad en la interpretaci\u00f3n de las pruebas serol\u00f3gicas. El tratamiento de la s\u00edfilis se basa en la administraci\u00f3n de penicilina o de doxiciclina en casos de alergia. Con azitromicina se han descrito fracasos terap\u00e9uticos y se han encontrado resistencias. Los pacientes que hayan sido diagnosticados y tratados deben de ser seguidos para evaluar la respuesta al tratamiento y diagnosticar posibles reinfecciones.\nIntroducci\u00f3n: las infecciones por adenovirus tienen una presentaci\u00f3n cl\u00ednica variable y son una importante causa de morbilidad en la infancia. Frecuentemente reciben tratamiento antibi\u00f3tico de forma innecesaria. Este estudio busca analizar las caracter\u00edsticas de los pacientes con infecci\u00f3n por adenovirus y ver si difieren de aquellos con infecci\u00f3n bacteriana. Pacientes y m\u00e9todos: se estudiaron 174 pacientes ingresados en un hospital terciario desde enero de 2009 hasta agosto de 2017 a los que se les detect\u00f3 adenovirus. Se analizaron las variables cl\u00ednicas y anal\u00edticas y se compararon con las de una muestra de pacientes diagnosticados de infecci\u00f3n bacteriana confirmada en el mismo centro en 2016.Resultados: la tasa de pacientes con infecci\u00f3n por adenovirus fue de 1,58/100 ingresos. El 64% eran varones, siendo la edad media de 17 meses. Los que solo presentaban s\u00edntomas gastrointestinales ten\u00edan una menor edad y resultados anal\u00edticos m\u00e1s favorables que los que solo mostraban s\u00edntomas respiratorios. Un 24,5% presentaban coinfecci\u00f3n por otro virus, observ\u00e1ndose en este grupo una mayor estancia hospitalaria (7,93 frente a 6,17 d\u00edas, p = 0,006). Los criterios anal\u00edticos de infecci\u00f3n bacteriana grave no mostraron diferencias significativas al comparar entre los pacientes infectados por adenovirus y los que ten\u00edan una infecci\u00f3n bacteriana confirmada, excepto una diferencia m\u00ednima, aunque estad\u00edsticamente significativa, al comparar las cifras de prote\u00edna C reactiva. Conclusiones: las variables anal\u00edticas y cl\u00ednicas estudiadas no son suficientes para discriminar entre infecci\u00f3n bacteriana y por adenovirus. Ser\u00eda adecuado descartar infecci\u00f3n por adenovirus sistem\u00e1ticamente antes de instaurar tratamiento antibi\u00f3tico.\nIntroducci\u00f3n: a pesar de los numerosos estudios publicados hasta la fecha sobre el tratamiento hospitalario de la bronquiolitis y de la prometedora eficacia del suero salino hipert\u00f3nico, lo cierto es que existe controversia al respecto. Material y m\u00e9todos: estudio observacional prospectivo que eval\u00faa la eficacia del suero hipert\u00f3nico al 3% frente al suero fisiol\u00f3gico en el tratamiento hospitalario de la bronquiolitis, en t\u00e9rminos de reducci\u00f3n de estancia y de puntuaci\u00f3n de escala cl\u00ednica de gravedad; en una segunda fase se analizan factores de riesgo asociados al reingreso por broncoespasmo de los mismos pacientes. Resultados: se analizan 67 de los 73 pacientes ingresados por bronquiolitis, de los cuales 9 recibieron fisiol\u00f3gico y 58 hipert\u00f3nico, con o sin broncodilatador asociado. La estancia hospitalaria fue de 6,07 \u00b1 3,12 d\u00edas para el grupo fisiol\u00f3gico, y de 6,67 \u00b1 4,36 d\u00edas para el grupo con hipert\u00f3nico. La media de la puntuaci\u00f3n (Wood-Downes modificado por Ferr\u00e9s) para el grupo con fisiol\u00f3gico fue de 3,67 \u00b1 1,1 y de 3,16 \u00b1 1,1 para los que recibieron hipert\u00f3nico. Para la segunda fase se obtiene una tasa de reingresos del 8,2%. Conclusiones: no encontramos diferencias significativas entre ambos grupos en tiempo de hospitalizaci\u00f3n ni en mejor\u00eda de escala cl\u00ednica y d\u00edas de oxigenoterapia. Pese al reducido tama\u00f1o muestral no observamos ninguna tendencia a favor de diferencias significativas en nuestra muestra. Los factores m\u00e1s relacionados con el reingreso han sido la edad menor a 6 meses, el sexo masculino, el tener hermanos mayores y el tabaquismo familiar.\nBackground: Enterovirus (EV) D68 is mainly associated with acute respiratory infection (ARI). Since 2014, when outbreaks in different countries were observed, this emerging virus was considered a potential threat to public health.\nMethods: During 2015\u20132017, the presence of enterovirus RNA was investigated in all respiratory samples of children younger than 15 years of age with ARI, obtained for virologic studies in the Pediatric Emergency Care Units and wards of 2 hospitals in Gipuzkoa (Spain), using a commercial multiplex real-time polymerase chain reaction. When enterovirus was detected, a polymerase chain reaction to amplify a specific viral polyprotein (VP1) gene region of EV-D68 was performed.\nResults: In 2016, EV-D68 circulation was associated to ARI, with the highest incidence in the spring months. EV-D68 was detected in 44 children, mean age 30.1 \u00b1 31.7 months old, 23 (52.3%) of them females and 17 (38.6%) with underlying respiratory medical conditions. Thirty-two patients (72%) required hospital admission, receiving the discharge diagnosis of recurrent wheezing (37.5%), asthmatic crisis (37.5%) or bronchiolitis (12.5%). Seven children (15.9%) needed the support of the pediatric intensive care unit. When coinfections were excluded, children with EV-D68 infection presented with increased work of breathing, recurrent wheezing or asthmatic crisis, more frequently than those with ARI associated with EV non-D68. Moreover, clinical outcomes (hospitalization, respiratory support) were more severe. All 44 EV-D68 strains detected belonged to lineage B3.\nConclusions: EV-D68 circulated widely in Gipuzkoa during 2016 and was associated with severe ARI. In children with severe ARI of unknown etiology, the presence of EV-D68 should be considered.\nConclusiones de los autores del estudio: la profilaxis antibi\u00f3tica no est\u00e1 indicada para la prevenci\u00f3n de cicatrices renales tras la primera o segunda infecci\u00f3n urinaria febril en ni\u00f1os sanos.\nComentario de los revisores: la incidencia de cicatrices renales tras una infecci\u00f3n urinaria febril en ni\u00f1os sanos es baja, en torno al 6%. No hay diferencias entre el grupo tratado profil\u00e1cticamente con antibi\u00f3ticos y el grupo control, por lo que la administraci\u00f3n de profilaxis antibi\u00f3tica no est\u00e1 justificada.\nDebido a la enfermedad aguda causada por la infecci\u00f3n de orina (IU) y al riesgo de da\u00f1o renal permanente tras sufrir una pielonefritis, a muchos ni\u00f1os se les administran antibi\u00f3ticos a largo plazo destinados a prevenir la recurrencia. Esta es la tercera actualizaci\u00f3n de una revisi\u00f3n publicada por primera vez en 2001 y actualizada en 2006 y 2011.\nEl objetivo es evaluar si la profilaxis antibi\u00f3tica a largo plazo fue m\u00e1s efectiva que el placebo / ning\u00fan tratamiento para prevenir la recurrencia de la IU en ni\u00f1os, y si es as\u00ed, qu\u00e9 antibi\u00f3tico fue el m\u00e1s efectivo. Tambi\u00e9n evaluamos los da\u00f1os del tratamiento antibi\u00f3tico a largo plazo.\nLa conclusi\u00f3n a la que llegan los autores es que los antibi\u00f3ticos a largo plazo pueden reducir el riesgo de que se repita una IU sintom\u00e1tica en ni\u00f1os que han tenido una o m\u00e1s IU previamente, pero el beneficio puede ser peque\u00f1o y debe considerarse junto con el mayor riesgo de resistencia microbiana.\nBackground: Hepatitis C virus (HCV) is the most commonly encountered blood transmittable hepatitis among cancer patients. Several studies have reported clustering of HCV infections in families or household contacts of infected cases. Data about the epidemiologic aspects of intrafamilial transmission from pediatric cancer patients are scarce and still debated. We aimed to identify the magnitude of horizontal intrafamilial transmission of HCV from infected pediatric oncology patients; its prevalence, risk factors and possible routes of transmission.\nMethods: One hundred fifty-seven (86 HCV positive, 71 HCV negative) pediatric oncology patients who received treatment and follow-up at Zagazig university Hospital-Egypt and their household family contacts (751) were enrolled in this cross-sectional case-control study. Blood samples were collected from 450 relatives of HCV infected cases (group 1) and 301 household contacts of HCV-negative cases (group 2) for analysis of HCV antibodies and HCV RNA to confirm positivity. Family contacts of HCV-infected cases were interviewed, and close-ended questionnaire was completed for each participant to determine risk factors and possible routes of HCV intrafamilial transmission.\nResults: Significantly higher HCV prevalence and chronicity rates were documented among relatives of HCV-infected cases as compared with contacts of HCV-negative cases (12.6% and 10.6% for group 1 vs. 7% and 5.3% for group 2, respectively). Risk factors of infection were calculated by univariate and logistic regression analysis among contacts of HCV-infected cases. Female caregivers, particularly mother (OR 5.1, 95% CI: 2\u201313.5), contact with index cases blood, either directly without using personal protective equipment (OR 7.8, 95% CI: 2.9\u201323.8) or indirectly through common use of sharps (razors, scissors) (OR 8.9, 95% CI: 3.5\u201320.5) and nail clippers (OR 2.1, 95% CI: 1.1\u20135.4) and giving care to infected cases (OR 2.9, 95% CI: 1.3\u201316.6) represented the real predictors of intrafamilial HCV infection.\nConclusions: Intrafamilial transmission of HCV from infected children to their relatives does occur. Parenteral route is the only documented way of transmission either directly or indirectly.\nDos art\u00edculos que analizan el aumento de casos de sarampi\u00f3n en Inglaterra, hecho patente en muchos otros pa\u00edses de nuestro entorno, as\u00ed como la incredulidad y hostilidad frente a la vacuna que han contribuido a la disminuci\u00f3n de las tasas de vacunaci\u00f3n de la triple v\u00edrica\nSalud p\u00fablica inglesa revela que los casos recientes de sarampi\u00f3n se produjeron principalmente en comunidades no vacunadas y estaban relacionados con viajes a pa\u00edses con grandes brotes actuales. Aunque las coberturas vacunales son elevadas con la primera dosis, (94.9% de los de 5 a\u00f1os), descienden a un 87,4% en las 2\u00aa dosis, muy por debajo del 95% recomendado por la Organizaci\u00f3n Mundial de la Salud para garantizar una inmunidad efectiva para el conseguir el efecto reba\u00f1o.\nEl mes pasado, un informe de Unicef mostr\u00f3 que alrededor de 169 millones de ni\u00f1os en todo el mundo no hab\u00edan recibido su primera dosis de la vacuna contra el sarampi\u00f3n entre 2010 y 2017, y la Organizaci\u00f3n Mundial de la Salud descubri\u00f3 que los casos de sarampi\u00f3n hab\u00edan aumentado en un 300% en todo el mundo entre enero y abril de 2019. , en comparaci\u00f3n con el mismo per\u00edodo en 2018.\nEsta disminuci\u00f3n de las tasas de vacunaci\u00f3n se ha atribuido a la vacilaci\u00f3n frente a la vacunaci\u00f3n de m\u00e9dicos y gobiernos, agravada por la difusi\u00f3n de supuestos efectos adversos no probados, propagados por grupos \u201cpseudocient\u00edficos\u201d en las redes sociales. Los argumentos se centran en la libertad individual y el derecho de los padres a tomar decisiones por sus propios hijos.\nLa OMS ha publicado directrices sobre c\u00f3mo responder en p\u00fablico a quienes rechazan las vacunas. Tal vez sea mejor enfocarse en m\u00e9todos efectivos para elevar las tasas de vacunaci\u00f3n y aceptar que algunos debates no se pueden ganar o si se ganan solo ser\u00e1n para quedar mal.\nLas infecciones neumoc\u00f3cicas son las principales causas de morbilidad y mortalidad en todo el mundo. Utilizamos datos de ingreso hospitalarios de rutina y an\u00e1lisis de modelos de series de tiempo para estimar el impacto de las vacunas conjugadas antineumoc\u00f3cicas siete y trece valentes (PCV7 y PCV13) en los ingresos hospitalarios debido a la enfermedad neumoc\u00f3cica en Inglaterra.\nSe redujeron sustancialmente los ingresos hospitalarios por bacteriemia, meningitis y neumon\u00eda en Inglaterra despu\u00e9s de la introducci\u00f3n de la vacunaci\u00f3n infantil.\nEl diagn\u00f3stico r\u00e1pido y preciso de la tuberculosis (TB) infantil es dif\u00edcil porque los ni\u00f1os a menudo no pueden producir la muestra de esputo necesaria para las pruebas convencionales. Las heces son un tipo de muestra alternativa que es f\u00e1cil de recoger en los ni\u00f1os. Los estudios que investigan el uso de heces para la detecci\u00f3n molecular de Mycobacterium tuberculosis (Mtb) han dado resultados prometedores. El objetivo fue evaluar las heces como una muestra alternativa al esputo para la detecci\u00f3n de Mtb en ni\u00f1os.\nLas muestras de heces analizadas con el m\u00e9todo TruTip y la amplificaci\u00f3n IS6110 produjeron estimaciones de sensibilidad y especificidad comparables a otras pruebas como el Xpert.\nDue to its innately intriguing nature and recent genomic technological advances, gut microbiome research has been at the epicentre of medical research for over a decade now. Despite the degree of publicisation, a comprehensive understanding and, therefore, acceptance of the area as a whole may be somewhat lacking within the broader medical community. This paper summarises the main analytical techniques and tools currently applied to compositional microbiome research. In addition, we outline five major lessons learnt from a decade of infant microbiome research, along with the current research gaps. Finally, we aim to provide an introduction and general guidelines relating to infant gut microbiome research for the practising paediatrician.\nWe searched and identified 17 randomised controlled trials (studies in which participants are assigned to one of two or more treatment groups using a random method), published before October 2018. All were conducted in Europe, and collectively included 3488 children. Twelve trials included children who were not prone to acute middle ear infections, whilst five trials included children who were prone to such infections.\nKey results\nOne-third fewer children not prone to acute middle ear infection who took probiotics experienced acute middle ear infections compared to children not taking probiotics. However, probiotics may not benefit children prone to acute middle ear infection. Taking probiotics did not impact on the number of days of school that children missed. None of the studies reported on the impact of probiotics on the severity of acute middle ear infection. There was no difference between the group taking probiotics and the group not taking probiotics in the number of children experiencing adverse events (harms).\nQuality of the evidence\nThe quality (or certainty) of the evidence was generally moderate (meaning that further research may change our estimates) or high (further research is unlikely to change our estimates). However, the trials differed in terms of types of probiotics evaluated, how often and for how long they were taken, and how the trial results were reported.\nActualidad bibliogr\u00e1fica junio 2019\nTop Ten\nEl objetivo de este estudio es conocer las caracter\u00edsticas epidemiol\u00f3gicas, cl\u00ednicas y anal\u00edticas de la primoinfecci\u00f3n por el virus de Epstein-Barr (VEB) en ni\u00f1os sin diagn\u00f3stico previo de ninguna enfermedad inmune y su relaci\u00f3n con la forma de presentaci\u00f3n cl\u00ednica.\nEstudio retrospectivo de pacientes entre 0 y 15 a\u00f1os con IgM s\u00e9rica frente a la c\u00e1pside viral del VEB positiva o indeterminada, durante un per\u00edodo de 22 meses. Se analizaron datos epidemiol\u00f3gicos, cl\u00ednicos y de laboratorio y se compararon seg\u00fan tuvieran una cl\u00ednica t\u00edpica (s\u00edndrome mononucle\u00f3sico) o no t\u00edpica.\nSe incluyeron 103 ni\u00f1os. La mediana de la edad fue de 7 a\u00f1os (3-12,5 a\u00f1os). El 63% de los pacientes presentaron cl\u00ednica t\u00edpica o s\u00edndrome mononucle\u00f3sico y el 37% una cl\u00ednica no t\u00edpica. La edad fue significativamente menor en el grupo de cl\u00ednica no t\u00edpica (p=0,03) y recibieron menos tratamiento antibi\u00f3tico (p=0,015). En los par\u00e1metros anal\u00edticos no hubo diferencias estad\u00edsticamente significativas excepto en la PCR, discretamente m\u00e1s elevada en el grupo de cl\u00ednica t\u00edpica (p=0,04). El 33% de los pacientes tuvieron anticuerpos heter\u00f3filos positivos. El 20% tuvieron una IgM frente a la c\u00e1pside viral indeterminada, la mayor\u00eda con cl\u00ednica oligosintom\u00e1tica o at\u00edpica. El 21% tuvieron IgM positivas para otros virus y 3 de ellos fueron posibles falsos positivos para el VEB.\nEn nuestra poblaci\u00f3n, la primoinfecci\u00f3n por VEB es frecuente en ni\u00f1os de menor edad, y en ellos predominan las formas oligosintom\u00e1ticas. El porcentaje de anticuerpos heter\u00f3filos positivos ha sido muy bajo en nuestra muestra. Los casos con IgM frente a la c\u00e1pside viral indeterminada son m\u00e1s frecuentes en el grupo de cl\u00ednica no t\u00edpica. Es com\u00fan detectar coinfecci\u00f3n con otros virus.\nM\u00e9todos: El Grupo de Infecciones Respiratorias de la Sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica llev\u00f3 a cabo una revisi\u00f3n de la bibliograf\u00eda. Los hallazgos se analizaron mediante la metodolog\u00eda GRADE, y se elaboraron unas recomendaciones. Resultados: No se recomienda el uso sistem\u00e1tico de pruebas diagn\u00f3sticas para la gripe en el \u00e1mbito ambulatorio y en urgencias hospitalarias en pacientes inmunocompetentes con un cuadro cl\u00ednico compatible. No se recomienda el uso de antivirales a la gran mayor\u00eda de los pacientes sanos y asm\u00e1ticos con gripe o sospecha de gripe estacional, si el objetivo es prevenir eventos graves. No se recomienda el uso de oseltamivir de forma sistem\u00e1tica en pacientes hospitalizados con gripe. Se recomienda tratar con oseltamivir a los pacientes con gripe y neumon\u00eda o enfermedad grave o a los pacientes cr\u00edticos, especialmente durante las primeras 48 h de enfermedad. Se recomienda el tratamiento de los pacientes con factores de riesgo, teniendo en cuenta su enfermedad de base. La vacunaci\u00f3n antigripal, junto a las medidas b\u00e1sicas de evitaci\u00f3n, contin\u00faan siendo la principal herramienta en la prevenci\u00f3n de la gripe.\nConclusi\u00f3n: En algunas situaciones hay datos suficientes para emitir recomendaciones claras. En otras situaciones los datos son incompletos y solo permiten hacer recomendaciones d\u00e9biles.\nLa infecci\u00f3n del tracto urinario se define como el crecimiento de microorganismos en orina recogida de forma est\u00e9ril, en un paciente con s\u00edntomas cl\u00ednicos compatibles. En ausencia de sintomatolog\u00eda el aislamiento de bacterias en urocultivo se denomina bacteriuria asintom\u00e1tica y no precisa tratamiento.\nLa infecci\u00f3n por Chlamydia trachomatis es un importante problema de salud p\u00fablica mundial y la principal causa bacteriana de infecciones de transmisi\u00f3n sexual. La infecci\u00f3n puede transmitirse a trav\u00e9s del canal del parto, pudiendo ocasionar nasofaringitis y/o conjuntivitis neonatal (habitualmente 5-12 d\u00edas tras el parto), as\u00ed como neumon\u00eda en los 3 primeros meses de vida1,2. El diagn\u00f3stico etiol\u00f3gico de estas infecciones es importante, porque la sintomatolog\u00eda no se diferencia de la causada por otros microorganismos y los tratamientos que no incluyan un macr\u00f3lido pueden no ser eficaces frente a C. trachomatis. El objetivo del presente trabajo fue investigar la tasa de transmisi\u00f3n perinatal de la infecci\u00f3n por C. trachomatis.\nEntre octubre/2010 y septiembre/2015 se estudi\u00f3 prospectivamente, mediante una t\u00e9cnica de amplificaci\u00f3n de \u00e1cidos nucleicos (TAAN) en tiempo real (Cobas\u00ae 4800 CT/NG, Roche), la presencia de C. trachomatis en 103 hijos de madres infectadas,\u2026\ndetectadas en un cribado puerperal realizado en el Hospital Universitario Donostia (HUD) 3 . Este estudio de investigaci\u00f3n fue aprobado por el Comit\u00e9 de \u00c9tica del HUD (acta 9/2010). Los ni\u00f1os, como todos los reci\u00e9n nacidos en el HUD, recibieron profilaxis ocular neonatal con pomada oft\u00e1lmica de tobramicina hasta octubre de 2013 o hidrocloruro de clortetraciclina con posterioridad. La transmisi\u00f3n vertical en el neonato se evalu\u00f3 7-10 d\u00edas tras el parto mediante una exploraci\u00f3n f\u00edsica y la obtenci\u00f3n de exudado far\u00edngeo, suplementado con exudado conjuntival en el \u00faltimo a\u00f1o del estudio y en los casos con sospecha de conjuntivitis. Los neonatos infectados fueron tratados por v\u00eda oral con eritromicina 14 d\u00edas mientras estuvo la formulaci\u00f3n disponible en el hospital o con posterioridad azitromicina 3 d\u00edas. Se realiz\u00f3 seguimiento cl\u00ednico durante 3 meses (instrucci\u00f3n a los padres para acudir a la consulta en caso de aparici\u00f3n de s\u00edntomas de conjuntivitis, neumon\u00eda o nasofaringitis, y confirmaci\u00f3n de la ausencia de s\u00edntomas telef\u00f3nicamente al finalizar el periodo).\nSe constat\u00f3 transmisi\u00f3n vertical en 11 (10,7%) ni\u00f1os (5 varones, 6 mujeres), distribuidos uniformemente en el per\u00edodo de estudio. El porcentaje ascendi\u00f3 al 15,5% (11/71) excluyendo los nacidos por ces\u00e1rea y/o de madres que recibieron tratamiento antibi\u00f3tico en las 48 h preparto (\n[tabla 1](https://www-clinicalkey-es.scsalud.a17.csinet.es/tbl0005) ). C. trachomatis se detect\u00f3 en el 8,7% de las muestras far\u00edngeas (9/103) y el 17,6% (6/34) de las conjuntivales (p = 0,15). Siete ni\u00f1os infectados estaban asintom\u00e1ticos y 4 (3,9% del total de vigilados) presentaban conjuntivitis, en un caso asociada a cuadro catarral. Todos los casos recibieron tratamiento antibi\u00f3tico (7 eritromicina, 4 azitromicina), resolvi\u00e9ndose la infecci\u00f3n tempranamente en 7/8 que acudieron al control microbiol\u00f3gico a los 15 d\u00edas; en otro caso, la detecci\u00f3n de C. trachomatis y la sintomatolog\u00eda (conjuntivitis) persisti\u00f3 durante 2 meses, por inadecuada dispensaci\u00f3n del tratamiento por los padres.\nCasos cl\u00ednicos\nLa enfermedad por ara\u00f1azo de gato (EAG) es una enfermedad benigna y autolimitada causada por Bartonella henselae. Cl\u00e1sicamente se presenta con linfadenopat\u00eda regional, pero en un 5-15% de casos se puede presentar de forma sist\u00e9mica\n[1](https://www.analesdepediatria.org/es-enfermedad-diseminada-por-aranazo-gato-articulo-S1695403318302777#bib0035) consider\u00e1ndose parte del diagn\u00f3stico diferencial de la fiebre de origen desconocido (FOD). Presentamos los casos de 2 pacientes con EAG diseminado atendidos en el hospital NCH, Columbus, Ohio, EE.UU.\nNi\u00f1o de 14 a\u00f1os sano, con fiebre de 16 d\u00edas,\u2026\nA healthy 2-year-old child was referred to the paediatric emergency department for febrile torticollis with 1 cm painful cervical lymph nodes. Blood tests showed 20.8 mg/L C reactive protein and an acute Epstein-Barr virus infection. The persistence of torticollis despite a regular intake of both paracetamol and ibuprofen for 2 weeks suggested another aetiology. A CT scan associated with MRI showed an inflammatory process at the C1\u2013C2 vertebrae (figure 1), and Kingella kingae-specific PCR was positive on biopsy. Cefamandole (150 mg/kg/day) was given intravenously for 7 days, followed by oral amoxicillin \u2026\nA 7-year-old girl developed severe neck stiffness and trismus while on treatment for a presumed throat infection. Examination findings included a fixed torticollis with restricted neck movements in all directions (figure 1); erythematous tonsils and cervical lymphadenopathy. Group A strep was cultured from her throat swab. She coincidentally had diabetes mellitus. CT neck with contrast revealed subluxation of C1/C2 (figure 2, left); and bilateral retropharyngeal, deep \u2026\nAn 11-year-old girl with trisomy 21 and severe atopic dermatitis was admitted for fever of 4 days and nonitchy diffuse thick crusted scaly rash of unknown duration. Prior to the onset of the rash, she had been maintained on topical triamcinolone 1% as treatment for atopic dermatitis. Physical examination revealed elevated temperature (38.7\u00b0C), tachycardia (127 beats per minute), diffuse dry hyperkeratotic crusts (\n[Figure](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/8928f869-9fde-474a-86bf-d0fe0783770f/gr1.jpg), A and B), and areas of skin tenderness and erythema ( [Figure](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/8928f869-9fde-474a-86bf-d0fe0783770f/gr1.jpg), B [arrow]). The rest of the examination was unremarkable. Laboratory evaluation showed leukocytosis and neutrophilia. Direct microscopy of skin scrapings revealed live scabies mites and eggs, confirming the diagnosis of Norwegian scabies. She was treated with topical permethrin 5% for 2 weeks, 7 daily doses of oral ivermectin, 200 \u03bcg/kg each (days 1, 2, 8, 9, 15, 22, and 29), and a 7-day course of clindamycin for possible superimposed bacterial infection. The rash improved within 1 week ( [Figure](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/8928f869-9fde-474a-86bf-d0fe0783770f/gr1.jpg), C and D). She had negative HIV testing, normal lymphocytic subset, and B cell panel. Immunoglobulin levels showed elevated IgG and IgE and normal IgM.\nA 27-month-old boy was referred to pediatric dermatology for the evaluation of crusts on his eyelashes; they had been present for 2 months and were increasing in number. The crusts had appeared after a trip to Bulgaria, where his family had been sleeping in several different hotels and places. Physical examination showed crusts on both eyelashes and a few crusts on the front part of his scalp. He had slight conjunctivitis and palpebral pruritis. The child was in good health and the physical examination was otherwise normal. His weight was 13.5 kg.\nFindings of a dermoscopy examination revealed that the crusts actually consisted of agglomerates of nits on the proximal side of the eyelashes, and several parasites were visible (\n[Figure](https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/e660b89d-d954-4705-a5e6-0403d82a8d85/gr1.jpg)). There were a few parasites on the front part of his scalp hair also. The hair on his father's chest had several nits. Parasitology examination revealed that the parasites were Phtirus pubis. The child and his parents were given oral ivermectin 400 \u03bcg/kg (day 1 and day 7) and topical ophthalmologic rifamycin ointment once a day for 7 days, along with manual removal of the nits and parasites. Complete remission was obtained after 3 weeks of treatment. After interrogation, we concluded that phthiriasis had been transmitted from the father's chest to the child, who used to sleep on the chest of his parents.\nPara profundizar\nTo determine whether treatment for urinary tract infections in children could be individualized using biomarkers for acute pyelonephritis.\nStudy design\nWe enrolled 61 children with febrile urinary tract infections, collected blood and urine samples, and performed a renal scan within 2 weeks of diagnosis to identify those with pyelonephritis. Renal scans were interpreted centrally by 2 experts. We measured inflammatory proteins in blood and urine using LUMINEX or an enzyme-linked immunosorbent assay. We evaluated serum RNA expression using RNA sequencing in a subset of children. Finally, for children with Escherichia coli isolated from urine cultures, we performed a polymerase chain reaction for 4 previously identified virulence genes.\nResults\nUrinary markers that best differentiated pyelonephritis from cystitis included chemokine (C-X-C motif) ligand (CXCL)1, CXCL9, CXCL12, C-C motif chemokine ligand 2, INF \u03b3, and IL-15. Serum procalcitonin was the best serum marker for pyelonephritis. Genes in the interferon-\u03b3 pathway were upregulated in serum of children with pyelonephritis. The presence of E coli virulence genes did not correlate with pyelonephritis.\nConclusions\nImmune response to pyelonephritis and cystitis differs quantitatively and qualitatively; this may be useful in differentiating these 2 conditions.\nAcute otitis media (AOM) is one of the most common childhood infections, generally thought to be caused by ascension of bacteria from the nasopharynx (NP) to the middle ear. Using 16S ribosomal RNA-based sequencing, we evaluated the relationship between the NP and middle ear fluid (MEF) microbiota in children with AOM with tympanostomy tubes (AOMT) as a proxy for AOM and explored whether microbiota profiling predicts natural disease course.\nMicrobiota profiles of paired NP and MEF samples of 94 children below 5 years of age with uncomplicated AOMT were determined.\nLocal diversity (P < 0.001) and overall microbiota composition (P < 0.001) of NP and MEF samples differed significantly, although paired NP and MEF samples were much more similar than unpaired samples (P < 0.001). High qualitative agreement between the presence of individual bacteria in both niches was observed. Abundances of Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes, Turicella otitidis, Klebsiella pneumoniae and Haemophilus spp. were strongly correlated between the 2 niches. Additionally, P. aeruginosa, S. aureus, T. otitidis and Streptococcus pneumoniae abundance in NP were predictive of the presence of a range of oral types of bacteria in MEF. Interestingly, there was no association between Moraxella catarrhalis in NP and MEF samples, which was highly present in NP but virtually absent in MEF. Finally, the NP microbiota composition could predict duration of AOMT, even better than MEF microbiota.\nWe observed substantial correlations between paired NP and MEF microbiota in children with AOMT. Our data also suggest that NP microbiota profiling deserves further exploration as tool for future treatment decisions.\nThe Mantoux tuberculin test (TST) is likely the oldest widely used test in contemporary diagnostics. In the past, when its obvious weaknesses were considered, it always \u201creceived a pass\u201d because of the lack of an alternative test. However, with the advent and improvement of interferon \u03b3 release assays (IGRAs), we feel it is past time to reconsider the widespread use of TSTs.\nExisten datos limitados acerca de los abscesos perianales (AP), con respecto a su etiolog\u00eda y tratamiento. Este estudio retrospectivo tiene como objetivo definir las caracter\u00edsticas de los ni\u00f1os con AP, detallar nuestra experiencia en el campo de las enfermedades infecciosas pedi\u00e1tricas y determinar los factores que influyen en los resultados cl\u00ednicos.\nEntre enero de 2005 y julio de 2015 se llev\u00f3 a cabo una revisi\u00f3n retrospectiva de ni\u00f1os con AP sin enfermedad subyacente en un hospital de referencia de nivel terciario. La informaci\u00f3n incluy\u00f3 caracter\u00edsticas demogr\u00e1ficas, s\u00edntomas, tama\u00f1o y localizaci\u00f3n del absceso, recurrencias de los abscesos, hallazgos de laboratorio y microbiol\u00f3gicos, modalidades de tratamiento, diagn\u00f3stico de enfermedades sist\u00e9micas al finalizar las investigaciones etiol\u00f3gicas y pron\u00f3stico.\nResultados\nEn el estudio se incluyeron 47 pacientes, con predominio masculino (93,6 frente a 6,4%, p<0,001). La mediana de edad fue de 7,7 meses (rango intercuart\u00edlico 1,8 a 13,7 meses) y 40 de los ni\u00f1os (85,1%) ten\u00edan menos de 2 a\u00f1os de edad. Cuatro AP drenaron espont\u00e1neamente y 7 curaron sin necesidad de drenaje (23,4%). Se aplic\u00f3 drenaje mediante incisi\u00f3n simple a 36 pacientes (76,5%) y 6 AP requirieron de fistulotom\u00eda (12,7%). Se observaron abscesos recurrentes en 25 pacientes (53,1%). Tres pacientes con AP recurrentes fueron diagnosticados de enfermedad inflamatoria intestinal al finalizar las investigaciones.\nConclusiones\nDe acuerdo con los hallazgos del presente estudio, la determinaci\u00f3n de la cifra de leucocitos, as\u00ed como de los reactantes de fase aguda, parece ser \u00fatil en la primera evaluaci\u00f3n de los ni\u00f1os con AP. En cuanto a las altas tasas de recurrencia en pacientes sometidos a procedimientos quir\u00fargicos, resulta razonable el uso de enfoques conservadores para pacientes menores de 2 a\u00f1os.\nTo develop a scale for the severity of mononucleosis.\nOne to 5 percent of college students develop infectious mononucleosis annually, and about 10% meet criteria for chronic fatigue syndrome (CFS) 6 months following infectious mononucleosis. We developed a severity of mononucleosis scale based on a review of the literature. College students were enrolled, generally when they were healthy. When the students developed infectious mononucleosis, an assessment was made as to the severity of their infectious mononucleosis independently by 2 physicians using the severity of mononucleosis scale. This scale was correlated with corticosteroid use and hospitalization. Six months following infectious mononucleosis, an assessment is made for recovery from infectious mononucleosis or meeting 1 or more case definitions of CFS.\nIn total, 126 severity of mononucleosis scales were analyzed. The concordance between the 2 physician reviewers was 95%. All 3 hospitalized subjects had severity of mononucleosis scores \u22652. Subjects with severity of mononucleosis scores of \u22651 were 1.83 times as likely to be given corticosteroids. Students with severity of mononucleosis scores of 0 or 1 were less likely to meet more than 1 case definition of CFS 6 months following infectious mononucleosis.\nThe severity of mononucleosis scale has interobserver, concurrent and predictive validity for hospitalization, corticosteroid use, and meeting criteria for CFS 6 months following infectious mononucleosis.\nThe Pediatric Infectious Disease Journal. 38(6):547-552\nBACKGROUND:\nThere are no recent descriptions of measles hospitalizations and complications in US children despite outbreaks within the past decade-including 2 in Minnesota (2011 and 2017). The objective of our study was to describe complications, hospital management and resource utilization for children hospitalized for measles at a US children's hospital.\nMETHODS:\nRetrospective case series of children (0-18 years of age) hospitalized for measles (observation/inpatient diagnosis code for measles) at Children's Minnesota, January 1, 2011, to September 1, 2017. Descriptive statistics were performed.\nRESULTS:\nThirty-three patients were included (7 from 2011 and 21 from 2017 outbreaks). Median age was 27 months (range, 6-95 months), 94% were Black or African American (73% Somali ethnicity), 88% had medical assistance and 91% were unvaccinated to measles. Poor feeding was a primary reason for admission (97%); additional complications included otitis media (42%), pneumonia (30%), tracheitis (6%) and keratitis (3%). Additional testing was common [chest radiographs (70%), blood cultures (64%), nonmeasles viral testing (42%)]. Seventy-three percent received antibiotics, 30% required oxygen and 21% received vitamin A. Median length of stay was 3.7 days (range, 1.1-26.2 days); 1 patient was readmitted. Median direct cost in 2017 was $5291 (interquartile range : $3907-$7519), and estimated total cost to the hospital for the 2017 outbreak was $1.3 million.\nCONCLUSIONS:\nClinicians should be aware of measles complications and treatment. Public and private health efforts should continue to focus on immunization, given significant implications of measles infections for patients and healthcare systems. Future studies may assess complications of measles across the United States as individual outbreaks often occur in specific populations, making generalization of results challenging.\nBACKGROUND:\nPertussis continues to be a significant public health problem despite high levels of vaccination. Although hospitalizations and deaths among children greater than 12 months of age are much less frequent than among infants less than 6 months of age, only limited information is available for this age group on other measures of morbidity.\nMETHODS:\nA cross-sectional study with a 6-week follow-up component was conducted in New South Wales, Australia in 2017 to measure morbidity among children 12-59 months of age notified to health authorities. Measures used included cough duration, cough severity, constitutional symptoms and impacts on the family. Associations between these outcomes and age group, vaccination status, asthma, treatment and family structure were explored.\nRESULTS:\nThree hundred and five of 472 (65%) notified cases were interviewed at baseline with approximately 20% having a severe cough with no trend in prevalence across age groups. Forty-eight percent of cases had experienced 3 or more constitutional symptoms with rates significantly higher among younger children. Children who had received an 18-month booster vaccination were significantly less likely to experience 3 or more constitutional symptoms (odds ratio: 0.46, 95% confidence interval: 0.22-0.97). Fifty-one percent of cases were still coughing at 6 weeks. One-third of carers initially reported having disrupted sleep 4 or more nights per week with substantial disruption to carers' sleep still recorded at 6 weeks.\nCONCLUSIONS:\nSubstantial morbidity was observed in this age group with some evidence that the reintroduction of an 18-month acellular pertussis booster lessened disease severity.\nClinical scenario\nA 3-year-old boy is brought into the accident and emergency department by his mother in visible respiratory distress. His mother explained that it started a few days ago with a fever and a bit of a cough and she thought that he had what all children got around this time of year. Since then, however, he has not got any better, and this morning when he woke up she noticed that he was breathing extremely quickly and making strange noises that sounded like grunts. The doctors diagnosed him with a severe community-acquired pneumonia and explained that he would have to be admitted for intravenous antibiotics and close observation. The next morning on the ward round the consultant was very worried about him as he was showing many of the features of very severe pneumonia. You have read that zinc could be useful in severe pneumonia in children and ask if it could help.\nClinical question\nAs an adjunct to standard treatment, does zinc (intervention) reduce mortality and/or accelerate recovery (outcome) in children under 5 years with severe pneumonia (patient)? \u2026\nCurrent BTS guidelines2 do not recommend zinc supplementation for children with severe pneumonia. This may reflect a presumption that their dietary intake is sufficient which may not be true in other parts of the world. Studies from low/middle-income countries have shown that while zinc does not accelerate recovery, it may reduce mortality. This effect should be assessed in children from high-income countries, and if effective, a correct dose is determined. OK, para casos cl\u00ednicos\nObjectives To determine the performance of procalcitonin (PCT), C reactive protein (CRP) and absolute neutrophil count (ANC) in identifying invasive bacterial infection (IBI) among well-appearing infants \u226421 days old with fever without source and no leukocyturia. To compare this performance with that in those 22\u201390 days old.\nDesign Substudy of a prospective single-centre registry performed between September 2008 and August 2017.\nSetting Paediatric emergency department of a tertiary teaching hospital.\nPatients 196 infants \u226421 days old and 1331 infants 22\u201390 days old.\nMain outcome measures Sensitivity and negative likelihood ratio of blood tests for ruling out IBI (positive blood or cerebrospinal fluid culture). Abnormal blood test results: PCT \u22650.5 ng/mL, CRP >20 mg/L and ANC >10 000/\u00b5L.\nResults Prevalence of IBI in infants \u226421 days old with normal or any abnormal blood test result was 3.6% and 6.8%, respectively (OR 0.52 (95% CI 0.13 to 2.01)), compared with 0.2% and 4.5% in older infants (OR 0.03 (95% CI 0 to 0.17)). Sensitivity and negative likelihood ratio of the blood tests for ruling out IBI in infants \u226421 days were 44.4% (95% CI 18.9% to 73.3%) and 0.79 (95% CI 0.43 to 1.44), respectively (vs 84.6% (95% CI 57.8% to 95.7%)%) and 0.19 (95% CI 0.05 to 0.67) in older infants). The values improved in infants with fever \u22656 hours aged 22\u201390 days, but not in those \u226421 days.\nConclusions PCT, CRP and ANC are not useful for ruling out IBI in febrile infants \u226421 days old. It is still recommended that these patients are admitted and given empirical antibiotic therapy, regardless of their general appearance or blood test results.\nObjectives This study aimed to prospectively collect detailed clinical information for all enterovirus (EV) and human parechovirus (HPeV) meningitis cases in infants aged <90 days in the UK and Ireland.\nParticipants, design and setting Prospective, active national surveillance during July 2014 to July 2015 through the British Paediatric Surveillance Unit. Reporting paediatricians completed questionnaires requesting information on clinical presentation, investigations, management and outcomes at hospital discharge and after 12 months.\nMain outcome measures To describe the clinical burden of EV and HPeV meningitis in infants aged <90 days.\nResults During the 13-month surveillance period, 703 cases (668 EV, incidence0.79/1,000 live- births; 35 HPeV, 0.04/1,000 live-births) were identified. The most common clinical presentations were fever (EV: 570/668(85%); HPeV: 28/35(80%)), irritability (EV: 441/668(66%); HPeV: 23/35(66%)) and reduced feeding (EV: 363/668(54%); HPeV 23/35(66%)). Features of circulatory shock were present in 27% (182/668) of EV and 43% (15/35) of HPeV cases. Overall, 11% (76/668) of EV and 23% (8/35) of HPeV cases required intensive care support. Nearly all cases (678/703, 96%) were confirmed by cerebrospinal fluid (CSF) PCR, with 52% (309/600) having normal CSF white cell count for age. Two infants with EV meningitis died (2/668, 0.3%) and four survivors (4/666, 0.6%) had long-term complications at 12 months\u2019 follow-up. Infants with HPeV meningitis survived without sequelae. Overall 189 infants had a formal hearing test and none had sensorineural hearing loss.\nConclusion The incidence of laboratory-confirmed EV/HPeV meningitis in young infants is more than twice that for bacterial meningitis. Less than 1% will develop severe neurological complications or die of their infection. Further studies are required to formally assess long-term neurodevelopmental sequelae.\nThe evidence is current up to 29 March 2019. We included 11 trials of PCVs versus control vaccines (meningococcus type C conjugate vaccine in three trials, and hepatitis A or B vaccine in eight trials) involving a total of 60,733 children. The PCVs used in the trials contained 7 to 11 different types of pneumococcus. None of the trials used the newer PCV containing 13 different types. Most trials were funded by pharmaceutical companies. Overall, risk of bias was low. In seven trials (59,415 children), children received PCVs in early infancy, and four trials included 1318 children aged one year and over who were either healthy or who had previous respiratory illness or frequent acute middle ear infections.\nAdministration of the licenced CRM197-PCV7 and PHiD-CV10 during early infancy is associated with large relative risk reductions in pneumococcal AOM. However, the effects of these vaccines on all-cause AOM is far more uncertain. We found no evidence of a beneficial effect on all-cause AOM of administering PCVs in high-risk infants, after early infancy (i.e. in children one year and above), and in older children with a history of respiratory illness. Compared to control vaccines, PCVs were associated with an increase in mild local reactions (redness, swelling), fever, and pain and/or tenderness. We found no evidence of a difference in more severe local reactions, fever, or serious adverse events judged causally related to vaccination.\nCon relaci\u00f3n a la reciente publicaci\u00f3n titulada \u00abPatolog\u00eda neurol\u00f3gica aguda por enterovirus: revisi\u00f3n de casos cl\u00ednicos en un hospital andaluz de tercer nivel tras brote epid\u00e9mico de Catalu\u00f1a\u00bb1 y dada la importancia y trascendencia del tema que trata desde el punto de vista neuropedi\u00e1trico, nos gustar\u00eda realizar algunas reflexiones y aportar algunos comentarios.\nActualidad bibliogr\u00e1fica mayo 2019\nTop ten\nThe Pediatric Infectious Disease Journal. 38(5):e107-e109\nBordetella pertussis is prevalent among infants, but its diagnosis is complicated by the fact that its signs and symptoms overlap with respiratory viruses. Indeed, when evaluating the etiology of infants less than 1 year of age suspected of having pertussis, we found that respiratory viruses frequently mimic B. pertussis and are more likely to be the causative agent.\nBackground: Detection of cytomegalovirus (CMV) DNA by real-time polymerase chain reaction (rt-PCR) in dried blood spots (DBSs) collected for newborn screening has been assessed for retrospective diagnosis of congenital CMV (cCMV) infection, with variable results (sensitivities ranging from 34% to 100%). We aimed to assess the accuracy of this technique in Spain in a large patient series.\nMethods: Ambispective, multicenter study including patients with confirmed cCMV from the Spanish Registry of cCMV patients. cCMV was established on the presence of CMV DNA in any body fluid, by positive culture findings or by molecular techniques during the first 2 weeks of life. Children in whom cCMV had been excluded were used as negative controls. Neonatal DBS samples were collected from both groups. The presence of CMV DNA was assessed by rt-PCR (RealStar CMV, Altona, Germany) in a central laboratory.\nResults: One-hundred three patients and 81 controls from 10 hospitals were included. The performance of CMV DNA determination in DBS for the diagnosis of cCMV was as follows (95% confidence interval): sensitivity 0.56 (0.47\u20130.65), specificity 0.98 (0.91\u20130.99), positive likelihood ratio 22.81 (5.74\u201390.58) and negative likelihood ratio 0.45 (0.36\u20130.56). Sensitivity increased with the birth viral load (bVL) log category. In cCMV patients, lower bVL was the single variable associated with a negative DBS rt-PCR result (P = 0.017).\nConclusions: The sensitivity of CMV rt-PCR in DBS in our series was low and correlated with the bVL. Thus, a negative DBS result would not rule out cCMV infection, especially in patients with a low viremia level at birth.\nBackground: Infective endocarditis (IE) remains a diagnostic and therapeutic challenge associated with high morbidity and mortality. We evaluated the microbial profile and clinical manifestation of IE in children.\nMethods: A retrospective study examining pediatric IE cases treated between 2000 and 2017 at the Department of Pediatric Cardiology, KU Leuven, was conducted. Clinical presentation, treatment, complications, outcome of IE, underlying microorganisms and congenital heart defects were reviewed.\nResults: Fifty-three patients were diagnosed with IE. Overall, 19 patients (36%) required cardiac surgery. Seven patients (13%) died. Eighty-seven percent of patients had an underlying congenital cardiac defect. Eighteen (34%) children presented with prosthetic graft IE. A causative organism was found in 49 (92%) cases: viridans group streptococci were identified in 17 (32%), Staphylococcus aureus in 13 (25%) and coagulase-negative staphylococci in 11 (20%) children. Community-acquired (CA) IE increased significantly from 8 (33%) cases in 2000\u20132007 to 20 (74%) cases in 2008\u20132017 (P < 0.01). Even with viridans streptococci being significantly more prevalent in the CA group (P < 0.01), we did not observe an increase of streptococcal IE from 2008 to 2017. Seventeen (32%) patients presented with hospital-acquired IE during the first year of life with 14 (82%) children after surgery and a prevalence of coagulase-negative staphylococci (53%).\nConclusions: The incidence of pediatric IE was similar over the investigated time period with a shift toward CA IE. Streptococci and staphylococci accounted for the majority of cases in both periods. Awareness of IE and its prevention is crucial in patients after implantation of prosthetic grafts.\nObjective To assess the effect of the duration of fever after the initiation of treatment (FAT) of febrile urinary tract infections (UTI) on the development of permanent renal lesions based on dimercaptosuccinic acid (DMSA) scintigraphy findings. To evaluate the FAT contribution to permanent renal lesion formation in relation to fever before treatment initiation (FBT), the presence of vesicourinary reflux (VUR), age and severity of infection.\nMethods The inpatient records of 148 children (median age: 2.4 months (11 days to 24 months)) with a first episode of UTI during a 3-year period were analysed. DMSA findings, and clinical and laboratory parameters were evaluated.\nResults Among the study population, 34/148 (22.97%) children had permanent renal lesions on the DMSA scan 6 months after a single episode of UTI. Twenty-three children (15.5%) had mild, 10 (6.7%) had moderate and 1 (0.6%) child had severe lesions on the DMSA. FAT prolongation >/48 hours was associated with older age (p=0.01) and increased absolute neutrophil count (p=0.042). The likelihood of lesions was significantly increased when FAT was \u226548 hours (R2=0.043, p=0.021). On multiple regression analysis, with the addition of FBT>/72 hours (0.022), the presence of VUR (p<0.001), C-reactive protein (p=0.027) and age (p=0.031), the effect of FAT on lesion development disappeared (p=0.15).\nConclusions Prolongation of FAT\u226548 hours of febrile UTI in children <2 years significantly contributes to the development of permanent renal lesions. However, delay in treatment initiation >/72 hours, the presence of VUR, older age and infection severity seem to be more significant predictors of the development of renal lesions.\nEl Erythrovirus B19 (anteriormente denominado parvovirus B19) es el agente etiol\u00f3gico del eritema infeccioso que afecta mayoritariamente durante la infancia y la adolescencia, pero tambi\u00e9n est\u00e1 relacionado con artropat\u00edas, crisis apl\u00e1sicas y abortos en adultos. El prop\u00f3sito de esta revisi\u00f3n es estudiar las caracter\u00edsticas de las infecciones causadas por Erythrovirus B19 diagnosticadas en nuestro hospital en los \u00faltimos 6 a\u00f1os y las diferencias entre la poblaci\u00f3n adulta y la pedi\u00e1trica.\nEstudio retrospectivo de los casos diagnosticados de Erythrovirus B19 mediante serolog\u00eda, entre enero de 2010 y diciembre de 2015.\nFueron diagnosticados 56 casos, 34 adultos (32 mujeres y 2 varones) y 22 menores de 18 a\u00f1os (12 ni\u00f1as y 10 ni\u00f1os). El 75% de los casos se dieron entre primavera y verano. Seis fueron en gestantes y en 2 hubo complicaciones graves que conllevaron la muerte fetal. En la poblaci\u00f3n pedi\u00e1trica los s\u00edntomas m\u00e1s frecuentes fueron fiebre (64%), exantema (50%) y anemia (55%). En adultos las artralgias (59%) y menos frecuentemente la anemia (41%), la fiebre (32%) y el exantema (29%).\nEn pediatr\u00eda la cl\u00ednica m\u00e1s frecuente es el exantema y la fiebre, y en adultos las artralgias. Tambi\u00e9n es frecuente la anemia, los casos m\u00e1s graves en presencia de enfermedad hematol\u00f3gica previa. Hay que destacar la grave afectaci\u00f3n que pueden sufrir los fetos en las gestantes.\nIntroducci\u00f3n\nLa gripe es una enfermedad generalmente benigna, pero en ocasiones puede ocasionar complicaciones graves. Existe controversia sobre los beneficios del tratamiento con antivirales.\nProporcionar unas recomendaciones sobre el tratamiento con oseltamivir en pacientes pedi\u00e1tricos con gripe, basadas en los mejores datos disponibles y v\u00e1lidas en nuestro medio.\nEl Grupo de Infecciones Respiratorias de la Sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica llev\u00f3 a cabo una revisi\u00f3n de la bibliograf\u00eda. Los hallazgos se analizaron mediante la metodolog\u00eda GRADE, y se elaboraron unas recomendaciones.\nNo se recomienda el uso sistem\u00e1tico de pruebas diagn\u00f3sticas para la gripe en el \u00e1mbito ambulatorio y en urgencias hospitalarias en pacientes inmunocompetentes con un cuadro cl\u00ednico compatible. No se recomienda el uso de antivirales a la gran mayor\u00eda de los pacientes sanos y asm\u00e1ticos con gripe o sospecha de gripe estacional, si el objetivo es prevenir eventos graves. No se recomienda el uso de oseltamivir de forma sistem\u00e1tica en pacientes hospitalizados con gripe. Se recomienda tratar con oseltamivir a los pacientes con gripe y neumon\u00eda o enfermedad grave o a los pacientes cr\u00edticos, especialmente durante las primeras 48h de enfermedad. Se recomienda el tratamiento de los pacientes con factores de riesgo, teniendo en cuenta su enfermedad de base. La vacunaci\u00f3n antigripal, junto a las medidas b\u00e1sicas de evitaci\u00f3n, contin\u00faan siendo la principal herramienta en la prevenci\u00f3n de la gripe.\nEn algunas situaciones hay datos suficientes para emitir recomendaciones claras. En otras situaciones los datos son incompletos y solo permiten hacer recomendaciones d\u00e9biles.\nThere is a great variability in the management of the young febrile infant.\n[1] 25-30% of young infants with a history of fever are afebrile on arrival to the ED. [2] Uncertainty over the prevalence of SBI in infants presenting afebrile to the ED may contribute to management variability. In the study conducted by Ramgopal et al, the prevalence of SBI was lower among infants afebrile on ED presentation compared with those who were febrile. Nevertheless, the rate of SBI remained substantial and the rate of invasive bacterial infection (bacteremia and meningitis) did not show significant differences among the infants who did and did not have fever documented in the ED. This suggests that clinical and laboratory evaluation in the ED should not be altered based solely on the infant\u2019s temperature at ED presentation.\n- Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.\n[Lancet Infect Dis. 2019 Apr;19(4):392-401](https://www.ncbi.nlm.nih.gov/pubmed/30938299).\nResumen: los hijos de madres vacunadas contra tos ferina en el tercer trimestre de embarazo tardan m\u00e1s en desarrollar anticuerpos propios frente a la enfermedad en caso de haber sido vacunada su madre durante el embarazo. Las consecuencias cl\u00ednicas de este dato est\u00e1n por establecer. No obstante, el nivel de antivcuerpos pasivos maternos en ni\u00f1os vacunados, soportar\u00eda perfectamente un retraso en el inicio de la vacunaci\u00f3n a los 3 meses de edad. Queda claro la interferencia de los anticuerpos maternos sobre la respuesta inmunitaria a la vacuna puesta al ni\u00f1o. Las consecuencias cl\u00ednicas de esta interferencia quedan por establecerse.\nThirty-three studies were reviewed and provide the best available evidence. The studies tested 6352 children (3 days to 17 years of age) who were receiving probiotics co-administered with antibiotics to prevent AAD. The participants received probiotics (Lactobacilli spp., Bifidobacterium spp., Streptococcus spp., or Saccharomyces boulardii alone or in combination), placebo (pills not including probiotics), other treatments thought to prevent AAD (i.e. diosmectite or infant formula) or no treatment. The studies were short-term, ranging in length from 5 days to 12 weeks. Analyses showed that probiotics are effective for preventing AAD. The incidence of AAD in the probiotic group was 8% (259/3232) compared to 19% (598/3120) in the control group, demonstrating a moderate reduction (11% fewer will suffer diarrhea). For every 9 children treated, probiotics will prevent one case of diarrhea. Further, evidence suggests that higher dose probiotics (\u2265 5 billion CFUs per day) reduce the incidence of AAD in the probiotic group by 8% (162/2029) compared to 23% (462/2009) in the control group, demonstrating a moderate to large reduction (15% fewer suffer diarrhea). Probiotics were generally well tolerated, and minor side effects (e.g. rash, nausea, gas, flatulence, abdominal bloating, constipation) occurred infrequently. . Evidence suggested that probiotics are effective for a moderate reduction in duration of diarrhea (almost one day). Among the various probiotics evaluated, Lactobacillus rhamnosus or Saccharomyces boulardii at 5 to 40 billion colony forming units/day appear most appropriate for preventing AAD in children receiving antibiotics. It is premature to draw conclusions about the effectiveness and safety of 'other' probiotic agents for preventing AAD. Although no serious probiotic-related side effects were observed among the mostly otherwise healthy children who participated in the studies, serious side effects have been reported in observational studies not included in this review, including severely debilitated or immuno-compromised children with underlying risk factors including central venous catheter (a flexible tube used to give medicines) use and disorders associated with bacterial or fungal translocation (the passage of bacteria from the gut to other areas of the body).\nIn this update sixteen studies (2036 children randomised, 1977 analysed) were included. Seven studies (612 children) compared two or more types of antibiotics, six (1088 children) compared antibiotics with placebo or no treatment, one four-armed study compared circumcision with and without antibiotic treatment, one study compared dose of antibiotic, and one three-armed study compared two different antibiotics as well as no treatment. Of the sixteen included studies only one study was judged to be at low risk of bias for all domains, with the majority judged to be at unclear risk of bias due to very poorly reported methodology.\nLong-term antibiotics may reduce the risk of repeat symptomatic UTI in children who have had one or more previous UTIs but the benefit may be small and must be considered together with the increased risk of microbial resistance.\nObjectives: To determine risk factors for complications in children with Staphylococcus aureus (S aureus) bacteremia, including methicillin resistance.\nStudy design: Single center, retrospective cohort study of children \u226418 years of age hospitalized with S aureus bacteremia. We compared clinical characteristics and outcomes between those with methicillin-sensitive S aureus (MSSA) and methicillin-resistant S aureus (MRSA) bacteremia. Multivariate regression models identified risk factors associated with developing complications and with longer duration of bacteremia.\nResults: We identified 394 episodes of S aureus bacteremia, 279 (70.8%) with MSSA, and 115 (29.2%) with MRSA. Primary site of infection was catheter-related in 34%, musculoskeletal in 30%, skin/soft tissue in 10.2%, pneumonia in 6.4%, and endovascular in 6.6%. Eight children (2.0%) died within 30 days because of S aureus bacteremia, 15 (3.5%) had recurrence within 30 days, and 38 (9.6%) had complications including septic emboli or a metastatic focus of infection. Methicillin resistance was associated with development of a complication (aOR 3.31; 95% CI 1.60-6.85), and catheter-related infections were less likely to be associated with a complication (aOR 0.40; 95% CI 0.15-1.03). In a Poisson regression analysis on duration of bacteremia, methicillin resistance, musculoskeletal infection, endovascular infection, black race, and delayed intervention for source control were significantly associated with longer duration of bacteremia.\nConclusions: In this cohort of children with S aureus bacteremia, MRSA infections ere associated with longer duration of bacteremia and a higher likelihood of complications.\nCasos cl\u00ednicos\nPara profundizar\nBackground: Staphylococcus aureus (SA) is a major cause of bacteremia in children. Methicillin-resistant SA (MRSA) is considered a public health threat; however, the differences in the prognosis of children with methicillin-susceptible SA (MSSA) versus MRSA bacteremia are not well defined.\nMethods: Data from all SA bacteremia events in children (0\u201316 years) from 2002 to 2016 in a single Israeli tertiary center were collected. Positive cultures within 48 hours of hospitalization were considered community associated (CA). Those obtained afterward or from children hospitalized within the previous year were considered health-care associated (HA).\nResults: We recorded 427 events, 284 (66%) were HA, 64 (15%) were MRSA and 9 (2%) were CA-MRSA. There was no increase in MRSA during the study period. In-hospital, 30-day and 1-year mortality were 3% (12 cases), 3.5% (16 cases), and 12% (50 cases), respectively. A multivariable analysis controlling for demographics, admitting department and prior morbidity showed an increased 1-year mortality in children with HA bacteremia (hazard ratio [HR] 4.1; 95% confidence interval [CI]: 1.3\u201312) and prior chronic disease (HR 3.4; 95% CI 1.2 to 9.0). MRSA was not independently associated with increased one-year mortality compared with MSSA: HR (95% CI: 1.4 [0.6\u20133.1]).\nConclusions: Short-term pediatric mortality after SA bacteremia is low. HA-SA bacteremia has an increased long-term risk for mortality, particularly in children with chronic diseases. Our data suggest mortality was not increased for MRSA compared with MSSA bacteremia. The very low rate of CA-MRSA bacteremia justifies the current practice not to include glycopeptides in the empiric treatment of CA bacteremia in Israel.\nResumen: an\u00e1lisis de la frecuencia y calidad de prescripci\u00f3n antibi\u00f3tica en urgencias pedi\u00e1tricas hospitalarias de 28 paises de la uni\u00f3n europea. Hay gran variabilidad en la prescripci\u00f3n entre todos los hospitales y pa\u00edses analizados. El 32% de los paciente recibe prescripci\u00f3n antibi\u00f3tica, pero var\u00eda entre los diferentes hospitales de los diferentes paises analizados desde un 19 a un 64%. La prescripci\u00f3n fue muy variable y con excesivo uso de antibi\u00f3ticos de segunda l\u00ednea\nThe Pediatric Infectious Disease Journal. 38(5):464-469\nBackground: Candidemia is the most frequent pediatric fungal infection, but incompletely elucidated in population-based settings. We performed a nationwide cohort study including all pediatric patients with candidemia in Denmark from 2004 to 2014 to determine age, incidence, species distribution, underlying diseases, patient management and outcomes.\nMethods: All candidemia episodes were identified through the active nationwide fungemia surveillance program. Susceptibility testing followed the EUCAST E.Def 7 (European Committee on Antifungal Susceptibility Testing, Edition Definitive) reference method. \u03c72 test, Fisher exact test and Venn diagrams were used for statistical analyses.\nResults: One hundred fifty-three pediatric patients (\u2264 15 years) with 158 candidemia episodes were identified. The overall annual incidence rate was 1.3/100,000 population, higher for neonates (5.7/100,000 live births) and low birth weight neonates (103.8/100,000 live births). From 2004 to 2009 to 2010 to 2014, the proportion of Candida albicans decreased from 74.4% to 64.7%, whereas fluconazole resistance increased from 7.8% to 17.7%. Virtually all patients had at least 1 underlying disease (98.6%) and multimorbidity was common (43.5%, \u22652 underlying diseases). Underlying diseases differed by age with heart malformations and gastrointestinal disease prevalent in children younger than 3 years. The overall 30-days mortality was 10.2% and highest for neonates (17.1%). Mortality increased from 2004 to 2010 to 2014, driven by an increase among older children.\nConclusion: This first nationwide epidemiologic study of pediatric candidemia confirmed a high incidence among neonates and a substantial burden of comorbidities. Moreover, an increasing proportion of fluconazole resistant nonalbicans species was observed. Our findings underline the importance of choosing correct treatment and continuous surveillance of pediatric candidemia.\nIntroducci\u00f3n: La dosis diaria definida (DDD), tiene limitaciones para la medici\u00f3n del consumo antimicrobiano en pediatr\u00eda. Se propone un dise\u00f1o aplicable en ni\u00f1os.\nM\u00e9todos: Se incluyeron ni\u00f1os (<16 a\u00f1os) de 10 hospitales espa\u00f1oles durante un periodo de 12 meses. A partir de la mediana de edad de la cohorte, utilizando tablas estandarizadas de la OMS, se obtuvo el peso correspondiente al percentil P50 de esa edad. Se calcul\u00f3 la DDD (gr) multiplicando el peso obtenido por la dosis recomendada (mg/kg) de cada antimicrobiano para su indicaci\u00f3n m\u00e1s com\u00fan.\nResultados: Un total de 40575 ni\u00f1os fueron incluidos. La mediana de edad fue 4,17 (RIQ: 1,36\u20138,98) y 4,81 (RIQ: 1,42\u20139,60) a\u00f1os para ni\u00f1os y ni\u00f1as, respectivamente. Peso medio para la edad: 17,08kg. DDD estandarizadas fueron calculadas para antimicrobianos representativos.\nConclusiones: Se ha propuesto un m\u00e9todo \u00fatil para monitorizar consumo antimicrobiano en pediatr\u00eda utilizando DDD adaptadas, que deber\u00e1 validarse en futuros estudios.\n\u00b7\n[Lactobacillus administration does not affect acute gastroenteritis](https://www.jpeds.com/article/S0022-3476(19)30288-4/fulltext). J Pediatr. 2019; 208: 294\u2013297\nThe lack of efficacy in the Schnadower et al study conflicts with several trials showing a reduction of diarrhea severity and duration in different settings. The use of a modified Vesikari score, onset of therapy, rotavirus immunization, and previous antibiotic courses, differ among trials. The Schnadower et al study sample size and subgroup analysis resolve most reproducibility issues. Also, it is unlikely that the North American microbiome, gastroenteritis etiology, or medical approach differ significantly from other developed parts of the world. In the same issue of the NEJM, another published negative RCT, with the same design and some authors in common, used a probiotic combination for which comparative data are not available.\n[1] Studies like these mark a novel trend in evidence-based medicine. Large, rigorous, RCTs challenge meta-analyses and dozens of heterogeneous studies of various quality that have previously provided the basis for acute gastroenteritis guidelines. Current guidelines recommend Lactobacillus GG as an adjunct to oral rehydration. [2] If the \u201cno treat\u201d option is applied widely, millions of children will be left without an active therapy while their parents request an effective intervention. [3]\nBackground: The epidemiology of tuberculosis (TB) is changing in the United Kingdom and globally. Childhood TB is a key indicator of recent transmission and provides a marker of wider TB control. We describe the recent epidemiology of childhood TB in the United Kingdom, how this compares to TB in adults, and document changes with time.\nMethods: TB cases notified in the United Kingdom between 2000 and 2015 were categorized as children (<15 years of age) or adults (\u226515 years of age). Descriptive analyses were carried out on demographic, clinical and microbiologic data. We carried out logistic regressions to identify risk factors associated with children having no microbiologic confirmation.\nResults: In the study period, 6293 TB cases (5%) in the United Kingdom were notified in children. Childhood TB incidence declined from 487 cases in 2000 (3.4 per 100,000) to 232 cases (2.0 per 100,000) in 2015. The majority (68%) of children with TB were UK born, with a high proportion of Pakistani (24%) and Black-African (22%) ethnicity. Sixty-four percent of children had pulmonary disease. Culture confirmation was low (24%). Children who were younger, UK born and those with extrapulmonary disease were less likely to have microbiologically confirmed TB. A high proportion (87%) of children completed treatment at last-recorded outcome, with few deaths (39 cases; 0.7%).\nConclusions: The incidence of TB in children in the United Kingdom has decreased in the past 16 years, with the majority of children completing TB treatment. Ongoing monitoring of childhood TB will provide a measure of the effectiveness of the national TB program.\nAs the global epidemic of obesity and type two diabetes in children and adults continues to be a major challenge to public health, an intriguing possible \u2018off-target\u2019 effect of the rotavirus vaccine and association with a reduction in the incidence of Type 1 diabetes, has been reported in JAMA Paediatrics. An Australian study from a team in Melbourne, JAMA Pediatr 2019;173(3):280-282. doi: 10.1001/jamapediatrics.2018.4578) and is the first report of epidemiological evidence of this possible and fascinating association.\nRotavirus (RV) infection has been proposed to trigger type 1 diabetes mellitus (DM1) and celiac disease (CD) by molecular mimicry in genetically susceptible children. If so, a live attenuated oral RV vaccine could also trigger these autoimmune diseases, or else, prevent the effect of wild-type RV infection.\nMethods: In Rotavirus Efficacy and Safety Trial, conducted between 2001 and 2003, the participant children received RotaTeq (Kenilworth, NJ) vaccine or placebo in 1:1 ratio. The surveillance was extended as Finnish Extension Study. A questionnaire was sent in 2015 to the parents of 19,133 Finnish Extension Study participants and 5764 (30%) returned the questionnaire. Diagnosis of DM1, biopsy-proven CD and other autoimmune disease over the 11\u201314 year period were inquired.\nResults: At the time of questionnaire, the prevalence of DM1 was similar in both groups, 0.97% (25 of 2580 children) in the placebo group and 1.04% (33 of 3184 children) in the vaccine group (P = 0.810). The prevalence of CD was significantly higher in placebo recipients (1.11%; confidence interval: 0.78%\u20131.6%) than in vaccine recipients (0.60%; confidence interval: 0.38%\u20130.93%) (P = 0.027).\nConclusions: RV vaccination using RotaTeq did not alter the occurrence of DM1 but decreased the prevalence of CD in childhood and adolescence. We propose that wild-type RV may trigger CD and the triggering effect can be prevented or reduced by RV vaccination.\nBackground: Bell\u2019s palsy is a peripheral paralysis of the seventh cranial nerve, whose etiology is unknown. Using polymerase chain reaction technology, it is possible to sample accessible body fluids and identify possible viral factors. The purpose of this research is to investigate its connection to the herpes virus family by testing for the presence of the virus in the saliva and tear fluid of Bell\u2019s palsy patients.\nMethods: Saliva and tears were collected from 42 children and adolescents suffering from idiopathic facial nerve paralysis. Polymerase chain reaction was used to test for the presence of the viruses Epstein-Barr virus, cytomegalovirus, herpes simplex virus 1 and 2, varicella zoster virus and human herpes virus 6 (HHV-6). Samples were also taken from a control group without paralysis. A second specimen was taken from patients who tested positive for HHV-6 several months after their recovery.\nResults: Of the 42 patients in the study group, 71% (30 patients) tested positive for HHV-6, compared with only 37% of the control group (P = 0.001). The prevalence of the other 5 viruses tested was low\u2014herpes simplex virus 1: 9.5%, Epstein-Barr virus: 9.5%, cytomegalovirus: 4.8%, varicella zoster virus: 2.3% and herpes simplex virus 2: 0%. Twenty-four of the 30 patients who were HHV-6-positive during their illness were reexamined following recovery. Only 13 patients (54.2%) excreted the virus after recovery from the paralysis.\nConclusions: Herpes 6 virus appears to play some role in the etiology of facial nerve paralysis. The virus was detected in the saliva of children during acute illness and decreased with resolution. Our research opens new insights linking HHV-6 to the etiology of Bell\u2019s palsy in children.\nThe Pediatric Infectious Disease Journal. 38(5):533-538\nBackground: This longitudinal study describes the associations between respiratory viral infections, rhinitis and the prevalence and density of the common nasopharyngeal bacterial colonizers, Streptococcus pneumoniae (Sp), Moraxella catarrhalis (Mc), Haemophilus influenzae (Hi) and Staphylococcus aureus.\nMethods: In an observational cohort study, 161 children attending day care centers in Bristol, United Kingdom, were recruited. Monthly nasopharyngeal swabs were taken and stored frozen in Skim-milk, tryptone, glucose and glycerin broth (STGG) broth. Quantitative polymerase chain reaction was used for detection of respiratory viruses and 4 bacterial species. t tests and logistic regression models were used for analysis.\nResults: The frequent colonisers, Sp, Mc and Hi were more frequently found at high density in contrast to Staphylococcus aureus although temporally, high-density carriage was short lived. Respiratory viral infections and symptoms of rhinitis were both independently and consistently associated with higher bacterial density with an observed 2-fold increase in density for Sp, Mc and Hi (P = 0.004\u20130.017).\nConclusions: For Sp and Hi, the association between young age and higher bacterial DNA density was explained by more frequent viral infection and increased nasal discharge, while the associations between some viral specie\u2019s and some bacterial species\u2019 density appear to be stronger than others. Increased colonization density and rhinitis may promote transmission of these commonly carried organism\n- Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.\n[Lancet Infect Dis. 2019;19:287-97](https://www.ncbi.nlm.nih.gov/pubmed/30765242)\nResumen: se trata de una ensayo cl\u00ednico controlado de fase tres, tras 10 a\u00f1os, en el que se compara la eficacia vacunal frente a varicela de la pauta de dos dosis de tetrav\u00edrica en comparaci\u00f3n con una dosis de triple v\u00edrica y una dosis de antivaricela con un grupo control que recibia dos dosis de triple v\u00edrica. La eficacia vacunal fue del 95,4% en el primer grupo, y del 67,2% en el segundo grupo que administra una dosis solamente. Los efectos secundarios fueron similares. Parece claro que la efectividad a10 \u00f1os vista es superior con dos dosis de varicela que con una.\nResumen: a trav\u00e9s de un estudio de comparaci\u00f3n de casos y controles entre m\u00e1s de 15.000 ni\u00f1os captados, se ha comprobado que la relaci\u00f3n monocitos/linfocitos activados CD4 y un marcador s\u00e9rico de RNA, podr\u00eda relacionarse con una mayor predisposici\u00f3n a desarrollar la enfermedad tuberculosa.\nTuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette-Gu\u00e9rin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector vaccine produced to prevent tuberculosis.\nThe search identified six studies relating to four Phase 2 randomized controlled trials enrolling 3838 participants. Funding was by government bodies, charities, and philanthropic donors. Five studies included infants, one of them infants born to HIV-positive mothers. One study included adults living with HIV. All trials included authors from Oxford University who led the laboratory development of the vaccine. Participants received intradermal MVA85A after BCG in some studies, and before selective deferred BCG in HIV-exposed infants.\nMVA85A added to BCG compared to BCG alone probably has no effect on the risk of developing microbiologically confirmed tuberculosis (RR 0.97, 95% CI 0.58 to 1.62; 3439 participants, 2 trials; moderate-certainty evidence), or the risk of starting on tuberculosis treatment (RR 1.10, 95% CI 0.92 to 1.33; 3687 participants, 3 trials; moderate-certainty evidence). MVA85A probably has no effect on the risk of developing latent tuberculosis (RR 1.01, 95% CI 0.85 to 1.21; 3831 participants, 4 trials; moderate-certainty evidence). Vaccinating people with MVA85A in addition to BCG did not cause life-threatening serious adverse effects (RD 0.00, 95% CI \u20130.00 to 0.00; 3692 participants, 3 trials; high-certainty evidence). Vaccination with MVA85A is probably associated with an increased risk of local skin adverse effects (3187 participants, 3 trials; moderate-certainty evidence), but not systemic adverse effect related to vaccination (144 participants, 1 trial; low-certainty evidence). This safety profile is consistent with Phase 1 studies which outlined a transient, superficial reaction local to the injection site and mild short-lived symptoms such as malaise and fever.\nOur searches of the medical literature revealed one relevant study, which was in infant botulism. The treatment was a single dose of a medicine made from human immune proteins (human-derived botulinum immune globulin intravenous, or BIG-IV). Fifty-nine infants received BIG-IV, and 63 infants received a placebo (inactive treatment). Each study participant was followed up for the duration of their hospitalization. This study was sponsored by the California Department of Health Services.\nWe found low- and moderate-certainty evidence supporting the use of BIG-IV in infant intestinal botulism. A single RCT demonstrated that BIG-IV probably decreases the duration of hospitalization; may decrease the duration of mechanical ventilation; and probably decreases the duration of tube or parenteral feeding. Adverse events were probably no more frequent with immune globulin than with placebo. Our search did not reveal any evidence examining the use of other medical treatments including serum trivalent botulism antitoxin.\nThe Pediatric Infectious Disease Journal. 38(5):e82-e86\nBackground: Infectious disease (ID) pandemics pose a considerable global threat and can disproportionately affect vulnerable populations including children. Pediatric clinical research in pandemics is essential to improve children\u2019s healthcare and minimize risks of harm by interventions that lack an adequate evidence base for this population. The unique features of ID pandemics require consideration of special processes to facilitate clinical research. We aimed to obtain consensus on pediatric clinician-researchers\u2019 perceptions of the priorities to feasibly conduct clinical pediatric pandemic research in Europe.\nMethods: Mixed method study in 2 stages, recruiting pediatric clinician-researchers with experience of conducting pediatric ID research in clinical settings in Europe. Stage 1 was an expert stakeholder workshop and interviews. Discussions focused on participant\u2019s experience of conducting pediatric ID research and processes to facilitate pandemic research. Information informed stage 2, an online consensus survey to identify pediatric inician-researchers priorities to enable ID pandemic research.\nResults: Twenty-three pediatric clinician-researchers attended the workshop and 39 completed the survey. Priorities were primarily focused on structural and operational requirements of research design and regulation: (1) clarity within the European Clinical Trials Directive for pediatric pandemic research; (2) simplified regulatory processes for research involving clinical samples and data; and (3) improved relationships between regulatory bodies and researchers.\nConclusions: Results suggest that changes need to be made to the current regulatory environment to facilitate and improve pediatric research in the pandemic context. These findings can provide expert evidence to research policy decision-makers and regulators and to develop a strategy to lobby for change.\nEl uso de la telemedicina comercial directa al consumidor (DTC) fuera del hogar m\u00e9dico pedi\u00e1trico est\u00e1 aumentando entre los ni\u00f1os, y las infecciones respiratorias agudas (IRA) son la afecci\u00f3n m\u00e1s com\u00fanmente diagnosticada en las visitas de telemedicina de DTC. Nuestro objetivo fue comparar la calidad de la prescripci\u00f3n de antibi\u00f3ticos para las IRA entre los ni\u00f1os en 3 entornos: telemedicina DTC, atenci\u00f3n en urgencias y la consulta de atenci\u00f3n primaria (PCP).\nEn las visitas de telemedicina (DTC), los ni\u00f1os con IRA ten\u00edan m\u00e1s probabilidades de recibir antibi\u00f3ticos y menos probabilidades de recibir tratamiento antibi\u00f3tico de acuerdo con las gu\u00edas cl\u00ednicas en comparaci\u00f3n con los ni\u00f1os que van a la consulta de atenci\u00f3n Primaria y o acuden a urgencias.\nPrevious studies have shown the strongest predictor of a \u201c5-star\u201d rating after a DTC telemedicine encounter for an ARTI is receipt of an antibiotic prescription,5 and adults with ARTIs receive more unnecessary antibiotic prescriptions at DTC telemedicine encounters than at primary care office visits. But what about children? The American Academy of Pediatrics discourages the use of DTC telemedicine outside of the medical home, and the American Telemedicine Association suggests that DTC telemedicine should not be used for children ,2 years old.\nBut for pediatric ARTIs, the DTC version seems to be at best a low-quality encounter and at worst a vehicle for antibiotic overuse.\nPediatrics May 2019, 143 (5) e20184064; DOI: 10.1542/peds.2018-4064\nEn esta revisi\u00f3n sistem\u00e1tica, se investiga el coste-eficacia de la profilaxis con palivizumab para el VRS estratificado por el marco de utilizaci\u00f3n y los subgrupos de poblaci\u00f3n infantil relevantes para la toma de decisiones sobre pol\u00edticas de salud.\nPalivizumab prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, because of its high cost, the value of this intervention is unclear.\nTo systematically review the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants <24 months of age.\nMedline, Embase, and Cochrane Library up to August 2018.\nTwo reviewers independently screened results to include economic evaluations conducted between 2000 and 2018 from Organization for Economic Cooperation and Development countries.\nTwo reviewers independently extracted outcomes. Quality appraisal was completed by using the Joanna Briggs Institute checklist. Costs were adjusted to 2017 US dollars.\nWe identified 28 economic evaluations (20 cost-utility analyses and 8 cost-effectiveness analyses); most were from the United States (n = 6) and Canada (n = 5). Study quality was high; 23 studies met >80% of the Joanna Briggs Institute criteria. Palivizumabprophylaxis ranged from a dominant strategy to having an incremental cost-effectiveness ratio of $2 526 203 per quality-adjusted life-year (QALY) depending on study perspective and targeted population. From the payer perspective, the incremental cost-effectiveness ratio for preterm infants (29-35 weeks' gestational age) was between $5188 and $791 265 per QALY, with 90% of estimates <$50 000 per QALY. Influential parameters were RSV hospitalization reduction rates, palivizumab cost, and discount rate.\nModel design heterogeneity, model parameters, and study settings were barriers to definitive conclusions on palivizumab's economic value.\nPalivizumab as RSV prophylaxis was considered cost-effective in prematurely born infants, infants with lung complications, and infants from remote communities\nBibliograf\u00eda abril 2019\nTop ten\nDiversos autores cuestionan la realizaci\u00f3n sistem\u00e1tica de una ecograf\u00eda renal en los lactantes con una primera infecci\u00f3n del tracto urinario (ITU), dada la alta sensibilidad de las ecograf\u00edas prenatales para la detecci\u00f3n de malformaciones mayores y la baja prevalencia de hallazgos cl\u00ednicamente significativos. Los objetivos de este trabajo son valorar el rendimiento diagn\u00f3stico de la ecograf\u00eda renal realizada despu\u00e9s de la primera ITU en pacientes menores de 2 a\u00f1os y analizar posibles factores de riesgo (FR) de presentar una ecograf\u00eda renal alterada.\nEstudio retrospectivo. Se incluyen los pacientes menores de 2 a\u00f1os diagnosticados de ITU en Urgencias entre julio de 2013 y diciembre de 2014. Se excluyen aquellos con enfermedad nefrourol\u00f3gica, ITU previas y sin ecograf\u00eda renal prenatal o postinfecci\u00f3n. Se considera ecograf\u00eda renal alterada la presencia de dilataci\u00f3n de las v\u00edas urinarias y/o anomal\u00edas estructurales. Los posibles FR evaluados son: sexo masculino, edad inferior a 3 meses, fiebre y microorganismo distinto a Escherichia coli. Se realiza estudio univariante y por regresi\u00f3n log\u00edstica multivariante.\nSe incluyen 306 pacientes. Presentan ecograf\u00eda renal alterada 35 (11,4%; IC 95% 8,3-15,5): 24 (68,6%) dilataci\u00f3n de las v\u00edas urinarias y 11 (31%) alteraciones estructurales. De las ecograf\u00edas alteradas, el 68,6% corresponden a varones, el 51,4% a una edad inferior a 3 meses, el 74,3% a ITU febriles y el 31,4% por microorganismo distinto a E. coli, respecto al 45% (p=0,009), el 31,7% (p=0,021), el 78,2% (p=0,597) y el 10% (p=0,001) de las ecograf\u00edas normales. En el an\u00e1lisis multivariante se mantienen como FR la edad inferior a 3 meses (OR 2,1; IC 95% 1,0-4,3; p=0,05) y un microorganismo distinto a E. coli (OR 3,8; IC 95% 1,7-8,7; p=0,002).\nEl rendimiento de la ecograf\u00eda renal despu\u00e9s de la primera ITU es bajo. Se deber\u00eda individualizar su indicaci\u00f3n seg\u00fan la presencia de FR: edad inferior a 3 meses y microorganismo distinto a E. coli.\nCasos cl\u00ednicos\nA 3-year-old boy presented to the emergency department for evaluation of 4 days of rash associated with fever and cough. A, Pink papules with scant yellow crusts on the cutaneous lips and oral commissures. B, Dark red targetoid papules and plaques with central vesicles on the right forearm, with sharp borders at the site of a cast. C, Targetoid morphology on the left hand.\nA 1-year-old boy presented with a 2-day history of fever and vomiting. His vaccination status was up to date, including 4 doses of the 13-valent pneumococcal conjugate vaccines and Hemophilus influenza type b vaccines. At presentation, there were no physical signs suggesting respiratory or circulatory compromise. His heart rate and respiratory rate were 150 beats per minute and 44 times per minute, respectively. His body temperature was 39.6\u00b0C\u2026\nAn 11-year-old girl presented with abdominal pain and lethargy. Chest X-ray revealed a well-defined opacity in the right lower zone, projected over the medial aspect of the right hemidiaphragm (figure 1). She was treated with two courses of antibiotics but remained symptomatic with a cough. Repeat X-rays demonstrated no change in the opacity.\nA 12-year-old farmer\u2019s boy presented with 4 weeks of left flank pain. On examination, a palpable mass below the right costal margin was noted. Investigations, including full blood count, C-reactive protein, and kidney and liver tests, were normal, except for mild eosinophilia (0.53\u00d7109/L). Immunological work-up was normal including immunoglobulins, lymphocyte subsets and serology for HIV. Ultrasonography and abdominal CT revealed an extensive lesion originating from segment V/VI to segment VIII with encasement and stenosis of the portal vein (figure 1). The boy reported contact with animals on the family\u2019s farm, such as dogs\nEn los \u00faltimos a\u00f1os ha aumentado el n\u00famero de ni\u00f1os que viajan con sus familias, ya sea por turismo o por regreso a su pa\u00eds de origen. Este hecho supone un incremento de las consultas de este tipo de pacientes en los servicios de urgencias, lo que abre el abanico de posibilidades diagn\u00f3sticas. La incidencia de la glomerulonefritis posinfecciosa ha disminuido considerablemente en las \u00faltimas d\u00e9cadas. En nuestro medio, la faringoamigdalitis estreptoc\u00f3cica contin\u00faa siendo la principal causa; sin embargo, en ni\u00f1os procedentes de pa\u00edses menos desarrollados, se debe tener en cuenta que las infecciones cut\u00e1neas tambi\u00e9n representan un origen frecuente de esta patolog\u00eda. Se presenta el caso de un ni\u00f1o de 11 a\u00f1os que acudi\u00f3 al servicio de urgencias por lesiones cut\u00e1neas y hematuria.\nLa psoriasis es una enfermedad inflamatoria cr\u00f3nica, sist\u00e9mica y recidivante de la piel, caracterizada por p\u00e1pulas y placas eritemato-escamosas, con caracter\u00edsticas cl\u00ednicas variables. La forma de presentaci\u00f3n m\u00e1s frecuente en los ni\u00f1os es la denominada en placas; existen otras formas m\u00e1s raras, pero con mejor pron\u00f3stico, como la psoriasis guttata. La patog\u00e9nesis de la enfermedad es desconocida, el factor desencadenante m\u00e1s frecuente en los ni\u00f1os es la infecci\u00f3n por estreptococo \u03b2-hemol\u00edtico del grupo A. Presentamos el caso de una ni\u00f1a con dermatitis perianal estreptoc\u00f3cica como principal desencadenante de psoriasis guttata.\nLa linfangitis aguda es la inflamaci\u00f3n de los conductos linf\u00e1ticos, y la etiolog\u00eda infecciosa es la m\u00e1s frecuente en la edad pedi\u00e1trica. Se presentan dos casos cl\u00ednicos de linfangitis tubular aguda, ambos con una lesi\u00f3n inicial por la picadura de un insecto.\nLa varicela es una enfermedad de distribuci\u00f3n universal. La vacunaci\u00f3n universal ha disminuido la incidencia de varicela en los \u00faltimos a\u00f1os. El herpes z\u00f3ster en los vacunados es posible, pero su incidencia es entre 4 y 12 veces menor que entre los no vacunados. En la infancia, el herpes z\u00f3ster suele ser leve, autolimitado, bien tolerado y habitualmente solo requiere tratamiento sintom\u00e1tico. Se presenta un caso de herpes z\u00f3ster en una ni\u00f1a vacunada cinco meses antes, con buena evoluci\u00f3n.\nLa acrodermatitis papulosa infantil se considera una dermatosis paraviral secundaria a diversas infecciones y ant\u00edgenos vacunales. El diagn\u00f3stico es cl\u00ednico y el tratamiento sintom\u00e1tico, con pron\u00f3stico excelente, ya que el cuadro es autolimitado y se resuelve sin lesiones residuales. Presentamos el caso de un ni\u00f1o que desarroll\u00f3 una acrodermatitis papulosa infantil tras una infecci\u00f3n por el virus de Epstein-Barr.\nLa parotiditis recurrente juvenil puede tener multitud de causas, es importante tener en cuenta, dentro de la etiolog\u00eda, el estudio de las subpoblaciones linfocitarias, ya que puede haber una relaci\u00f3n patog\u00e9nica con la deficiencia de c\u00e9lulas natural killer. Se presenta el caso cl\u00ednico de una paciente de diez a\u00f1os con parotiditis recurrente secundaria a dicho proceso.\nLa neumon\u00eda adquirida en la comunidad es una causa importante de morbilidad y mortalidad en Pediatr\u00eda. La gran mayor\u00eda de las neumon\u00edas se resuelven de forma ambulatoria, sin necesidad de realizar un diagn\u00f3stico etiol\u00f3gico. La edad es el par\u00e1metro que mejor se correlaciona con el agente causal, sin embargo, hasta un 20-30% de los casos se debe a una infecci\u00f3n mixta por diferentes g\u00e9rmenes. Lo m\u00e1s frecuentemente descrito son coinfecciones por virus y bacterias, especialmente virus respiratorio sincitial con Streptococcus pneumoniae y Mycoplasma pneumoniae. La asociaci\u00f3n de tres o m\u00e1s pat\u00f3genos es excepcional. El papel de la coinfecci\u00f3n es desconocido en cuanto a pron\u00f3stico y evoluci\u00f3n, ni se puede precisar si los agentes son concomitantes en el tiempo o agravantes evolutivos. Presentamos el caso de una ni\u00f1a con una neumon\u00eda por Mycoplasma pneumoniae que presenta cl\u00ednica y radiograf\u00eda compatible con Streptococcus pneumoniae y adem\u00e1s serolog\u00eda positiva IgM para virus de Epstein-Barr y parvovirus B19.\nLactante 20 meses de edad que ingresa en el servicio de urgencias por cuadro de 6 horas de evoluci\u00f3n, consistente en: aparici\u00f3n de lesiones ampollosas y esfacelaci\u00f3n de la piel que inicia en regi\u00f3n genital, posteriormente en axilas, regi\u00f3n perioral y cuello asociado a irritabilidad, sin picos febriles. La superficie final comprometida fue del 40% de la superficie corporal total, por lo que requiri\u00f3 manejo en unidad de cuidados intensivos pedi\u00e1tricos (UCIP).\nComo antecedente de importancia, fue diagnosticado de otitis media aguda y tratado con amoxicilina durante 7 d\u00edas.\nAl examen f\u00edsico inicial se encuentra irritable, con lesiones ampollosas que corresponden al 3% de la superficie corporal total, signo de Nicolsky positivo. Afebril\nExploraciones complementarias: Hemograma muestra leucocitosis con neutrofilia, Prueba r\u00e1pida de estreptococo beta hemol\u00edtico grupo A negativo. Cultivo far\u00edngeo positivo para SAMS sensible a clindamicina.\nTratamiento y evoluci\u00f3n: Se inici\u00f3 manejo antibi\u00f3tico con ampicilina/sulbactam. A los tres d\u00edas de estancia hospitalaria las lesiones progresan en cara, t\u00f3rax, espalda y extremidades, sin compromiso de palmas, plantas o mucosas por lo que se modifica tratamiento por oxacilina y clindamicina. Se traslad\u00f3 a la unidad de cuidados intensivos pedi\u00e1tricos (UCIP) dado compromiso del 40% de la superficie corporal total. No precis\u00f3 soporte vasopresor ni ventilatorio durante los seis d\u00edas. Posteriormente evoluci\u00f3n favorable con mejor\u00eda de lesiones en piel (figura 3) y egreso a los 14 d\u00edas de hospitalizaci\u00f3n.\nPara profundizar\nThe human microbiome\u2014the collection of microorganisms that inhabit our bodies\u2014has been suggested to play a role in a vast number of diseases, as well as in the maintenance of normal health. There has been an exponential rise in such reports, in part because of new rapid and affordable sequencing technologies. However, developing our understanding from qualitative description to quantitative modeling is essential for incorporation into routine clinical care. Here, we cover the basics of microbiome research and discuss some important examples relevant for pediatric infectious diseases.\nTo develop a parent-reported Pediatric Rhinosinusitis Symptom Scale (PRSS) that could be used to monitor symptoms of young children with acute sinusitis in response to therapy.\nWe developed an 8-item symptom severity scale and evaluated its internal reliability, construct validity, and responsiveness in children 2-12 years of age with acute sinusitis. Parents of 258 children with acute sinusitis completed the PRSS at the time of diagnosis, as a diary at home, and at the follow-up visit at days 10-12. Based on psychometric results and additional parent feedback, we revised the scale. We evaluated the revised version in 185 children with acute sinusitis.\nCorrelations between the scale and reference measures on the day of enrollment were in the expected direction and of the expected magnitude. PRSS scores at the time of presentation correlated with radiographic findings (P < .001), functional status (P < .001), and parental assessment of overall symptom severity (P < .001). Responsiveness (standardized response mean) and test\u2013retest reliability of the revised scale were good (2.17 and 0.75, respectively).\nWe have developed an outcome measure to track the symptoms of acute sinusitis. Data presented here support the use of the PRSS as a measure of change in symptom burden in clinical trials of children with acute sinusitis.\nLa enfermedad de Kawasaki (EK) es una vasculitis multisist\u00e9mica asociada a lesiones en las arterias coronarias. Las infecciones podr\u00edan ser un desencadenante de la inflamaci\u00f3n. Nuestro objetivo fue describir la presencia de infecciones en los ni\u00f1os con EK y analizar las caracter\u00edsticas cl\u00ednicas y la presencia de alteraciones coronarias en estos casos.\nAn\u00e1lisis retrospectivo de los pacientes incluidos en la red KAWA-RACE entre 2011 y 2016. Se estudi\u00f3 tanto a los pacientes que tuvieron una identificaci\u00f3n microbiol\u00f3gica confirmada (IMC) en el periodo agudo como a los que presentaron antecedente de infecci\u00f3n previa reciente (IPR) las 4 semanas anteriores.\nSe incluy\u00f3 a un total de 621 ni\u00f1os, de los cuales 101 (16,3%) tuvieron una IMC y 107 (17,2%) una IPR. Encontramos una significativa menor afectaci\u00f3n ecocardiogr\u00e1fica en el grupo de IPR respecto a los ni\u00f1os sin infecci\u00f3n previa (23 vs. 35%; p 0,01), con menor proporci\u00f3n no significativa de las alteraciones coronarias globales (16 vs. 25%; p 0,054). Sin embargo, no se detectaron diferencias en la proporci\u00f3n de aneurismas en ninguno de los 2grupos (IMC o IPR) respecto al resto de los pacientes sin infecciones asociadas.\nEn nuestro estudio no encontramos diferencias en la incidencia de aneurismas coronarios en ni\u00f1os con y sin IMC o IPR, por lo que ante la sospecha de EK debe iniciarse siempre tratamiento, aunque se tenga infecci\u00f3n confirmada microbiol\u00f3gicamente.\nIntegrated antibiotic resistance (AR) surveillance is one of the objectives of the World Health Organization global action plan on antimicrobial resistance. Urban wastewater treatment plants (UWTPs) are among the most important receptors and sources of environmental AR. On the basis of the consistent observation of an increasing north-to-south clinical AR prevalence in Europe, this study compared the influent and final effluent of 12 UWTPs located in seven countries (Portugal, Spain, Ireland, Cyprus, Germany, Finland, and Norway). Using highly parallel quantitative polymerase chain reaction, we analyzed 229 resistance genes and 25 mobile genetic elements. This first trans-Europe surveillance showed that UWTP AR profiles mirror the AR gradient observed in clinics. Antibiotic use, environmental temperature, and UWTP size were important factors related with resistance persistence and spread in the environment. These results highlight the need to implement regular surveillance and control measures, which may need to be appropriate for the geographic regions.\nIn this secondary analysis of the Randomized Intervention for Children with Vesicoureteral Reflux cohort, we found that daily prophylaxis with trimethoprim-sulfamethoxazole was not associated with an increased or decreased risk of skin and soft tissue infections, pharyngitis or sinopulmonary infections in otherwise healthy children 2\u201371 months of age.\nLa incidencia de cicatrices renales tras una infecci\u00f3n urinaria febril en ni\u00f1os sanos es baja, en torno al 6%. No hay diferencias entre el grupo tratado profil\u00e1cticamente con antibi\u00f3ticos y el grupo control Los resultados de este estudio permiten concluir que no est\u00e1 indicada la profilaxis antibi\u00f3tica generalizada\ntras una ITU en t\u00e9rminos de prevenci\u00f3n de nuevas cicatrices renales. Habr\u00eda que valorar la eficacia en pacientes con anomal\u00edas cong\u00e9nitas del ri\u00f1\u00f3n y el tracto urinario.\nEl objetivo del estudio era determinar si el tratamiento para las infecciones del tracto urinario en ni\u00f1os se podr\u00eda individualizar utilizando biomarcadores que diferenciaran la pielonefritis aguda de la cistitis.\nLos marcadores urinarios que mejor diferenciaron la pielonefritis de la cistitis inclu\u00edan el ligando de quimiocina (C-X-C motif) ligando (CXCL)1, CXCL9, CXCL12, C-C motif quimiocina ligando 2, INF \u03b3 e IL-15 . La procalcitonina s\u00e9rica fue el mejor marcador s\u00e9rico para la pielonefritis. Los genes en la v\u00eda del interfer\u00f3n-\u03b3 se regulan al alza en el suero de ni\u00f1os con pielonefritis. La presencia de genes de virulencia de E. coli no se correlacion\u00f3 con la pielonefritis.\nLa respuesta inmune a la pielonefritis y la cistitis difiere cuantitativa y cualitativamente; Esto puede ser \u00fatil para diferenciar estas 2 condiciones.\nWhile adverse events following immunization (AEFI) are frequent, there are limited data on the safety of reimmunizing patients who had a prior AEFI. Our objective was to estimate the rate and severity of AEFI recurrences.\nWe analyzed data from the AEFI passive surveillance system in Quebec, Canada, that collects information on reimmunization of patients who had a prior AEFI. Patients with an initial AEFI reported to the surveillance system between 1998 and 2016 were included. Rate of AEFI recurrence was calculated as number of patients with recurrence/total number of patients reimmunized.\nOverall, 1350 patients were reimmunized, of which 59% were 2 years of age or younger. The AEFI recurred in 16% (215/1350) of patients, of whom 18% (42/215) rated the recurrence as more severe than the initial AEFI. Large local reactions extending beyond the nearest joint and lasting 4 days or more had the highest recurrence rate (67%, 6/9). Patients with hypotonic hyporesponsive episodes had the lowest rate of recurrence (2%, 1/50). Allergic-like events recurred in 12% (76/659) of patients, but none developed anaphylaxis. Of 33 patients with seizures following measles mumps rubella with/without varicella vaccine, none had a recurrence. Compared with patients with nonserious AEFIs, those with serious AEFIs were less often reimmunized (60% versus 80%; rate ratio: 0.8; 95% confidence interval: 0.66\u20130.86).\nMost patients with a history of mild or moderate AEFI can be safely reimmunized. Additional studies are needed in patients with serious AEFIs who are less likely to be reimmunized.\nWe found 55 relevant studies with 216,480 participants. The trials took place in several locations worldwide. These studies compared a rotavirus vaccine versus placebo or versus no vaccine for infants and young children. The vaccines tested were RV1 (36 trials with 119,114 participants), RV5 (15 trials with 88,934 participants), and Rotavac (four trials with 8432 participants). Fifty-one studies were funded or co-funded by vaccine manufacturers, while four were independent of manufacturer funding.\nIn the first two years of life, RV1:\n\u25cfprevents more than 80% of severe cases of rotavirus diarrhoea in countries with low death rates (high-certainty evidence)\n\u25cfprevents 35% to 63% of severe rotavirus diarrhoea in countries with high death rates (high-certainty evidence)\n\u25cfprobably prevents 37% to 41% of severe cases of diarrhoea from all causes (such as any viral infection, bacterial infection, or parasitic infection) in countries with low death rates (moderate-certainty evidence)\n\u25cfprobably prevents 18% to 27% of severe cases of diarrhoea from all causes in countries with high death rates (moderate- to high-certainty evidence).\nIn the first two years of life, RV5:\n\u25cfprobably prevents 82% to 92% of severe cases of rotavirus diarrhoea in countries with low death rates (moderate-certainty evidence)\n\u25cfprevents 41% to 57% of severe cases of rotavirus diarrhoea in countries with high death rates (high-certainty evidence)\n\u25cfprobably prevents 15% of severe cases of diarrhoea from all causes in countries with high death rates (moderate- to high-certainty evidence); we did not identify any studies that reported on diarrhoea from all causes in countries with low death rates.\nIn the first two years of life, Rotavac:\n\u25cfprobably prevents more than 50% of severe cases of rotavirus diarrhoea in India, a country with high death rates (moderate-certainty evidence)\n\u25cfprobably prevents 18% of severe cases of diarrhoea from all causes in India (moderate-certainty evidence). Rotavac has not been evaluated in a randomized controlled trial in a country with low death rates.\nWe found little or no difference in the number of serious adverse events (moderate- to high-certainty evidence), or intussusception cases (low- to very low-certainty evidence), between those receiving RV1, RV5, or Rotavac compared with placebo or no intervention\nTo monitor parental vaccine attitudes, a survey was conducted in 2008 and in 2016. In both years (90%\u201389%) reported full immunization of their children, and a stable majority (71%\u201366%) supported documentation of vaccination before entering kindergarten. However, a declining confidence in official recommendations from 87% to 72% (P < 0.0001) in 2008 and 2016, respectively, was documented, requiring effort to rebuild it.\nWe included five studies (162 participants); three were conducted in hospital dermatology departments. Participants were 12 to 77 years old (100 males; 62 females). One study was funded by a pharmaceutical company. The severity of the condition ranged from mild to severe. Streptococcus bacteria were found in the throats of 14% of people.\nWe found only five trials (N = 162), which assessed the effects of five comparisons (systemic antibiotic treatment (penicillin, azithromycin) or tonsillectomy). Two comparisons (erythromycin compared to no treatment, and rifampicin compared to placebo) did not measure any of the outcomes of interest. There was very low-quality evidence for the outcomes that were measured, Therefore, we are uncertain of both the efficacy and safety of antistreptococcal interventions for guttate and chronic plaque psoriasis.\nThe included trials were at unclear or high risk of bias and involved only a small number of unrepresentative participants, with limited measurement of our outcomes of interest. The studies did not allow investigation into the influence of Streptococcal infection, and a key intervention (amoxicillin) was not assessed.\nFurther trials assessing the efficacy and tolerance of penicillin V or amoxicillin are needed in children and young adults with guttate psoriasis.\nDuring 2000 to 2018, 1831 children were screened as part of tuberculosis contact investigation at the Stockholm Northern Clinic. The risk of a child having a positive tuberculin skin test was 33% and positive interferon-gamma release assay 12%. The risk of tuberculosis disease was 6.1% (tuberculin skin test) and 13% (interferon-gamma release assay) in positive-testing children.\nMolecular diagnostic methods enhance the sensitivity and broaden the spectrum of detectable respiratory viruses in febrile infants \u226490 days of life. We describe the occurrence of respiratory viruses in this population, as well as the rates of serious bacterial infection (SBI) and respiratory viral coinfection with regard to viral characteristics.\nThis was a prospective observational cohort study performed in the emergency department that included previously healthy febrile infants \u226490 days of life. Clinical and historical characteristics were documented, and a respiratory nasal wash specimen was obtained from each patient. This sample was tested for 17 common respiratory pathogens, and a chart review was conducted to ascertain whether the infant was diagnosed with an SBI.\nIn a 12-month period, 67% of the 104 recruited febrile infants were positive for a respiratory virus. The most commonly detected viruses were rhinovirus, respiratory syncytial virus, enterovirus and influenza. The rate of respiratory viral and SBI coinfection was 9% overall, and infants with either a systemic respiratory virus or negative viral testing were 3 times more likely to have an SBI than those with viruses typically restricted to the respiratory mucosa (95% confidence interval: 1.1, 9.7).\nRespiratory viruses are readily detectable via nasopharyngeal wash in febrile infants \u226490 days of life. With the enhanced sensitivity of molecular respiratory diagnostics, rates of coinfection of respiratory viruses and SBI may be higher than previously thought. Further investigation utilizing molecular diagnostics is needed to guide usage in febrile infants \u226490 days.\nLa detecci\u00f3n de enterovirus deber\u00eda formar parte de las gu\u00edas de pr\u00e1ctica cl\u00ednica sobre la fiebre sin foco en ni\u00f1os de 2 a\u00f1os o menos. Esta prueba podr\u00eda disminuir la duraci\u00f3n de la estancia hospitalaria y reducir la exposici\u00f3n a antibi\u00f3ticos para pacientes de bajo riesgo ingresados desde el Servicio de Urgencias con enfermedad febril.\nRespiratory illnesses are a major contributor to pediatric hospitalizations, with influenza and respiratory syncytial virus (RSV) causing substantial morbidity and cost each season. We compared the characteristics and outcomes of children 0\u201359 months of age who were hospitalized with laboratory-confirmed influenza or RSV between 2009 and 2014 in Ontario, Canada.\nWe included hospitalized children who were tested for influenza A, influenza B and RSV and were positive for a single virus. We characterized individuals by their demographics and healthcare utilization patterns and compared their hospital outcomes, in-hospital cost and postdischarge healthcare use by virus type and by presence of underlying comorbidities.\nWe identified and analyzed 7659 hospitalizations during which a specimen tested positive for influenza or RSV. Children with RSV were the youngest whereas children with influenza B were the oldest [median ages 6 months (interquartile range: 2\u201317 months) and 25 months (interquartile range: 10\u201345 months), respectively]. Complex chronic conditions were more prevalent among children with all influenza (sub)types than RSV (31%\u201334% versus 20%). In-hospital outcomes were similar by virus type, but in children with comorbidities, postdischarge outcomes varied. We observed no differences in in-hospital cost between viruses or by presence of comorbidities [overall median cost: $4150 Canadian dollars (interquartile range: $3710\u2013$4948)].\nInfluenza and RSV account for large numbers of pediatric hospitalizations. RSV and influenza were similar in terms of severity and cost in hospitalized children. Influenza vaccination should be promoted in pregnant women and young children, and a vaccine against RSV would mitigate the high burden of RSV.\nLa gripe es una enfermedad com\u00fan de las v\u00edas respiratorias, que afecta a todas las edades. Los lactantes son poblaci\u00f3n de alto riesgo, en la que no est\u00e1 autorizado el uso de antivirales. La utilizaci\u00f3n de vitamina D est\u00e1 muy extendida con diversas pautas y a diferentes edades. En este estudio que analizamos se eval\u00faa la efectividad y seguridad de altas dosis de vitamina D en lactantes. La vitamina D se muestra eficaz y segura en la prevenci\u00f3n de la gripe a dosis de 1200 unidades d\u00eda, pero estos datos son poco confiables por las deficiencias metodol\u00f3gicas del estudio analizado.\nAlthough maternal tetanus immunisation has been effectively implemented for many years in the developing world,1 there has been a renewed global interest in maternal immunisation programmes over the past several years.2\u20135 This has been driven partly by the severity of the 2009 H1N1 influenza pandemic in pregnant women and the safety provided by the widespread maternal immunisation programme implemented in response to the pandemic.6 7 It has also been increasingly appreciated that maternal immunisations are an excellent way to provide protection to young infants before their own primary immunisation series would begin. There are several reasons that immunising pregnant women is an attractive vaccination strategy. First, by immunising the pregnant woman there is the potential to prevent the targeted infection in both the pregnant woman and her infant. This approach is often referred to as a \u2018two-fer\u2019 with protection for two individuals with the administration of only one vaccine. Second, there is a particular window of susceptibility in infants before the onset of infant immunisation that maternal immunisation could help to bridge. Third, during gestation, pregnant women are often more accessible to medical care than in other times of their lives, making vaccine implementation during this time more efficient. Finally, pregnant women should not be excluded from potentially beneficial vaccines based solely on their pregnancy status. They should ethically reap the benefits of effective vaccines.\nThe goal of this report is to focus on four specific vaccines that are targeted for maternal immunisation. Two of the vaccines, influenza and pertussis, are already being administered to pregnant women as part of recommended national immunisation programmes. Two additional vaccines, group B Streptococcus (GBS) and respiratory syncytial virus (RSV) vaccines, are in clinical trials in pregnant women and it is anticipated that one or both would be available for routine use in the \u2026\nPassive transplacental immunity against respiratory syncytial virus (RSV) appears to mediate in the protection of the infant for the first 6 months of life. Lower environmental exposure in pregnant women to RSV epidemic may influence the susceptibility of these infants to infection by lowering the levels of antibodies that are transferred to the fetus.\nTo contrast the risk of severe disease progression in infants with acute bronchiolitis by RSV, according to the mother's level of exposure to epidemic.\nRetrospective cohort study of previously healthy infants with RSV-acute bronchiolitis during 5 epidemics was made. We compared the severity of the infection in those born during the period of risk (when is less likely the mother's exposure to epidemic and the transfer of antibodies to the fetus: October 15th\u2013December 15th in our latitude) with the rest of acute bronchiolitis. Bivariate analysis was performed regarding birth in period of risk and the rest of variables, using the Chi-square test. Multivariate logistic regression analysis was performed to study possible classical confounding factors.\n695 infants were included in the study. 356 infants were born during the period of risk. Of the 56 patients requiring admission to PICU, 40 of them (71.4%) were born in this period (p=0.002). In the multivariate analysis, the birth in the period of risk showed a 6.5 OR (95% CI: 2.13\u201319.7) independently of the rest of variables.\nThe worst clinical disease progression of the acute bronchiolitis by the RSV in less than 6 months age is related to lower exposure of the pregnant woman to the RSV epidemic.\nTo evaluate the clinical manifestations, management, and outcomes of Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin (BCG) osteitis/osteomyelitis.\nWe reviewed 71 cases of BCG osteitis/osteomyelitis registered in Taiwan's vaccine injury compensation program (VICP) in 1998-2014. Demographic, clinical, laboratory, treatment, and outcome data were compared according to site(s) of infection.\nInvolvement of a long bone of the lower extremity was present in 36.6% of the children, followed by foot bone (23.9%), rib or sternum (15.5%), upper extremity long bone (9.9%), hand bone (7%), multiple bones (4.2%), and vertebrae (2.8%). Children with lower extremity long bone involvement had a longer interval from receipt of BCG vaccine to presentation (median, 16.0 months; P = .02), and those with foot bone infection had higher rates of swelling (94.1%; P = .02) and local tenderness (76.5%; P = .004). Surgical intervention was performed in 70 children, with no significant difference in the number of procedures by site (median, 1.0 procedure per patient). Among the 70 children who received antimicrobial therapy, those with vertebral and multifocal infections had a longer duration of treatment (P < .001) and/or second-line antituberculosis medications (P = .002). Three children with vertebral and multifocal infections had major sequelae with kyphosis or leg length discrepancy. Outcomes were good for children with involvement of the ribs, sternum, and peripheral bones without multifocal involvement. The average time for functional recovery was 6.2 \u00b1 3.9 months.\nChildren with BCG osteitis/osteomyelitis in different bones had distinct presentations and outcomes. Pediatricians should consider BCG bone infection in young vaccinated children with insidious onset of signs and symptoms, and consider affected site(s) in the management plan.\nLos datos de este estudio son aplicables a nuestro medio. Los resultados de este aconsejan mantener la recomendaci\u00f3n de la amoxicilina-clavul\u00e1nico como tratamiento de primera elecci\u00f3n en ni\u00f1os con bronquiectasias y exacerbaci\u00f3n leve o moderada (sin fibrosis qu\u00edstica ni infecci\u00f3n por Pseudomonas aeruginosa) hasta disponer de m\u00e1s estudios que confirmen estos resultados. La azitromicina podr\u00eda ser una alternativa en casos de resistencia a \u03b2-lact\u00e1micos, alergias a amoxicilina, efectos adversos o riesgo de falta de cumplimiento del tratamiento.\nAl hilo de la obligatoriedad de las vacunas para entrar en las escuelas infantiles de la red p\u00fablica en Galicia me pareci\u00f3 interesante este art\u00edculo:\nAnte un brote de sarampi\u00f3n de seis meses, el Condado de Rockland en Nueva York declar\u00f3 el estado de emergencia y prohibi\u00f3 que los ni\u00f1os menores de 18 a\u00f1os no vacunados ingresaran en escuelas, tiendas, restaurantes y lugares de culto. No se incluyen espacios al aire libre como parques infantiles. \"La multa por violar la orden es de hasta seis meses de c\u00e1rcel o una multa de $ 500 (\u00a3 379; \u20ac 444) o ambas\u201d.\nEl objetivo era conseguir que los padres vacunen a sus hijos. La tasa de vacunaci\u00f3n para el Condado de Rockland es de 72.9%, por debajo de la tasa estatal.\n\u201cEs una oportunidad para que todos en nuestra comunidad hagan lo correcto. \"Debemos hacer todo lo que est\u00e9 a nuestro alcance para poner fin a este brote y proteger la salud de quienes no pueden ser vacunados por razones m\u00e9dicas y de los ni\u00f1os que son demasiado peque\u00f1os para ser vacunados\".\nLa rub\u00e9ola es una enfermedad contagiosa prevenible por vacunaci\u00f3n que causa que aproximadamente 100,000 ni\u00f1os nazcan con el s\u00edndrome de rub\u00e9ola cong\u00e9nita cada a\u00f1o en todo el mundo. Destacar estos brotes para evidenciar que estas enfermedades inmunoprevenibles siguen teniendo una incidencia y prevalencia muy importante en un mundo globalizado.\nEn Etiop\u00eda se produjeron 18 brotes de rub\u00e9ola cada a\u00f1o. El 8 de febrero de 2018, la oficina de manejo de emergencias de salud p\u00fablica de Yeka sub-city woreda report\u00f3 dos casos sospechosos de sarampi\u00f3n. Al investigar el brote para identificar su etiolog\u00eda, describirlo e implementar medidas de control, se confirm\u00f3 que el brote era de rubeola\nEn Etiop\u00eda, actualmente, la vacuna contra la rub\u00e9ola no se ha incluido en los programas de inmunizaci\u00f3n rutinarios infantiles.\nTras el estudio del brote se recomienda establecer un sistema de vigilancia de rub\u00e9ola, realizar un estudio de seroprevalencia de rub\u00e9ola en mujeres en edad f\u00e9rtil y establecer una vigilancia del s\u00edndrome de rubeola cong\u00e9nita para proporcionar informaci\u00f3n basada en la evidencia para la introducci\u00f3n de la vacuna de la rubeola.\nA 22-day-old baby presents at your emergency department with a 3-hour history of poor feeding and fever. Blood and cerebrospinal fluid cultures reveal late-onset group B streptococcal (LOGBS) meningitis and bacteraemia. This child has a dizygotic twin who is asymptomatic. You wonder if it is necessary to test, hospitalise and give antibiotics to the asymptomatic twin?\nIn an asymptomatic child whose twin has an LOGBS infection (patient), is it necessary to do immediate evaluation, discontinue breast feeding and prescribe antibiotics (intervention) to avoid serious complications of group B streptococcal (GBS) disease (outcome)?\nThe global resurgence of pertussis in countries with high vaccination coverage has been a concern of public health.\nNasopharyngeal swabs were collected for Bordetella pertussis culture from children with suspected pertussis. Clinical and vaccination information were reviewed through electronic medical chart and immunization record. Antibiotics susceptibility was evaluated using E-test for erythromycin, azithromycin, clarithromycin and sulfamethoxazole/trimethoprim. The MLST genotypes and 7 antigenic genes (ptxP, ptxA, ptxC, Prn, fim3, fim2 and tcfA) of Bordetella pertussis were identified by polymerase chain reaction amplification and sequencing.\nDuring January 2016 to September 2017, a total of 141 children 1\u201348 months of age were culture-confirmed with pertussis, of whom 98 (69.5%) were younger than 6 months, 25 (17.7%) had completed at least 3 doses of DTaP and 75 (53.2%) had a clear exposure to household members with persistent cough. Fully vaccinated cases manifested milder disease than unvaccinated and not-fully vaccinated cases. All strains were MLST2. High-virulent strains characteristic of ptxP3/prn2/ptxC2 constituted 41.1% (58/141) and were all susceptible to macrolides while low-virulent strains characteristic of ptxP1/prn1/ptxC1 constituted 58.9% (83/141) and 97.6% (81/83), respectively, were highly resistant to macrolides.\nPertussis is resurging among infants and young children in Shanghai, and household transmission is the main exposure pathway. The high-virulent strains harboring ptxP3/prn2/ptxC2 and the macrolide-resistant Bordetella pertussis strains are quite prevalent. These issues impose a public health concern in Shanghai. Our findings are important to modify the DTaP vaccination strategy and the management guideline of pertussis in China.\nBackground: Childhood tuberculosis (TB) is acquired after exposure to an infectious TB case, often within the household. We prospectively screened children 6\u201359 months of age, exposed and unexposed to an infectious TB case within the same household, for latent tuberculosis infection (LTBI), in Dar es Salaam, Tanzania.\nWe collected medical data and clinical specimens (to evaluate for helminths, TB and HIV coinfections) and performed physical examinations at enrollment and at 3-month and 6-month follow-up surveys. LTBI was assessed using QuantiFERON-TB Gold (QFT) at enrollment and at 3 months.\nIn total, 301 children had complete data records (186 with TB exposure and 115 without known TB exposure). The median age of children was 26 months (range: 6\u201358); 52% were females, and 4 were HIV positive. Eight children (3%) developed TB during the 6-month follow-up. We found equal proportions of children with LTBI among those with and without exposure: 20% (38/186) versus 20% (23/115) QFT-positive, and 2% (4/186) versus 4% (5/115) indeterminate QFT. QFT conversion rate was 7% (22 children) and reversion 8% (25 children). Of the TB-exposed children, 72% initiated isoniazid preventive therapy, but 61% of parents/caregivers of children with unknown TB exposure and positive QFT refused isoniazid preventive therapy.\nIn this high burden TB setting, TB exposure from sources other than the household was equally important as household exposure. Nearly one third of eligible children did not receive isoniazid preventive therapy. Evaluation for LTBI in children remains an important strategy for controlling TB but should not be limited to children with documented TB exposure.\nTuberculosis (TB) remains a major public health issue among children worldwide. Data on TB transmission in children living in low-incidence countries is limited.\nWe studied TB transmission in ethnic Danish children younger than 15 years of age between 2000 and 2013. Identification of children with TB disease and information on demographics and TB contacts were retrieved from the national TB surveillance register and the International Reference Laboratory of Mycobacteriology.\nIn total, 88 children with TB disease were identified in the study period, corresponding to a mean annual incidence of 6.9 per 1,000,000 children younger than 15 years of age. The male to female ratio was 1.3. Median age was 5 years (interquartile range, 3\u20138.5). Seventy-three (83%) children had a known TB contact of which 60% was among household contacts with recent TB, predominantly parents. Sixty-six (75%) children were classified as part of epidemiologic clusters. Thirty-five (40%) children had culture verified TB of which information on genotypes was available for 34 (97%). Of these, 35% belonged to cluster C2/1112\u201315, the most prevalent cluster among adult Danes.\nWe found on-going TB transmission in Danish children within the households of a low TB incidence population. These findings emphasize the need for early diagnosis of TB in children, thorough contact tracing and increased focus on risk groups.\nThe Pediatric Infectious Disease Journal. 38(4):384-389, April 2019.\nAntimicrobial resistance is low in Norway, but to prevent an increase, the Norwegian Government has launched a National Strategy including a 30% reduction of broad-spectrum antibiotics (BSA) in hospitals within 2020. BSA are defined as second- and third-generation cephalosporins, carbapenems, piperacillin/tazobactam and quinolones. There are no recent studies of antibiotic use in Norwegian hospitalized children. The aim of this study was to describe the use of antibiotics with emphasis on BSA in Norwegian hospitalized children and neonates to detect possibilities for optimization.\nData were extracted from 8 national point prevalence surveys of systemic antibiotic prescriptions in Norwegian hospitals between 2015 and 2017. The choices of antibiotics were compared with the empirical recommendations given in available Norwegian guidelines. In total, 1323 prescriptions were issued for 937 patients.\nTwenty-four percent of pediatric inpatients were given antibiotics. Adherence to guidelines was 48%, and 30% (95% confidence interval: 27%\u201333%) of all patients on antibiotics received BSA. We identified only small variations in use of BSA between hospitals. One-third of the patients on antibiotic therapy received prophylaxis whereof 13% were given BSA. In 30% of prescriptions with BSA, no microbiologic sample was obtained before treatment.\nThis study reveals an excess of prescriptions with BSA in relation to the low resistance rate in Norway. Our findings reveal areas for improvement that can be useful in the forthcoming antibiotic stewardship programs in Norwegian pediatric departments.\nBibliograf\u00eda marzo 2019\nTOP TEN\n\u00b7\n[Pertussis (whooping cough)](https://www.ncbi.nlm.nih.gov/pubmed/30796107) BMJ 2019;364:l401\nEs un art\u00edculo que hace una revisi\u00f3n exhaustiva del manejo de la tosferina y presentan evidencia y orientaci\u00f3n recientes sobre la prevenci\u00f3n a trav\u00e9s de la vacunaci\u00f3n, haciendo un amplio repaso de la literatura. Se hace eco de la facilidad para la p\u00e9rdida diagn\u00f3stica o el retraso ya que la tosferina imita la presentaci\u00f3n de una infecci\u00f3n viral del tracto respiratorio superior y, en ocasiones, puede presentarse de forma at\u00edpica.\nEste art\u00edculo tiene un inter\u00e9s a\u00f1adido al finalizar desde la perspectiva del paciente: La aportaci\u00f3n de un padre sobre el caso cl\u00ednico de su hija afectada por la tosferina, reflexionando sobre las secuelas a largo plazo de la tos ferina y el tratamiento de la tos asociada a esta enfermedad infecciosa.\n\u00b7\n[Beta-Hemolytic Nongroup A Streptococcal Pharyngitis in Children](https://www.jpeds.com/article/S0022-3476(18)31555-5/fulltext). J Pediatr. 2018 Dec 6. pii: S0022-3476(18)31555-5\nTo evaluate the epidemiology, clinical features, and antibiotic prescribing patterns for nongroup A streptococci (NGAS) in children.\nStudy design\nThroat cultures obtained for pharyngitis were assessed at a large community-based health system over 10 years. Epidemiologic and clinical features of children with NGAS were compared with children with group A Streptococcus (GAS) and negative cultures. Antibiotic prescribing patterns were evaluated.\nResults\nA total of 224 328 rapid streptococcal antigen tests and 116 578 throat cultures were performed. Clinical analysis was completed for 602 GAS-positive patients, 535 NGAS-positive patients, and 480 patients with negative cultures. Incidence of NGAS did not vary annually or by season but increased with age from 2% at \u22645 years to 7% at 18 years of age. Patients with NGAS were more likely than those with negative cultures to have tonsillar exudate (20.3% vs 13.1%, P = .003) and enlarged tonsils (28.6% vs 19.3%, P < .001). Modified Centor scores did not differ between groups (score \u22652, P = 1.0; score \u22653, P = .50). Patients with GAS were more likely than those with NGAS to have fever (32.6% vs 24.5%, P = .003), palatal petechiae (14.0% vs 3.1%, P < .001), and modified Centor score \u22652 (47.8% vs 27.1%; P < .001). Of patients with NGAS, 65% were prescribed antibiotics.\nConclusions\nNGAS likely exist in both carriage and infectious states and incidence increases with age. Infections associated with NGAS are milder than with GAS, and complications are rare. Laboratory reporting of NGAS results in high antibiotic use, despite current recommendations against treatment.\n\u00b7\n[Future Research in the Immune System of Human Milk](https://www.jpeds.com/article/S0022-3476(18)31670-6/fulltext). J Pediatr. 2018 Dec 6. pii: S0022-3476(18)31670-6\nApart from a few discoveries in the 19th and early 20th centuries, little was known about the complex immune system in human milk and its many benefits to the recipient infant. Research during the latter part of the 20th century and this century demonstrated that the human milk immune system is significantly different from that produced by other mammals and that breastfeeding protects against many common infections, reduces inflammation, and lessens the likelihood of certain chronic diseases in later life.\nOsteoarticular infection frequently remains microbiologically unconfirmed in the pediatric age. Kingella kingae has emerged as a major etiological agent of osteomyelitis and septic arthritis in children aged less than 4 years. Recently, the implementation of molecular detection assays (MDA) has established the real role of this microorganism in osteoarticular infections.\nWe conducted a retrospective study in a cohort of pediatric patients. Only 40% strains of K. kingae were identified by one of the culture methods used but 100%of them tested positive by real-time PCR. In patients aged over 4 years (54.8% with septic arthritis) S. aureus was the most frequent pathogen and was found in 54.8% out of 31 cases. Most S. aureus isolates (15 out of 18) grew both in BCB and routine culture, while the other 3 were only isolated in BC. Etiological diagnosis was exclusively attributable to real-time PCR in 17 out of 49 cases (34.7%). Overall, patients with arthritis were younger (1.5 vs 6.5 years) and more often diagnosed with K. kingae infections (34.3% vs 9.5%) than those affected with osteomyelitis. This study shows that the bacterial etiology of osteoarticular infections in children is closely related to the age of patient, and clearly outlines three different periods. During the first months of life osteoarticular infection is an infrequent event but usually caused by group B streptococci, as in late-onset neonatal sepsis . K. kingae almost exclusively affects infants and toddlers, in fact, in 22 out of 25 (88%) K. kingae cases, patients were aged between six months and two years. Because K. kingae osteoarticular infections usually associate negative gram stain (100% in this study), mild clinical symptoms and mild alteration of plasmatic inflammation markers, differential diagnosis with noninfectious causes of arthritis (i.e. transient synovitis of the hip) is difficult. In these cases, culture in SBCB is important to isolate the microorganism, but MDA are critical for proper diagnosis and early treatment. That is why, specific K. kingae MDA should be available as a routine test in hospitals with pediatric patients. MDA also improve the detection of S. pneumoniae and N. meningitidis. In patients aged >4 years, S. aureus remains the main cause of both arthritis and osteomyelitis,5 in our study 94.4% cases. Due to the efficiency of routine cultures for S. aureus, inoculation of samples in BCB does not improve the isolation rate. Moreover, previous studies have shown that S. aureus-specific PCR assays offer no advantages over classical cultures.\nCasos cl\u00ednicos\n\u00b7\n[Recurrent Vulvar Ulcers and \u201cCradle Cap\u201d in a 2-Year-Old](https://www.jpeds.com/article/S0022-3476(18)31373-8/fulltext). [J Pediatr.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Recurrent+Vulvar+Ulcers+and+%E2%80%9CCradle+Cap%E2%80%9D+in+a+2-Year-Old) 2018 Oct 12. pii: S0022-3476(18)31373-8\nA 2-year-old white female with recurrent methicillin-resistant Staphylococcus aureus otitis media and persistent \u201ccradle cap\u201d was referred for dermatologic evaluation of recurrent, painful vaginal ulcers present for 10 months. The symptoms began with severe vaginal pain during urination and diaper changes. She subsequently developed painful, solitary, bilateral ulcers on the labia majora that responded minimally to topical menthol-zinc oxide and clobetasol. Observation without treatment led to resolution of the ulcers within 3 weeks; the ulcers reoccurred 2 months later.\nNi\u00f1a de 7 a\u00f1os, que estando previamente bien, presenta acceso de tos intensa con un v\u00f3mito posterior. Tras el mismo, aprecian dificultad respiratoria grave. A su llegada a urgencias tras estabilizaci\u00f3n se realiza radiograf\u00eda de t\u00f3rax donde se aprecia una gran lesi\u00f3n qu\u00edstica derecha con nivel hidroa\u00e9reo e im\u00e1genes ondulantes, \u00absigno del nen\u00fafar\u00bb sugestivas de quiste hidat\u00eddico pulmonar (QHP) complicado.\nSe ampl\u00eda estudio con TC y, ante la mala situaci\u00f3n cl\u00ednica, se decide ex\u00e9resis quir\u00fargica urgente . Los estudios microbiol\u00f3gicos y anatomopatol\u00f3gicos confirman la etiolog\u00eda hidat\u00eddica del quiste.\nLa hidatidosis es una zoonosis producida por Echinococcus granulosus. Espa\u00f1a es un \u00e1rea de alta endemicidad\n[2](https://www.analesdepediatria.org/es-insuficiencia-respiratoria-subita-como-primera-articulo-S1695403318301309#bib0025). En ni\u00f1os la afectaci\u00f3n pulmonar es m\u00e1s frecuente ya que las caracter\u00edsticas el\u00e1sticas del pulm\u00f3n permiten un crecimiento m\u00e1s r\u00e1pido [3](https://www.analesdepediatria.org/es-insuficiencia-respiratoria-subita-como-primera-articulo-S1695403318301309#bib0030). Pueden ser asintom\u00e1ticos y diagnosticarse de forma casual o presentar un cuadro cl\u00ednico grave al romperse hacia el \u00e1rbol bronquial o pleura. La cirug\u00eda del QHP, asociada al tratamiento con albendazol, es el manejo terap\u00e9utico habitual.\nLa cerebelitis aguda (CA) es una disfunci\u00f3n cerebelosa aguda (ataxia, nistagmo o dismetr\u00eda) asociada a menudo a fiebre, cefalea, n\u00e1useas y alteraci\u00f3n del nivel de consciencia\n[1,2](https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0035). Suele ocurrir como trastorno infeccioso, postinfeccioso o posvacunaci\u00f3n, aunque hay casos en los que no se evidencia ning\u00fan desencadenante [3-5](https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0045).\nSe denomina ataxia cerebelosa aguda a aquellos casos en los que no hay traducci\u00f3n en la neuroimagen, y CA a aquellos casos en que s\u00ed encontramos . La RM cerebral la prueba diagn\u00f3stica de elecci\u00f3n. La TC craneal en el momento agudo es \u00fatil para descartar otra etiolog\u00eda.\nLa inflamaci\u00f3n del cerebelo puede comprimir el tallo cerebral e inducir alteraciones del nivel de consciencia, que pueden enmascarar la etapa inicial de signos cerebelosos, pudiendo presentarse incluso como coma y disfunci\u00f3n auton\u00f3mica. Esta entidad, en la que predominan los s\u00edntomas de hipertensi\u00f3n intracraneal (HTIC) sobre los cerebelosos, y que se asocia a importante componente inflamatorio, se conoce como cerebelitis aguda fulminante\n[1](https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0035) y es una entidad a tener en cuenta en los casos de HTIC de aparici\u00f3n brusca [1](https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0035).\nEn los casos leves sin progresi\u00f3n de la cl\u00ednica, ni im\u00e1genes radiol\u00f3gicas propias de los casos fulminantes, una actitud conservadora con monitorizaci\u00f3n estrecha suele ser suficiente. En casos moderados y graves, los corticoides son la primera l\u00ednea de tratamiento e incluso puede ser necesario un drenaje ventricular externo (DVE) frente a la hidrocefalia.\nSe presentan 3 pacientes diagnosticados de CA, con edades comprendidas entre los 7 y 12 a\u00f1os, sin antecedentes de inter\u00e9s.\nEl primer paciente consult\u00f3 por v\u00f3mitos y decaimiento, presentando a su llegada un cuadro vagal con disminuci\u00f3n de la consciencia, hipoton\u00eda y deterioro neurol\u00f3gico. En TC craneal se apreci\u00f3 hipodensidad subcortical en el hemisferio cerebeloso izquierdo . Ingres\u00f3 en UCI-P, donde se solicit\u00f3 una RM cerebral plante\u00e1ndose el diagn\u00f3stico diferencial entre un proceso isqu\u00e9mico de fosa posterior, encefalitis y CA, por lo que se monitoriz\u00f3 y se inici\u00f3 tratamiento antiagregante, aciclovir y corticoides. A las 12h de su ingreso present\u00f3 un aumento de la presi\u00f3n intracraneal y anisocoria, por lo que se realiz\u00f3 TC cranea y tras los hallazgos se decidi\u00f3 craniectom\u00eda descompresiva con colocaci\u00f3n de un DVE, con estabilidad posterior. Se inici\u00f3 rehabilitaci\u00f3n, presentando tendencia a la mejor\u00eda neurol\u00f3gica pero con secuelas presentes en el control a los 4 meses (tambi\u00e9n secuelas en RM de control) .\nTanto el segundo como el tercer paciente consultaron por cefalea de aprox 1 semana que se hab\u00eda intensificado, limitando las actividades diarias e impidiendo el sue\u00f1o junto con v\u00f3mitos. Tanto la exploraci\u00f3n f\u00edsica como la TC craneal fueron normales, por lo que ingresaron para analgesia. Dada la ausencia de mejor\u00eda se decidi\u00f3 realizar RM cerebral, tras la cual fueron diagnosticados de CA y fueron monitorizados y tratados con corticoides. Evolucionaron favorablemente ( tambi\u00e9n RM).\nPara profundizar\nObjectives\nWe aimed to describe the knowledge, attitudes and beliefs primary care professionals involved in administration of childhood vaccines in Barcelona have about vaccines and vaccination.\nMethods\nIn 2016/17, surveys were administered in person to every public primary care centre (PCC) with a paediatrics department (n = 41). Paediatricians and paediatric nurses responded to questions about disease susceptibility, severity, vaccine effectiveness, vaccine safety, confidence in organisations, key immunisation beliefs, and how they vaccinate or would vaccinate their own children. We used standard descriptive analysis to examine the distribution of key outcome and predictor variables and performed bivariate and multivariate analysis.\nResults\nCompleted surveys were returned by 277 (81%) of 342 eligible participants. A quarter of the respondents reported doubts about at least one vaccine in the recommended childhood vaccination calendar. Those with vaccine doubts chose the response option \u2018vaccine-hesitant\u2019 for every single key vaccine belief, knowledge and social norm. Specific vaccine knowledge was lacking in up to 40% of respondents and responses regarding the human papilloma virus vaccine were associated with the highest degree of doubt. Being a nurse a risk factor for having vaccine doubts (adjusted odds ratio (ORa) = 2.0; 95% confidence interval (95% CI): 1.1\u20133.7) and having children was a predictor of lower risk (ORa = 0.5; 95% CI: 0.2\u20130.9).\nTo the Editor:\nAmbroggio et al\n[1] report on lung ultrasonography as a viable alternative to chest radiography to detect pneumonia in children. [2] They emphasize both the higher specificity of chest radiography for many findings compared with lung ultrasonography and the operator's skill in the diagnostic process.\nIn a large, well-conducted meta-analysis on the role of imaging for the diagnosis of pediatric pneumonia, Balk et al\n[3] analyzed data from 12 studies including 1510 patients and calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of chest radiography and lung ultrasonography. Despite a significantly better sensitivity of lung ultrasonography (95.5% vs 86.8%), values for specificity (95.3% vs 98.2%), PPV (99.0% vs 99.6%), and NPV (63.1% vs 43.6%) were comparable between lung ultrasonography and chest radiography. The authors point out the limitation in measuring PPV and NPV in their meta-analysis, because the included studies were reflective not of the general population, but rather of a population of patients with high clinical suspicion for community-acquired pneumonia. PPV and NPV are dependent on the disease incidence, which thus influences validation of data. Furthermore, most studies included chest radiography in the diagnostic criteria for pneumonia in addition to clinical presentation, thereby skewing chest radiography results to higher specificity and inflating the intrinsic value itself. Performing studies that do not include chest radiography as part of diagnostic standard may overcome this problem.\nThere is a growing evidence of the accuracy of lung ultrasonography over chest radiography in the diagnosis of pneumonia. However, the real impact in the clinical practice of substituting chest radiography with lung ultrasonography has not been adequately studied. Until this step is completed, lung ultrasonography may be particularly useful in the detection of pneumonia in clinical settings were chest radiography is not readily available.\nAmbroggio, L., Shah, S.S., and Coley, B.D. Reply. J Pediatr. 2018; 196: 329\u2013330\nBackground: To examine whether inappropriate antibiotic treatment for an initial bout of acute bronchitis in childhood affects patterns of future healthcare utilization and antibiotic prescribing.\nMethods: We conducted a retrospective analysis of children with at least 1 acute bronchitis episode, defined as the 14-day period after an acute bronchitis visit, born in 2008 and followed through 2015 in a nationally representative commercial claims database. We predicted the likelihood of returning for a subsequent acute bronchitis episode, and being prescribed an antibiotic as part of that episode, as a function of whether or not the child was prescribed an antibiotic as part of the first acute bronchitis episode controlling for patient, provider and practice characteristics.\nResults: Children prescribed an antibiotic as part of their initial acute bronchitis episode were more likely both to have a subsequent acute bronchitis episode (hazard ratio = 1.23; 95% confidence interval: 1.17\u20131.30) and to be prescribed an antibiotic as part of that second episode (hazard ratio = 2.13; 95% confidence interval: 1.99\u20132.28) compared with children who were not prescribed as part of their first episode. Children diagnosed with asthma were more likely to experience a second visit for acute bronchitis, but less likely to receive an antibiotic as part of that second episode.\nConclusions: Inappropriate antibiotic prescribing for a child\u2019s initial acute bronchitis episode of care predicted likelihood of subsequent acute bronchitis episodes and antibiotic prescriptions. Providers should consider the downstream effect of inappropriate antibiotic prescribing for acute bronchitis in childhood.\nSetenta personas, la mayor\u00eda de ellas ni\u00f1os, han muerto de sarampi\u00f3n en Filipinas desde comienzos de 2019, el 79% de los muertos este a\u00f1o no estaban vacunados. Ahora se extiende por la capital densamente poblada de Manila, as\u00ed como en otras cuatro regiones, y el gobierno insta a los padres a que vacunen a sus hijos de forma gratuita.\nLa mayor brecha en Europa ha sido en Ucrania, donde el estallido de la guerra en 2014 interrumpi\u00f3 gravemente los programas de inmunizaci\u00f3n. Ucrania es l\u00edder mundial en casos de sarampi\u00f3n, con 53 218 casos en 2018, o 121 por cada 100 000 personas. En la \u00faltima semana se registraron unos 3142 casos en Ucrania. Pero el paciente promedio es mayor que en Filipinas, y ha habido menos muertes, 16 desde que comenz\u00f3 el 2019.\nEn este mismo art\u00edculo se menciona que la Academia Americana de Pediatr\u00eda ha pedido a Facebook que haga m\u00e1s para eliminar toda la informaci\u00f3n enga\u00f1osa sobre las vacunas de su sitio web. Facebook ha aceptado ingresos por publicidad de grupos como Vax Truther, Anti-Vaxxer y Vaccines Revealed. El peri\u00f3dico brit\u00e1nico The Guardian obtuvo acceso a grupos cerrados en Facebook donde los miembros reciben informaci\u00f3n falsa contra las vacunas, a menudo por personas con un claro inter\u00e9s financiero en desacreditar las vacunas. Uno de estos grupos, llamado Vitamina C y Medicina Ortomolecular para una Salud \u00d3ptima, le dice a sus 49000 miembros que \"no es un grupo anti-vax\", pero su administrador escribi\u00f3 en un mensaje: \"Hasta que se vuelvan seguras y no se gu\u00eden por el dinero, evitar\u00eda todas las vacunas \". Katie Gironda, que dirige otro grupo de Facebook llamado Vitamina C contra el da\u00f1o de las vacunas figura en LinkedIn como directora ejecutiva de un negocio en l\u00ednea llamado Revitalize Wellness, que vende dosis altas de vitamina C. Las advertencias sobre las vacunas se intercalan con las instrucciones para \"comprar ahora\" para la vitamina C.\nLa efectividad directa de la vacunaci\u00f3n contra el rotavirus infantil implementada en 2006 en los Estados Unidos se ha evaluado ampliamente, sin embargo, la comprensi\u00f3n de la efectividad de la vacuna a nivel de la poblaci\u00f3n a\u00fan es incompleta.\nSe ha visto que los beneficios de la vacuna se extendieron a individuos no vacunados en todos los grupos de edad, lo que sugiere que los beb\u00e9s son importantes impulsores de la transmisi\u00f3n de la enfermedad en toda la poblaci\u00f3n y por lo tanto tambi\u00e9n la vacunaci\u00f3n protege a toda la poblaci\u00f3n.\nLa evidencia reciente sugiere que las infecciones virales est\u00e1n involucradas en un modelo animal de enfermedad cel\u00edaca. Estudios prospectivos han mostrado una mayor prevalencia de infecciones en ni\u00f1os antes del diagn\u00f3stico de enfermedad cel\u00edaca. Los estudios previos de adenovirus y enterovirus se han limitado a dise\u00f1os transversales, y la causalidad inversa es una posible explicaci\u00f3n para estas observaciones.\nEn este estudio longitudinal, encuentran que una mayor frecuencia de infecciones por enterovirus se asoci\u00f3 con un mayor riesgo de enfermedad cel\u00edaca. En conjunto, sus resultados son compatibles con un mecanismo por el cual las infecciones virales pueden romper la barrera de la mucosa con un aumento de la translocaci\u00f3n de los p\u00e9ptidos de gluten a la mucosa como el evento inicial en la p\u00e9rdida de tolerancia. Especulan que los enterovirus pueden proporcionar una se\u00f1al de peligro que activa las c\u00e9lulas dendr\u00edticas que act\u00faan como c\u00e9lulas presentadoras de ant\u00edgenos para las c\u00e9lulas T reactivas al gluten CD4 en presencia de p\u00e9ptidos de gluten modificados con transglutaminasa.\nDado el n\u00famero limitado de casos, se necesitan estudios similares y, preferiblemente, estudios de intervenci\u00f3n para llegar a conclusiones sobre la causalidad. La identificaci\u00f3n de virus espec\u00edficos como desencadenantes de la enfermedad cel\u00edaca puede tener implicaciones para las estrategias preventivas y justificar estudios futuros para aclarar los mecanismos\nAt present, the evidence on the effectiveness and safety of antibiotic treatment for newborns with confirmed, highly probable or possible congenital syphilis is sparse, implying that we are uncertain about the estimated effect. One trial compared benzathine penicillin with no intervention for infants with possible congenital syphilis. Low-quality evidence suggested penicillin administration possibly reduce the proportion of neonates with clinical manifestations of congenital syphilis, penicillin administration increased the serological cure at the third month. These findings support the clinical use of penicillin in neonates with confirmed, highly probable or possible congenital syphilis. High- and moderate-quality evidence suggests that there are probably no differences between benzathine penicillin and procaine benzylpenicillin administration for the outcomes of absence of clinical manifestations of syphilis or serological cure.\nEl estreptococo del grupo B ( Streptococcus agalactiae, GBS) es la causa m\u00e1s com\u00fan de sepsis neonatal y meningitis en muchos pa\u00edses desarrollados. En el Reino Unido, el GBS causa una enfermedad invasiva en los primeros seis d\u00edas de vida en aproximadamente uno de cada 2000 nacidos vivos. Para prevenir la enfermedad de inicio temprano, el tratamiento recomendado a nivel internacional es la profilaxis antibi\u00f3tica intraparto, generalmente penicilina intravenosa. El Reino Unido recomienda una estrategia basada en el riesgo, en la cual a las mujeres embarazadas que presentan factores de riesgo para una infecci\u00f3n por GBS de inicio temprano se les ofrece profilaxis antibi\u00f3tica durante el parto.\nLos defensores del cribado universal apuntan a los pa\u00edses de Europa y Am\u00e9rica del Norte donde se recomienda el cribado y donde se han observado reducciones en la infecci\u00f3n por EGB de inicio temprano. Pero la evidencia muestra que la efectividad del cribado, es incierto y que la detecci\u00f3n tiene da\u00f1os potenciales. En el art\u00edculo explican por qu\u00e9 el Comit\u00e9 Nacional de Detecci\u00f3n del Reino Unido decidi\u00f3 no introducir la detecci\u00f3n de rutina: tratamiento excesivo, peligros potenciales desconocidos de la detecci\u00f3n y tratamiento profil\u00e1ctico con antibi\u00f3ticos durante el parto, y beneficio incierto.\nEl enfoque actual llevar\u00eda a que el 99.8% de las mujeres con resultado positivo en la prueba de detecci\u00f3n y sus beb\u00e9s reciban una profilaxis innecesaria con antibi\u00f3ticos durante el parto. La falta de evidencia de alta calidad sobre los resultados cl\u00ednicos hace que sea imposible cuantificar si la prueba de detecci\u00f3n de GBS universal tendr\u00eda alg\u00fan beneficio y evaluar si la profilaxis con antibi\u00f3ticos intraparto a gran escala es segura. Ellos concluyen que actualmente no se puede recomendar un programa universal de detecci\u00f3n de cultivos prenatales.\nIntroducci\u00f3n. El objetivo del estudio fue evaluar la seguridad y la eficacia de la combinaci\u00f3n de ledipasvir/sofosbuvir en la infecci\u00f3n cr\u00f3nica por el genotipo 1 y 4 del virus de la hepatitis C (VHC) en pacientes pedi\u00e1tricos. M\u00e9todos. Se incluy\u00f3 a pacientes de entre 6 y 18 a\u00f1os. La duraci\u00f3n y la dosis de los f\u00e1rmacos antivirales se administraron seg\u00fan la edad del paciente, el estadio de fibrosis y los tratamientos previos con interfer\u00f3n pegilado y ribavirina. La variable principal de eficacia fue el porcentaje de pacientes con una respuesta virol\u00f3gica sostenida 12 semanas (RVS12) despu\u00e9s del tratamiento. Resultados Nueve pacientes con una mediana de edad de 14,8 a\u00f1os fueron tratados con combinaci\u00f3n de ledipasvir/sofosbuvir. Cinco pacientes hab\u00edan recibido previamente tratamiento con interfer\u00f3n pegilado+ribavirina. Ocho pacientes ten\u00edan alg\u00fan grado de fibrosis. La mediana de la carga viral previa al tratamiento fue de 6,2 log con negativizaci\u00f3n del ARN del VHC 6 semanas despu\u00e9s de comenzar el tratamiento en el 100% de los pacientes. Todos los pacientes mantuvieron una respuesta viral sostenida a las 12 semanas. Tres pacientes (33,3%) tuvieron alg\u00fan tipo de efecto adverso (2 dolores de cabeza y un afta oral). La mediana de seguimiento posterior al tratamiento fue de 24 semanas.\nConclusiones. El tratamiento con ledipasvir/sofosbuvir en pacientes pedi\u00e1tricos con infecci\u00f3n cr\u00f3nica por VHC de genotipo 1 y 4 es seguro y efectivo con RVS12, similar a lo reportado en adultos.\n[Euro Surveill.](https://www.ncbi.nlm.nih.gov/pubmed/30782268) 2019 Feb;24(7). doi: 10.2807/1560-7917.ES.2019.24.7.1700857\nWorldwide, under-fives mortality has halved since 1990 from 93 to 41 deaths per 1000 live births in 2016. However, progress has been very uneven. Child mortality is still highest in Africa (76 per 1000 live births) (\n[figure 1](https://adc.bmj.com/content/104/3/227#F1)) and neonatal mortality has declined at a slower rate so is now approaching 50% of all under-fives mortality. [1](https://adc.bmj.com/content/104/3/227#ref-1) Research and programmatic efforts are focussed on reducing child mortality in the highest burden areas. An intriguing and controversial idea to reduce mortality has arisen from mass antimicrobial distribution programmes for the prevention of blindness caused by trachoma.\nA 6-year-old boy presents to Accident and Emergency with fever, lethargy and a spreading purpuric rash. Despite fluid resuscitation with 40 mL/kg he remains clinically shocked with tachycardia, cool peripheries, prolonged capillary refill time and lactic acidosis. Anaesthetics arrive to intubate and you as the paediatric registrar are asked to prescribe a peripheral vasoactive drug infusion. You remember that the advanced paediatric life support course you recently attended advised starting either dopamine or epinephrine in the setting of cold shock but wonder if there is evidence to support one over the other.\nStructured clinical question\nIn children with septic shock unresponsive to 40 mL/kg fluid resuscitation (population) does initial peripheral venous administration of epinephrine (intervention) compared with dopamine (comparison) improve mortality (outcome)?\nThe Pediatric Infectious Disease Journal. 38(3):e54-e56\nHemophagocytic lymphohistiocytosis (HLH) is not one condition but descriptive of a life-threatening, hyper-inflammatory syndrome with multiorgan involvement with a variety of triggers, both genetic and environmental. It is described as primary HLH (familial HLH) and secondary HLH (acquired following malignancy, rheumatologic disorders, primary immune deficiencies or infection alone). Infections commonly precipitate HLH in those with primary HLH, in combination with an underlying disease (malignancy, rheumatologic or primary immune deficiency) or may be the sole trigger.\n[1](https://journals.lww.com/pidj/Fulltext/2019/03000/Hemophagocytic_Lymphohistiocytosis_and_Infections_.28.aspx#R1-28) Many people with \u201csecondary\u201d HLH may also have potentially pathogenic polymorphisms in an HLH- associated gene. [2](https://journals.lww.com/pidj/Fulltext/2019/03000/Hemophagocytic_Lymphohistiocytosis_and_Infections_.28.aspx#R2-28) Rapid diagnosis of HLH and initiation of appropriate treatment is essential to reduce mortality from this condition\nLos anticuerpos monoclonales contra el virus sincitial respiratorio (VRS; palivizumab) se recomiendan para la profilaxis de los beb\u00e9s de alto riesgo durante las temporadas de bronquiolitis, pero no para el tratamiento de la bronquiolitis por VRS. Nuestro objetivo fue determinar si palivizumab ser\u00eda \u00fatil en ni\u00f1os peque\u00f1os con bronquiolitis aguda por VRS.\nSe incluyeron 420 ni\u00f1os en el estudio, de los cuales completaron 413.\nCONCLUSIONES: El palivizumab intravenoso no parece ayudar o da\u00f1ar a los beb\u00e9s peque\u00f1os con bronquiolitis aguda por VRS positiva.\n\u00b7\n[Cerebrospinal Fluid Shunt Infection: Emerging Paradigms in Pathogenesis that Affect Prevention and Treatment](https://www.jpeds.com/article/S0022-3476(18)31673-1/fulltext). [J Pediatr.](https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Cerebrospinal+Fluid+Shunt+Infection%3A+Emerging+Paradigms+in+Pathogenesis+that+Affect+Prevention+and+Treatment) 2018 Dec 6. pii: S0022-3476(18)31673-1\nIn this medical progress report, we outline the epidemiology and healthcare utilization associated with cerebrospinal fluid (CSF) shunt-associated infections in the US, the clinical features of CSF shunt infection, and our evolving understanding of the prevention and treatment of CSF shunt infection. We describe an emerging paradigm in CSF shunt infection under active investigation.\n- Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study.\n[J Pediatr.](https://www.ncbi.nlm.nih.gov/pubmed/?term=*+%E2%80%A2%09Trends+and+Predictors+of+Clostridium+difficile+Infection+among+Children%3A+A+Canadian+Population-Based+Study) 2018 Nov 15. pii: S0022-3476(18)31548-8\nTo assess time trends in Clostridium difficile infection (CDI) rates, and predictors of CDIs, including recurrent CDIs, in children.\nStudy design\nData were extracted from Manitoba Health Provider Claims, and other population registry datasets from 2005 to 2015. CDI was identified from the Manitoba Health Public Health Branch Epidemiology and Surveillance population-based laboratory-confirmed CDI dataset. Children aged 2-17 years with CDI were matched by age, sex, area of residence, and duration of residence in Manitoba with children without CDI. The rates and time trends of CDIs using previously recommended definitions were determined. Predictors of CDI subtypes were determined using multivariable logistic regression models. Cox regression analysis was used to assess for the potential predictors of recurrent CDI.\nResults\nChildren with and without CDI were followed for 828 and 2753 persons-years, respectively. The overall CDI rate during the study period was 7.8 per 100 000 person-years. There was no significant change in CDI rates over the observation period. Comorbid conditions, more prevalent among children with CDI than matched controls, included Hirschsprung disease (P < .001) and inflammatory bowel disease (P < .0001). Recurrent CDIs (>2 occurrences) were responsible for 10% of CDI episodes (range, 2-6 infections). Predictors of recurrence included malignancy (hazard ratio, 3.0, 95% CI, 1.1-8.8), diabetes (hazard ratio, 4.8; 95% CI, 1.1-21.4), and neurodegenerative diseases (hazard ratio, 8.4; 95% CI, 1.9-37.5).\nConclusions\nThe incidence of CDI is stable among children in Manitoba. Children with Hirschsprung disease and inflammatory bowel disease are more susceptible to CDI, and those with malignancy, diabetes. and neurodegenerative disorders are more likely to develop recurrent CDI.\nBackground: Fluoroquinolone (FQ) prescription rates have increased over the last 10 years despite recent warnings of serious adverse effects such as peripheral neuropathy and tendinopathy. Currently, there are no published data on the extent or appropriateness of FQ prescribing in children.\nMethods: Drug prescription data from the PharMetrics Plus health claims database (United States) were analyzed to examine dispensing of ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, or gemifloxacin to children from 2006 to 2015. Based on American Academy of Pediatrics recommendations, an algorithm was created to quantify inappropriate FQ prescriptions, which was further stratified by age and FQ type.\nResults: Among a cohort of 2,754,431 children, 372,357 prescriptions for an oral FQ were dispensed between 2006 and 2015. An increase was observed in FQ prescriptions from 2006 to 2013, with numbers coming down in 2014 and 2015. Ciprofloxacin was the most frequently prescribed FQ (334,268 prescriptions) followed by levofloxacin (19,386), moxifloxacin (18,434) and combined ofloxacin/gemifloxacin prescriptions (369). Of the FQ prescriptions in children, 48% were prescribed to those 10 years of age or younger, and 22% were deemed inappropriate.\nConclusions: Our study suggests an increase in the prescribing of FQs, mostly ciprofloxacin, over a 10-year period, although numbers have decreased slightly in 2014 and 2015. At least 1 in 5 prescriptions were deemed unnecessary. In light of recent FQ safety warnings and lack of long-term safety data with FQ use in children and potential risk of increasing antibiotic resistance, clinicians are advised to refrain from using FQs for uncomplicated community-acquired infections.\nActualidad bibliogr\u00e1fica febrero 2019\nTop ten\n\u00b7\n[Gu\u00eda de uso de antimicrobianos en ni\u00f1os con tratamiento ambulatorio](http://www.madrid.org/bvirtual/BVCM020261.pdf). Servicio madrile\u00f1o de Salud. Consejer\u00eda de Sanidad e la Comunidad de Madrid. Disponible en http://www.comunidad.madrid/publicacion/ref/20261\n\u00b7\n[Scabies: New Opportunities for Management and Population Control](https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx). The Pediatric Infectious Disease Journal. 38(2):211-213\nScabies is a skin condition caused by infestation with the microscopic mite Sarcoptes scabiei var hominis. Common scabies causes severe itch, mite burrows and secondary skin lesions. Scabies has a strong causal relationship with impetigo\n[1](https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R1-26) which can lead to more severe skin and soft tissue infections, invasive bacterial infections and post-streptococcal sequelae. [2](https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R2-26) Crusted scabies is a rare form, usually affecting people with immunosuppression and characterized by hyperkeratotic skin containing thousands to millions of mites.\nThe World Health Organization (WHO) adopted scabies as a neglected tropical disease (NTD) in 2017.\n[3](https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R3-26) This recognition has led to increasing global awareness and efforts toward scabies control and even elimination as a public health problem. The 2018 meeting of the WHO NTD Strategic Technical Advisory Group Working Group on Monitoring and Evaluation noted \u201cstrong initial evidence for ivermectin-based mass drug administration (MDA) for control of scabies in endemic populations and that simplified clinical case definitions for field surveys are available; however, there is currently no global strategy for scabies control.\u201d [4](https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R4-26) With an increasing global focus on scabies, it is timely to review recent advances in the understanding of scabies epidemiology, diagnosis, treatment and public health control.\n\u00b7Antibiotic Recommendations for Acute Otitis Media and Acute Bacterial Sinusitis: Conundrum No More.\n[Pediatr Infect Dis J.](https://www.ncbi.nlm.nih.gov/pubmed/29570583) 2018 Dec;37(12):1255-1257\nThere has been a substantial change in the prevalence and microbiologic characteristics of cases of acute otitis media secondary to the widespread use of pneumococcal conjugate vaccines. Current trends in nasopharyngeal colonization and the microbiology of acute otitis media support a change in the recommendation for antibiotic management of acute otitis media and acute bacterial sinusitis in children.\nBackground: The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) hypothesis suggests an association between group A beta-hemolytic streptococcus (GABHS) infections and subsequent onset or exacerbation of neuropsychiatric symptoms, such as obsessive-compulsive disorder or tic disorders.\nMethods: We performed a systematic review and meta-analysis including longitudinal, prospective studies on exacerbations of neuropsychiatric symptoms associated with GABHS infections in children with PANDAS. We searched PubMed and EMBASE through August 14, 2017. Two independent reviewers extracted data and we used random-effects analysis to calculate rate ratios (RR).\nResults: Three studies were included with a total of 82 PANDAS cases and 127 control children with obsessive-compulsive disorder or chronic tic disorder. PANDAS cases had a nonsignificantly increased RR of 2.33 [95% confidence interval [CI]: 0.63\u20138.70, P = 0.21, I 2 = 28.3%] for exacerbations of neuropsychiatric symptoms in temporal proximity to a GABHS infection and no increased risk of GABHS infections (RR = 0.99, 95% CI: 0.56\u20131.73, P = 0.97, I 2 = 45%) compared with the control children. However, PANDAS cases had an increased risk of neuropsychiatric exacerbations in general with a RR of 1.54 (95% CI: 1.12\u20132.11, P = 0.008, I 2 = 0%) compared with the control children. The studies had methodologic heterogeneity, high risk of selection bias and differed concerning case definition and infection measures.\nConclusions: Our findings did not show significant evidence concerning higher rates of temporally associated GABHS infections and exacerbations of neuropsychiatric symptoms in children with PANDAS. The included studies were small and limited by low GABHS rates and exacerbations. Future studies with large population sizes and routine evaluations are needed to thoroughly examine the PANDAS hypothesis.\nM\u00e1s de 80 000 personas en 47 de los 53 pa\u00edses europeos contrajeron el sarampi\u00f3n en 2018, con un 61% hospitalizados y 72 muertes Seg\u00fan la OMS.\nEl n\u00famero total de personas infectadas con el virus en 2018 fue el m\u00e1s alto de esta d\u00e9cada: tres veces el total informado en 2017 (23 927 casos) y 15 veces el m\u00ednimo hist\u00f3rico registrado en 2016 (5273 casos).\nA pesar de que en la regi\u00f3n europea haya m\u00e1s ni\u00f1os vacunados contra la enfermedad que nunca, el progreso en la vacunaci\u00f3n es desigual entre los pa\u00edses y dentro de ellos. Esto deja a los grupos de personas susceptibles desprotegidas, particularmente en los pa\u00edses de ingresos medios\nEl Plan Europeo de Acci\u00f3n de Vacunas 2015-2020 (EVAP) establece una estrategia respaldada por los 53 estados miembros para eliminar el sarampi\u00f3n y la rub\u00e9ola. Al menos el 95% de cada poblaci\u00f3n debe ser inmune, a trav\u00e9s de dos dosis de vacunaci\u00f3n o exposici\u00f3n previa al virus, para garantizar la protecci\u00f3n de la comunidad para todos, incluidos los beb\u00e9s demasiado peque\u00f1os para ser vacunados y otros que no pueden ser inmunizados debido a enfermedades existentes y enfermedades m\u00e9dicas.\nBackground: Implementing matrix-assisted laser desorption ionization\u2013time of flight and multiplex polymerase chain reaction has been associated with decreased mortality and hospital length of stay in adults, but the impact in pediatrics is less understood.\nMethods: This pre\u2013post quasi-experimental study compared antibiotic prescribing for positive blood cultures in patients \u226421 years of age collected in 2012 (preintervention) and in 2015 (after matrix-assisted laser desorption ionization\u2013time of flight/multiplex polymerase chain reaction). Time to effective and optimal antimicrobial therapy was evaluated using Cox proportional hazards regression. Time to ideal optimal therapy was estimated as the earliest potential initiation of optimal therapy. Antibiotic use and clinical outcomes were measured.\nResults: There were 242 and 192 positive monomicrobial blood cultures in 2012 and 2015, respectively. Postintervention, time to optimal therapy (73.8 vs. 48.8 hours; P < 0.001) and organism identification (55.6 vs. 29.5 hours; P < 0.001) were reduced, and patients were more likely to receive optimal therapy by 7 days (hazard ratio, 1.85; P < 0.001). In the ideal scenario in 2015, there was an 8.8-hour delay in initiating optimal therapy based on the time that sufficient microbiologic data were available. Postintervention, time to effective therapy (2.8 vs. 2.7 hours; P = 0.782) and clinical outcomes did not differ. Unnecessary antibiotic duration for probable contaminants (skin flora) (43.1 vs. 29.7 hours; P = 0.027), vancomycin for methicillin-sensitive Staphylococcus aureus (54.0 vs. 41.3 hours; P = 0.008) and nonpenicillin/ampicillin antibiotics for group A Streptococcus, group B Streptococcus and Enterococcus faecalis (87.2 vs. 33.4 hours; P < 0.001) were reduced postintervention.\nConclusions: Rapid diagnostics reduced time to optimal antimicrobial therapy and unnecessary antibiotic use without worse clinical outcomes.\nIntroducci\u00f3n: La informaci\u00f3n existente sobre el impacto de la gripe en la poblaci\u00f3n infantil espa\u00f1ola es escasa. El trabajo pretende estudiar la incidencia de hospitalizaci\u00f3n, cl\u00ednica, comorbilidades y el estado vacunal en los ni\u00f1os hospitalizados.\nM\u00e9todos: Estudio retrospectivo, observacional, por revisi\u00f3n de historias cl\u00ednicas, en menores de 15 a\u00f1os hospitalizados por gripe adquirida en la comunidad, confirmada microbiol\u00f3gicamente, durante 2temporadas gripales (2014-2015 y 2015-2016). El estudio se realiz\u00f3 en 10 hospitales de 6 ciudades, que atienden aproximadamente al 12% de la poblaci\u00f3n infantil espa\u00f1ola.\nResultados: Fueron hospitalizados 907 ni\u00f1os con gripe (447<2 a\u00f1os), con una tasa media anual de incidencia de hospitalizaci\u00f3n de 0,51 casos/1.000 ni\u00f1os (IC del 95% 0,48-0,55). El 45% present\u00f3 enfermedades subyacentes consideradas factores de riesgo para gripe grave, y la mayor parte de ellos (74%) no hab\u00edan sido vacunados. El porcentaje con enfermedades subyacentes aument\u00f3 con la edad, desde el 26% en menores de 6 meses al 74% en mayores de 10 a\u00f1os. El 10% de los casos (n=92) precisaron cuidados intensivos pedi\u00e1tricos por fallo respiratorio agudo.\nConclusi\u00f3n: La gripe es causa importante de hospitalizaci\u00f3n en la poblaci\u00f3n infantil espa\u00f1ola. Los menores de 6 meses de edad y los ni\u00f1os con enfermedades subyacentes constituyen una parte mayoritaria (> 50%) de los casos. Una gran parte de las formas graves de gripe en poblaci\u00f3n infantil podr\u00edan ser evitada si se cumplieran las indicaciones de vacunaci\u00f3n.\nCasos cl\u00ednicos\nNeonato de de 2 semanas de vida. Consultan por secreci\u00f3n purulenta de ambo. Recien nacido a t\u00e9rmino, parto vaginal espont\u00e1neo. No hab\u00eda recibido profilaxis ocular despu\u00e9s del parto, y la madre no se hab\u00eda sometido a pruebas prenatales para detectar la infecci\u00f3n por clamidia o gonorrea. Una muestra de secreci\u00f3n ocular obtenida del beb\u00e9 y un hisopo endocervical obtenido de la madre dieron positivo para el ADN de Chlamydia trachomatis y negativo para el ADN de Neisseria gonorrhoeae por reacci\u00f3n en cadena de la polimerasa. La transmisi\u00f3n perinatal de C. trachomatis o N. gonorrhoeae puede causar conjuntivitis neonatal, conocida como oftalmia neonatorum. El paciente recibi\u00f3 2 semanas de eritromicina oral, y adem\u00e1s se una dosis \u00fanica de azitromicina oral a sus padres. Los s\u00edntomas del se resolvieron dentro de los 5 d\u00edas posteriores al inicio del tratamiento.\nStaphylococcus aureus y estreptococos del grupo viridans son los organismos causantes m\u00e1s comunes, mientras que el estreptococo del grupo A (SGA) es menos frecuente.\n1er caso: ni\u00f1a de 14 a\u00f1os previamente sana, presenta tres d\u00edas de fiebre, fatiga y cambios en el estado mental y un d\u00eda de cojera.\nSignos vitales: T\u00aa 39,8\u00baC; FC 130 lpm; TA 100/71 mmHg; FR 18 rpm y SatO2 98%.\nExploraci\u00f3n: Estaba orientada pero extra\u00f1amente charlatana y grosera. La \u00favula y la faringe posterior estaban cubiertas de hemorragias petequiales que suger\u00edan faringitis estreptoc\u00f3cica. No se auscultaron soplos card\u00edacos. El segundo y el quinto dedos del pie izquierdo presentaban coloraci\u00f3n negruzca, ten\u00eda petequias en la palma de la mano derecha y plantas de pies y el dorso del pie izquierdo estaba eritematoso, c\u00e1lido e hinchado\nLaboratorio: Signos de coagulaci\u00f3n intravascular diseminada (CID) con un recuento elevado de gl\u00f3bulos blancos y una prote\u00edna C reactiva elevada\nEn dos de los tres cultivos de sangre creci\u00f3 Streptococcus pyogenes (T6 M6, emm 6.104).\nSe estableci\u00f3 el diagn\u00f3stico de celulitis y esta infecci\u00f3n de la piel y los tejidos blandos del dedo del pie y del pie causaban bacteriemia y CID.\nSe sospech\u00f3 que la SGA era el microorganismo causante y se inici\u00f3 tratamiento con ampicilina / sulbactam intravenosa (IV) y clindamicina.\nSobre la base de los resultados del antibiograma, la ampicilina / sulbactam se cambi\u00f3 por ampicilina y se continu\u00f3 con clindamicina\nSu estado mental casi se hab\u00eda normalizado al final del primer d\u00eda de hospitalizaci\u00f3n y estaba completamente despierta y alerta el d\u00eda 3.\nAl tercer d\u00eda se escuch\u00f3 un soplo sist\u00f3lico de eyecci\u00f3n y la ecocardiograf\u00eda mostr\u00f3 regurgitaci\u00f3n mitral con vegetaci\u00f3n de la v\u00e1lvula mitral.\nTambi\u00e9n tuvo hallazgos de infartos en la corteza temporal izquierda profunda, el bazo y el ri\u00f1\u00f3n.\nDos semanas despu\u00e9s, desarroll\u00f3 una erupci\u00f3n eritematosa en todo el cuerpo. Se sospech\u00f3 una erupci\u00f3n por drogas y se cambi\u00f3 de ampicilina y clindamicina a cefotaxima.\nDebido a la gravedad resultante de la regurgitaci\u00f3n mitral, se someti\u00f3 a una reparaci\u00f3n de la v\u00e1lvula mitral despu\u00e9s de 10 semanas de tratamiento con antibi\u00f3ticos.\n2\u00ba caso: Un ni\u00f1o de 17 meses se present\u00f3 en un hospital municipal por fiebre. Ten\u00eda antecedentes de cierre espont\u00e1neo de un defecto del tabique ventricular (CIV) a los 5 meses de edad con insuficiencia mitral leve residual. Presentaba un historial de 2 d\u00edas de fiebre y de irritabilidad de 1 d\u00eda. Fue remitido a nuestro hospital debido a un recuento elevado de gl\u00f3bulos blancos y una prote\u00edna C reactiva elevada.\nLos signos vitales iniciales fueron: T\u00aa 40.6 \u00b0 C, TAS 100 mmHg, FC 157 latidos / min, FR 60 respiraciones / min y Sat. 97%. No ten\u00eda petequias conjuntivales, ni hemorragias en astillas de las u\u00f1as, ni erupci\u00f3n. No se auscultaban soplos.\nLa evaluaci\u00f3n inicial de laboratorio mostraba un recuento de gl\u00f3bulos blancos de 14.300 c\u00e9lulas / ml y un nivel de prote\u00edna C reactiva de 30.89 mg / dL. Se extrajeron hemocultivos tanto en el hospital municipal como en nuestro hospital con 12 horas de diferencia, y se inici\u00f3 tratamiento emp\u00edrico con ampicilina IV y cefotaxima por una posible bacteriemia.\nEn dos cultivos de sangre crecieron S. pyogenes (T4 M4, emm 4.0).\nEn el d\u00eda 5 de ingreso, la ecocardiograf\u00eda mostr\u00f3 una vegetaci\u00f3n en un aneurisma septal membranoso del lado derecho y se le diagnostic\u00f3 de endocarditis infecciosa. Sobre la base de los resultados de las pruebas de susceptibilidad, se retir\u00f3 la cefotaxima y solo se continu\u00f3 con ampicilina. Mientras recib\u00eda terapia con antibi\u00f3ticos, no desarroll\u00f3 ninguna complicaci\u00f3n, como hipertensi\u00f3n pulmonar o embolia pulmonar. La ampicilina IV se continu\u00f3 durante 4 semanas adicionales despu\u00e9s de que se determin\u00f3 que los hemocultivos de seguimiento eran negativos y finalmente fue dado de alta. El paciente no ha mostrado signos de insuficiencia card\u00edaca durante el per\u00edodo de seguimiento de 2 a\u00f1os\nConclusi\u00f3n: El SGA es un organismo etiol\u00f3gico raro de la EI, y hay pocos informes de endocarditis por SGA con informaci\u00f3n espec\u00edfica sobre los tipos de serotipos (de la prote\u00edna M) / emm (genes que codifican la prote\u00edna M). En general, la mayor\u00eda de los tipos de serotipos/emm asociados con SGA generalmente causan solo una infecci\u00f3n leve, pero como muestra este informe, tambi\u00e9n puede asociarse con una enfermedad invasiva grave como la EI.\nEn relaci\u00f3n al segundo caso destacar que las directrices de profilaxis antibi\u00f3tica de la Academia Americana del Coraz\u00f3n de 2007 para la prevenci\u00f3n de la EI, ya no consideran que las lesiones card\u00edacas cong\u00e9nitas no reparadas teng\u00e1n un riesgo alto o moderado de EI. Sin embargo Knirsch et a.l sostienen que deben considerarse un riesgo de por vida las cardiopat\u00edas cong\u00e9nitas no operadas, reparadas o solucionadas espontaneamente, incluyendo la CIV\nAn 18-year-old was admitted to our hospital in December 2017 after 2 days of fever, caugh and dyspnea. NO clinical relevant history, no recent travel and a completed vaccination calendar. The patient accomplished sepsis clinical criteria, and examination revealed no neurologic findings or skins lesions. Laboratory findings were leucopenia, coagulopathy and elevation of acute phase reagents. Torax X-ray showed a bilateral infiltrate. The patient evolved to acute respiratory failure, which required admission to our Intensive Care Unit for respiratory support. Empirical antimicrobial treatment with meropenem, levofloxacin and oseltamivir was started after collection of blood and urine cultures and nasopharyngeal exudate for PCR testing for Influenza viruses. Urine and nasopharyngeal samples were negative.In blood culture, the isolate was Neisseria meningitidis serogroup C/W. The strain was susceptible to Cefotaxime (MIC \u2264 0.016 g/mL). Clinicians were informed and the patient underwent targeted therapy with Cefotaxime at a dose of 2 g/8 h for 7 days, with favorable outcome (any clinical consequence of the infection) . The isolate was identified as N. meningitidis serogroup W, genosubtype P1.5,2 (PorA VR1:5, VR2:2). The disease is seasonal, being more frequent in the winter months. In Spain we have attended a similar scenario tan in the restnof Europe: on the one hand a decrease on the incidence of IMD by serogroup C and B. On the other hand, the number of IMD due to non-frequent serogroups (W and Y) has also increased (8.2% of W and 5.2% of Y in 2015\u20132016 season).These serogroups are nowadays considered as emerging and they should be considered in patients with clinical suspicion of meningococcal infection. The possibility of quadrivalent conjugate vaccine implementation in Spain should be evaluated. This case report illustrates the emerging importance of these local-acquired non-B/C meningococcal infections which have to be considered as a differential diagnosis in patients with either sepsis of respiratory origin with or without neurological or skin findings.\nNeonato de 9 d\u00edas que consulta por fiebre de 38 \u25e6C de 2 h, irritabilidad y rechazo de apoyo sobre el lado izdo. No otra sintomatolog\u00eda. Antecedentes perinatales : SGB positivo, con profilaxis antibi\u00f3tica incompleta, sin cl\u00ednica de infecci\u00f3n neonatal en maternidad. Hermano de 6 anos normovacunado y sin cl\u00ednica infecciosa. EF: zona eritematosa e indurada en regi\u00f3n malar izquierda, caliente y dolorosa, que engloba el \u00e1ngulo submandibular. No se observan puertas de entrada superficiales ni en mucosa oral. Leve oclusi\u00f3n ocular izquierda, sin lateralizaci\u00f3n de la comisura bucal. Resto normal. En la anal\u00edtica destacan leucocitosis con neutrofilia con series roja y plaquetaria normales. Ionograma, perfiles renal y hep\u00e1tico y amilasa normales. PCR 11 mg/l y PCT 0,11 ng/ml. Las citoqu\u00edmicas de orina y LCR fueron normales. EN ecograf\u00eda de partes blandas, se aprecia un aumento de tama\u00f1o de la par\u00f3tida izda, hipervascularizada, y con ganglios intra y extra parot\u00eddeos, de aspecto reactivo, sin colecciones que sugieran abscesos ni dilataciones ductales Ingresa con sospecha de parotiditis neonatal con tto iv emp\u00edrico con ampicilina y cefotaxima. A las 12 h comienza con secreci\u00f3n a trav\u00e9s del conducto de Stenon; se recoge muestra del exudado y se sustituye la antibioterapia por cloxacilina y cefotaxima. Tanto en el cultivo de este exudado, como en el hemocultivo se identifican SARM, Staphylococcus mitis y Staplylococcus salivaris, por lo que se completa tratamiento con cloxacilina intravenosa durante 10 d\u00edas. Los cultivos de orina y LCR resultan negativos. P ermanece afebril desde las 48 h del ingreso, con mejor\u00eda progresiva de la induraci\u00f3n y del eritema mandibular, desapareciendo la secreci\u00f3n purulenta por el conducto de Stenon hasta el 4.\u25e6 d\u00eda de ingreso. El hemocultivo de control y la serolog\u00eda IgM de parotiditis resultan negativos.\nLa parotiditis bacteriana es excepcional en neonatos y lactantes debido a los anticuerpos maternos. La infecci\u00f3n puede producirse por flujo bacteriano retr\u00f3grado a trav\u00e9s del conducto de Stenon, y con menor frecuencia por siembra hemat\u00f3gena . El S. aureus es el microorganismo aislado m\u00e1s com\u00fan. En segundo lugar, y con mayor asociaci\u00f3n con cl\u00ednica generalizada y meningitis, se encuentra la infecci\u00f3n por SGB. Tambi\u00e9n se han descrito infecciones por otros bacilos gramnegativos, anaerobios y estreptococos. El diagn\u00f3stico es cl\u00ednico. La afectaci\u00f3n unilateral es la m\u00e1s frecuente. La fiebre se encuentra en menos de la mitad de los casos, habitualmente asociada a bacteriemia. El nivel s\u00e9rico de amilasa se eleva en pocas ocasiones, debido a la inmadurez de esta actividad de la isoenzima salival en reci\u00e9n nacidos. El cultivo positivo del exudado purulento del conducto ipsilateral de Stenon o de la aspiraci\u00f3n de la gl\u00e1ndula afectada es patognom\u00f3nico. Cuando este resulta negativo, el crecimiento bacteriano del hemocultivo en este contexto cl\u00ednico sugiere altamente el diagn\u00f3stico. La prematuridad, el sexo masculino, la necesidad de sonda nasog\u00e1strica y la deshidrataci\u00f3n son factores de riesgo. El pron\u00f3stico es bueno. Algunos autores consideran la cloxacilina como tto de elecci\u00f3n dada la alta frecuencia de S. aureus como agente causal, no obstante, cuando exista la posibilidad de infecci\u00f3n por SGB, el tto emp\u00edrico debe ser una C3G hasta resultado de cultivos. Complicaciones: septicemia y meningitis, f\u00edstulas salivales y abscesos, par\u00e1lisis facial y mediastinitis, que pueden llegar a precisar cirug\u00eda\nPara profundizar\nProbiotics, usually in the form of live Lactobacillus species, have become popular as both a treatment and a preventative agent for a wide variety of childhood conditions. For example, there is evidence that they work in antibiotic-related diarrhoea, necrotising enterocolitis and possibly infantile colic. So if the diarrhoea that occurs in straightforward viral gastroenteritis is partly due to an altered intestinal microbiome, would you expect them to help this as well? You might, but two robust new studies suggest that they don\u2019t. The NEJM published two large randomised double-blind placebo-controlled \u2026\nLa producci\u00f3n de biopel\u00edculas por Haemophilus influenzae y Streptococcus pneumoniae se ha relacionado con la patog\u00e9nesis de la otitis media, principalmente en casos cr\u00f3nicos y recurrentes. Se estudi\u00f3 \u201cin vitro\u201d la producci\u00f3n de biopel\u00edculas por estas 2 especies aisladas en solitario o juntas de la nasofaringe de ni\u00f1os con otitis media aguda. En general, 89/94 (94.6%) de los casos con aislamiento combinado de S. pneumoniae o H. influenzae mostraron producci\u00f3n de biopel\u00edculas. Este estudio enfatiza la alta proporci\u00f3n de producci\u00f3n de biopel\u00edculas por cepas de H. influenzae y S. pneumoniae aisladas de la nasofaringe de ni\u00f1os con otitis media aguda, lo que refuerza los resultados de estudios que sugieren la importancia de las biopel\u00edculas en la patog\u00e9nesis de la otitis media aguda.\nResumen: Las infecciones respiratorias agudas (IRA) representan una causa importante de morbilidad y mortalidad en los ni\u00f1os, y siguen siendo un importante problema de salud p\u00fablica, y afectan especialmente a los ni\u00f1os menores de 5 a\u00f1os de pa\u00edses de bajos ingresos. Se realiz\u00f3 un an\u00e1lisis de datos secundarios de un estudio transversal previo realizado en ni\u00f1os con un diagn\u00f3stico probable de tos ferina desde enero de 2010 hasta julio de 2012. Todas las muestras se analizaron mediante reacci\u00f3n en cadena de la polimerasa (PCR) para las siguientes etiolog\u00edas: Influenza-A, Influenza -B, RSV-A, RSV-B, Adenovirus, virus Parainfluenza 1, virus Parainfluenza 2, virus Parainfluenza 3, Mycoplasma pneumoniae y Chlamydia pneumoniae En un total de 288 pacientes el pat\u00f3geno aislado m\u00e1s com\u00fan fue el adenovirus (49%), seguido de Bordetella pertussis (41%), neumon\u00eda por Mycoplasma (26%) y la Influenza B (19,8%). Las coinfecciones se informaron en el 58% de las muestras y la asociaci\u00f3n m\u00e1s com\u00fan se encontr\u00f3 entre B. pertussis y Adenovirus (12.2%).\nHubo una alta prevalencia de adenovirus, Mycoplasma pneumoniae y otras etiolog\u00edas en pacientes con un diagn\u00f3stico probable de tos ferina. A pesar de la presencia de tos persistente que dura por lo menos dos semanas y otras caracter\u00edsticas cl\u00ednicas altamente sospechosas de tos ferina, se deben considerar las etiolog\u00edas secundarias en ni\u00f1os menores de 5 a\u00f1os para brindar un tratamiento adecuado.\nObjective Traveller\u2019s diarrhoea (TD) is one of the most frequent illnesses affecting children returning from tropical countries. The purpose of this study was to assess the distribution of pathogens associated with TD in children using a multiplex PCR assay on stool samples.\nDesign All the children admitted for TD in two university hospitals from 1 August to 15October during 2014 and 2015 were included in a prospective study. Stool samples were tested by a multiplex PCR FilmArray GI panel detecting 22 pathogens. Performances for the detection of major enteropathogenic bacteria (Salmonella, Shigella and Campylobacter spp) by multiplex PCR and conventional culture methods were compared. The prevalence of extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae was also determined.\nResults Fifty-nine children were included. In 58 cases (98%), at least one pathogen was identified, including 9 different enteropathogenic bacteria, 5 viruses and 2 parasites. Multiplex PCR enhanced the enteropathogenic bacteria detection by 25%. The most frequent pathogens were enteroaggregative Escherichia coli (n=32), enteropathogenic E. coli (n=26), enterotoxigenic E. coli (n=19), Salmonella enterica, enteroinvasive E. coli/Shigella (n=16 each), Cryptosporidium, sapovirus (n=11 each), Campylobacter jejuni, norovirus (n=10 each), rotavirus (n=9), Giardia (n=8) and Shiga-toxin-producing E. coli (n=4). Fifty-two coinfections were observed, notably including bacteria and viruses (n=21), multiple bacteria (n=14), or bacteria and parasites (n=10). ESBL were detected in 28 cases. Multiplex PCR could optimise the number of treated patients by 27% compared with stool cultures.\nConclusion Multiplex PCR on stools revealed a high prevalence of diverse enteric pathogens and coinfections in children with TD. Major enteropathogenic bacteria were more frequently detected by multiplex PCR compared with conventional culture. Finally, this technique allows the start of appropriate and early antibiotic treatment and seems to optimise the number of correctly treated patients.\nBackground: Outpatient parenteral antimicrobial therapy offers the option of treating children requiring intravenous antibiotics for acute urinary tract infection (UTI)/pyelonephritis at home. We aimed to determine the outcomes of treating patients with UTI/pyelonephritis using outpatient parenteral antimicrobial therapy directly from the emergency department (ED) without admission to hospital.\nMethods: This was a retrospective study (August 2012\u2013July 2016) of children with UTI/pyelonephritis treated with parenteral antibiotics via a peripheral cannula directly from ED to home under a hospital-in-the home (HITH) program. Data collection included demographics, clinical features, length of stay, complications, and readmissions to hospital.\nResults: There were 62 patient episodes of UTI/pyelonephritis transferred directly from ED to HITH. Fifty-eight (94%) had systemic features including fever, vomiting and/or tachycardia. Eighteen (29%) patients had an underlying condition. Nine (15%) received intravenous fluids and 8 (13%) antiemetics in ED. The outpatient parenteral antimicrobial therapy course was successfully completed in 56 (90%) patients. Of 6 (10%) patients who were readmitted, 2 were discharged within 24 hours, and none were severely unwell. Two (3%) had a blocked cannula, with no antibiotic complications. HITH patients were treated for a combined total of 142 days at home resulting in a cost saving of Australian dollar 108,914 (US dollar 82,775). However, only 8% of children deemed to require a course of intravenous antibiotics were transferred directly home from ED. Compared with patients concurrently admitted to hospital, fewer on HITH were less than 1 year of age (13% vs. 33%; odds ratio: 0.3; P < 0.01).\nConclusions: Selected patients presenting to ED with UTI/pyelonephritis may be treated directly via HITH, including some with underlying conditions and/or systemic features.\n\u00b7\n[Risk Factors for Delayed Antimicrobial Treatment in Febrile Children with Urinary Tract Infections](https://www.jpeds.com/article/S0022-3476(18)31300-3/fulltext). [J Pediatr.](https://www.ncbi.nlm.nih.gov/pubmed/30340935) 2019 Feb;205:126-129.\nTo identify factors associated with delayed antimicrobial treatment in febrile children with urinary tract infection (UTI).\nWe reviewed data from 802 children with UTI enrolled in 2 previously conducted prospective studies (Randomized Intervention for Children with Vesicoureteral Reflux and Careful Urinary Tract Infection Evaluation) and extracted data on possible predictors of delayed treatment including age, sex, history of UTI, ethnicity, race, primary caregiver's education level, insurance, and income. We used univariate and multivariable analyses to investigate the relationship between these predictors and treatment delay.\nWe included 660 febrile patients with a mean age of 17.0 months old. Older age and commercial insurance were associated with delayed treatment on univariate analysis. Compared with younger children, treatment was delayed by an average of 26.2 hours in children \u226512 months of age. This relationship remained significant on multivariable analysis. Treatment also was delayed by an average of 12.6 hours in patients with commercial insurance. Race, ethnicity, primary caregiver's education level, and income were not associated with delayed treatment.\nConclusions\nOlder age was a consistent predictor of delayed antimicrobial treatment. Delays in the initiation of antimicrobial therapy for UTI has previously been associated with renal scarring. Educating parents with older children regarding the management of fever as well as providers regarding prompt evaluation and management may help to reduce renal scarring.\nResumen: en una revisi\u00f3n sistem\u00e1tica sobre 565 estudios en relaci\u00f3n a resistencias antibi\u00f3ticas y factores relacionados, encuentran que los factores principalmente relacionados son la exposici\u00f3n previa a antibi\u00f3ticos, padecer alguna enfermedad subyacente y haber sido sometido a procedimientos invasivos. LA transmisi\u00f3n a trav\u00e9s de alimentos de origen animal y la transmisi\u00f3n a trav\u00e9s de aguas no limpias, estuvieron tambi\u00e9n con frecuencia implicadas.\nResumen: An\u00e1lsisi de ventas de antibi\u00f3tico de 70 pa\u00edses para ni\u00f1os, en funci\u00f3n de la calificaci\u00f3n de la OMS en grupos (AWaRe: Access, Watch y Reserve). LA prescripci\u00f3n en Espa\u00f1a sale muy bien parada comparativamente con el resto de paises, ya que presecribimos gran cantidad de antibi\u00f3ticos del grupo access, siendo el 4\u00ba pais (Tras Eslovenia, Hoanda y Brasil) en mejor adecuaci\u00f3n de la prescripci\u00f3n a la propuesta de la OMS de los grupos AWaRe\nBackground: The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study is a nationwide longitudinal antibiotic resistance surveillance program specific to bacterial pathogens commonly encountered in ocular infections. We evaluated in vitro resistance rates and trends among isolates obtained from pediatric patients (\u226417 years of age).\nMethods: Clinical centers across the United States were invited to submit ocular isolates of Staphylococcus aureus, coagulase-negative staphylococci (CoNS), Streptococcus pneumoniae, Haemophilus influenzae and Pseudomonas aeruginosa to a central laboratory. Minimum inhibitory concentrations for various antibiotic classes were determined by broth microdilution per Clinical and Laboratory Standards Institute guidelines and interpreted as susceptible, intermediate or resistant based on available breakpoints. Longitudinal trends were analyzed using a Cochran-Armitage test for linear trends in a proportion.\nResults: Of 4829 isolates collected from January 2009 to December 2016, 995 isolates, sourced primarily from hospitals and referral centers, were obtained from pediatric patients (n = 286 H. influenzae, n = 284 S. aureus, n = 213 CoNS, n = 150 S. pneumoniae and n = 62 P. aeruginosa). With few exceptions, P. aeruginosa and H. influenzae were generally susceptible to the antibiotics tested. Of S. aureus and CoNS isolates, respectively, 56% and 72% were resistant to azithromycin and 24% and 47% were methicillin-resistant (MR); concurrent resistance to other drug classes and multidrug resistance (\u22653 drug classes) were prevalent among MR staphylococci. Of S. pneumoniae isolates, 38% and 35% demonstrated resistance to azithromycin and penicillin, respectively. Besifloxacin had the lowest minimum inhibitory concentration against the Gram-positive isolates.\nConclusions: These in vitro data suggest antibiotic resistance is common among staphylococcal and pneumococcal isolates collected from pediatric patients with ocular infections. Methicillin resistance was prevalent among staphylococci with many strains demonstrating multidrug resistance. These findings may not be representative of resistance trends in community-based practices.\nCONCLUSIONES: En este estudio, en el que se muestran las tendencias del VPH en una comunidad de EE. UU.> 10 a\u00f1os despu\u00e9s de la introducci\u00f3n de la vacuna 4-valente contra el VPH y despu\u00e9s de la introducci\u00f3n de la vacuna 9-valente, se encontr\u00f3 evidencia de la efectividad de la vacuna y protecci\u00f3n de reba\u00f1o. Se necesita m\u00e1s investigaci\u00f3n para evaluar las tendencias en la vacuna VPH 9-valente despu\u00e9s de alcanzarse mayores tasas de vacunaci\u00f3n de esta \u00faltima.\nCONCLUSIONES: A partir de este an\u00e1lisis de datos individuales agrupados a nivel de pacientes, encontramos una reducci\u00f3n de efectividad de LAIV4 contra la influenza A / H1N1pdm09 en comparaci\u00f3n con la vacuna inactivada, que es consistente con los resultados publicados de los estudios individuales incluidos.\n\u00b7\n[Is primary meningococcal arthritis in children more frequent than we expect? Two pediatric case reports revealed by molecular test.](https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3602-y) BMC Enfermedades Infecciosas 2018 18 : 703\nLa presentaci\u00f3n cl\u00ednica de los dos ni\u00f1os (6 y 9 a\u00f1os) se caracteriz\u00f3 por signos de artritis. Por reacci\u00f3n en cadena de la polimerasa en tiempo real (RT-PCR), identificamos el serogrupo Y de N. meningitidis en el l\u00edquido articular en ambos casos. Despu\u00e9s del tratamiento antimicrobiano espec\u00edfico, las condiciones cl\u00ednicas de los dos pacientes mejoraron r\u00e1pidamente durante la hospitalizaci\u00f3n. Conclusiones. Creemos que la incidencia de la artritis meningoc\u00f3cica se puede subestimar en los entornos donde el uso de la RT-PCR es limitado\nLa artritis meningoc\u00f3cica primaria es una enfermedad infecciosa rara que ocurre en menos del 3% de las infecciones meningoc\u00f3cicas y se caracteriza por artritis sin meningitis, fiebre, erupci\u00f3n o inestabilidad hemodin\u00e1mica. Es una forma infrecuente de enfermedad meningoc\u00f3cica que se presenta como artritis s\u00e9ptica aislada sin ning\u00fan otro signo de enfermedad meningoc\u00f3cica invasiva (EMI). Es cl\u00ednicamente imposible diferenciar la AMP de otros tipos de artritis s\u00e9ptica. El cultivo de l\u00edquido sinovial y las pruebas moleculares son fundamentales para la confirmaci\u00f3n de la AMP. Se discuten dos casos de AMP diagnosticados por reacci\u00f3n en cadena de polimerasa en tiempo real (RT-PCR) luego del ingreso de dos ni\u00f1os en enero y marzo de 2017.\n\u00b7\n[Chest physiotherapy for pneumonia in children](https://www.ncbi.nlm.nih.gov/pubmed/30601584). Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD010277. DOI: 10.1002/14651858.CD010277.pub3\nWe included three new RCTs for this update, for a total of six included RCTsinvolving 559 children aged from 29 days to 12 years with pneumonia who were treated as inpatients. Pneumonia severity was described as moderate in one trial, severe in two trials, and was not stated in three trials. The studies assessed five different interventions: effects of conventional chest physiotherapy (3 studies, 211 children), positive expiratory pressure (1 study, 72 children), continuous positive airway pressure (CPAP) (1 study, 94 children), bubble CPAP (bCPAP) (1 study, 225 children), and assisted autogenic drainage (1 studies, 29 children). The included studies were conducted in Bangladesh, Brazil, China, Egypt, and South Africa. The studies were overall at low risk of bias. Blinding of participants was not possible in most studies, but we considered that the outcomes were unlikely to be influenced by the lack of blinding.\nWe could draw no reliable conclusions concerning the use of chest physiotherapy for children with pneumonia due to the small number of included trials with differing study characteristics and statistical presentation of data. Future studies should consider the following key points: appropriate sample size with adequate power to detect expected differences, standardisation of chest physiotherapy techniques, appropriate outcomes (such as duration of leukocytosis, and airway clearance), and adverse effects.\n\u00b7\n[Adverse events in people taking macrolide antibiotics versus placebo for any indication.](https://www.cochrane.org/news/featured-review-adverse-events-people-taking-macrolide-antibiotics-versus-placebo-any) Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD011825. DOI: 10.1002/14651858.CD011825.pub2\nPeople treated with a macrolide antibiotic experienced gastrointestinal adverse events such as nausea, vomiting, abdominal pain, and diarrhoea more often than those treated with placebo.\nTaste disturbances were reported more often by people taking macrolides than those taking a placebo. However, as very few studies reported on these adverse events, these results should be interpreted with caution.\nHearing loss was reported more often by people taking macrolide antibiotics, however only four studies reported this outcome.\nMacrolides caused less cough and fewer respiratory tract infections than placebo.\nWe did not find any evidence that macrolides caused more cardiac disorders, liver disorders, blood infections, skin and soft tissue infections, changes in liver enzymes, appetite loss, dizziness, headache, respiratory symptoms, itching, or rashes than placebo.\nWe did not find more deaths in people treated with macrolides than in those treated with placebo.\nVery limited information was available to assess if people treated with a macrolide antibiotic were at greater risk of developing resistant bacteria than those treated with placebo. However, bacteria that did not respond to macrolide antibiotics were more commonly identified immediately after treatment in people taking a macrolide than in those taking a placebo, but differences in resistance thereafter were inconsistent.\n\u00b7\n[Antiamoebic drugs for treating amoebic colitis.](https://www.cochrane.org/CD006085/INFECTN_antiamoebic-drugs-treating-amoebic-colitis) Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD006085. DOI: 10.1002/14651858.CD006085.pub3\nThis review included 41 studies, most of which were conducted in countries considered to be highly endemic for amoebiasis. Most trials were old: 30 were conducted before 1998. Trials varied in the inclusion criteria used to enrol participants and in the definition and timing of measured outcomes. Stool microscopy with direct wet saline smear was the method used most often to detect the presence of E histolytica in stools. Study participants ranged in age from seven months to 80 years. Included trials reported a variety of comparisons and involved 25 individual drugs, two herbal products, and 15 different combinations.\nThe review shows that in individuals with amoebic colitis, tinidazole may be better for reducing clinical symptoms (low-certainty evidence) and probably results in fewer adverse events when compared with metronidazole (moderate-certainty evidence). However, we do not know whether it is more effective for eradicating amoebae from the stools. Combination drug therapy may be more effective than metronidazole alone for eradicating amoebae (low-certainty evidence), but we are uncertain which drug combination is most effective, and if combination treatment will lead to more rapid resolution of clinical symptoms or in more adverse events (very low-certainty evidence). Evidence is insufficient to allow conclusions regarding efficacy of the other antiamoebic drugs.\n\u00b7\n[Adenovirus-Associated Central Nervous System Disease in Children](https://www.jpeds.com/article/S0022-3476(18)31366-0/fulltext). J Pediatr. 2019 Feb;205:130-137\nTo characterize the spectrum and salient clinical features of adenovirus-associated neurologic disease in immunocompetent children.\nStudy design\nPreviously healthy children (aged 1 month-18 years) with central nervous system (CNS) disease associated with adenovirus infection were identified via the Encephalitis Registry (1996-2016) and Microbiology Database (2000-2016) at The Hospital for Sick Children, Toronto, and by systematic review of the literature. The data were pooled and analyzed to identify the spectrum of illness, clinical outcome, and risk factors for death or neurologic impairment.\nResults\nNeurologic complications associated with adenovirus infection in our institution included febrile seizures, encephalitis, acute disseminated encephalomyelitis, and aseptic meningitis. A total of 48 immunocompetent children with adenovirus-associated CNS disease were included in the pooled analysis\u201438 from the literature and 10 from our institution. In 85% of cases, the virus was detected in the respiratory or gastrointestinal tract, but not the cerebrospinal fluid. Eighteen of the 48 (38%) patients either died or suffered permanent neurologic sequelae. Predictors of adverse outcome included younger age, coagulopathy, the absence of meningismus, serotype 2 virus, and the presence of seizures. After multivariable adjustment, only seizures remained a significant risk factor.\nConclusion\nAdenovirus is a rare cause of CNS disease in immunocompetent children. Disease spectrum is variable, ranging from mild aspetic meningitis and fully reversible encephalopathy to severe, potentially fatal, acute necrotizing encephalopathy.\nResumen: las infeciones por paraecovirus son la segunda causas m\u00e1s probable de meningitis viral en ni\u00f1os, principalmente en menores de 90 d\u00edas. Esta revisi\u00f3n pretende ofrecer una propuesta sobre el conocimiento de la infecci\u00f3n, sus manifestaciones cl\u00ednicas y los procedimientos diagn\u00f3sticos, para favorecer su abordaje basado en la evidencia y desvelar las principales prioridades en investigaci\u00f3n. Las manifestaciones cl\u00ednicas incluyen encefalitis, meningitis, miocarditis y septicemia que pueden determinar importantes secuelas neurol\u00f3gicas en lactantes peque\u00f1os. EL diagn\u00f3stico se puede hacer mediante PCR para detectar trazas de \u00e1cido nucl\u00e9ico del virus.\nBackground: A paucity of studies investigated the association between human parechovirus (HPeV) central nervous system (CNS) infection and motor and neurocognitive development of children. This study describes the gross-motor function (GMF) in young children during 24 months after HPeV-CNS infection compared with children in whom no pathogen was detected.\nMethods: GMF of children was assessed with Alberta Infant Motor Scale, Bayley Scales of Infant and Toddler Development or Movement Assessment Battery for Children. We conducted multivariate analyses and adjusted for age at onset, maternal education and time from infection.\nResults: Of 91 included children, at onset <24 months of age, 11 had HPeV-CNS infection and in 47 no pathogen was detected. Nineteen children were excluded because of the presence of other infection, preterm birth or genetic disorder, and in 14 children, parents refused to consent for participation. We found no longitudinal association between HPeV-CNS infection and GMF (\u03b2 = \u22120.53; 95% confidence interval: \u22121.18 to 0.07; P = 0.11). At 6 months, children with HPeV-CNS infection had suspect GMF delay compared with the nonpathogen group (mean difference = 1.12; 95% confidence interval: \u22121.96 to \u22120.30; P = 0.03). This difference disappeared during 24-month follow-up and, after adjustment for age at onset, both groups scored within the normal range for age. Maternal education and time from infection did not have any meaningful influence.\nConclusions: We found no longitudinal association between HPeV-CNS infection and GMF during the first 24-month follow-up. Children with HPeV-CNS infection showed a suspect GMF delay at 6-month follow-up. This normalized during 24-month follow-up.\nLos parechovirus humanos (HPeV) son unos virus sin envoltura y altamente resistes a las condiciones ambientales que presentan un genoma ARN y pertenecen a la familia Picornaviridae. Se han descrito 16 tipos distintos aunque los HPeV-1, 2 y 3 parecen ser los que presentan un mayor tropismo por el ser humano. La mayor\u00eda de infecciones causadas por estos virus son leves (s\u00edndromes febriles, cuadros respiratorios) aunque pueden llegar a determinar procesos s\u00e9pticos y afectaciones del sistema nervioso central. Afectan preferentemente a la poblaci\u00f3n infantil con una edad inferior a los 2 meses [1,2]. Existe en nuestro pa\u00eds todav\u00eda pocos estudios\nEnteroviruses (EVs) are well-known causes of sepsis in neonates and infants. In recent years, the extent to which parechoviruses may be contributing to neonatal and infant morbidity and mortality has begun to emerge.\n[1\u20133](https://journals.lww.com/pidj/Fulltext/2019/02000/Comparing_the_Clinical_Severity_of_Disease_Caused.29.aspx#R1-29)\nEVs and human parechoviruses (HPeVs) are nonenveloped, single-stranded, positive-sense RNA viruses and members of the Picornavirus family. They are common causes of neonatal and infant sepsis, worldwide.\nEVs exist as multiple serotypes, subdivided into various genus, including echoviruses, Coxsackie A and B viruses and the numbered EVs. HPeVs exist in at least 17 genotypes, of which genotypes 1\u20136 are most commonly found in humans, with genotype 3 being most commonly responsible for sepsis in neonates and infants.\nWhereas most episodes of EV and HPeV neonatal and infant sepsis are self-limiting, more severe illness can occur, and there are current concerns regarding longer term sequelae, particularly in HPeV infections, where there is more significant neurologic involvement. Previous studies have found that the clinical presentation of the 2 viruses are often indistinguishable.\n[1](https://journals.lww.com/pidj/Fulltext/2019/02000/Comparing_the_Clinical_Severity_of_Disease_Caused.29.aspx#R1-29) , [3](https://journals.lww.com/pidj/Fulltext/2019/02000/Comparing_the_Clinical_Severity_of_Disease_Caused.29.aspx#R3-29)\nOur diagnostic virology laboratory has only recently (since mid 2014) introduced routine testing for parechoviruses as part of our neonatal and infant sepsis workup. We examined the demographics, laboratory results and clinical notes for pediatric patients admitted with sepsis with laboratory-confirmed human EV or HPeV infections of the cerebrospinal fluid (CSF), during February 2014 to August 2017.\nVaricella is a common vaccine-preventable disease that usually presents as a mild disorder but can lead to severe complications. Before the implementation of universal varicella vaccination (UVV) in some European countries, the burden of varicella disease was broadly similar across the region. Despite this, countries adopted heterogeneous varicella vaccination strategies. UVV is currently recommended in 12 European countries. Known barriers to UVV implementation in Europe include (1) a perceived low disease burden and low public health priority; (2) cost-effectiveness and funding availability; (3) concerns related to a shift in varicella disease and incidence of herpes zoster and (4) safety concerns related to measles, mumps, rubella and varicella\u2013associated febrile seizures after the first dose. Countries that implemented UVV experienced decreases in varicella incidence, hospitalizations and complications, showing overall beneficial impact. Alternative strategies targeting susceptible individuals at higher risk of complications have been less effective. This article discusses ways to overcome the barriers to move varicella forward as a truly vaccine preventable disease.\nExiste una controversia sobre el efecto potencial de la vacunaci\u00f3n infantil contra la varicela en la incidencia de Herpes Zoster (HZ). El objetivo de este estudio es explorar el efecto de varias suposiciones sobre el aumento de la inmunidad VZV ex\u00f3gena y end\u00f3gena en la incidencia de HZ en la poblaci\u00f3n general despu\u00e9s de la introducci\u00f3n de la vacunaci\u00f3n rutinaria contra la varicela infantil. Una posible raz\u00f3n de la disparidad entre los modelos matem\u00e1ticos y los datos epidemiol\u00f3gicos puede deberse al papel del refuerzo end\u00f3geno, resultante de la reactivaci\u00f3n asintom\u00e1tica del VZV [ 17 , 34 ], desde el modelo inicial de Brisson et al. y modelos posteriores, enfocados solo en el refuerzo ex\u00f3geno. Por lo tanto, el refuerzo end\u00f3geno podr\u00eda explicar en parte la divergencia entre la evidencia del mundo real sobre la carga de HZ en los pa\u00edses que utilizan la vacunaci\u00f3n contra la varicela infantil y las proyecciones de modelos basadas en supuestos de aumento ex\u00f3geno.\nLas infecciones respiratorias agudas (IRA) de etiolog\u00eda viral son una entidad que predomina en la edad pedi\u00e1trica. Aunque las causadas por el VRS y los virus gripales son las prevalentes en la \u00e9poca invernal, las t\u00e9cnicas de amplificaci\u00f3n molecular ha permitido comprobar que el 20-40% son coinfecciones1,2.\nDurante el per\u00edodo 2014-2017 se ha estudiado la presencia de virus respiratorios en todos los pacientes < 2 a\u00f1os con sospecha de IRA, tanto de v\u00edas altas como bajas, que acud\u00edan a urgencias. La detecci\u00f3n de los virus respiratorios se realiz\u00f3 mediant RT-PCR m\u00faltiple (Anyplex\u2122 RV16, Seegen, Corea) que detecta de forma simult\u00e1nea y diferencial 16 virus distintos.\nA lo largo del estudio se han detectado 803 casos de gripe: gripe A 64,1% y gripe B 25,9%; as\u00ed mismo se han detectado 992 casos de infecci\u00f3n por el VRS: VRS-A 59,2% y VRS-B 40,8%.\nLos casos de coinfecci\u00f3n entre los virus gripales y el VRS han sido 48. Los 48 casos han representado el 5,9% de todos los virus gripales detectados (89,5% tipo A). Los casos de coinfecci\u00f3n por el VRS representaron el 4,8% de todos los VRS ( 62,5% VRS-B).\nEl 58,3% de los casos se presentaron en menores de un a\u00f1o. El 43,7% de los casos se presentaron en diciembre, el 25% en enero, el 14,5% en febrero, el 12,5% en noviembre y el 4,1% en marzo.\nLas IRA en estos pacientes fueron: s\u00edndrome gripal (41,6%), bronquiolitis (31,3%), bronquitis (18,7%) y neumon\u00eda (8,3%). Precisaron ingreso hospitalario 11 casos y ninguno falleci\u00f3.\nEN las \u00faltimas temporadas hemos observado una elevada incidencia del VRS-B representando cerca del 58%. Esta tendencia explicar\u00eda el mayor n\u00famero de coinfecciones observado entre los virus gripales y el VRS-B (62,5%).\nEl virus gripal B, a pesar de que afectan preferentemente a la poblaci\u00f3n infantil, es el que ha mostrado un menor n\u00famero de coinfecciones (10,5%); este dato podr\u00eda deberse a que este virus se presenta a partir de edades superiores a las del VRS4.\nParece pues que la asociaci\u00f3n entre los virus gripales y el VRS es una entidad que se presenta con una incidencia muy baja y que es dif\u00edcil de interpretar desde el punto de la implicaci\u00f3n patog\u00e9nica directa en las IRA en los menores de un a\u00f1o.\nIntroducci\u00f3n. La bronquiolitis aguda (BA) es una de las enfermedades respiratorias m\u00e1s frecuentes en los lactantes. Sin embargo, los criterios utilizados para su diagn\u00f3stico son heterog\u00e9neos. M\u00e9todos: Estudio de metodolog\u00eda Delphi con expertos espa\u00f1oles en BA, buscando los puntos de consenso sobre el diagn\u00f3stico de BA. Posteriormente se realiz\u00f3 un estudio transversal mediante encuesta on-line dirigida a todos los pediatras espa\u00f1oles, contactados a trav\u00e9s de correo electr\u00f3nico enviados por nueve sociedades cient\u00edficas pedi\u00e1tricas. Se hizo an\u00e1lisis descriptivo y factorial de los resultados de la encuesta, buscando si los criterios diagn\u00f3sticos empleados se relacionaban con variables demogr\u00e1ficas, geogr\u00e1ficas o con la subespecialidad pedi\u00e1trica. Resultados: Los 40 expertos participantes alcanzaron un consenso en muchos aspectos (primer episodio de dificultad respiratoria y aumento de la frecuencia respiratoria, diagn\u00f3stico en cualquier estaci\u00f3n del a\u00f1o, y utilidad de la identificaci\u00f3n de virus para el diagn\u00f3stico), pero manteniendo opiniones enfrentadas en cuestiones importantes como la edad m\u00e1xima aceptable para el diagn\u00f3stico. A la encuesta on-line respondieron 1297 pediatras. Los criterios diagn\u00f3sticos que aplican son heterog\u00e9neos y est\u00e1n fuertemente asociados con la subespecialidad pedi\u00e1trica. Su acuerdo con el consenso de expertos y con est\u00e1ndares internacionales es muy bajo. Conclusiones.Los criterios usados en Espa\u00f1a para el diagn\u00f3stico de BA son heterog\u00e9neos. Esas diferencias pueden causar variabilidad en la pr\u00e1ctica cl\u00ednica.\nIntroducci\u00f3n. Helicobacter pylori constituye un problema de salud mundial principalmente por el elevado porcentaje de infecci\u00f3n y la ineficacia en los tratamientos. Para prevenir la infecci\u00f3n resulta clave conocer la edad de adquisici\u00f3n.\nPacientes. Participaron 67 madres y sus respectivos hijos. Para evaluar la presencia de H. pylori, las deposiciones de la madre y de su hijo fueron analizadas mediante el test HpSA.\nResultados. El 71,6% (48/67) de las embarazadas a t\u00e9rmino fueron H. pylori positivas. En los reci\u00e9n nacidos, el 8,96% (6/67) de ellos presentaron colonizaci\u00f3n/infecci\u00f3n persistente para H. pylori. Durante el primer mes de vida se observ\u00f3 una prevalencia e incidencia de infecci\u00f3n del 23,9 y 13%, respectivamente.\nConclusi\u00f3n. Los resultados, en conjunto, sugieren que durante el primer mes de vida existe un alto riesgo de infecci\u00f3n por H. pylori, pudiendo ser esta incluso de tipo persistente.\nBackground: Coccidioidomycosis is not as well described in the pediatric population as it is in the adult population. We describe clinical findings, diagnosis and management of coccidioidomycosis in 108 pediatric patients seen in an outpatient clinic in the California Central Valley, an area endemic for coccidioidomycosis.\nMethods: We reviewed medical records of a convenience sample of pediatric patients (\u226417 years of age) diagnosed with coccidioidomycosis who visited an infectious diseases clinic in Madera, CA, during January 1 to October 1, 2012. We described demographic characteristics, symptoms, diagnostic testing, extent of infection (acute/pulmonary or disseminated), treatment and management.\nResults: Of 108 patients, 90 (83%) had acute/pulmonary coccidioidomycosis and 18 (17%) had disseminated disease. The median age at diagnosis was 9 years (range, 5 months to 17 years). Only 3 (3%) patients were immunocompromised. Before coccidioidomycosis diagnosis, 72 (82%) patients received antibiotics, and 31 (29%) had at least 1 negative coccidioidomycosis serology at the time of or before diagnosis. Coccidioidomycosis was diagnosed significantly later after symptom onset among patients with disseminated (median, 57 days) than with acute/pulmonary (median, 16 days) disease (p < 0.01). A total of 104 (96%) patients received antifungal therapy, 51 (47%) visited an emergency room and 59 (55%) were hospitalized with a median stay of 44 days (range, 1\u2013272 days).\nConclusions: Substantial acute/pulmonary and disseminated coccidioidomycosis was seen among pediatric patients at this infectious disease clinic in California. In endemic areas, increased coccidioidomycosis awareness and vigilance among families and providers is necessary to facilitate early diagnosis and appropriate management.\nObjective To describe the risk of death and hospitalisation until adolescence of children after group B streptococcus (GBS) infection during infancy.\nDesign Population-based cohort study.\nSetting New South Wales, Australia.\nPatients All registered live births from 2000 to 2011.\nInterventions Comparison of long-term outcomes in children with the International Statistical Classification of Diseases and Related Health Problems-10th Revision discharge codes corresponding to GBS infections and those without.\nMain outcome measures Death and hospitalisation.\nResults A total of 1206 (0.1%) children (936 (77.6%)\u226537 weeks\u2019 gestation) were diagnosed with GBS infection. Over the study period, infection rates decreased from 2.1 (95% CI 1.8 to 2.4) to 0.7 (95% CI 0.5 to 0.9) per 1000 live births. Infants with GBS infection were born at lower gestation (mean 37.6 vs 39.0 weeks), were more likely very low birth weight (<1500 g, OR 9.1(95% CI 7.4 to 11.3)), born premature (OR 3.9(95% CI 3.4 to 4.5)) and have 5 min Apgar scores \u22645 (OR 6.7(95% CI 5.1 to 8.8)). Children with GBS had three times the adjusted odds of death (adjusted OR (AOR) 3.0(95% CI 2.1 to 4.3)) or rehospitalisations (AOR 3.1(95% CI 2.7 to 3.5)). Thirty-six (3.0%) with GBS died, with >50% of deaths occurring <28 days. Children with GBS were hospitalised more frequently (median 2 vs 1), for longer duration (mean 3.7 vs 2.2 days) and were at higher risk for problems with genitourinary (OR 3.1(95% CI 2.8 to 3.5)) and nervous (OR 2.0 (95% CI1.7 to 2.3)) systems.\nConclusions Despite decreasing GBS rates, the risk of poor health outcomes for GBS-infected children remains elevated, especially during the first 5 years. Survivors continue to be at increased risk of death and chronic conditions requiring hospitalisations, such as cerebral palsy and epilepsy.\nThe fetal repercussions of Zika virus (ZIKV) infection during pregnancy is of interest for maternal and child health.1 Studies on the psychomotor and neurodevelopment of children exposed in utero to arboviruses, especially non-microcephalic children, are lacking. At a maternity university hospital in Brazil, we started following the development of children, without microcephaly, born to mothers infected with ZIKV during pregnancy, searching for early warning signs of abnormalities. A normal head circumference for term newborns was defined, according to the 2016 WHO recommendation, as higher than 31.9 cm for boys and higher than 31.5 cm for girls.2 We used the Alberta Infant Motor Scale for the evaluation of motor development, and the Denver II test for tracking development in personal/social, fine motor/adaptive, language \u2026\nShort individualised treatment of paediatric bone and joint infections, based on clinical and laboratory response, has the potential to reduce the duration of antibiotic therapy, but only few data exist on this treatment.1\u20134 In Denmark, short individualised treatment was recommended from 2012.\nThis is a retrospective study of all children aged 3 months to 16 years with bone and joint infections treated between 2012 and 2016 at two paediatric departments in Copenhagen. Children with osteomyelitis (OM) were included if the diagnosis was confirmed by MRI, positron emission tomography-CT, technetium bone scintigraphy or X-ray. Children with septic arthritis (SA) \u2026\n\u00b7\n[Screening and Serial Neutrophil Counts Do Not Contribute to the Recognition or Diagnosis of Late-Onset Neonatal Sepsis](https://www.jpeds.com/article/S0022-3476(18)31295-2/fulltext). J Pediatr. 2019 Feb;205:105-111\nObjective\nTo determine the validity of screening and serial neutrophil counts in predicting the absence/presence of late-onset sepsis (LOS) in infants with central venous catheters.\nStudy design\nRetrospective study of infants admitted to the neonatal intensive care unit (2009-2013) at Parkland Hospital with a central venous catheter and \u22651 LOS evaluations. Infants were categorized as proven or suspect LOS or uninfected based on results of blood cultures, clinical illness, and duration of antibiotics. Receiver operating curves (ROCs) were constructed to predict the absence or presence of LOS using Manroe reference ranges for total and immature neutrophils and the immature to total neutrophil ratio at 0, 12, and 24 hours after blood culture and the neutrophil value score, which assesses serial values.\nResults\nOf the 497 infants with a central venous catheter, 179 underwent \u22651 LOS evaluations, and 140 of 179 (78%) had \u22651 complete evaluations (2 blood cultures and neutrophil values at 0, 12, and 24 hours), resulting in 188 complete LOS evaluations. The gestational age was 28 \u00b1 4 weeks and LOS evaluation occurred at 29 \u00b1 34 days (SD; 4-197 days). Sixty-one (35%) infants had proven LOS, 48 (23%) were suspect, and 71 (38%) were noninfected. ROC comparing proven vs noninfected was \u22640.56 for total neutrophils, immature neutrophils, and immature to total neutrophil ratio at 0, 12, and 24 hours and similar for proven + suspect vs noninfected. ROC for neutrophil value scores and absence of LOS was 0.56.\nConclusions\nScreening neutrophil values are poor predictors of LOS in neonates with a central venous catheter, as are serial neutrophils and the neutrophil value score. Alternative biomarkers are needed.\n\u00b7\n[Maternal Education Is Inversely Related to Vaccination Delay among Infants and Toddlers](https://www.jpeds.com/article/S0022-3476(18)31301-5/fulltext). J Pediatr. 2019 Feb;205:120-125\nObjective\nTo determine the association between parents' level of education and delay in vaccination among infants and toddlers.\nStudy design\nA case\u2013control study done in 2015-2016. Charts of 2- to 4-year-old children vaccinated in 5 neighborhood Maternal-Child Health Centers (MCHCs) in southern Israel were examined for demographic variables. Five vaccination opportunities between age 7 months and 18 months were selected to test for delays. In each MCHC, children vaccinated at the longest time-period after planned vaccination dose (fifth quintile) were compared with those vaccinated during the middle quintile. Using this relative delay approach rather than absolute delay approach permitted us to adjust the findings to the prevailing environmental and to cultural and programmatic variations between the various neighborhoods. Each of the planned vaccination visits and overall, demographic and health behavior-related variables that were significantly associated to delays by univariate analysis were tested by multivariate analysis and further adjusted by using stepwise logistic regression, using goodness of fit measures.\nResults\nData for 2072 subjects were collected (398-426 per MCHC). Fathers' education was not associated with delays. In contrast, mothers' education was inversely associated with the probability of vaccination delay by 4%-9% (depending on the vaccination visit) for each year of schooling beyond 10 years.\nConclusion\nUsing the relative delay approach, we demonstrated that maternal education, measured by schooling years, was independently inversely associated with risk of vaccination delay. This suggests that education can be regarded as an important positive component of the overall disease prevention planning at national and global levels.\nWe included three studies with a total of 122 children (62/60 in intervention/control arms) aged up to 12 months that investigated nasal CPAP compared with supportive (or \"standard\") therapy. We included one new trial (72 children) that contributed data to the assessment of respiratory rate and need for mechanical ventilation for this update. The included studies were single-centre trials conducted in France, the UK, and India. Two studies were parallel-group RCTs and one was a cross-over RCT. The evidence provided by the included studies was low quality; we assessed high risk of bias for blinding, incomplete outcome data, and selective reporting, and confidence intervals were wide.\nThe effect of CPAP on the need for mechanical ventilation in children with acute bronchiolitis was uncertain due to imprecision around the effect estimate (3 RCTs, 122 children; risk ratio (RR) 0.69, 95% confidence interval(CI) 0.14 to 3.36; low-quality evidence). None of the trials measured time to recovery. Limited, low-quality evidence indicated that CPAP decreased respiratory rate (2 RCTs, 91 children; mean difference (MD) -3.81, 95% CI-5.78 to -1.84). Only one trial measured change in arterial oxygen saturation, and the results were imprecise (19 children; MD -1.70%, 95% CI -3.76 to 0.36). The effect of CPAP on change in arterial partial carbon dioxide pressure (pCO\u2082) was imprecise (2 RCTs, 50 children; MD -2.62 mmHg, 95% CI-5.29 to 0.05; low-quality evidence). Duration of hospital stay was similar in both CPAP and supportive care groups (2 RCTs, 50 children; MD 0.07 days, 95% CI -0.36 to 0.50; low-quality evidence). Two studies did not report about pneumothorax, but pneumothorax did not occur in one study. No studies reported occurrences of deaths. Several outcomes (change in partial oxygen pressure, hospital admission rate (from emergency department to hospital), duration of emergency department stay, and need for intensive care unit admission) were not reported in the included studies.\nActualidad bibliogr\u00e1fica enero 2019\nTop ten\nEn cuanto a las vacunas financiadas, se recomienda emplear el esquema 2+1 (2, 4 y 11 meses) con vacunas hexavalentes (DTPa-VPI-Hib-HB) y con antineumoc\u00f3cica conjugada13-valente. Se emplear\u00e1n esquemas de 2 dosis para triple v\u00edrica (12 meses y 3-4 a\u00f1os) y varicela (15 meses y 3-4 a\u00f1os). La segunda dosis se podr\u00eda aplicar como vacuna tetrav\u00edrica.\nSe recomienda vacunaci\u00f3n sistem\u00e1tica universal frente al VPH, tanto a chicas como a chicos, preferentemente a los 12 a\u00f1os, debi\u00e9ndose realizar un mayor esfuerzo para mejorar las coberturas. La nueva vacuna de 9 genotipos ampl\u00eda la cobertura para ambos sexos.\nSe recomienda que la vacuna antimeningoc\u00f3cica conjugada tetravalente (MenACWY) se introduzca en el calendario financiado a los 12 meses y a los 12-14 a\u00f1os, aconsej\u00e1ndose un rescate hasta los 19 a\u00f1os. Igualmente, se recomienda en los mayores de 6 semanas de edad con factores de riesgo o que viajen a pa\u00edses de elevada incidencia de estos serogrupos\nRespecto a las vacunas no financiadas, se recomienda la antimeningoc\u00f3cica B, con esquema 2+1, solicitando su entrada en el calendario. Es recomendable vacunar a todos los lactantes frente al rotavirus.\nA primeros del mes de diciembre del reci\u00e9n acabado 2018, los\n[medios de comunicaci\u00f3n](https://www.heraldo.es/noticias/aragon/zaragoza/2018/12/13/investigan-brote-enfermedad-desconocida-empleados-del-matadero-zuera-1282758-2261126.html) informaron de un brote de una enfermedad exantem\u00e1tica entre trabajadores de un matadero en la localidad de Zuera (Zaragoza). Al final del mes, los [servicios de salud p\u00fablica de Arag\u00f3n](http://www.aragon.es/estaticos/GobiernoAragon/Departamentos/SanidadBienestarSocialFamilia/Sanidad/Profesionales/13_SaludPublica/18_Vigilancia_Epidemiologica/BEsA_201852.pdf) confirmaron que se trataba de rubeola y que el brote hab\u00eda afectado hasta ese momento a 12 personas. Son los [primeros casos de rubeola en Arag\u00f3n desde 2012](https://www.heraldo.es/noticias/aragon/zaragoza/2018/12/27/se-elevan-doce-los-afectados-por-rubeola-matadero-zuera-1284697-2261126.html), a\u00f1o en el que se registraron [28 casos en varias localidades](http://www.aragon.es/DepartamentosOrganismosPublicos/Departamentos/Sanidad/AreasTematicas/SanidadProfesionales/SaludPublica/ProgramasSalud/ci.mas_completo_01_Programa_de_Vacunaciones.detalleDepartamento) de la regi\u00f3n.\nLo destacable del caso es que este brote trunca la\n[tendencia mostrada por la rubeola](http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/pdf_2018/Informe_anual_del_Plan_Nacional_de_Eliminacion_del_Sarampion_y_de_la_Rubeola_Espana_2017.pdf#page=34) en Espa\u00f1a en los \u00faltimos a\u00f1os, con un total de 14 casos en el quinquenio 2013-2017, y 15 casos en 2018 (esta cifra es a\u00fan provisional).\nCasos cl\u00ednicos\nEs un hongo dermatofito zoon\u00f3tico ( pertenece a Trichophyton mentagrophytes complex). Su principal reservorio son peque\u00f1os roedores, en especial cobayas. Tambi\u00e9n se ha aislado en perros y gatos. Puede causar ti\u00f1a corporis, ti\u00f1a faciei , querion de Celso y Excepcionalmente onicomicosis2. Se caracteriza por producir lesiones muy inflamatorias, sobre todo en ni\u00f1os. Adem\u00e1s de en ni\u00f1os, su aislamiento es frecuente entre adolescentes e inmunodeprimidos. Al inicio de la infecci\u00f3n, las lesiones cut\u00e1neas pueden ser confundidas con imp\u00e9tigo.\nNi\u00f1a de 3 a\u00f1os con lesi\u00f3n inflamatoria con secreci\u00f3n en la cabeza de 2 meses diagnosticada como querion de Celso. Inicialmente aparecieron lesiones en boca y nariz tratadas con antibi\u00f3tico t\u00f3p. (sospecha de imp\u00e9tigo). M\u00e1s tarde surgieron nuevas placas eritematosas con costra melic\u00e9rica en zona parieto-occipital tratadas con mupirocina t\u00f3p. y amoxicilina-clavul\u00e1nico vo. Se deriv\u00f3 a dermatolog\u00eda diagnostic\u00e1ndose de ti\u00f1a capitis, con tto t\u00f3pico: terbinafina crema y sertaconazol nitrato en gel. Antecedentes : ti\u00f1a corporis del padre, pose\u00edan una cobaya, con lesiones d\u00e9rmicas. Dos semanas despu\u00e9s las lesiones abscesificaron . Se realiz\u00f3 drenaje c/ 48h, envi\u00e1ndose muestra de exudado y pelos al laboratorio. Nuevo tto itraconazol vo (62,5mg/d\u00eda) + crema de miconazol/hidrocortisona durante 3 semanas.\nNi\u00f1a de 8 a\u00f1os con placa de alopecia en cuero cabelludo de m\u00e1s de un mes de evoluci\u00f3n (las lesiones comenzaron en la mama izda. y se extendieron hasta el cuero cabelludo). Sus cobayas hab\u00edan presentado alopecia. Se recogi\u00f3 muestra para cultivo y se paut\u00f3 tratamiento con terbinafina 125mg/24h durante 1 mes y terbinafina crema por las ma\u00f1anas m\u00e1s furoato de mometasona/\u00e1cido salic\u00edlico en crema por las noches.\nEn ambos casos, se identific\u00f3 Arthroderma benhamiae .\n\u00c9ste causa habitualmente afecciones leves que responden al tto t\u00f3pico con ciclopirox, imidazoles o terbinafina. En los casos de afectaci\u00f3n m\u00e1s extensa y ti\u00f1a capitis se requiere tto v.o. En la mayor\u00eda de los casos se han usado terbinafina, griseofulvina, itraconazol o fluconazol durante un m\u00ednimo de 4-6 semanas4.\nPVL genes are consistently associated with skin and soft-tissue infections2 in immunocompetent young patients .PVL toxin can be produced by both (MSSA) and MRSA strains and is associated with more severe infections, regardless of methicillin resistance.3 Case of 12-years old, healthy girl born in Venezuela with low socioeconomic status. She had been living in Spain for the last seven months. The patient started with progressive worsening flu-like symptoms, high fever and cough that progressed to haemoptysis in less than 24 h presenting sudden death at her home while sleeping. The autopsyestablished multiple organ failure after bilateral abscessed pneumonia as a cause of death. MRSA resistant to clindamycin and erythromycin, . Typing of MRSA strains was performed and detection of PVL genes by PCR: positive PVL and mecA genes.\nThe status of colonization of the patient's cohabitants was studied ( family members and 2 roommates from Ecuador) : swab of any suspicious lesion, nose, throat, perineum and inguinal area. Contacts underwent a five-day decolonization treatment: intranasal mupirocin ointment three times a day, gargle with an antiseptic solution and chlorhexidine 4% as liquid soap in place of body wash and shampoo. A sister of the deceased was found to be carrying MRSA in mucous, which was negative for the PVL gene. Additional measures: regular vacuuming, dusting, cleaning hard surfaces and soft furnishings with soap and water and/or 1:10 diluted bleach.\nThe emergence of PVL-MRSA is more recent in Spain (mainly from South America immigrants) than in the rest of Europe.1 One of the most important life-threatening conditions due to PVL-Staphylococcus aureus (PVL-SA) is hemorrhagic necrotizing pneumonia with a high mortality rate. A PVL-SA infection should be suspected if a patient with influenza-like illness associate haemoptysis, hypotension, high fever, leukopenia and/or multilobal lung infiltrates, which can be cavitated,9 especially in epidemic flu period.\nVar\u00f3n de 10 anos, sin antecedentes con lesi\u00f3n en la rodilla derecha de 4 meses sin cl\u00ednica extracut\u00e1neas, tras una ca\u00edda con abrasi\u00f3n cut\u00e1nea. EF: una placa ovalada eritematosa de 6 cm, de color rojo-viol\u00e1ceo, con m\u00faltiples p\u00e1pulas queratocostrosas de aspecto granulomatoso y sin exudaci\u00f3n ni drenaje purulento . Inicialmente se diagnostic\u00f3 como reacci\u00f3n a cuerpo extrano, \u02dc paut\u00e1ndose corticoides t\u00f3picos de potencia muy alta sin objetivarse mejor\u00eda cl\u00ednica. Ten\u00eda una tortuga en su domicilio con la que se hab\u00eda estado banando. SE tom\u00f3 biopsia con punch y creci\u00f3 Mycobacterium marinum . Se inici\u00f3 tto con claritromicina (500 mg/12 h), consiguiendo la curaci\u00f3n a los 3 meses y que se mantuvo 2 meses m\u00e1s. Su reservorio principal es el agua de mar y el agua estancada, siendo los principales factores de riesgo las actividades relacionadas con peces, as\u00ed como el contacto con agua contaminada de acuarios, tanques de agua o piscinas= \u00abgranuloma de las piscinas o acuarios\u00bb. Requiere puerta de entrada. Los cuadros diseminados o con afectaci\u00f3n extracut\u00e1nea son excepcionales, aunque localmente puede producir sinovitis u osteomielitis. El tto de elecci\u00f3n es la antibioterapia sist\u00e9mica emp\u00edrica ( antibiograma si fracaso terap\u00e9utico). En aquellos casos con lesiones \u00fanicas, la ex\u00e9resis quir\u00fargica puede ser una opci\u00f3n . Los f\u00e1rmacos m\u00e1s empleados son minociclina, doxiciclina, claritromicina, etambutol, rifampicina y cotrimoxazol (claritromicina = primera elecci\u00f3n). La duraci\u00f3n recomendada del tratamiento es de 6 meses o al menos hasta 2 meses tras curaci\u00f3n . En los casos con afectaci\u00f3n osteotendinosa se recomienda combinaci\u00f3n de m\u00edn. 2 f\u00e1rmacos,: claritromicina junto con rifampicina o etambutol, precisando muchas veces el desbridamiento y mayor duraci\u00f3n.\nCat-scratch disease (CSD) is a zoonotic infection caused by Bartonella henselae that usually results in lymphadenopathy.1 Although uncommon, CSD can also present as bone lesions.2\nA 2-year-old girl was hospitalised for a fever of an unknown cause for >10 days. Physical examination revealed non-tender bilateral cervical lymphadenopathy. Tosufloxacin was administered. On the 12th day of hospitalisation, her fever resolved, but her mother noticed the child\u2019s unusual gait. MRI revealed multiple small \u2026\nPara profundizar\nHemos le\u00eddo con inter\u00e9s el art\u00edculo de Cano-Portero et al.1 sobre la epidemiolog\u00eda de la tuberculosis (TB) en Espana\u02dc en el ano\u02dc 2015. Seg\u00fan los autores, se declararon 335 casos de TB en menores de 15 anos \u02dc en Espana. \u02dc Sus datos difieren del Informe del ECDC del mismo a\u00f1o (270 casos pedi\u00e1tricos). Esta discrepancia senala \u02dc la necesidad de mejorar la coordinaci\u00f3n institucional para determinar con precisi\u00f3n el alcance de la TB pedi\u00e1trica en nuestro pa\u00eds.\nEspana\u02dc es un pa\u00eds de baja prevalencia de TB, con una incidencia de 10,5/100.000 habitantes en 2015, y un 7% de casos pedi\u00e1tricos. La TB infantil todav\u00eda es un problema significativo en nuestro medio, siendo Espana\u02dc el pa\u00eds de Europa Occidental con m\u00e1s casos pedi\u00e1tricos. Los ni\u00f1os \u02dc son especialmente vulnerables a la TB, con mayor riesgo de desarrollar formas graves, especialmente los menores de 2 anos, \u02dc donde la tasa de progresi\u00f3n alcanza el 50%3. En la cohorte pTBred (Red Espanola \u02dc de TB Pedi\u00e1trica (pTBred)4, 2014, integrada en la Red Europea pTBnet) hemos profundizado en el origen de los casos: pa\u00eds de nacimiento del 98,4% de los ninos \u02dc (81,1% espanoles) \u02dc y del 98,2% de sus progenitores (55,9% extranjeros). En nuestro registro, la tasa de confirmaci\u00f3n es del 36,9%, coincidiendo con la literatura7. Un 11,2% de los ninos \u02dc presentaron alg\u00fan tipo de resistencia, siendo el 5,6% resistentes a isoniazida, y el 1% MDR. De forma destacada, el \u00faltimo informe anual del ECDC2 tampoco dispone de datos sobre TB resistente en Espana, \u02dc a diferencia de otros pa\u00edses europeos, a pesar de ser Espana\u02dc uno de los pa\u00edses con mayor inmigraci\u00f3n procedente de Europa del Este, donde la TB MDR es un problema de gran magnitud.\nThe epidemiology of Mycoplasma pneumoniae (Mp) among US children (<18 years) hospitalized with community-acquired pneumonia (CAP) is poorly understood.\nMethods\nIn the Etiology of Pneumonia in the Community study, we prospectively enrolled 2254 children hospitalized with radiographically confirmed pneumonia from January 2010\u2013June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp using real-time polymerase chain reaction (PCR). Clinical and epidemiological features of Mp PCR\u2013positive and \u2013negative children were compared using logistic regression. Macrolide susceptibility was assessed by genotyping isolates.\nResults\nOne hundred and eighty two (8%) children were Mp PCR\u2013positive (median age, 7 years); 12% required intensive care and 26% had pleural effusion. No in-hospital deaths occurred. Macrolide resistance was found in 4% (6/169) isolates. Of 178 (98%) Mp PCR\u2013positive children tested for copathogens, 50 (28%) had \u22651 copathogen detected. Variables significantly associated with higher odds of Mp detection included age (10\u201317 years: adjusted odds ratio [aOR], 10.7 [95% confidence interval {CI}, 5.4\u201321.1] and 5\u20139 years: aOR, 6.4 [95% CI, 3.4\u201312.1] vs 2\u20134 years), outpatient antibiotics \u22645 days preadmission (aOR, 2.3 [95% CI, 1.5\u20133.5]), and copathogen detection (aOR, 2.1 [95% CI, 1.3\u20133.3]). Clinical characteristics were non-specific.\nConclusions\nUsually considered as a mild respiratory infection, Mp was the most commonly detected bacteria among children aged \u22655 years hospitalized with CAP, one-quarter of whom had codetections. Although associated with clinically nonspecific symptoms, there was a need for intensive care in some cases. Mycoplasma pneumoniae should be included in the differential diagnosis for school-aged children hospitalized with CAP.\nEl neumomediastino espont\u00e1neo se define como la presencia de aire dentro del mediastino. Se origina generalmente por una fuga de aire por aumento de presi\u00f3n en el alveolo. La incidencia en la edad pedi\u00e1trica se encuentra entre 1/8000 y 1/15 000, con dos picos de edad: menores de cuatro a\u00f1os y de entre 13 a 17 a\u00f1os. En el primer grupo suele asociarse a una infecci\u00f3n del tracto respiratorio, una crisis asm\u00e1tica o por aspiraci\u00f3n de cuerpo extra\u00f1o, mientras que en el segundo suele originarse tras actividad f\u00edsica intensa. Se ha descrito la implicaci\u00f3n de virus como influenza o bocavirus en la fisiopatolog\u00eda de esta entidad, pero hasta el momento muy pocos casos se han descrito en relaci\u00f3n con el virus respiratorio sincitial. La cl\u00ednica m\u00e1s frecuente es dolor tor\u00e1cico junto con disnea y enfisema subcut\u00e1neo como signo caracter\u00edstico. El diagn\u00f3stico en casi todos los casos lo dar\u00e1 la radiograf\u00eda de t\u00f3rax. El manejo depender\u00e1 del grado de afectaci\u00f3n y su repercusi\u00f3n, por lo que variar\u00e1 desde observaci\u00f3n hasta ingreso en una Unidad de Cuidados Intensivos. El tratamiento ser\u00e1 de soporte y el de las complicaciones asociadas, no se suelen dar recurrencias y el pron\u00f3stico suele ser bueno en la mayor parte de los casos.\nIn 1999, the United Kingdom (UK) was the first country to introduce meningococcal group C (MenC) conjugate vaccination. This vaccination programme has evolved with further understanding, new vaccines and changing disease epidemiology.\nAim\nTo characterise MenC disease and population protection against MenC disease in England.\nMethods\nBetween 1998/99\u20132015/16, surveillance data from England for laboratory-confirmed MenC cases were collated; using the screening method, we updated vaccine effectiveness (VE) estimates. Typing data and genomes were obtained from the Meningitis Research Foundation Meningococcus Genome Library and PubMLST Neisseria database. Phylogenetic network analysis of MenC cc11 isolates was undertaken. We compared bactericidal antibody assay results using anonymised sera from 2014 to similar data from 1996\u20131999, 2000\u20132004 and 2009.\nResults\nMenC cases fell from 883 in 1998/99 (1.81/100,000 population) to 42 cases (0.08/100,000 population) in 2015/16. Lower VE over time since vaccination was observed after infant immunisation (p = 0.009) and a single dose at 1\u20134 years (p = 0.03). After vaccination at 5\u201318 years, high VE was sustained for \u2265 8 years; 95.0% (95% CI: 76.0\u2013 99.5%). Only 25% (75/299) children aged 1\u201314 years were seroprotected against MenC disease in 2014. Recent case isolates mostly represented two cc11 strains.\nConclusion\nHigh quality surveillance has furthered understanding of MenC vaccines and improved schedules, maximising population benefit. The UK programme provides high direct and indirect protection despite low levels of seroprotection in some age groups. High-resolution characterisation supports ongoing surveillance of distinct MenC cc11 lineages.\nLa carga de enfermedad derivada de las infecciones de transmisi\u00f3n sexual (ITS) compromete la salud sexual, reproductiva y del reci\u00e9n nacido. La presencia de unas ITS facilita la transmisi\u00f3n de otras, como el VIH, y provoca cambios celulares que preceden algunos tipos de c\u00e1ncer. Todo ello hace de las ITS un problema de salud p\u00fablica de primer orden no controlado. En Espa\u00f1a, la infecci\u00f3n gonoc\u00f3cica sigue creciendo desde el inicio de la d\u00e9cada del 2000, mientras que la s\u00edfilis se mantiene estable en unos niveles altos desde el 2011. Ambas son m\u00e1s frecuentes en varones. Chlamydia trachomatis es la ITS m\u00e1s prevalente, afectando principalmente a mujeres de 20-24 a\u00f1os.\nLas unidades de ITS son el instrumento fundamental para abordar este problema. Tratan con poblaciones especialmente vulnerables a estas infecciones y son esenciales para su control mediante intervenciones que disminuyen la eficiencia de su transmisi\u00f3n y la duraci\u00f3n de la infectividad. Adem\u00e1s, son la principal fuente del conocimiento epidemiol\u00f3gico de las mismas.\nFosfomicina tiene un efecto sin\u00e9rgico o, como m\u00ednimo, aditivo en combinaci\u00f3n con casi todos los antimicrobianos ensayados merced a su elevada difusi\u00f3n y a su mecanismo de acci\u00f3n \u00fanico. En la actualidad, la gu\u00eda de la Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica de tratamiento de la infecci\u00f3n persistente o complicada por SARM recomienda la combinaci\u00f3n de fosfomicina y daptomicina 17 . Esta recomendaci\u00f3n presumiblemente se ver\u00e1 reforzada cuando se publiquen los resultados de un ensayo en marcha que compara la actividad combinada de fosfomicina y daptomicina frente a daptomicina en monoterapia en el tratamiento de la infecci\u00f3n por SARM 18 .\nPor otra parte, la combinaci\u00f3n de fosfomicina con otros antimicrobianos tambi\u00e9n ha demostrado sinergia in vitrofrente a microorganismos gramnegativos multirresistentes 19 y existe experiencia cl\u00ednica publicada sobre su empleo a altas dosis y de forma combinada en el tratamiento de las enterobacterias productoras de carbapenemasas 202122 y de Pseudomonas spp. extensamente resistentes 23 .\nFosfomicina se considera como un antimicrobiano bastante seguro y bien tolerado. Una mol\u00e9cula que, siendo antigua, est\u00e1 a\u00fan por definir su total posicionamiento y que cuanto m\u00e1s conocemos de ella, m\u00e1s beneficios potenciales se encuentran\nAs one of the most frequent and serious adverse reactions during tuberculosis (TB) treatment, antituberculosis drug-induced liver injury (ATLI) in children has been studied insufficiently compared with adults. We aimed to determine the incidence and risk factors of ATLI in children during the first 2 months of TB therapy.\nA total of 41 children with TB and treated with first-line anti-TB drugs were prospectively followed-up for the development of ATLI. Liver function tests were performed at baseline and after 2 weeks of therapy. Subsequent tests were conducted at 4, 6 and 8 weeks if the initial 2-week measurement was abnormal or if symptoms of hepatotoxicity were reported.\nATLI was detected in 11 (27%) patients within 14 to 42 days from the start of therapy, with most of them (54%) occurred after 2 weeks. TB treatment was stopped immediately in 6 of 11 patients who developed ATLI, and no recurrent hepatotoxicity after drug reintroductions in these patients. Univariate analysis showed that ATLI was significantly associated with TB meningitis ( P < 0.01), hypoalbuminemia ( P < 0.05) and hepatotoxic comedications ( P < 0.01). Age, sex, nutritional status, HIV status and baseline liver function abnormalities were not associated with ATLI. Multivariate analysis identified hypoalbuminemia and hepatotoxic comedications (both P < 0.1) tend to be independently associated with ATLI.\nChildren with hypoalbuminemia and use of hepatotoxic comedications are suggested to be monitored closely for the development of ATLI\nBreve art\u00edculo sobre la epidemiolog\u00eda de los enterovirus relacionados con los brotes de par\u00e1lisis fl\u00e1cida en el sudeste asi\u00e1tico y actualmente en EEUU. Se analiza la importancia de su reconocimiento y diagn\u00f3stico etiol\u00f3gico, as\u00ed como las respuestas individuales de los hu\u00e9spedes y las posibilidades terap\u00e9uticas frente a los enterovirus no polio, principalmente D68 y A71\nLung ultrasonography for the diagnosis of pneumonia has been around since as early as 1970,1 although it is only in recent years with the growing interest in point-of-care ultrasound that more studies have been published with regard to its use in children. Even though pneumonia is one of the most common and potentially serious illnesses that affects children throughout the world, studies of pneumonia are often difficult to interpret in context with each other because of the variability in definitions used, as well as the lack of an easy gold standard. Many organisations, such as the World Health Organization (WHO) and British Thoracic Society, define pneumonia solely based on clinical findings, which can largely over-represent true cases of pneumonia (eg, children with bronchiolitis or viral-induced wheezing will often meet the case definition of pneumonia). Attempts to refine the definition of pneumonia by adding radiographic criteria (eg, parenchymal infiltrates on chest radiography) to the clinical criteria are also problematic given the variable test characteristics of chest radiography for pneumonia,2 variabilities in interpretation even among radiologists,3 problems with ionising radiation exposure and cost, and given that many clinical guidelines do not require the use of chest radiography for the management of suspected community-acquired pneumonia.\nFurther complicating this issue is the fact that the causative pathogen of \u2026\nThe numbers in this study are small and it is hard to draw firm conclusions, but it nonetheless raises the question of whether every child with a sonographic consolidation should receive an antibiotic course of treatment, and if not, what that threshold should be.\nOf 97 included patients, CR was positive for pneumonia in 44/97 (45%) and lung ultrasound was positive in 57/97 (59%). Ultrasound sensitivity was 91% (95% CI 78% to 98%) and specificity was 68% (95% CI 54% to 80%). Ultrasound results displayed greater consistency with CR and patient outcomes when sonographic consolidation exceeded 1 cm. Thirteen of 57 patients with sonographic consolidation improved without antibiotics.\nConclusion Lung ultrasound may have a role as first-line imaging in patients with possible pneumonia, with higher specificity for consolidations exceeding 1 cm.\nConclusions Viral infection in febrile infants <60 days of age is associated with a decreased, but not negligible (30% relative) SBI risk, compared with non-viral-infected febrile infants.\nA 4-month-old boy with Down syndrome (DS) attended the general paediatric clinic for routine follow-up. With winter approaching the registrar asked, as children with DS are at increased risk of respiratory tract infections (RTIs), should this baby receive palivizumab prophylaxis, even if there is no congenital heart disease (CHD)?\nShould children with DS without CHD or prematurity (population) receive palivizumab prophylaxis (intervention) to improve outcome (outcome)?\nConclusion Although many of the studies above are either retrospective9 10 12 13 or prospective observational9 18 20 22\u201324 studies, and a well-designed randomised controlled trial would be desirable, a recent meta-analysis examining DS and the risk of severe RSV concluded that children with DS without additional risk factors were at significantly greater risk of worse clinical outcomes.25 Therefore, the available evidence supports that children with DS are at increased risk of hospitalisation from RSV-related RTI and have more severe disease, necessitating longer hospital stays and more often requiring ventilatory support.11\u201313 24 Importantly, this appears to be independent of cardiac history,7 9\u201312 24 25 and therefore we would advocate that every child with DS be offered prophylaxis to reduce morbidity and improve outcomes. Several studies completed show that palivizumab is efficacious in reducing the incidence of hospitalisation due to RSV in children with DS with and without CHD.21\u201323 Lastly, it has been suggested that RSV-related disease occurs for longer, in the second year of life and beyond in children with DS,10 12 so should these children receive the vaccine for a second bronchiolitis season as indicated?\nAs our understanding of b-lactam allergy evolves, the importance of avoiding nondiscriminantly labeling children as allergic as well as delabeling children who are not allergic becomes more important. Most children with recorded b-lactam allergy are not in fact allergic, and there are significant unintended health consequences of use of alternative antibiotics. An allergy evaluation for children with a history of allergy benefits both the child, the population and the health care system.\nBetween 2000 and 2012, the national estimated incidence rate of pediatric mastoiditis, a rare but serious complication of acute otitis media, was highest in 2006 (2.7/100,000 population) and lowest in 2012 (1.8/100,000 population). This measure provides a baseline for public health surveillance in the pneumococcal conjugate vaccine era as stewardship efforts target antibiotic use in acute otitis media\nLarge epidemiologic studies evaluating the etiologies, management decisions and outcomes of infants and children with meningitis and encephalitis in the United States are lacking.\nChildren 0\u201317 years of age with meningitis or encephalitis as assessed by International Classification of Diseases, Ninth Revision, codes available in the Premier Healthcare Database during 2011\u20132014 were analyzed.\nSix thousand six hundred sixty-five patients with meningitis or encephalitis were identified; 3030 (45.5%) were younger than 1 year of age, 295 (4.4%) were 1\u20132 years of age, 1460 (21.9%) were 3\u20139 years of age, and 1880 (28.2%) were 10\u201317 years of age. Etiologies included enterovirus (58.4%), unknown (23.7%), bacterial (13.0%), noninfectious (3.1%), herpes simplex virus (1.5%), other viruses (0.7%), arboviruses (0.5%) and fungal (0.04%). The majority of patients were male [3847 (57.7%)] and healthy [6094 (91.4%)] with no reported underlying conditions. Most underwent a lumbar puncture in the emergency department [5363 (80%)] and were admitted to the hospital [5363 (83.1%)]. Antibiotic therapy was frequent (92.2%) with children younger than 1 year of age with the highest rates (97.7%). Antiviral therapy was less common (31.1%). Only 539 (8.1%) of 6665 of patients received steroids. Early administration of adjunctive steroids was not associated with a reduction in mortality ( P = 0.266). The overall median length of stay was 2 days. Overall mortality rate (0.5%) and readmission rates (<1%) was low for both groups.\nMeningitis and encephalitis in infants and children in the United States are more commonly caused by viruses and are treated empirically with antibiotic therapy and antiviral therapy in a significant proportion of cases. Adjunctive steroids are used infrequently and are not associated with a benefit in mortality.\nGlobally, there is wide variation in streptococcal titer upper limits of normal (ULN) for antistreptolysin O (ASO) and anti-deoxyribonuclease B (ADB) used as an evidence of recent group A streptococcal infection to diagnose acute rheumatic fever (ARF).\nWe audited ASO and ADB titers among individuals with ARF in New Zealand (NZ) and in Australia\u2019s Northern Territory. We summarized streptococcal titers by different ARF clinical manifestations, assessed application of locally recommended serology guidelines where NZ uses high ULN cut-offs and calculated the proportion of cases fulfilling alternative serologic diagnostic criteria.\nFrom January 2013 to December 2015, group A streptococcal serology results were available for 350 patients diagnosed with ARF in NZ and 182 patients in Northern Territory. Median peak streptococcal titers were similar in both settings. Among NZ cases, 267/350 (76.3%) met NZ serologic diagnostic criteria, whereas 329/350 (94.0%) met Australian criteria. By applying Australian ULN titer cut-off criteria to NZ cases, excluding chorea, ARF definite cases would increase by 17.6% representing 47 cases.\nASO and ADB values were similar in these settings. Use of high ULN cut-offs potentially undercounts definite and probable ARF diagnoses. We recommend NZ and other high-burden settings to use globally accepted, age-specific, lower serologic cut-offs to avoid misclassification of ARF.\nEnterovirus-D68 (EV-D68) is a respiratory virus within the genus Enterovirus and the family of Picornaviridae . Genetically, it is closely related to rhinovirus that replicates in the respiratory tract and causes respiratory disease. Since 2014, EV-D68 has been associated with the neurologic syndrome of acute flaccid myelitis (AFM).\nIn October 2016, questionnaires were sent out to a European network including 66 virologists and clinicians, to develop an inventory of EV-D68\u2013associated AFM cases in Europe. Clinical and virologic information of case patients was requested. In addition, epidemiologic information on EV testing was collected for the period between March and October 2016.\nTwenty-nine cases of EV-D68\u2013associated AFM were identified, from 12 different European countries. Five originated from France, 5 from Scotland and 3 each from Sweden, Norway and Spain. Twenty-six were children (median age 3.8 years), 3 were adults. EV-D68 was detected in respiratory materials (n = 27), feces (n = 8) and/or cerebrospinal fluid (n = 2). Common clinical features were asymmetric flaccid limb weakness, cranial nerve deficits and bulbar symptoms. On magnetic resonance imaging, typical findings were hyperintensity of the central cord and/or brainstem; low motor amplitudes with normal conduction velocities were seen on electromyography. Full clinical recovery was rare (n = 3), and 2 patients died. The epidemiologic data from 16 European laboratories showed that of all EV-D68\u2013positive samples, 99% was detected in a respiratory specimen.\nFor 2016, 29 EV-D68\u2013related AFM cases were identified in mostly Western Europe. This is likely an underestimation, because case identification is dependent on awareness among clinicians, adequate viral diagnostics on respiratory samples and the capability of laboratories to type EVs\nF. necrophorum was identified in 13% (19/149) of mastoiditis cases with an identifiable agent. Its incidence increased 7-fold from 2.8% in 2012 to 20.4% in 2015 ( P = 0.02). F. necrophorum infection had unique clinical, laboratory and prognostic features. The vast majority had complications and underwent surgical intervention. The predictive model used 4 parameters to define high-risk patients for F. necrophorum infection at admission: females, winter/spring season, prior antibiotic treatment and a C-reactive protein value >20 mg/dL (area under receiver operating characteristic curve 0.929).\nClinicians should be aware of the increasing incidence of F. necrophorum mastoiditis and consider anaerobic cultures and specific anaerobic coverage in high-risk patients\nRESULTADOS: Observamos disminuciones dram\u00e1ticas en la administraci\u00f3n de antibi\u00f3ticos durante los 14 a\u00f1os de estudio. A pesar de la evidencia previa de una meseta en las tasas, hubo disminuciones adicionales sustanciales entre 2010 y 2014. Si bien las tasas de uso de antibi\u00f3ticos disminuyeron en general, la fracci\u00f3n de prescripci\u00f3n asociada con los diagn\u00f3sticos individuales fue relativamente estable. La prescripci\u00f3n de diagn\u00f3sticos para los cuales los antibi\u00f3ticos no est\u00e1n claramente indicados parece haber disminuido.\nCONCLUSIONES: Estos datos revelaron otro per\u00edodo de marcado declive de 2010 a 2014 despu\u00e9s de una meseta relativa durante varios a\u00f1os para la mayor\u00eda de los grupos de edad. Los esfuerzos para disminuir la prescripci\u00f3n innecesaria contin\u00faan teniendo un impacto en el uso de antibi\u00f3ticos en la pr\u00e1ctica ambulatoria.\nThis is the largest cohort of HPeV3 cases with clinical data and pediatrician-assessed neurodevelopmental follow-up to date. Developmental concerns were identified in 11 children at early follow-up. Abnormal magnetic resonance imaging during acute infection did not specifically predict poor neurodevelopmental in short-term follow-up. Continued follow-up of infants and further imaging correlation is needed to explore predictors of long-term morbidity.\nIn this systematic review and meta-analyses, serious infections were uncommon and not significantly increased among patients with JIA receiving biologic agents compared with controls. However, the analyses were underpowered and study periods were relatively short. Ongoing careful monitoring for serious infections remains necessary for all patients with JIA, and particularly those receiving biologic agents.\nRESULTADOS: Se observaron un total de 1596 adolescentes elegibles durante el ensayo de 7 meses. Un tercio de los adolescentes visit\u00f3 una cl\u00ednica de intervenci\u00f3n. Los adolescentes que asistieron a una cl\u00ednica de intervenci\u00f3n ten\u00edan m\u00e1s probabilidades de ser m\u00e1s j\u00f3venes (11 a 12 a\u00f1os) que aquellos que asistieron a una cl\u00ednica de control (72.4% vs 49.8%; P <.001). No se observaron diferencias en raza o sexo. La proporci\u00f3n de adolescentes con un cambio observado en el estado de la vacuna fue mayor para los que acudieron a una cl\u00ednica de intervenci\u00f3n (64,8%) en comparaci\u00f3n con la cl\u00ednica de control (50,1%; odds ratio, 1,82; intervalo de confianza del 95%, 1,47\u20132,25; p <0,001). Los adolescentes cuyos padres vieron el video ten\u00edan una probabilidad 3 veces mayor de recibir una dosis de la vacuna contra el VPH (78.0%; odds ratio, 3.07; intervalo de confianza del 95%, 1.47\u20136.42; P = .003).\nCONCLUSIONES: Las intervenciones educativas realizadas en un entorno cl\u00ednico prometen mejorar los comportamientos de vacunaci\u00f3n.\nObjective To improve the prediction of pediatric pneumonia by developing a series of models based on clinically distinct subgroups. We hypothesized that these subgroup models would provide superior estimates of pneumonia risk compared with a single pediatric model. Study design We conducted a secondary analysis of a prospective cohort being evaluated for radiographic pneumonia in an urban pediatric emergency department (ED). Using multivariate modeling, we created 4 models across subgroups stratified by age and presence of wheezing to predict the risk of pneumonia. Results A total of 2351 patients were included in the study. In this series, the prevalence of pneumonia was 8.5%, and 21.6% were hospitalized. The highest prevalence of pneumonia was in children aged >2 years without wheezing (13.3%). Children aged <2 years with wheezing had the lowest prevalence of pneumonia (4.0%). The most\naccurate model was for children aged <2 years with wheezing (area under the curve [AUC], 0.80), and the poorest performing model was for those aged <2 years without wheezing (AUC, 0.64). The AUC of a combination of the 4 subgroup models was 0.76 (95% CI, 0.72-0.80). The precision of the models\u2019 estimates (expected vs observed) was + 3.7%.\nConclusions Using 4 complementary prediction models for pediatric pneumonia, an accurate risk of pneumonia can be calculated. These models can provide the basis for clinical decision making support to guide the use of chest radiographs and promote antibiotic stewardship.\nThe prevalence of serious bacterial infection is lower in infants aged \u226460 days with a history of fever compared with those who are febrile on arrival to the ED. The small risk reduction in this group is unlikely to alter decision making.\nAmong febrile infants \u226460 days old with IBI, prematurity, ill appearance, and bacterial meningitis (vs bacteremia without meningitis) were associated with adverse outcomes. These factors can inform clinical decision-making for febrile young infants with IBI.\nLas biopel\u00edculas bacterianas se han relacionado con infecciones del tracto respiratorio superior y resistencia a los antibi\u00f3ticos, lo que genera serias preocupaciones con respecto al tratamiento de dichas infecciones. Varios estudios en ni\u00f1os propensos a la otitis demostraron que la administraci\u00f3n intranasal de Streptococcus salivarius 24 SMB y Streptococcus oralisson 89a es segura y bien tolerada y puede reducir el riesgo de otitis media aguda. El objetivo de esta investigaci\u00f3n es evaluar su capacidad de interferir con la biopel\u00edcula de los pat\u00f3genos t\u00edpicos del tracto respiratorio superior. El estudio concluye que ambos act\u00faan como probi\u00f3ticos para el tratamiento y prevenci\u00f3n de las v\u00edas respiratorias superiores.\nRESULTADOS: De 2014 a 2016, se registraron 166 casos de enfermedad meningoc\u00f3cica en personas de 18 a 24 a\u00f1os, con una incidencia anual promedio de 0,17 casos por 100 000 habitantes. Se identificaron seis brotes de serogrupo B en los campus universitarios, lo que representa el 31.7% de los casos del serogrupo B en estudiantes universitarios durante este per\u00edodo. El RR de la enfermedad meningoc\u00f3cica (MenB) del serogrupo B en estudiantes universitarios versus estudiantes no colegiados fue de 3.54 (95% intervalo de confianza: 2.21-5.41), y el RR de los serogrupos C, W e Y combinados fue 0.56 (95% intervalo de confianza: 0.27 \u20131.14). Los complejos clonales de serogrupo B m\u00e1s comunes identificados fueron CC32 / ET-5 y CC41 / 44 linaje 3.\nCONCLUSIONES: Aunque la incidencia es baja, entre los j\u00f3venes de 18 a 24 a\u00f1os, los estudiantes universitarios tienen un mayor riesgo de contraer la enfermedad de MenB espor\u00e1dica y asociada a brotes. Los proveedores, estudiantes universitarios y padres deben estar conscientes de la disponibilidad de vacunas MenB.\nAunque los factores anteriores deben considerarse al hacer recomendaciones de salud p\u00fablica, a nivel individual, la decisi\u00f3n de vacunar a un adolescente con la vacuna MenB es mucho m\u00e1s sencilla. Las infecciones meningoc\u00f3cicas son potencialmente mortales. Tenemos evidencia de otros pa\u00edses de que las vacunas MenB son efectivas. Las vacunas de MenB est\u00e1n cubiertas por las compa\u00f1\u00edas de seguros y el Programa de vacunas para ni\u00f1os, incluso bajo la recomendaci\u00f3n de la Categor\u00eda B. Y ahora podemos decir que los estudiantes universitarios tienen un mayor riesgo de contraer la enfermedad de MenB. Los pediatras y los proveedores de atenci\u00f3n primaria tienen una raz\u00f3n m\u00e1s convincente para recomendar la vacuna MenB para sus pacientes que anticipan asistir a la universidad. Como m\u00ednimo, los pediatras deben educar a los estudiantes y las familias sobre el mayor riesgo de infecciones de MenB en estudiantes universitarios en los Estados Unidos e informarles que hay 2 vacunas disponibles que pueden proteger a los estudiantes universitarios de esta infecci\u00f3n. Los efectos secundarios relacionados con la vacunaci\u00f3n con MenB son relativamente m\u00ednimos. Los estudiantes y los padres pueden tomar una decisi\u00f3n informada acerca de recibir MenB.", "language": null, "image": null, "pagetype": null, "links": ["#main-content", "/user/login", "https://www.facebook.com/pages/Asociaci%C3%B3n-Espa%C3%B1ola-de-Pediatr%C3%ADa-de-Atenci%C3%B3n-Primaria-AEPap/297021720318323", "http://twitter.com/aepap", "https://vimeo.com/aepap", "https://instagram.com/aepap.oficial", "https://es.pinterest.com/revistapap/", "/rss.xml", "/", "/la-aepap", "/la-aepap/junta-directiva", "/la-aepap/documentos", "/la-aepap/participamos", "/user/register", "/la-aepap/10o-aniversario-curso-de-actualizacion-de-la-aepap", "/la-aepap/contacto", "/la-aepap/aepap-resumen-periodo-2010-2015", "/agenda/convocatorias-becas-y-premios", "/la-aepap/revistas", "/la-aepap/premios", "/la-aepap/memorias-anuales", "/la-aepap/elecciones-aepap-2020", "/federadas", "http://www.pediatrasandalucia.org/", "/federadas/aragon", "/federadas/asturias", "http://www.apapib.es/", "http://www.apapcanarias.org/", "/federadas/cantabria", "/federadas/castilla-y-la-mancha", "https://apapcyl.es/", "https://pediatresap.cat/", "/federadas/comunidad-valenciana", "/federadas/euskadi-pais-vasco", "https://spapex.es/", "http://www.agapap.org/", "http://www.arpap.org/", "http://www.ampap.es/", "http://www.apermap.com/", "http://www.anpenavarra.org/", "/grupos", "/grupos/grupo-de-cooperacion-inmigracion-y-adopcion", "/grupos/grupo-de-docencia", "/grupos/grupo-de-educacion-para-la-salud", "/grupos/grupo-de-investigacion", "/grupos/grupo-de-pbe", "http://previnfad.aepap.org", "/grupos/grupo-de-tdah-y-desarrollo-psicoeducativo", "http://www.respirar.org/index.php/grupo-vias-respiratorias/grupo-vias-respiratorias", "/grupos/grupo-de-patologia-infecciosa", "/grupos/grupo-de-pediatria-social-y-comunitaria", "/node/5005", "/grupos/grupo-laboral-profesional", "/grupos/grupo-vacunaepap", "/grupos/grupo-de-ecografia-clinica-pediatrica", "/grupos/grupo-de-gastroenterologia-y-nutricion", "/grupos/grupo-de-relaciones-con-pediatria-europea", "/grupos/grupo-de-sueno", "/grupos/papenred", "/actualidad/noticias-aepap", "/actualidad/noticias-aepap", "/actualidad/noticias-externas", "/actualidad/comunicados-y-notas-de-prensa", "/actualidad/sala-de-prensa", "/actualidad/boletines-aepap", "/laboral/bolsa-de-trabajo", "/laboral/bolsa-de-trabajo", "/agenda", "/agenda/actividades-aepap", "/agenda/convocatorias-becas-y-premios", "/agenda/actividades-no-aepap", "/agenda/enviar-actividad", "/biblioteca", "/biblioteca/programa-de-formacion-de-la-aepap", "http://formatio.aepap.org", "/biblioteca/cursos", "/biblioteca/reuniones", "/biblioteca/revistas", "/biblioteca/libros", "/biblioteca/guias", "/biblioteca/ayuda-en-la-consulta", "/biblioteca/videoteca", "/biblioteca/otros", "/biblioteca/programa-de-salud-infantil", "/vacunas/calendarios-espanoles", "/vacunas/calendarios-espanoles", "/vacunas/calendarios-espanoles/calendarios-extranjeros-y-viajes", "/vacunas/noticias-de-vacunas", "https://www.familiaysalud.es/las-vacunas", "https://www.aepap.org/grupos/grupo-de-patologia-infecciosa/vacunas", "http://previnfad.aepap.org/recomendacion/vacunas-rec", "http://www.familiaysalud.es/", "http://www.familiaysalud.es/salud-joven", "/coronavirus", "/coronavirus/aepap-responde", "/coronavirus/pediatria-de-atencion-primaria", "/coronavirus/documentos-para-la-consulta-de-pediatria-de-ap", "/coronavirus/pediatria", "/coronavirus/recursos-para-las-familias", "/coronavirus/recopilando-recopilaciones", "/", "/grupos", "/grupos/grupo-de-patologia-infecciosa", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica", "https://www.analesdepediatria.org/es-enfermedad-invasiva-por-streptococcus-pyogenes-articulo-S169540331930030X", "https://www.analesdepediatria.org/es-infecciones-invasivas-por-estreptococo-del-articulo-S1695403319302723", "https://www.analesdepediatria.org/es-documento-posicionamiento-asociacion-espanola-pediatria-sociedad-articulo-S169540331930270X", "https://adc.bmj.com/content/104/12/1173", "http://dx.doi.org/10.1016/S1473-3099(19)30446-3", "https://www.nejm.org/doi/full/10.1056/NEJMra1807761", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013479/full", "https://www.ncbi.nlm.nih.gov/pubmed/31255301", "https://pubmed.ncbi.nlm.nih.gov/25744474", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003871.pub3/full", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008521.pub4/full", "https://journals.lww.com/pidj/Fulltext/2019/12000/Treatment_of_Urinary_Tract_Infections_Caused_by.23.aspx", "https://www.nejm.org/doi/full/10.1056/NEJMicm1904420", "https://adc.bmj.com/content/104/12/1237", "https://adc.bmj.com/content/104/12/1237#ref-1", "https://adc.bmj.com/content/104/12/1237#ref-2", "https://adc.bmj.com/content/104/12/1237#T1", "https://www.jpeds.com/article/S0022-3476(19)31101-1/fulltext", "https://pediatrics.aappublications.org/content/early/2019/11/19/peds.2019-0630", "https://pediatrics.aappublications.org/content/early/2019/11/19/peds.2019-2541", "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30395-0/fulltext", "https://pubmed.ncbi.nlm.nih.gov/31548079", "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30396-2/fulltext", "https://pubmed.ncbi.nlm.nih.gov/31548081", "https://pediatrics.aappublications.org/content/early/2019/11/14/peds.2019-1791", "https://jamanetwork.com/journals/jamapediatrics/article-abstract/2749340", "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30126-4/fulltext", "https://pubmed.ncbi.nlm.nih.gov/31178289", "https://www.analesdepediatria.org/es-enfermedad-meningococica-invasiva-ninos-adultos-articulo-S1695403318305599", "https://pediatrics.aappublications.org/content/early/2019/11/12/peds.2019-1509", "https://journals.lww.com/pidj/Fulltext/2019/12000/The_Volume_of_Pediatric_Blood_Culture.31.aspx", "https://journals.lww.com/pidj/Fulltext/2019/12000/Prevalence_of_Bacterial_Infection_in_Febrile.2.aspx", "https://jamanetwork.com/journals/jamapediatrics/article-abstract/2748691", "https://jamanetwork.com/journals/jamapediatrics/article-abstract/2748691", "https://jamanetwork.com/journals/jamapediatrics/article-abstract/2751741", "https://www.nejm.org/doi/full/10.1056/NEJMoa1903869", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790888/", "https://jamanetwork.com/journals/jamapediatrics/article-abstract/2751746", "https://journals.lww.com/pidj/Fulltext/2019/12000/Molecular_Characterization_of_Streptococcus.3.aspx", "https://www.jpeds.com/article/S0022-3476(19)30962-X/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/31477383", "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33005-8/fulltext", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548991/pdf/main.pdf", "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30323-8/fulltext", "https://pubmed.ncbi.nlm.nih.gov/31543249", "https://journals.lww.com/pidj/Fulltext/2019/12000/Increasing_Rates_of_Pediatric_Empyema_and_Disease.8.aspx", "https://journals.lww.com/pidj/Fulltext/2019/12000/Clostridium_difficile_Infection_in_Children_.12.aspx", "https://www.jpeds.com/article/S0022-3476(19)30965-5/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Diversity+of+Serotype+Replacement+After+Pneumococcal+Conjugate+Vaccine+Implementation+in+Europe", null, null, null, null, null, "https://www.ncbi.nlm.nih.gov/pubmed/?term=Penicillin+V+four+times+daily+for+five+days+versus+three+times+daily+for+10+days+in+patients+with+pharyngotonsillitis+caused+by+group+A+streptococci%3A+randomised+controlled%2C+open+label%2C+non-inferiority+study", "https://www.bmj.com/content/367/bmj.l5723", "https://www.ncbi.nlm.nih.gov/pubmed/31201033", "https://www.ncbi.nlm.nih.gov/pubmed/31201033", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/390657e4-dcc8-4fc4-8df3-121ecfdff579/gr1.jpg", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/a36d1d1c-f816-48a7-902b-e35f1c9872e5/fx1.jpg", "http://www.jpeds.com/", "https://www.jpeds.com/article/S0022-3476(19)30654-7/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Larva+Eruption%3A+A+Furuncle+in+a+Returned+Traveller", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/6d53df2d-1962-4848-b406-fe892ff8d54c/gr1.jpg", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/1c35c824-9247-4260-ba6d-6c0c68a45240/gr2.jpg", "https://www.jpeds.com/cms/10.1016/j.jpeds.2019.05.037/attachment/c661d16f-9215-4a14-98fe-c4d3b71fd82c/mmc1.mp4", "http://www.jpeds.com/", "https://journals.lww.com/pidj/Fulltext/2019/10000/Fever_Without_a_Focus__A_Rare_Presentation_of.31.aspx", "https://journals.lww.com/pidj/Fulltext/2019/10000/Fever_Without_a_Focus__A_Rare_Presentation_of.31.aspx#R1-31", "https://journals.lww.com/pidj/Fulltext/2019/10000/Panton_Valentine_Positive_Staphylococcus_aureus_in.27.aspx", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-infeccion-parotidea-por-mycobacterium-malmoense-S0213005X19301156", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-infeccion-parotidea-por-mycobacterium-malmoense-S0213005X19301156", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bacteremia+caused+by+Herbaspirillum+huttiense+in+a+newborn", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bacteremia+caused+by+Herbaspirillum+huttiense+in+a+newborn", "https://pediatrics.aappublications.org/content/144/4/e20191642", "https://pediatrics.aappublications.org/content/144/4/e20191642", "https://pediatrics.aappublications.org/content/144/4/e20191564", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-vigilancia-contactos-tuberculosis-como-podemos-S0213005X19301697", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-demora-diagnostica-como-principal-factor-S0213005X18303781", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Impact+and+clinical+profiles+of+Mycoplasma+pneumoniae+co-detection+in+childhood+community-acquired+pneumonia", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-neumonias-adquiridas-comunidad-por-staphylococcus-S0213005X18303768", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-neumonias-adquiridas-comunidad-por-staphylococcus-S0213005X18303768", "https://journals.lww.com/pidj/Abstract/2019/10000/Multiplex_Polymerase_Chain_Reaction_Panel_for.10.aspx", "https://journals.lww.com/pidj/Abstract/2019/10000/Intestinal_Parasitic_Infections_in_Internationally.4.aspx", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011055.pub2/full", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000371.pub7/full", "https://pediatrics.aappublications.org/content/144/4/e20190174", "https://pediatrics.aappublications.org/content/144/4/e20190174", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-infecciones-por-chlamydia-trachomatis-incluye-S0213005X19301314", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-infecciones-por-chlamydia-trachomatis-incluye-S0213005X19301314", "https://adc.bmj.com/content/104/10/1013.1.citation-tools", "https://pediatrics.aappublications.org/content/144/4/e20190543", "https://pediatrics.aappublications.org/content/144/4/e20190348", "https://pap.es/articulo/12848/patron-cutaneo-en-cielo-estrellado-el-polimorfismo-de-la-enfermedad-boca-mano-pie", "https://pap.es/articulo/12863/la-versatilidad-del-adenovirus-humano-en-el-paciente-inmunocompetente", "https://pap.es/articulo/12866/otitis-media-aguda-una-causa-poco-frecuente-de-sindrome-de-lemierre", "https://adc.bmj.com/content/104/10/993.citation-tools", "https://journals.lww.com/pidj/Citation/2019/10000/Insights_From_the_Geographic_Spread_of_the_Lyme.20.aspx", "https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx", "https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R1-23", "https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R2-23", "https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R3-23", "https://journals.lww.com/pidj/Fulltext/2019/10000/Respiratory_Syncytial_Virus_Vaccines__Are_We.23.aspx#R4-23", "https://journals.lww.com/pidj/Fulltext/2019/10000/Lack_of_Efficacy_of_Lactobacillus_reuteri_DSM.1.aspx", "https://journals.lww.com/pidj/Abstract/2019/10000/Clinical_Characteristics_of_Primary_HHV_6B.3.aspx", "https://journals.lww.com/pidj/Abstract/2019/10000/Asymptomatic_Pharyngeal_Carriage_of_Kingella.5.aspx", "https://journals.lww.com/pidj/Abstract/2019/10000/Management_of_Orbital_Complications_of_Acute.6.aspx", "https://www.jpeds.com/article/S0022-3476(19)30796-6/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=DNA+Viremia+Is+Associated+with+Hyperferritinemia+in+Pediatric+Sepsis", "https://adc.bmj.com/content/104/10/979.citation-tools", "https://www.ncbi.nlm.nih.gov/pubmed/31530719", "https://pediatrics.aappublications.org/content/144/4/e20191475", "https://journals.lww.com/pidj/Fulltext/2019/06001/What_Can_We_Do_About_Antimicrobial_Resistance_.8.aspx", "https://www.jpeds.com/article/S0022-3476(19)30677-8/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Low+Risks+and+High+Rewards+of+Penicillin+Allergy+Delabeling%3A+An+Algorithm+to+Expedite+the+Evaluation", "https://www.ncbi.nlm.nih.gov/pubmed/31310597", "https://journals.lww.com/pidj/Fulltext/2019/06001/When_to_Think_of_Rickettsia.5.aspx", "https://www.analesdepediatria.org/es-recomendaciones-vacunacion-frente-al-rotavirus-articulo-S1695403319302413", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-executive-summary-gesida-consensus-document-S0213005X18301678", "https://journals.lww.com/pidj/Fulltext/2019/06001/Viral_Bacterial_Interactions_in_Children__Impact.4.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/31310596", "https://journals.lww.com/pidj/Fulltext/2019/06001/Parasites_in_Human_Stool__To_Ignore_or_Not_To.11.aspx", "https://www.bmj.com/content/366/bmj.l5141", "https://www.jpeds.com/article/S0022-3476(19)30558-X/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Prolonged+PR+Interval+and+Erythema+Marginatum+in+a+Child+with+Acute+Rheumatic+Fever%2B", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/c5c02c73-ecef-41c7-b3e9-2fcd933f2c95/gr1.jpg", null, "https://www.jpeds.com/article/S0022-3476(19)30533-5/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Prolonged+PR+Interval+and+Erythema+Marginatum+in+a+Child+with+Acute+Rheumatic+Fever%2B", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/0f3e6336-d3af-4696-864b-dd3942b201a6/gr1.jpg", "https://journals.lww.com/pidj/Abstract/2019/09000/Mittens_and_Booties_Syndrome__A_Unique.23.aspx", "https://adc.bmj.com/content/104/8/808", "https://www.jpeds.com/article/S0022-3476(19)30541-4/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Gastroenteritis%2C+Hepatitis%2C+Encephalopathy%2C+and+Human+Herpesvirus+6+Detection+in+an+Immunocompetent+Child%3A+Benefits+and+Risks+of+Syndromic+Multiplex+Molecular+Panel+Testing", "https://www.jpeds.com/article/S0022-3476(19)30514-1/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Online+ExtraChronic+Herpes+Simplex+Virus+Infection+in+an+Immunosuppressed+Girl", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/6ef313fa-d3ca-4fe2-bcfc-730a9163e6c9/gr1.jpg", "https://journals.lww.com/pidj/Fulltext/2019/09000/Complicated_Head_and_Neck_Infections_Following.25.aspx", "https://www.analesdepediatria.org/es-una-complicacion-digestiva-infeccion-por-articulo-S1695403318303126", "https://www.analesdepediatria.org/es-una-complicacion-digestiva-infeccion-por-articulo-S1695403318303126", "https://journals.lww.com/pidj/Fulltext/2019/09000/False_Vaccine_Contraindications_Among_Healthcare.20.aspx", "https://www.analesdepediatria.org/es-que-hemos-aprendido-sobre-rotavirus-articulo-S1695403319300761", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-epidemiologia-descriptiva-infeccion-por-yersinia-S0213005X18303707", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-epidemiologia-descriptiva-infeccion-por-yersinia-S0213005X18303707", "https://journals.lww.com/pidj/Fulltext/2019/06001/Biomarkers_for_Infection_in_Children__Current.3.aspx", "https://journals.lww.com/pidj/Fulltext/2019/09000/Demographics,_Complications_and_Resource.24.aspx", "https://journals.lww.com/pidj/Fulltext/2019/09000/Measles_Transmission_in_a_Fully_Vaccinated_Closed.27.aspx", "https://journals.lww.com/pidj/Fulltext/2019/08000/Highly_Sensitive_Molecular_Assay_for_Group_A.1.aspx", "https://adc.bmj.com/content/104/9/916.1", "https://adc.bmj.com/content/104/9/919", "https://journals.lww.com/pidj/Fulltext/2019/06001/Why_Should_We_Advocate_Maternal_Immunization_.7.aspx", "https://journals.lww.com/pidj/Abstract/2019/09000/Excluding_Clinically_Significant_Bacteremia_by_24.6.aspx", "https://journals.lww.com/pidj/pages/currenttoc.aspx", "https://journals.lww.com/pidj/Fulltext/2019/09000/Revisiting_Bacterial_Interference_in_the_Age_of.17.aspx", "https://journals.lww.com/pidj/Abstract/2019/09000/Validation_of_the_British_Thoracic_Society.7.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/30531312", "https://journals.lww.com/pidj/Fulltext/2019/06001/To_LP_or_not_to_LP__Identifying_the_Etiology_of.9.aspx", "https://journals.lww.com/pidj/Fulltext/2019/06001/Endemic_Mycoses_in_Children.12.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/31257821", "https://journals.lww.com/pidj/Fulltext/2019/09000/Comparison_of_Nonpolio_Enteroviruses_in_Children.4.aspx", "https://journals.lww.com/pidj/Fulltext/2019/06001/Congenital_Cytomegalovirus_and_Neonatal_Herpes.13.aspx", "https://pediatrics.aappublications.org/content/144/2/e20183095", "https://journals.lww.com/pidj/Abstract/2019/08000/Clinical_Characteristics_of_Saffold_Virus.3.aspx", "https://journals.lww.com/pidj/Abstract/2019/09000/Invasive_Haemophilus_influenzae_Disease_at_Texas.8.aspx", "https://journals.lww.com/pidj/Citation/2019/09000/Global_Elimination_of_Chronic_Hepatitis.5.aspx", "https://journals.lww.com/pidj/Abstract/2019/08000/Broad_range_PCR_Application_in_a_Large_Academic.4.aspx", "https://journals.lww.com/pidj/Fulltext/2019/08000/Undernutrition,_Host_Immunity_and_Vulnerability_to.24.aspx", "https://journals.lww.com/pidj/Abstract/2019/09000/Recurrent_Pneumococcal_Meningitis_in_Children__A.3.aspx", "https://journals.lww.com/pidj/Abstract/2019/08000/Epidemiology_of_Serious_Bacterial_Infections_in.18.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Narcolepsy+and+Pandemic+Influenza+Vaccination%3A+What+We+Need+to+Know+to+be+Ready+for+the+Next+Pandemic", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009417.pub2/full", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012448.pub2/full", "https://www.bmj.com/content/366/bmj.l5162", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC88938/", "https://doi.org/10.1016/j.anpedi.2019.04.018", "https://www.analesdepediatria.org/es-caracteristicas-clinicas-epidemiologicas-las-neumonias-articulo-S1695403318305472", "https://www.analesdepediatria.org/es-caracteristicas-clinicas-epidemiologicas-las-neumonias-articulo-S1695403318305472", "https://journals.lww.com/pidj/Abstract/2019/07000/The_Clinical_Presentation_of_Pediatric_Mycoplasma.9.aspx", "https://journals.lww.com/pidj/Fulltext/2019/07000/Management_of_Suspected_Antibiotic_Reactions_in.25.aspx", "https://journals.lww.com/pidj/Fulltext/2019/07000/Management_of_Suspected_Antibiotic_Reactions_in.25.aspx#R1-25", "https://journals.lww.com/pidj/Fulltext/2019/07000/A_Pediatric_Infectious_Disease_Perspective_on.11.aspx", "https://journals.lww.com/pidj/Fulltext/2019/07000/A_Pediatric_Infectious_Disease_Perspective_on.11.aspx#R1-11", "https://journals.lww.com/pidj/Fulltext/2019/07000/A_Pediatric_Infectious_Disease_Perspective_on.11.aspx#R1-11", "https://journals.lww.com/pidj/Fulltext/2019/07000/A_Pediatric_Infectious_Disease_Perspective_on.11.aspx#R2-11", "https://pap.es/articulo/12820/enfermedad-tuberculosa-en-la-edad-pediatrica-experiencia-de-diez-anos", "https://pap.es/articulo/12800/?id=12800&titulo=", "https://pap.es/articulo/12814/tos-hipoxemia-y-dificultad-respiratoria-en-el-periodo-neonatal-no-siempre-es-lo-que-parece", "https://pap.es/articulo/12815/linfadenopatias-por-picaduras-de-garrapatas-a-proposito-de-dos-casos", "https://adc.bmj.com/content/104/7/706", "https://pediatrics.aappublications.org/content/144/1/e20183466", "https://pediatrics.aappublications.org/content/144/1/e20191276", "https://pediatrics.aappublications.org/content/144/1/e20191375", "https://pediatrics.aappublications.org/content/144/1/e20183604", "https://pediatrics.aappublications.org/content/144/1/e20183090", "https://www.analesdepediatria.org/es-sacroileitis-piogena-lecciones-aprendidas-una-articulo-S1695403318305484", "https://journals.lww.com/pidj/Abstract/2019/07000/Pediatric_Infectious_Sacroiliitis_.10.aspx", "https://www.analesdepediatria.org/es-abscesos-cervicales-profundos-infantiles-experiencia-articulo-S1695403318303655", "https://adc.bmj.com/content/104/7/615", "https://adc.bmj.com/content/104/7/616", "https://www.ncbi.nlm.nih.gov/pubmed/30700406", "https://adc.bmj.com/content/104/7/640", "https://adc.bmj.com/content/104/7/694", "https://journals.lww.com/pidj/Fulltext/2019/07000/Management_of_Herpes_Simplex_Virus_Keratitis_in.33.aspx", "https://journals.lww.com/pidj/Fulltext/2019/07000/Management_of_Herpes_Simplex_Virus_Keratitis_in.33.aspx#R1-33", "https://adc.bmj.com/content/104/7/629", "https://seq.es/resumen-del-articulo/may-30/", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-sifilis-S0213005X19300072", "https://pap.es/articulo/12804/infeccion-por-adenovirus-que-requiere-ingreso-hospitalario-epidemiologia-datos-analiticos-y-manejo", "https://pap.es/articulo/12805/tratamiento-hospitalario-de-la-bronquiolitis-moderada-grave-suero-salino-hipertonico-o-fisiologico-analisis-de-factores-de-riesgo-asociados-al-reingreso", "https://journals.lww.com/pidj/Fulltext/2019/07000/Enterovirus_D68_Causing_Acute_Respiratory.7.aspx", "http://archivos.pap.es/FrontOffice/PAP/front/Articulos/Articulo/_IXus5l_LjPq02N5se33_MZ2fB0HOkRmCFnQGpFOCARTfpaZuecp-LIE_-NFUA1oGCl1FHOUiFdc", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001534.pub4/full", "https://journals.lww.com/pidj/Abstract/2019/07000/Intrafamilial_Transmission_of_Hepatitis_C_Virus.8.aspx", "https://www.bmj.com/content/365/bmj.l2335", "https://www.bmj.com/content/365/bmj.l2244/article-info", "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4119-8", "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4188-8", "https://adc.bmj.com/content/104/7/701", "https://www.ncbi.nlm.nih.gov/pubmed/31210358", "https://www.analesdepediatria.org/es-primoinfeccion-por-el-virus-epstein-barr-articulo-S169540331830345X", "https://www.analesdepediatria.org/es-recomendaciones-sobre-el-diagnostico-tratamiento-articulo-S1695403319301389", "https://www.analesdepediatria.org/es-es-transmision-vertical-chlamydia-trachomatis-articulo-S169540331830225X", "https://www.analesdepediatria.org/es-es-transmision-vertical-chlamydia-trachomatis-articulo-S169540331830225X", "https://www-clinicalkey-es.scsalud.a17.csinet.es/tbl0005", "https://www.analesdepediatria.org/es-enfermedad-diseminada-por-aranazo-gato-articulo-S1695403318302777", "https://www.analesdepediatria.org/es-enfermedad-diseminada-por-aranazo-gato-articulo-S1695403318302777#bib0035", "https://adc.bmj.com/content/104/6/558", "https://adc.bmj.com/content/104/6/610", "https://www.jpeds.com/article/S0022-3476(19)30157-X/fulltext", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/8928f869-9fde-474a-86bf-d0fe0783770f/gr1.jpg", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/8928f869-9fde-474a-86bf-d0fe0783770f/gr1.jpg", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/8928f869-9fde-474a-86bf-d0fe0783770f/gr1.jpg", "https://www.jpeds.com/article/S0022-3476(19)30164-7/fulltext", "https://els-jbs-prod-cdn.literatumonline.com/cms/attachment/e660b89d-d954-4705-a5e6-0403d82a8d85/gr1.jpg", "https://www.jpeds.com/article/S0022-3476(19)30027-7/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Host+and+Bacterial+Markers+that+Differ+in+Children+with+Cystitis+and+Pyelonephritis", "https://journals.lww.com/pidj/Abstract/2019/06000/Respiratory_Microbiota_Predicts_Clinical_Disease.21.aspx", "https://pediatrics.aappublications.org/content/143/6/e20183327?sso=1&sso_redirect_count=1&nfstatus=401&nftoken=00000000-0000-0000-0000-000000000000&nfstatusdescription=ERROR%3A+No+local+token", "https://pediatrics.aappublications.org/content/143/6/e20183327?sso=1&sso_redirect_count=1&nfstatus=401&nftoken=00000000-0000-0000-0000-000000000000&nfstatusdescription=ERROR%3A+No+local+token", "https://www.analesdepediatria.org/es-absceso-perianal-ninos-perspectiva-desde-articulo-S1695403318301772", "https://www.jpeds.com/article/S0022-3476(19)30123-4/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=A+Validated+Scale+for+Assessing+the+Severity+of+Acute+Infectious+Mononucleosis", "https://journals.lww.com/pidj/Abstract/2019/06000/Measles_Hospitalizations_at_a_United_States.1.aspx", "https://journals.lww.com/pidj/Abstract/2019/06000/Pertussis_Morbidity_in_Children_12_59_Months_of.2.aspx", "https://adc.bmj.com/content/104/6/605.1", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Should+zinc+be+used+as+an+adjunct+therapy+in+severe+pneumonia+in+Western+Europe%3F", "https://adc.bmj.com/content/104/6/513", "https://adc.bmj.com/content/104/6/552", "https://journals.lww.com/pidj/Fulltext/2019/05000/Respiratory_Viruses_Frequently_Mimic_Pertussis_in.28.aspx", "https://insights.ovid.com/pubmed?pmid=30199483", "https://journals.lww.com/pidj/Abstract/2019/05000/Clinical_Characteristics_of_Infective_Endocarditis.2.aspx", "https://adc.bmj.com/content/104/5/466", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Fever+duration+during+treated+urinary+tract+infections+and+development+of+permanent+renal+lesions", "https://www.analesdepediatria.org/es-infecciones-por-erythrovirus-b19-seis-articulo-S1695403318302261", "https://www.analesdepediatria.org/es-oseltamivir-el-tratamiento-gripe-ninos-articulo-S1695403319300268", "https://www.jpeds.com/article/S0022-3476(19)30286-0/fulltext", null, null, "https://www.ncbi.nlm.nih.gov/pubmed/30938299", "https://www.cochrane.org/CD004827/IBD_probiotics-prevention-antibiotic-associated-diarrhea-children", "https://www.cochrane.org/CD001534/RENAL_long-term-antibiotics-preventing-recurrent-urinary-tract-infection-children", "https://www.jpeds.com/article/S0022-3476(18)31719-0/fulltext", "https://journals.lww.com/pidj/Abstract/2019/05000/Staphylococcus_aureus_Bacteremia_in_Children_.3.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/30827808", "https://journals.lww.com/pidj/Abstract/2019/05000/Pediatric_Candidemia_Epidemiology_and_Morbidities_.4.aspx", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-antimicrobial-defined-daily-dose-adjusted-S0213005X18302556", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-antimicrobial-defined-daily-dose-adjusted-S0213005X18304002", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-in-reply-to-antimicrobial-defined-S0213005X19300229", "https://www.jpeds.com/article/S0022-3476(19)30288-4/fulltext", null, null, null, "https://www.analesdepediatria.org/es-la-importancia-vigilancia-epidemiologica-los-articulo-S1695403318303849", "https://journals.lww.com/pidj/Abstract/2019/05000/The_Changing_Landscape_of_Childhood_Tuberculosis.6.aspx", "https://adc.bmj.com/content/104/5/443", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Archivist%3A+Can+the+rotavirus+vaccination+reduce+the+incidence+of+Type+1+diabetes%3F", "https://journals.lww.com/pidj/Fulltext/2019/05000/Rotavirus_Vaccination_Does_Not_Increase_Type_1.24.aspx", "https://journals.lww.com/pidj/Abstract/2019/05000/Does_Herpes_6_Infection_Have_a_Role_in_Bell_s.8.aspx", "https://journals.lww.com/pidj/Fulltext/2019/05000/High_density_Bacterial_Nasal_Carriage_in_Children.22.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/30765242", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464092/pdf/emss-82568.pdf", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012915.pub2/epdf/abstract", "https://www.ncbi.nlm.nih.gov/pubmed/30993666", "https://journals.lww.com/pidj/Abstract/2019/05000/Priority_Needs_for_Conducting_Pandemic_relevant.5.aspx", "https://pediatrics.aappublications.org/content/143/5/e20182491", "https://pediatrics.aappublications.org/content/143/5/e20190631", "https://www.ncbi.nlm.nih.gov/pubmed/31040196", "https://vacunasaep.org/profesionales/noticias/migrantes-en-europa-ecdc", "https://ecdc.europa.eu/en/publications-data/public-health-guidance-screening-and-vaccination-infectious-diseases-newly", "http://communications.elsevier.com/r/?id=h8b069ac,fdfb46b3,fdfb523e", "https://www.jpeds.com/article/S0022-3476(18)31679-2/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Casting+New+Light+on+Hand-Foot-and-Mouth+Disease", "https://www.jpeds.com/article/S0022-3476(18)31420-3/fulltext", "https://www.jpeds.com/issue/S0022-3476(19)X0003-7", "https://adc.bmj.com/content/104/4/384", "http://dx.doi.org/10.1136/archdischild-2018-314960", "https://adc.bmj.com/content/104/4/407", "https://pap.es/articulo/12784/piodermitis-y-hematuria-en-paciente-viajero", "https://pap.es/articulo/12764/psoriasis-guttata-asociada-a-dermatitis-perianal-estreptococica", "https://pap.es/articulo/12768/eritema-tubular-tras-picadura-de-insecto", "https://pap.es/articulo/12772/herpes-zoster-tras-primera-dosis-de-vacuna-de-varicela-en-paciente-inmunocompetente", "https://pap.es/articulo/12786/acrodermatitis-papulosa-infantil-tras-infeccion-por-virus-de-epstein-barr", "https://pap.es/articulo/12779/parotiditis-recurrente-y-deficit-de-celulas-natural-killer-coincidencia-o-patogenia", "https://pap.es/articulo/12783/neumonia-muy-atipica-en-paciente-de-dos-anos", "http://www.revistapediatria.org/rp/article/view/129", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-eficacia-del-albendazol-topico-el-S0213005X18301885", "https://journals.lww.com/pidj/Fulltext/2019/04000/The_Microbiome_The_Explanation_for__Almost_.25.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/30545562", "https://www.ncbi.nlm.nih.gov/pubmed/30545562", "https://www.analesdepediatria.org/es-infecciones-previas-o-coincidentes-con-articulo-S1695403318303084", "http://advances.sciencemag.org/content/5/3/eaau9124", "http://dx.doi.org/10.1126/sciadv.aau9124", "https://uticalc.pitt.edu/", "https://insights.ovid.com/pubmed?pmid=30882730", "https://evidenciasenpediatria.es/articulo/7140/la-profilaxis-antibiotica-es-innecesaria-para-prevenir-las-cicatrices-renales-tras-infeccion-urinaria-en-ninos-sanos", "https://www.ncbi.nlm.nih.gov/pubmed/30905425", "https://journals.lww.com/pidj/Fulltext/2019/04000/Rate_of_Recurrence_of_Adverse_Events_Following.8.aspx", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008521.pub4/full", "https://journals.lww.com/pidj/Fulltext/2019/04000/Tracking_Changes_in_Vaccine_Attitudes_and.28.aspx", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011571.pub2/epdf/full", "https://journals.lww.com/pidj/Fulltext/2019/04000/Effective_Tuberculosis_Contact_Investigation_Using.29.aspx", null, "https://journals.lww.com/pidj/Abstract/2019/04000/The_Risk_of_Serious_Bacterial_Infection_in_Febrile.5.aspx", "https://evidenciasenpediatria.es/articulo/7387/pcr-a-enterovirus-en-la-fiebre-sin-foco-pensad-en-mi", "https://vacunasaep.org/profesionales/gripe-oms-composicion-vacuna-2019-20-H3N2", "https://journals.lww.com/pidj/Abstract/2019/04000/Characteristics_and_Outcomes_of_Young_Children.6.aspx", null, "https://evidenciasenpediatria.es/articulo/7331/gripe-en-lactantes-hay-evidencia-del-uso-de-la-vitamina-d3", "https://adc.bmj.com/content/104/4/316", "https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-does-exposure-pregnant-women-epidemic-S0213005X18302337", "https://www.jpeds.com/article/S0022-3476(18)31689-5/fulltext", "https://evidenciasenpediatria.es/articulo/7345/manejo-de-las-exacerbaciones-no-graves-en-ninos-con-bronquiectasias-que-hay-de-nuevo", "https://www.bmj.com/content/364/bmj.l1481", "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-3873-y", "https://adc.bmj.com/content/104/4/401.1", "https://journals.lww.com/pidj/Abstract/2019/04000/Bordetella_pertussis_Infection_in_Infants_and.7.aspx", "https://journals.lww.com/pidj/Abstract/2019/04000/Immunologic_based_Diagnosis_of_Latent_Tuberculosis.1.aspx", "https://journals.lww.com/pidj/Abstract/2019/04000/Tuberculosis_Transmission_in_Danish_Children__A.2.aspx", "https://journals.lww.com/pidj/Abstract/2019/04000/Potential_for_More_Rational_Use_of_Antibiotics_in.9.aspx", "https://www.ncbi.nlm.nih.gov/pubmed/30796107", "https://www.jpeds.com/article/S0022-3476(18)31555-5/fulltext", "https://www.jpeds.com/article/S0022-3476(18)31670-6/fulltext", "https://pediatrics.aappublications.org/content/143/3/e20190065", "https://www.jpeds.com/article/S0022-3476(18)31373-8/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Recurrent+Vulvar+Ulcers+and+%E2%80%9CCradle+Cap%E2%80%9D+in+a+2-Year-Old", "https://www.analesdepediatria.org/es-insuficiencia-respiratoria-subita-como-primera-articulo-S1695403318301309", "https://www.analesdepediatria.org/es-insuficiencia-respiratoria-subita-como-primera-articulo-S1695403318301309#bib0025", "https://www.analesdepediatria.org/es-insuficiencia-respiratoria-subita-como-primera-articulo-S1695403318301309#bib0030", "https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528", "https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0035", "https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0045", "https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0035", "https://www.analesdepediatria.org/es-cerebelitis-aguda-fulminante-una-entidad-articulo-S1695403318301528#bib0035", "https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.6.1800117", "https://www.jpeds.com/article/S0022-3476(18)31674-3/fulltext", null, null, null, "https://journals.lww.com/pidj/Abstract/2019/03000/Inappropriate_Antibiotic_Prescribing_for_Acute.13.aspx", "https://journals.lww.com/pidj/Fulltext/2019/03000/Risk_Factors_for_Severe_Community_aquired.4.aspx", "https://www.bmj.com/content/364/bmj.l739", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Effects+of+the+rotavirus+vaccine+program+across+age+groups+in+the+United+States%3A+analysis+of+national+claims+data%2C+2001%E2%80%932016", "https://www.ncbi.nlm.nih.gov/pubmed/?term=*%E2%80%A2%09Enterovirus+as+trigger+of+coeliac+disease%3A+nested+case-control+study+within+prospective+birth+cohort", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012071.pub2/full", "https://www.bmj.com/content/364/bmj.l463", "https://www.analesdepediatria.org/es-combinacion-ledipasvir-sofosbuvir-como-tratamiento-infeccion-articulo-S1695403318303175", "https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.7.1700857", "https://www.ncbi.nlm.nih.gov/pubmed/30782268", "https://adc.bmj.com/content/104/3/227", "https://adc.bmj.com/content/104/3/227#F1", "https://adc.bmj.com/content/104/3/227#ref-1", "https://adc.bmj.com/content/104/3/303.1", "https://journals.lww.com/pidj/Citation/2019/03000/Health_Risks_of_Flood_Disasters.27.aspx", "https://journals.lww.com/pidj/Fulltext/2019/03000/Hemophagocytic_Lymphohistiocytosis_and_Infections_.28.aspx", "https://journals.lww.com/pidj/Fulltext/2019/03000/Hemophagocytic_Lymphohistiocytosis_and_Infections_.28.aspx#R1-28", "https://journals.lww.com/pidj/Fulltext/2019/03000/Hemophagocytic_Lymphohistiocytosis_and_Infections_.28.aspx#R2-28", "https://pediatrics.aappublications.org/content/143/3/e20182308", "https://www.jpeds.com/article/S0022-3476(18)31673-1/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Cerebrospinal+Fluid+Shunt+Infection%3A+Emerging+Paradigms+in+Pathogenesis+that+Affect+Prevention+and+Treatment", "https://www.ncbi.nlm.nih.gov/pubmed/?term=*+%E2%80%A2%09Trends+and+Predictors+of+Clostridium+difficile+Infection+among+Children%3A+A+Canadian+Population-Based+Study", "https://journals.lww.com/pidj/Abstract/2019/03000/Oral_Fluoroquinolone_Prescribing_to_Children_in.12.aspx", "http://www.madrid.org/bvirtual/BVCM020261.pdf", "https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx", "https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R1-26", "https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R2-26", "https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R3-26", "https://journals.lww.com/pidj/Fulltext/2019/02000/Scabies__New_Opportunities_for_Management_and.26.aspx#R4-26", "https://www.ncbi.nlm.nih.gov/pubmed/29570583", "https://journals.lww.com/pidj/Fulltext/2019/02000/Antibiotic_Recommendations_for_Acute_Otitis_Media.32.aspx", "https://journals.lww.com/pidj/Abstract/2019/02000/Streptococcal_Infections_and_Exacerbations_in.22.aspx", "https://www.bmj.com/content/364/bmj.l634", "https://www.jpeds.com/article/S0022-3476(18)31142-9/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/30244984", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Ideal+and+Actual+Impact+of+Rapid+Diagnostic+Testing+and+Antibiotic+Stewardship+on+Antibiotic+Prescribing+and+Clinical+Outcomes+in+Children+With+Positive+Blood+Cultures.", "https://www.analesdepediatria.org/es-hospitalizaciones-infantiles-asociadas-infeccion-por-articulo-S169540331830300X", "https://www.nejm.org/doi/full/10.1056/NEJMicm1808613", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357504/", "http://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-infections-by-emerging-serogroups-neisseria-S0213005X18301654", "http://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-tumefaccion-region-malar-un-neonato-S0213005X18300041", "https://adc.bmj.com/content/104/2/146", "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3657-9", "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-3671-6", "https://www.ncbi.nlm.nih.gov/pubmed/29982173", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Selected+Children+With+Complicated+Acute+Urinary+Tract+Infection+May+Be+Treated+With+Outpatient+Parenteral+Antibiotic+Therapy+at+Home+Directly+From+the+Emergency+Department.", "https://www.jpeds.com/article/S0022-3476(18)31300-3/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/30340935", "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30296-2/fulltext", "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30547-4/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Antibiotic+Resistance+Among+Pediatric-Sourced+Ocular+Pathogens%3A+8-Year+Findings+From+the+Antibiotic+Resistance+Monitoring+in+Ocular+Microorganisms+(ARMOR)+Surveillance+Study", "http://pediatrics.aappublications.org/content/143/2/e20181902", "http://pediatrics.aappublications.org/content/143/2/e20182094", "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3602-y", "https://www.ncbi.nlm.nih.gov/pubmed/30601584", "https://www.cochrane.org/news/featured-review-adverse-events-people-taking-macrolide-antibiotics-versus-placebo-any", "https://www.cochrane.org/CD006085/INFECTN_antiamoebic-drugs-treating-amoebic-colitis", "https://www.jpeds.com/article/S0022-3476(18)31366-0/fulltext", "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30288-3/fulltext", "https://journals.lww.com/pidj/Abstract/2019/02000/Longitudinal_Association_Between_Human.4.aspx", "https://seq.es/wp-content/uploads/2018/12/reina20dec2018.pdf", "https://journals.lww.com/pidj/Fulltext/2019/02000/Comparing_the_Clinical_Severity_of_Disease_Caused.29.aspx", "https://journals.lww.com/pidj/Fulltext/2019/02000/Comparing_the_Clinical_Severity_of_Disease_Caused.29.aspx#R1-29", "https://journals.lww.com/pidj/Fulltext/2019/02000/Comparing_the_Clinical_Severity_of_Disease_Caused.29.aspx#R1-29", "https://journals.lww.com/pidj/Fulltext/2019/02000/Comparing_the_Clinical_Severity_of_Disease_Caused.29.aspx#R3-29", "https://journals.lww.com/pidj/Fulltext/2019/02000/Implementing_Universal_Varicella_Vaccination_in.20.aspx", "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-3759-z", "https://www.analesdepediatria.org/es-coinfecciones-respiratorias-entre-los-virus-articulo-S1695403318301073", "https://www.analesdepediatria.org/es-heterogeneidad-criterios-el-diagnostico-bronquiolitis-articulo-S169540331830314X", "https://journals.lww.com/pidj/Citation/2019/02000/BCG_Vaccination_and_All_Cause_Neonatal_Mortality.23.aspx", "http://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-avance-resumen-dinamica-infeccion-por-helicobacter-pylori-S0213005X18301770", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Pediatric+Coccidioidomycosis%3A+Case+Series+From+a+California+Pediatric+Infectious+Diseases+Clinic.", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Long-term+outcomes+after+group+B+streptococcus+infection%3A+a+cohort+study", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Letter%3A+Congenital+Zika+infection%3A+neurology+can+occur+without+microcephaly", "file:///C:/Users/Jaime/Downloads/Short%20individualised%20treatment%20of%20bone%20and%20joint%20infections%20in%20Danish%20children", "https://www.jpeds.com/article/S0022-3476(18)31295-2/fulltext", "https://www.jpeds.com/article/S0022-3476(18)31301-5/fulltext", "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010473.pub3/epdf/abstract", "https://www.sciencedirect.com/science/article/pii/S169540331830376X?via%3Dihub", "https://vacunasaep.org/profesionales/noticias/un-brote-de-rubeola-en-aragon-trunca-la-tendencia", "https://www.heraldo.es/noticias/aragon/zaragoza/2018/12/13/investigan-brote-enfermedad-desconocida-empleados-del-matadero-zuera-1282758-2261126.html", "http://www.aragon.es/estaticos/GobiernoAragon/Departamentos/SanidadBienestarSocialFamilia/Sanidad/Profesionales/13_SaludPublica/18_Vigilancia_Epidemiologica/BEsA_201852.pdf", "https://www.heraldo.es/noticias/aragon/zaragoza/2018/12/27/se-elevan-doce-los-afectados-por-rubeola-matadero-zuera-1284697-2261126.html", "http://www.aragon.es/DepartamentosOrganismosPublicos/Departamentos/Sanidad/AreasTematicas/SanidadProfesionales/SaludPublica/ProgramasSalud/ci.mas_completo_01_Programa_de_Vacunaciones.detalleDepartamento", "http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/pdf_2018/Informe_anual_del_Plan_Nacional_de_Eliminacion_del_Sarampion_y_de_la_Rubeola_Espana_2017.pdf#page=34", "https://www.jpeds.com/article/S0022-3476(18)31256-3/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Mycoplasma+pneumoniae-Induced+Red+Fingers", "https://www.analesdepediatria.org/es-pdf-S1695403318300341", "https://www.ncbi.nlm.nih.gov/pubmed/29609896", "https://ac.els-cdn.com/S0213005X17301246/1-s2.0-S0213005X17301246-main.pdf?_tid=8be72ecb-83bf-4075-8e83-4bc68c773ae8&acdnat=1547582000_8cb1603eb9301bd2ff7894412848b4cf", "https://www.jpeds.com/article/S0022-3476(18)31231-9/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Cutaneous+Leishmaniasis+in+a+Boy+from+Belize", "https://www.jpeds.com/article/S0022-3476(18)31149-1/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Persistent+Facial+Swelling+in+an+8-Year-Old", "https://adc.bmj.com/content/104/1/11", "https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2%09Images+in+paediatrics%3A+Femoral+bone+lesions+accompanying+cat-scratch+disease", "https://ac.els-cdn.com/S0213005X18301800/1-s2.0-S0213005X18301800-main.pdf?_tid=dbf6b66b-1c34-419f-bdb2-0aae9cad132a&acdnat=1547582394_0debf342b1bbffc084022e7cc80d5678", "https://www.ncbi.nlm.nih.gov/pubmed/29788037", "https://pap.es/articulo/12737/virus-respiratorio-sincitial-no-solo-bronquiolitis-en-lactantes", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Serogroup+C+Neisseria+meningitidis+disease+epidemiology%2C+seroprevalence%2C+vaccine+effectiveness+and+waning+immunity%2C+England%2C+1998%2F99+to+2015%2F16", "https://ac.els-cdn.com/S0213005X18302994/1-s2.0-S0213005X18302994-main.pdf?_tid=13a9cada-5923-4ac7-8311-c6db57f5a759&acdnat=1547582291_fe7062dc8c9c3d8ec36043f77d74bd41", "https://ac.els-cdn.com/S0213005X18302738/1-s2.0-S0213005X18302738-main.pdf?_tid=72c26758-487d-420b-8ac7-1cc9b6eaaf35&acdnat=1547582113_edab8d19748c5e55beb174ca1921167a", "https://journals.lww.com/pidj/Abstract/2019/01000/Antituberculosis_Drug_induced_Liver_Injury_in.11.aspx", "https://www.bmj.com/content/363/bmj.k5246", "https://adc.bmj.com/content/104/1/2", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Point-of-care+lung+ultrasonography+for+pneumonia+in+children%3A+does+size+really+matter%3F", "https://adc.bmj.com/content/104/1/12", "https://www.jpeds.com/article/S0022-3476(18)31580-4/fulltext", "https://adc.bmj.com/content/104/1/94.1", "https://www.jpeds.com/article/S0022-3476(18)31365-9/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Importance+of+Delabeling+%CE%B2-Lactam+Allergy+in+Children", "https://journals.lww.com/pidj/Fulltext/2019/01000/National_Incidence_of_Pediatric_Mastoiditis_in_the.23.aspx", "https://journals.lww.com/pidj/Abstract/2019/01000/Epidemiology_of_Meningitis_and_Encephalitis_in.9.aspx", "https://journals.lww.com/pidj/Abstract/2019/01000/Streptococcal_Serology_in_Acute_Rheumatic_Fever.6.aspx", "https://www.jpeds.com/article/S0022-3476(18)31386-6/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=European+advocacy+organizations+respond+to+PANS%2FPANDAS+article", "https://journals.lww.com/pidj/Fulltext/2019/01000/Twenty_nine_Cases_of_Enterovirus_D68_associated.4.aspx", "https://journals.lww.com/pidj/Abstract/2019/01000/Fusobacterium_necrophorum_as_an_Emerging_Pathogen.3.aspx", "http://pediatrics.aappublications.org/content/143/1/e20181259", "https://journals.lww.com/pidj/Fulltext/2019/01000/Human_Parechovirus_3_in_Infants___Expanding_Our.1.aspx", "https://www.jpeds.com/article/S0022-3476(18)31239-3/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Risk+of+Serious+Infections+Associated+with+Biologic+Agents+in+Juvenile+Idiopathic+Arthritis%3A+A+Systematic+Review+and+Meta-Analyses", "http://pediatrics.aappublications.org/content/143/1/e20181457", "https://www.jpeds.com/article/S0022-3476(18)31251-4/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Estimating+Risk+of+Pneumonia+in+a+Prospective+Emergency+Department+Cohort", "https://www.jpeds.com/article/S0022-3476(18)31217-4/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Risk+of+Serious+Bacterial+Infection+in+Infants+Aged+%E2%89%A460+Days+Presenting+to+Emergency+Departments+with+a+History+of+Fever+Only", "https://www.jpeds.com/article/S0022-3476(18)31240-X/fulltext", "https://www.ncbi.nlm.nih.gov/pubmed/30545317", "http://pediatrics.aappublications.org/content/143/1/e20182130", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Meningococcal+Disease+Among+College-Aged+Young+Adults%3A+2014%E2%80%932016", "http://pediatrics.aappublications.org/content/143/1/e20183372", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Increased+Risk+of+MenB+Infection+in+College+Students%3A+Time+to+Reconsider+Vaccine+Recommendations%3F", "/grupos/grupo-de-patologia-infecciosa/integrantes", "/grupos/grupo-de-patologia-infecciosa/presentacion-y-objetivos", "/grupos/grupo-de-patologia-infecciosa/documentos-del-gpi", "/grupos/grupo-de-patologia-infecciosa/temas-de-la-la-z", "/grupos/grupo-de-patologia-infecciosa/casos-clinicos", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica/bibliografia-de-2023", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica/bibliografia-de-2022", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica/bibliografia-de-2021", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica/bibliografia-de-2020", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica/bibliografia-de-2019", "/grupos/grupo-de-patologia-infecciosa/actualidad-bibliografica/articulos-previos-organizados-por", "/grupos/grupo-de-patologia-infecciosa/uso-racional-de-antibioticos-y-resistencias-bacterianas", "/grupos/grupo-de-patologia-infecciosa/vacunas", "/grupos/grupo-de-patologia-infecciosa/informacion-para-familias", "/grupos/grupo-de-patologia-infecciosa/viajes-internacionales", "/grupos/grupo-de-patologia-infecciosa/alertas-epidemiologicas", "/grupos/grupo-de-patologia-infecciosa/contenido/recursos", "/grupos/grupo-de-patologia-infecciosa/contacto", "/grupos/grupo-de-patologia-infecciosa/docencia", "/grupos/grupo-de-patologia-infecciosa/investigacion", "https://www.facebook.com/pages/Grupo-de-Patolog%C3%ADa-Infecciosa-de-la-AEPap/1415580632016358", "https://twitter.com/GPI_AEPap", "https://gpiaepap.wordpress.com", "/grupos/grupo-de-cooperacion-inmigracion-y-adopcion", "/grupos/grupo-de-docencia", "/grupos/grupo-de-educacion-para-la-salud", "/grupos/grupo-de-investigacion", "/grupos/grupo-de-pbe", "http://previnfad.aepap.org", "/grupos/grupo-de-tdah-y-desarrollo-psicoeducativo", "http://www.respirar.org/index.php/grupo-vias-respiratorias/grupo-vias-respiratorias", "/grupos/grupo-de-patologia-infecciosa", "/grupos/grupo-de-pediatria-social-y-comunitaria", "/node/5005", "/grupos/grupo-laboral-profesional", "/grupos/grupo-vacunaepap", "/grupos/grupo-de-ecografia-clinica-pediatrica", "/grupos/grupo-de-gastroenterologia-y-nutricion", "/grupos/grupo-de-relaciones-con-pediatria-europea", "/grupos/grupo-de-sueno", "/grupos/papenred", "https://www.aepap.org/la-aepap/documentos/codigo-etico-de-la-aepap", "https://www.aepap.org/la-aepap/documentos/el-catalogo-de-la-aepap", "https://www.aepap.org/la-aepap/documentos/10o-aniversario", "https://www.aepap.org/la-aepap/contacto", "http://perlinfad.wordpress.com/", "http://www.respirar.org/index.php/grupo-vias-respiratorias/protocolos", "http://www.aepap.org/gtsiaepap/?page_id=130", "https://www.familiaysalud.es/noticias/salud-mental-infantil-y-juvenil-el-gran-problema", "https://www.familiaysalud.es/noticias/problemas-de-espalda", "https://www.familiaysalud.es/sintomas-y-enfermedades/organos-de-los-sentidos/oidos/la-otitis-del-verano", "/aggregator/sources/3", "http://internetenlaconsulta.wordpress.com/", "https://sello.clickdatos.es/index.php?contrato=CT1805-1056&web=www.aepap.org", "https://www.aepap.org/aviso-legal-y-responsabilidad", "https://www.aepap.org/politica-de-privacidad", "https://www.aepap.org/politica-cookies", "/equipo-de-la-web", "http://ateneatech.com"]}